<SEC-DOCUMENT>0001824293-21-000010.txt : 20210810
<SEC-HEADER>0001824293-21-000010.hdr.sgml : 20210810
<ACCEPTANCE-DATETIME>20210810080929
ACCESSION NUMBER:		0001824293-21-000010
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210810
DATE AS OF CHANGE:		20210810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vallon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001824293
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824369909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40034
		FILM NUMBER:		211158488

	BUSINESS ADDRESS:	
		STREET 1:		TWO LOGAN SQUARE
		STREET 2:		100 N. 18TH STREET, SUITE 300
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		(267) 207-3606

	MAIL ADDRESS:	
		STREET 1:		TWO LOGAN SQUARE
		STREET 2:		100 N. 18TH STREET, SUITE 300
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ck0001824293-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:545a0cb1-db3f-4c1d-8b23-fea1d98a8647,g:1675d0ed-3cfa-4512-b65d-428038bee998,d:e97965356b784378b02d7326d25aa562--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ck0001824293="http://www.vallon-pharma.com/20210630" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ck0001824293-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80L2ZyYWc6NjY0MWYzZmFlM2Y1NDk4Yjg1MTM2OTdjOTExYTIxNWYvdGFibGU6NzU0MjkwNWYzNmYyNGM4MGE4NGFlNjgxOWM3MmQxY2MvdGFibGVyYW5nZTo3NTQyOTA1ZjM2ZjI0YzgwYTg0YWU2ODE5YzcyZDFjY18yOS0xLTEtMS0xNDM0_45d40320-bb3e-4dd1-a9ca-fcd74eb372f1">0001824293</ix:nonNumeric><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80L2ZyYWc6NjY0MWYzZmFlM2Y1NDk4Yjg1MTM2OTdjOTExYTIxNWYvdGFibGU6NzU0MjkwNWYzNmYyNGM4MGE4NGFlNjgxOWM3MmQxY2MvdGFibGVyYW5nZTo3NTQyOTA1ZjM2ZjI0YzgwYTg0YWU2ODE5YzcyZDFjY18zMC0xLTEtMS0xNDM4_92728026-f68b-487a-90b9-08afb6ab95ef">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80L2ZyYWc6NjY0MWYzZmFlM2Y1NDk4Yjg1MTM2OTdjOTExYTIxNWYvdGFibGU6NzU0MjkwNWYzNmYyNGM4MGE4NGFlNjgxOWM3MmQxY2MvdGFibGVyYW5nZTo3NTQyOTA1ZjM2ZjI0YzgwYTg0YWU2ODE5YzcyZDFjY18zMS0xLTEtMS0xNDM4_39cf15f0-1abe-4d2c-9ca5-074ecce0ca2c">2021</ix:nonNumeric><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80L2ZyYWc6NjY0MWYzZmFlM2Y1NDk4Yjg1MTM2OTdjOTExYTIxNWYvdGFibGU6NzU0MjkwNWYzNmYyNGM4MGE4NGFlNjgxOWM3MmQxY2MvdGFibGVyYW5nZTo3NTQyOTA1ZjM2ZjI0YzgwYTg0YWU2ODE5YzcyZDFjY18zMi0xLTEtMS0xNDM4_2e1bfceb-5631-4837-a05a-68251a930743">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80L2ZyYWc6NjY0MWYzZmFlM2Y1NDk4Yjg1MTM2OTdjOTExYTIxNWYvdGFibGU6NzU0MjkwNWYzNmYyNGM4MGE4NGFlNjgxOWM3MmQxY2MvdGFibGVyYW5nZTo3NTQyOTA1ZjM2ZjI0YzgwYTg0YWU2ODE5YzcyZDFjY18zMy0xLTEtMS0xNDQx_9bb3b8cc-a9d2-4b08-a150-c5a4bc235d8e">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="idb6e392c488e43689ffc16945c65d467_D20210212-20210212" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81NjkvZnJhZzo2MjkxY2ZkZWZmN2I0M2M5OTE0NzdjNzVkNDY1YzI0Mi90YWJsZTozYjQyM2MxMjIwODM0ZWI1OTE5OWQ3Njc2NWI5YTE1Ny90YWJsZXJhbmdlOjNiNDIzYzEyMjA4MzRlYjU5MTk5ZDc2NzY1YjlhMTU3XzEtMS0xLTEtMTU0OQ_35b1e05b-f729-42d0-904a-3186bb158cb0">0.025</ix:nonFraction><ix:nonNumeric contextRef="i727458f1ed4c4be384fc367ff6dbf535_D20200501-20200531" name="ck0001824293:DebtInstrumentPaymentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfNTQ5NzU1ODE0MDcxNg_347c90b0-2a8b-4e03-a46b-c55366ecabe5">P1Y6M0D</ix:nonNumeric><ix:nonNumeric contextRef="id368a2d31edc42a0b69cd67c1ee5bee0_I20210212" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfOTg4_8a453afd-a308-407d-aa87-5aea5009f0de">P5Y0M0D</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ck0001824293-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i34b302c75dba4c628d85244f68002a60_I20210806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i6b79fcafbff642fa848ff1901341ccd7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic895252214e44777813c5b78a8d4444f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61ac3f94b5f149979bd71ad52587031e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe37a5900c304ce28d7ecdea6420b23a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if56d5eae60d046f096e356f7a5042dcb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3e856b37c19403f8329a07be3454d4e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibafcc59176d54d99a4b6f080f91bebfe_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50024d555c8a4c84929dda5920ed007b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5765e73948fa479394575bdc1358aa9a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie620d3313620467383dee26f0f0a3c7c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i238b94d82c304fccbc90bb50080061c5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac63187c14bf4722bde64d421ce98362_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibffb387820b54b48a3579ed3b5009547_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie769608b479948f496d2bb6a432fac37_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief43562ce2e047b9817ddf36217940df_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa5c17d856644cd3b88a05d18f8e6bfe_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife011d6dbed94ffeaeb46db11c3e48e3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff321e9d1ca24eeb985f787da4129ad1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa79d0de6ea5497ebb25e7f4d8686d52_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31e1e141d8814e4090f2d3e21275625e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i143f796f80894c99aac56a13b900ee21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d46e3841ca64fbb811bcae232cd7200_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd589b362dd643cabf0c87233e57e988_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d33cef40f034ce2a44f35ae028bb669_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63727a089ddc482397d5b8b38b53f131_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b512a400b941aba498ea638f7583ed_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea416d58bba48c59aae046eaf6963ee_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5eb9251ed6a246158ebed555043580de_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie850734f1a4c4bdc9dbd84239c0edf92_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i466406119fd042e78b23e14be880ebc6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie683a1421b7e42d5869006a49ce417bb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c283f6cb704453592615c899f3cf9d8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86f5891de57c4edfb483409095deae5b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02909c7ca37a4096874b575c77575a27_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a315f92ff66436b99d5d04a5d936d46_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d32c5625af443af9e9ab4f13da85869_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib40eca850643445aa3fb581f3a267821_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3a045458c344fe6b012e31e07176174_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d756267a38641f49152d284b506e41c_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i78d2a9fcaf4742528def995407f4d94d_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic49837a0734b43478ec5edc5f65ef833_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb6e392c488e43689ffc16945c65d467_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81624bcf1ddd410e8384985a52ed244e_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i727458f1ed4c4be384fc367ff6dbf535_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice4617251d084359a4b1673e32105777_D20210111-20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-11</xbrli:startDate><xbrli:endDate>2021-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c9d5a032e74fedb51994d35e423ac4_I20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bc882349d4b44458f3fcac805712aaa_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d10d62088b94b7ca91599063bdd7713_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5a7c424887d4d268f63dad57f3d0c22_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9d38d7df6fa442f80a3d6ebe4c56f9c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id368a2d31edc42a0b69cd67c1ee5bee0_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b87e9f4d00f4885821da6e21e067a39_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba0a050f6bca41bc803a3fd1b6bef4b6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3621a5e4b5684da1868630577f530cf2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782b28a8f85447788786cb2c7f4d69fb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id40c60f62dab45c18759442084ff92e9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27c7675abef34248a1f00e6bcf04c49d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5ce2baeed89423c922e27b6c8e36bba_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if64b7ec5ca7045d089a7f58dd9d61741_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i887713052e054612a1e185929791f55d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04385040180f467690e4c12dc8d54a53_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc2622def42a4874aedf69d387f68fb9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06e1e9850961407ca3e9d3986c0b7169_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0864fed0eeb54c0887a8eeeaa3029b17_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5f07cccdbc84951b24e82c3340132e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8af83bde4e7d4b5986d02a1be122c2df_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:MediceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60901d5d21aa4ec69b330ba52b51042b_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47a4058978b54caa86791e0df0e0a693_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie57e0b7edd14462ebede9f2bd8aad12c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c968c9ac274451f8c6acd6b1628a443_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie97965356b784378b02d7326d25aa562_1"></div><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTE0_91123be4-8fc1-4689-8564-30d62fd99c0d">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NTU0YmQxZThkM2U4NGRjYzkxZWM4YWIyYTJjZjFhMzAvdGFibGVyYW5nZTo1NTRiZDFlOGQzZTg0ZGNjOTFlYzhhYjJhMmNmMWEzMF8wLTAtMS0xLTEwMjY_1c06e5e7-74f2-4f0b-b5a4-4dc9b7e9c23b">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTU0_9adb1ea0-7f9e-4702-95b9-05a0d5ac59b8">June 30, 2021</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6ZWJmZmQzMDk5ODRiNDNhNDkyNmEzNzY3Y2IwZjQ5ZWEvdGFibGVyYW5nZTplYmZmZDMwOTk4NGI0M2E0OTI2YTM3NjdjYjBmNDllYV8wLTAtMS0xLTEwMjg_184f7f2f-4616-4da5-a2e5-1cded3e5a632">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from_________to_________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTEx_061717eb-8d44-4113-8932-e5e2acc3f637">001-40034</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="text-align:center"><img src="ck0001824293-20210630_g1.jpg" alt="ck0001824293-20210630_g1.jpg" style="height:63px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTEz_465781a4-7e62-4890-b175-208b79788cd0">VALLON PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NjkyOTA5M2RkODQyNDM3MjgyMDJmOWQ3ZTg3ZTI5OTEvdGFibGVyYW5nZTo2OTI5MDkzZGQ4NDI0MzcyODIwMmY5ZDdlODdlMjk5MV8wLTAtMS0xLTEwNDk_277dca42-da1f-419d-afb9-2d6ae5c1dc53">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NjkyOTA5M2RkODQyNDM3MjgyMDJmOWQ3ZTg3ZTI5OTEvdGFibGVyYW5nZTo2OTI5MDkzZGQ4NDI0MzcyODIwMmY5ZDdlODdlMjk5MV8wLTItMS0xLTEwNTE_0e74b148-d037-4096-ba54-4de4d71dd10c">82-4369909</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Identification No.)&#160;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NjkyOTA5M2RkODQyNDM3MjgyMDJmOWQ3ZTg3ZTI5OTEvdGFibGVyYW5nZTo2OTI5MDkzZGQ4NDI0MzcyODIwMmY5ZDdlODdlMjk5MV8zLTAtMS0xLTExNzMvdGV4dHJlZ2lvbjplNTQ4MTZkMDI5NTU0NzE2ODM2ZGNiYTFiYjU1ODk4Ml8yNzQ4Nzc5MDY5NTEy_691947bb-3040-4bb3-9edf-77e95d61d235">100 N. 18th Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NjkyOTA5M2RkODQyNDM3MjgyMDJmOWQ3ZTg3ZTI5OTEvdGFibGVyYW5nZTo2OTI5MDkzZGQ4NDI0MzcyODIwMmY5ZDdlODdlMjk5MV8zLTAtMS0xLTExNzMvdGV4dHJlZ2lvbjplNTQ4MTZkMDI5NTU0NzE2ODM2ZGNiYTFiYjU1ODk4Ml8yNzQ4Nzc5MDY5NTg5_fbda1fe8-067d-4a39-b083-8bb7bad9cd0a">Suite 300</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NjkyOTA5M2RkODQyNDM3MjgyMDJmOWQ3ZTg3ZTI5OTEvdGFibGVyYW5nZTo2OTI5MDkzZGQ4NDI0MzcyODIwMmY5ZDdlODdlMjk5MV8zLTAtMS0xLTExNzMvdGV4dHJlZ2lvbjplNTQ4MTZkMDI5NTU0NzE2ODM2ZGNiYTFiYjU1ODk4Ml8yNzQ4Nzc5MDY5NjI3_c2f9df1f-9710-49b8-9800-270b6c20110f">Philadelphia</ix:nonNumeric>, <ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NjkyOTA5M2RkODQyNDM3MjgyMDJmOWQ3ZTg3ZTI5OTEvdGFibGVyYW5nZTo2OTI5MDkzZGQ4NDI0MzcyODIwMmY5ZDdlODdlMjk5MV8zLTAtMS0xLTExNzMvdGV4dHJlZ2lvbjplNTQ4MTZkMDI5NTU0NzE2ODM2ZGNiYTFiYjU1ODk4Ml8yNzQ4Nzc5MDY5NjMy_f6617047-cd93-4387-86ea-4b2fb24ec89a">PA</ix:nonNumeric>  <ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NjkyOTA5M2RkODQyNDM3MjgyMDJmOWQ3ZTg3ZTI5OTEvdGFibGVyYW5nZTo2OTI5MDkzZGQ4NDI0MzcyODIwMmY5ZDdlODdlMjk5MV8zLTAtMS0xLTExNzMvdGV4dHJlZ2lvbjplNTQ4MTZkMDI5NTU0NzE2ODM2ZGNiYTFiYjU1ODk4Ml8yNzQ4Nzc5MDY5Njk2_43288622-d3cb-439d-b183-20ac167600d9">19103</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> (<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8xMDk5NTExNjI5OTU4_9cf46636-2d1b-4d49-9415-5831d2a8126b">267</ix:nonNumeric>)-<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8xMDk5NTExNjI5OTU0_fc7a3f74-60da-4265-a03c-c77a09ec1e78">207-3606</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6Zjc1NjI1OWZjMjcyNDIzODk0NjU5ZjYyNTVhNjkyMWQvdGFibGVyYW5nZTpmNzU2MjU5ZmMyNzI0MjM4OTQ2NTlmNjI1NWE2OTIxZF8xLTAtMS0xLTExODU_6d8ee716-5536-4fb6-a176-91eae53bced6">Common Stock, par value $0.0001<br/>per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6Zjc1NjI1OWZjMjcyNDIzODk0NjU5ZjYyNTVhNjkyMWQvdGFibGVyYW5nZTpmNzU2MjU5ZmMyNzI0MjM4OTQ2NTlmNjI1NWE2OTIxZF8xLTItMS0xLTEwMzA_2eda2738-8d0e-4253-8fc9-3dabcef5c999">VLON</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6Zjc1NjI1OWZjMjcyNDIzODk0NjU5ZjYyNTVhNjkyMWQvdGFibGVyYW5nZTpmNzU2MjU5ZmMyNzI0MjM4OTQ2NTlmNjI1NWE2OTIxZF8xLTQtMS0xLTExOTEvdGV4dHJlZ2lvbjphMjQwYzRjMTY3OTE0NDdiYTE5NjYxZmI1MmY2NmYxZl8yNzQ4Nzc5MDY5NDcx_6640ae0c-6190-48d1-84c0-51912dada128">NASDAQ</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTM1_16de5ed8-80f4-45c7-93eb-1437055eacbd">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTM2_1184ad98-a402-403f-91df-8430bedad2bc">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6OWEzYWM2YzQ5ODZjNGU4Mjg2MzMyOTAzZDc1N2FiYzMvdGFibGVyYW5nZTo5YTNhYzZjNDk4NmM0ZTgyODYzMzI5MDNkNzU3YWJjM18xLTAtMS0xLTEwNTM_bd085198-8c6c-4cc4-891f-ae822d17167a">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6OWEzYWM2YzQ5ODZjNGU4Mjg2MzMyOTAzZDc1N2FiYzMvdGFibGVyYW5nZTo5YTNhYzZjNDk4NmM0ZTgyODYzMzI5MDNkNzU3YWJjM18xLTMtMS0xLTEwNTc_987451c2-dc42-4736-b67a-d7211b53abd1">x</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6OWEzYWM2YzQ5ODZjNGU4Mjg2MzMyOTAzZDc1N2FiYzMvdGFibGVyYW5nZTo5YTNhYzZjNDk4NmM0ZTgyODYzMzI5MDNkNzU3YWJjM18yLTEtMS0xLTEwNTU_1c4e1d45-eebc-47be-8689-54db846dfee2">x</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNzg0_940b20aa-f74e-4b2c-96cf-707977682966">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTc0_59330821-3894-4dc8-bd9b-3916df99824e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of August 6, 2021, <ix:nonFraction unitRef="shares" contextRef="i34b302c75dba4c628d85244f68002a60_I20210806" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTI0_7e17540c-fac2-425e-baf1-1c8cb28bad4e">6,812,836</ix:nonFraction> shares of the Registrant&#8217;s Common Stock were outstanding.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_7"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_13">PART&#160;I. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_16">Financial Statements</a> (unaudited)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_19">Balance Sheets as of June 30, 2021 (unaudited) and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_22">Statements of Operations (unaudited) for the three and six months ended June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_25">Statements of Stockholders&#8217; Equity (Deficit) (unaudited) for the three and six months ended June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_28">Statements of Cash Flows (unaudited) for the six months ended June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_31">Notes to Unaudit</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_31">ed </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_31">Interim </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_31">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_67">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_67">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_100">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_100">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_100">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_103">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_103">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_103">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_106">PART&#160;II. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_106">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_106">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_109">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_109">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_109">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_112">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_112">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_112">20</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_127">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_127">22</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_130">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie97965356b784378b02d7326d25aa562_130">23</a></span></div></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_10"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that are based on management&#8217;s beliefs and assumptions and on information currently available to management. Some of the statements in the sections captioned &#8220;Part I&#8212;Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and elsewhere in this Quarterly Report contain forward-looking statements. In some cases, you can identify forward-looking statements by the following words: &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of our clinical trials and non-clinical studies demonstrating safety and efficacy of our product candidates, and other positive results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of initiation of our future clinical trials, and the reporting of data from our completed, current and future preclinical and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the market opportunity for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of the number of patients in the United States who suffer from ADHD or narcolepsy and the number of patients that will enroll in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the beneficial characteristics, safety and efficacy of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings and approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the further development and manufacturing of our product candidates, including ADMIR;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected potential benefits of strategic collaborations with third parties, including MEDICE Arzneimittel Putter GmbH &amp; Co. KG (&#8220;Medice&#8221;), which is affiliated with one of our principal stockholders, Salmon Pharma, and represented by one member of our board of directors, and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">existing regulations and regulatory developments in the United States, the European Union, and other geographic territories;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to hire additional personnel, and our ability to attract and retain such personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the COVID-19 pandemic on our operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain the listing of our common stock on The Nasdaq Capital Market.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. You should refer to the &#8220;Risk Factors&#8221; section of this Quarterly Report for a discussion of other important factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. If the forward-looking statements prove to be inaccurate; the inaccuracy may be material. In light of the significant uncertainties in these forward- looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this Quarterly Report represents our views as of the date of this Quarterly Report. We anticipate that subsequent events and developments will cause our views to change, however, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this Quarterly Report, whether as a result of any new information, future events or otherwise. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report includes trademarks and registered trademarks of Vallon Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Quarterly Report may be trademarks or registered trademarks of their respective owners.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Quarterly Report, unless the context requires otherwise, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Vallon Pharmaceuticals, Inc.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_13"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="ie97965356b784378b02d7326d25aa562_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="ie97965356b784378b02d7326d25aa562_19"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMy0xLTEtMS0w_340be2b5-a91a-4d82-8574-28d21c87fefb">10,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMy0zLTEtMS0w_41073bac-7f32-453b-af61-4ab932fa8dd1">109</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNC0xLTEtMS00OA_6dba0616-2cf5-4a12-9180-71d69aeaffda">944</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNC0zLTEtMS0w_3dca3f74-5ca7-4067-badb-abe865c1f79d">565</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNS0xLTEtMS0xMDI0_50b2bbda-8673-4655-b6f9-ef850bc67ea9">11,404</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNS0zLTEtMS0w_629691f8-a294-4831-a1be-086046d2c1f7">674</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNi0xLTEtMS0w_d523feda-3b6e-43e8-b8d1-2435d7b95541">243</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNi0zLTEtMS0w_a32a29d7-b436-4730-a515-252beb6de06f">279</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNy0xLTEtMS01Mg_8adca70b-446e-4941-9b2b-ed35654963a8">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNy0zLTEtMS0w_1d13893e-9d2c-4968-a0eb-572d4b27f21a">2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfOC0xLTEtMS0w_fd8bd3b6-1ec3-4238-bc2d-47d2432ca043">11,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfOC0zLTEtMS0w_89b0c0fc-69da-428f-a427-4fda8df08565">955</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTItMS0xLTEtMA_686beeb4-55f9-481d-b7de-895d750e3644">886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTItMy0xLTEtMA_fc63d4da-60c3-4fae-b350-eab3b435b7ea">1,226</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTMtMS0xLTEtNTc_683ad932-ea49-4743-9658-de1aaa529391">694</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTMtMy0xLTEtMA_6d20b9a3-cb61-400a-bb33-db7c78e13513">847</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable, current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTQtMS0xLTEtMA_0ffbd79c-097e-422c-9e32-6e9a6609e892">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:NotesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTQtMy0xLTEtMA_b8f458ba-4adc-4900-9a04-8963091a999b">47</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTUtMS0xLTEtNjE_da238913-5641-46a1-86d8-429a8d16ab00">91</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTUtMy0xLTEtMA_56a90e2a-3885-4bda-abe8-a338de76cd07">105</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTYtMS0xLTEtMA_afc2ed09-14c9-43dd-891b-a3cf7a71533a">1,671</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTYtMy0xLTEtMA_8fa93354-467b-4f7c-b473-f794550b6e49">2,225</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTctMS0xLTEtMA_ffda80ec-10ae-443d-850e-ed4430c5aed8">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:LongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTctMy0xLTEtMA_bc6e31f1-147f-4366-a9c2-b02d1e55daec">14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTgtMS0xLTEtNjU_2328f5e1-36d0-48a0-8fec-8c39d79a8e84">123</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTgtMy0xLTEtMA_1b5339b0-0809-4c08-aa20-53d777b39aca">170</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTktMS0xLTEtMA_00f4e713-833b-4d7e-b35c-d52d8bd131c6">1,794</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTktMy0xLTEtMA_6e03b646-66f0-44fb-8f50-fa0e23d60290">2,409</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjEtMS0xLTEtMTk5NA_3cd7b6f9-f878-4b9e-9ac2-0eebcc401516"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjEtMy0xLTEtMTk5Ng_b426df9e-72fd-4be4-b2b2-c1beb1e8a3b2"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity (deficit):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2XzE4_4bf1bb38-9875-4f39-8d47-928ac41ec3d8"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2XzE4_b27b3166-dfbe-4a57-8d66-76c645957377">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2XzMy_143265dc-17f2-4ded-a936-7d7d733c265f"><ix:nonFraction unitRef="shares" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2XzMy_20837609-4414-4c33-958e-8ba71632c6d9">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of June&#160;30, 2021 and December&#160;31, 2020; <ix:nonFraction unitRef="shares" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2Xzcw_26422d54-e86a-41b0-9a55-7cc8e28663e6"><ix:nonFraction unitRef="shares" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2Xzcw_a665de09-c25a-432c-a390-50c2d3d957bb">6,812,836</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2Xzc3_87e7fe20-74d1-453e-97c1-b7fcb2a38a53"><ix:nonFraction unitRef="shares" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2Xzc3_fa55df69-b22f-40fe-8f9f-8c829efd792f">4,506,216</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMS0xLTEtMA_e69a35cb-5d0d-4a2f-849c-56db7fb705ee">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMy0xLTEtMA_be1e8d79-1690-4d9e-aab8-58acf7f892a7">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjMtMS0xLTEtNzM_1e3e46dd-c2ce-4b6d-834c-2bb31633613f">27,402</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjUtMy0xLTEtMA_b72cab36-4da0-4944-af14-849fb163bbb0">11,145</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMS0xLTEtNzc_ee157762-70f5-4b8b-9ce0-5b70f4653284">17,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjYtMy0xLTEtMA_184b09cc-f5b6-4edd-a5e0-e8cf30c518d4">12,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjUtMS0xLTEtMTI3Mw_8517c0bf-2b0f-43e9-8d7d-d3f9f58a8afe">9,853</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjctMy0xLTEtMA_e605f179-7fe7-4417-9745-33318b3fa886">1,454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity (deficit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjgtMS0xLTEtMA_c167cde0-0363-4cbd-a89a-35ce245c493a">11,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjgtMy0xLTEtMA_0394d09c-e228-4df9-90ef-7e82060c2963">955</ix:nonFraction></span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_22"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:10pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue-related party</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMy0xLTEtMS0w_31dd145e-8b03-4514-a4ac-fd316120eb8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMy0zLTEtMS0w_8f107906-5a7f-49d7-95b2-72f3020ae0ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMy01LTEtMS0xMjE_d17953a7-ff51-4013-b292-ad0148a0fcd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMy03LTEtMS0w_638a1d02-e9ec-488a-b260-caed544b4d70">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNS0xLTEtMS0xNTE_a8bb2bff-5ea7-4a9a-bcc6-61cde0dff1fe">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNS0zLTEtMS0w_6eba41bd-f28a-4b47-9b9d-e72c55c299dd">808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNS01LTEtMS0xMTQ_f4e786f3-2f9f-4e1f-83cd-080fb8d80e2c">2,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNS03LTEtMS0w_65c61d64-7c2c-4061-bdf5-5343819a31e1">1,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNi0xLTEtMS0xNTE_435ee7a1-be0b-4ed8-84a8-937925fdda76">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNi0zLTEtMS0w_c8a8e258-5ef8-4340-9d1a-0b1768ae8017">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNi01LTEtMS0xMTA_635309eb-bcc6-411d-baa9-e4edfb5f194e">1,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNi03LTEtMS0w_fdd676db-8251-4eec-a8ce-bdfd88059e06">701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNy0xLTEtMS0w_84ed2c4b-ecb7-4210-8380-2f29b2cd55e6">2,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNy0zLTEtMS0w_3a94669b-7adb-45c2-8e03-b50484fe0398">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNy01LTEtMS0w_66e0065d-80d8-41e4-bb56-6581b9405590">4,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNy03LTEtMS0w_2a421e3a-6b55-4e2e-8faf-60f0122071a7">2,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOC0xLTEtMS0w_68a42e63-4f6c-4dd0-ace9-9ba04706b601">2,310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOC0zLTEtMS0w_c6ec917b-24fa-4d62-b265-edfca0cb31fb">1,135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOC01LTEtMS0w_45b4e906-cc9f-4655-8ec5-b62f14d39ceb">4,912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOC03LTEtMS0w_85226b68-4619-474f-8bd2-deec0a0a562d">2,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOS0xLTEtMS0w_dfe5e5bd-cd3f-4e8d-a124-760fb4a9b79a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOS0zLTEtMS0w_5fbe1348-b18c-4147-b0cc-ba6679d8a6e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOS01LTEtMS0w_59017b5f-6481-4c3f-b83b-f028f5b2d822">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOS03LTEtMS0w_b0b1aaca-7ce2-44b1-a867-9c68a2c40da5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTAtMS0xLTEtMA_ae891dea-6042-4395-9416-3953c44577c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTAtMy0xLTEtMA_08e1039c-599a-4e34-a01d-6626c81d18cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTAtNS0xLTEtMA_d84c5ced-67a9-4f08-99a3-1806c7a434ed">89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTAtNy0xLTEtMA_2a2cc0e3-ea42-40bb-87f3-1ae9ee48d9fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTEtMS0xLTEtMTQ3_e3e941bc-b310-4b02-8446-ea8a19f12862">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTEtMy0xLTEtMA_0564110d-910a-4717-acf3-029ee1321cd9">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTEtNS0xLTEtMTM5_e0126353-c037-4512-86fd-aaead25f5ab6">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTEtNy0xLTEtMA_2809b4d2-1e06-4396-8a23-12e29643e296">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTItMS0xLTEtMA_dc1d292a-a5e7-4298-bef8-d1f6f6c91f17">2,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTItMy0xLTEtMA_18494711-6d4d-4c44-b158-f983b43d5a10">1,147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTItNS0xLTEtMA_273e7158-3694-421c-9994-ac147644b316">4,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTItNy0xLTEtMA_01ac486a-d122-486a-859a-99ab9301a764">2,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share of common stock, basic and diluted</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtMS0xLTEtMA_267c2318-b4df-4709-8195-6344eae8894f"><ix:nonFraction unitRef="usdPerShare" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtMS0xLTEtMA_61374a24-4bb0-4be1-9660-aba80734d0b2">0.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtMy0xLTEtMA_80b75de7-444b-441e-8da8-d5a70d5ac39e"><ix:nonFraction unitRef="usdPerShare" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtMy0xLTEtMA_918165d0-7c95-4aeb-8b66-ac7b640871a9">0.25</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtNS0xLTEtMA_594b3605-106b-4dcd-aef7-730a8d7af326"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtNS0xLTEtMA_91623ebc-749c-4fee-b3c3-24c95408f7ec">0.79</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtNy0xLTEtMA_3eebce8c-a18c-4a9d-8dda-4d936a070e7b"><ix:nonFraction unitRef="usdPerShare" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtNy0xLTEtMA_b378dcee-3be4-4d46-b2c5-a69f1a6cf892">0.51</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtMS0xLTEtNTk5_94ae9fda-98fc-472d-a005-bf862bdd7244"><ix:nonFraction unitRef="shares" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtMS0xLTEtNTk5_a68c1300-148f-418f-9c10-1f0052b5c424">6,812,836</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtMy0xLTEtMA_93e75d4b-3457-475a-92d5-075ce7ca13f7"><ix:nonFraction unitRef="shares" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtMy0xLTEtMA_ad1abc61-fc8c-4bf6-afdc-f3eee52f10d3">4,506,216</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtNS0xLTEtNjA1_66288e3f-1fc6-4638-ad6b-defa9cbd5b51"><ix:nonFraction unitRef="shares" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtNS0xLTEtNjA1_ce919846-783f-4cbe-a43e-80bf15c97a5e">6,264,854</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtNy0xLTEtMA_5bbd37b1-7f4a-498e-817b-112dbe2e79f2"><ix:nonFraction unitRef="shares" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtNy0xLTEtMA_b2cedd9f-b925-459e-a2ba-30219142cb0b">4,506,216</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_25"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Changes in Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61ac3f94b5f149979bd71ad52587031e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfMi0xLTEtMS0w_00f4044e-38a8-49bf-80f3-75abdce04fce">4,506,216</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe37a5900c304ce28d7ecdea6420b23a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfMi01LTEtMS0w_aa2e4beb-d474-4dd1-aacc-66ce160cd7c4">10,991</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if56d5eae60d046f096e356f7a5042dcb_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfMi03LTEtMS0w_3d932c05-17f3-431a-ac2d-3d462492718c">7,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e856b37c19403f8329a07be3454d4e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfMi05LTEtMS0w_5b0480b8-4ee6-4d7e-a90a-5ecda46240da">3,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibafcc59176d54d99a4b6f080f91bebfe_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfMy01LTEtMS0w_4e812cf1-9fdd-46ef-b786-38a2ada4cca0">35</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50024d555c8a4c84929dda5920ed007b_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfMy05LTEtMS0w_c361636a-ed59-46ef-9fa3-5a47d768ae7c">35</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5765e73948fa479394575bdc1358aa9a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNC03LTEtMS0w_49ac8970-9ea9-46f1-9865-0bd3679afdf6">1,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50024d555c8a4c84929dda5920ed007b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNC05LTEtMS0w_f55ecb74-2026-4a41-a968-15b5a420a70c">1,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March&#160;31,&#160;2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie620d3313620467383dee26f0f0a3c7c_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNS0xLTEtMS0w_124d1236-1ba1-4133-a8de-0cea110e046b">4,506,216</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i238b94d82c304fccbc90bb50080061c5_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNS01LTEtMS0w_324694ed-6044-4736-8f16-8c5b4b5f8ba7">11,026</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac63187c14bf4722bde64d421ce98362_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNS03LTEtMS0w_f52d9cfb-8bec-4e2b-9e61-24a8ac1095e9">8,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffb387820b54b48a3579ed3b5009547_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNS05LTEtMS0w_7d63134c-5072-4c83-a363-5ca770b54073">2,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie769608b479948f496d2bb6a432fac37_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNy01LTEtMS0w_21f48517-0881-46be-a9aa-12a29413ae34">28</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNy05LTEtMS0w_ff7c2ba1-99a4-4a42-a4da-67f044a16fed">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief43562ce2e047b9817ddf36217940df_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfOC03LTEtMS0w_5caba09a-a016-4614-91ab-540677866bfc">1,147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfOC05LTEtMS0w_f8a9086b-2671-44da-97c7-d7e85f095cfe">1,147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa5c17d856644cd3b88a05d18f8e6bfe_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfOS0xLTEtMS0w_a57ed225-f5b9-4391-9cf2-b1a1062d45ad">4,506,216</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife011d6dbed94ffeaeb46db11c3e48e3_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfOS01LTEtMS0w_e84f97b8-2d1f-4d6c-b785-83da12b75f86">11,054</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff321e9d1ca24eeb985f787da4129ad1_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfOS03LTEtMS0w_415ffe7a-4e91-4a64-8557-1ad7b6068852">10,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa79d0de6ea5497ebb25e7f4d8686d52_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfOS05LTEtMS0w_40508f80-6edc-43e0-b262-fc8639777ef2">969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity&#160;(Deficit)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance,&#160;December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31e1e141d8814e4090f2d3e21275625e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMi0xLTEtMS0w_522e2279-54da-4261-bb93-52cd4006f882">4,506,216</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i143f796f80894c99aac56a13b900ee21_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMi01LTEtMS0w_31db3e4a-66cb-40eb-8f02-34bf27ad9719">11,145</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d46e3841ca64fbb811bcae232cd7200_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMi03LTEtMS0w_a3af10d3-eee3-4753-a9d9-8e7b68b8986a">12,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMi05LTEtMS0w_cc435fa7-a0a8-4f66-8c47-c5a6aae52c6d">1,454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd589b362dd643cabf0c87233e57e988_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMy0xLTEtMS0w_d2868603-c62a-4dea-9669-2ac66d25fbdd">54,906</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d33cef40f034ce2a44f35ae028bb669_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMy01LTEtMS0w_5262fdaa-59cf-4443-811a-bea8ed0f1f5c">439</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63727a089ddc482397d5b8b38b53f131_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMy05LTEtMS0w_2d6c3630-cc93-4b0c-b6b3-260fe04f1f22">439</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for IPO, net of issuance expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd589b362dd643cabf0c87233e57e988_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNC0xLTEtMS0w_e485d005-d58c-4e2f-987c-3ac840b28e34">2,250,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d33cef40f034ce2a44f35ae028bb669_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNC01LTEtMS0w_c51ade59-ef0d-45ab-8c07-350b136514b5">15,104</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63727a089ddc482397d5b8b38b53f131_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNC05LTEtMS0w_f0969801-0c4b-4153-bf3c-10c54ab7d3c9">15,104</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd589b362dd643cabf0c87233e57e988_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNS0xLTEtMS0w_45cdf56a-a7c1-4d8d-a74b-cc3000882a9f">1,714</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d33cef40f034ce2a44f35ae028bb669_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNS01LTEtMS0w_a787fe6b-5402-4497-9f15-a0154187e3a6">9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63727a089ddc482397d5b8b38b53f131_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNS05LTEtMS0w_3453702c-9567-428e-9075-e656d02ba616">9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of Underwriters Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d33cef40f034ce2a44f35ae028bb669_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNi01LTEtMS0w_54d159e3-e6a8-4cbb-9f8b-f82eeeb0920e">399</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63727a089ddc482397d5b8b38b53f131_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNi05LTEtMS0w_f63d7a73-4395-40c2-b1d5-b88cbffc0307">399</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d33cef40f034ce2a44f35ae028bb669_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNy01LTEtMS0w_7bac4acb-2188-4895-af3d-e6b9fa0620dd">168</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63727a089ddc482397d5b8b38b53f131_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNy05LTEtMS0w_5bbee011-a1d6-4574-a3de-6097f4b34309">168</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6b512a400b941aba498ea638f7583ed_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfOC03LTEtMS0w_d01d0a73-778b-4a21-abbe-7fcd7f85ae26">2,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63727a089ddc482397d5b8b38b53f131_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfOC05LTEtMS0w_c67a477f-4eab-42d3-8ce3-b430d1cd966d">2,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March&#160;31,&#160;2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifea416d58bba48c59aae046eaf6963ee_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfOS0xLTEtMS0w_475647fa-c2b3-4eec-aa31-69e422bf90ea">6,812,836</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb9251ed6a246158ebed555043580de_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfOS01LTEtMS0w_69213538-3530-440e-93a3-2941d824bfdf">27,264</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie850734f1a4c4bdc9dbd84239c0edf92_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfOS03LTEtMS0w_ced44101-45fa-46c9-b0b8-b5e5d87e166e">15,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466406119fd042e78b23e14be880ebc6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfOS05LTEtMS0w_f84986db-4b20-4cb4-8606-fa702f8571d7">12,027</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie683a1421b7e42d5869006a49ce417bb_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTAtNS0xLTEtMjMx_b1ed3e42-b0e1-4534-bf2b-6c018869927b">138</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTAtOS0xLTEtMjQx_4d864871-94fd-4f35-8419-d97cac2cc6e8">138</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c283f6cb704453592615c899f3cf9d8_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTEtNy0xLTEtMjM2_fd7d46ed-4002-41d1-9338-152886d1038a">2,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTEtOS0xLTEtMjQy_a44e6acc-a1c2-4c18-8022-bc647b45e70f">2,312</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86f5891de57c4edfb483409095deae5b_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTMtMS0xLTEtMA_7f208f0b-0971-4ef6-9b6e-97864422a67e">6,812,836</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02909c7ca37a4096874b575c77575a27_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTMtNS0xLTEtMA_f45535df-00bf-472f-beda-53b51c11c14a">27,402</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a315f92ff66436b99d5d04a5d936d46_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTMtNy0xLTEtMA_65e50153-79a7-4339-87a4-c8fbd8ef29e6">17,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTMtOS0xLTEtMA_225c6075-8ff8-4bbd-a6fc-f84e1d419da7">9,853</ix:nonFraction></span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim financial statements. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_28"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMy0xLTEtMS0w_cef1b213-4809-4fc2-a62b-3ecff5500443">4,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMy0zLTEtMS0w_e1ad6834-0738-41bb-b287-295528785104">2,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of finance lease right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfNS0xLTEtMS0w_81494815-80e5-4e66-9b06-3cc09e3e5cec">36</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfNS0zLTEtMS0w_ccdbe690-b6c8-42bb-a2c3-1551782335d8">37</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfNi0xLTEtMS0xODg_05e806b1-6e6a-4f76-86f2-dd516a6d25c5">306</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfNi0zLTEtMS0w_bcc33416-0d9f-4bbf-96bd-c3deff807489">63</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfNy0xLTEtMS0w_c48296f9-891f-4c2b-9bf8-6639e6c67540">89</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfNy0zLTEtMS0w_9fb13b2a-db57-4941-90d5-b5375379e129">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forgiveness of PPP note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" name="ck0001824293:ForgivenessOfDebtInstrument" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfOC0xLTEtMS0w_b879b61c-fbf5-489f-b24c-2c54cae74573">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="ck0001824293:ForgivenessOfDebtInstrument" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfOC0zLTEtMS0w_3d528cbc-c90d-4200-83a2-90aa55f918a5">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest, depreciation and other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" name="us-gaap:OtherNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfOS0xLTEtMS0xODg_09f921b8-cf46-4317-a5d2-662b47d40457">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" name="us-gaap:OtherNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfOS0zLTEtMS0w_390342f5-9b6d-46f4-b69d-c298cdd879fa">1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTEtMS0xLTEtMTkz_97b110c3-e454-438c-bc18-506db62eaf3c">379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTEtMy0xLTEtMA_05f4d7e7-a0d4-44d0-9ecf-8f0e5e62ca56">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTItMS0xLTEtMTkz_66443332-0019-4348-8728-25d0673c6b69">330</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTItMy0xLTEtMA_8bcc55c7-2319-4164-9498-206e55f6eca5">262</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTMtMS0xLTEtMTkz_0b3915ef-5910-43a6-84c2-3a4504ea98be">153</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTMtMy0xLTEtMA_59472807-1b4f-413e-9c2a-ed0210448848">128</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTQtMS0xLTEtMA_5ba852e4-1c2c-419c-acb1-6b3a95ec9285">5,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTQtMy0xLTEtMA_a48e2b0f-fc24-45fc-8e06-8ec386fc0239">1,834</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTctMS0xLTEtMA_8a259192-31b1-4014-a8a2-17c300dd573b">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTctMy0xLTEtMA_1d9e7f8e-ab99-4f32-ba5f-1e368ed5eb9c">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTgtMS0xLTEtMA_077b1e22-a2df-479c-b02e-e8e0489d9370">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTgtMy0xLTEtMA_251d180f-e987-403b-b256-9e791ed07aae">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from PPP loan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjEtMS0xLTEtMA_6730d0aa-7978-4040-9af8-50e341f9f67f">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjEtMy0xLTEtMA_ba79a2a9-dcf8-48db-a4b0-b8d33f58ba10">61</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from common stock, net of offering expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjItMS0xLTEtMA_7c7a7c76-14db-451d-af73-c949123d60a6">15,503</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjItMy0xLTEtMA_d52a2583-8d6d-420c-b114-7392a799fcfe">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjMtMS0xLTEtMA_2413ae75-bd8f-456c-bd5a-03de20a5af3b">350</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjMtMy0xLTEtMA_17ac1c98-2d4f-4410-881c-f2a21ce69e8a">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of finance lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjQtMS0xLTEtMTk3_47ba46c5-e271-43a0-a0e1-b97391c3a5ac">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjQtMy0xLTEtMA_240f3bd3-ed10-4ac1-b1ab-fe67ef859c8a">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjUtMS0xLTEtMA_f3710ef9-1e6b-4302-be5e-49079fccb018">15,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjUtMy0xLTEtMA_20eeadce-0aa4-483f-a485-32bf2ffe7614">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjctMS0xLTEtMTQ3MQ_72096782-772e-45ec-a7e4-a98c299e7ec0">10,351</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjctMy0xLTEtMA_06e29ed0-56d7-4976-ab0a-dc474446c80c">1,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjgtMS0xLTEtMA_bf907819-079a-433c-85f5-7a7e1b1b7c8b">109</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e856b37c19403f8329a07be3454d4e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjgtMy0xLTEtMA_d0afd6b8-dea1-418f-a867-15d4f8f084aa">3,821</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjktMS0xLTEtMA_016fdc4f-2f86-4618-8bb3-1b637e72559c">10,460</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa79d0de6ea5497ebb25e7f4d8686d52_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjktMy0xLTEtMA_4cb92757-6bc4-49ef-b611-2764d95af13e">1,999</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flows information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of convertible notes to common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMzMtMS0xLTEtMA_d0a95aac-48e8-4e97-bba8-d5cf10b67877">350</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMzMtMy0xLTEtMA_66af227c-972e-4856-8745-f617a0a6438b">&#8212;</ix:nonFraction></span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_31"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div id="ie97965356b784378b02d7326d25aa562_34"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMjc0ODc3OTA3NjUwNw_3d671f84-20e0-446d-9322-b0fcf5e178fe" continuedAt="i636f2bc91e394ad495e6a2b00ca8b2f8" escape="true">ORGANIZATION AND DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="i636f2bc91e394ad495e6a2b00ca8b2f8"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vallon Pharmaceuticals, Inc. (Vallon or the Company), based in Philadelphia, PA was incorporated in Delaware on January 11, 2018, which is the date of inception.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company&#8217;s lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#174;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The Company plans to develop other abuse-deterrent products, which have potential for abuse in their current forms, beginning with the development of ADMIR, an abuse deterrent formulation of Ritalin, for which the Company is conducting formulation development work.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company completed an initial public offering (IPO) of its common stock, selling <ix:nonFraction unitRef="shares" contextRef="i3d32c5625af443af9e9ab4f13da85869_D20210201-20210228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfOTcy_7c4cc056-cf71-4c59-b7d1-0e5b2476c0e5">2,250,000</ix:nonFraction> shares at $<ix:nonFraction unitRef="usdPerShare" contextRef="ib40eca850643445aa3fb581f3a267821_I20210228" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfOTg1_5954f8f9-dce3-4ba5-b403-51c698b7b9be">8.00</ix:nonFraction> per share. As a result of the IPO, the Company received approximately $<ix:nonFraction unitRef="usd" contextRef="i3d32c5625af443af9e9ab4f13da85869_D20210201-20210228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMTA1OA_c1e63987-df1f-4039-9b4f-31b5d4c3d4c7">15,500</ix:nonFraction> in net proceeds, after deducting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i3d32c5625af443af9e9ab4f13da85869_D20210201-20210228" decimals="-3" format="ixt:numdotdecimal" name="ck0001824293:StockIssuanceCostsDiscountsAndCommissions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMTEzNw_0debbb7f-a78b-4f79-8fa4-213275024703">1,600</ix:nonFraction> and estimated offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="if3a045458c344fe6b012e31e07176174_D20210201-20210228" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMTE4OQ_169f5748-0cf2-4977-b66f-3fa33a8d0719">905</ix:nonFraction> payable by the Company.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, our Chief Executive Officer, pursuant to which we issued convertible promissory notes (the 2021 Convertible Notes) for cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i3d756267a38641f49152d284b506e41c_D20210101-20210131" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMTUzNQ_17c12f28-2984-4a3d-a64c-f272dae51766">350</ix:nonFraction>. The 2021 Convertible Notes bear an interest rate of <ix:nonFraction unitRef="number" contextRef="i78d2a9fcaf4742528def995407f4d94d_I20210131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMTU5MQ_316bbf3c-41b9-4071-a533-8ec9d94bee43">7.0</ix:nonFraction>% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes were convertible into shares of our capital stock offered to investors in any subsequent equity financing after the date of their issuance in which we issued any of our equity securities (a Qualified Financing) and were convertible at a twenty percent (<ix:nonFraction unitRef="number" contextRef="i3d756267a38641f49152d284b506e41c_D20210101-20210131" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMTk0OQ_70d21f7d-0d54-4070-89c1-33769a9c087a">20</ix:nonFraction>%) discount to the price per share offered in such Qualified Financing. Such Qualified Financing included the IPO and as a result, the 2021 Convertible Notes converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i3d756267a38641f49152d284b506e41c_D20210101-20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMjEzOQ_c157c2a0-101f-475b-83d2-c7fae0d2bca7">54,906</ix:nonFraction> shares of our common stock immediately prior to the closing of IPO.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div id="ie97965356b784378b02d7326d25aa562_37"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNy9mcmFnOmY3YTE1MWJkN2YxZjRkNmM4MWJmMGE4YjE1MGMwZTg1L3RleHRyZWdpb246ZjdhMTUxYmQ3ZjFmNGQ2YzgxYmYwYThiMTUwYzBlODVfMjc0ODc3OTA3MTc4OA_6919c9a5-fd91-43bf-8bd3-2f3f10453ff1" continuedAt="ib25133bac2d1434d8f75f5123f5f197c" escape="true">LIQUIDITY</ix:nonNumeric></span></div><ix:continuation id="ib25133bac2d1434d8f75f5123f5f197c"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception and has incurred $<ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNy9mcmFnOmY3YTE1MWJkN2YxZjRkNmM4MWJmMGE4YjE1MGMwZTg1L3RleHRyZWdpb246ZjdhMTUxYmQ3ZjFmNGQ2YzgxYmYwYThiMTUwYzBlODVfNDY4_231cadbc-79f2-4996-9a1b-5498b6444748">17,549</ix:nonFraction> in accumulated deficit through June&#160;30, 2021. The Company has financed its working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a Paycheck Protection Program (PPP) promissory note.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company completed a $<ix:nonFraction unitRef="usd" contextRef="ic49837a0734b43478ec5edc5f65ef833_D20210101-20210131" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNy9mcmFnOmY3YTE1MWJkN2YxZjRkNmM4MWJmMGE4YjE1MGMwZTg1L3RleHRyZWdpb246ZjdhMTUxYmQ3ZjFmNGQ2YzgxYmYwYThiMTUwYzBlODVfNzU0_81e793fa-8ca2-4fe9-ae61-fd93ac4723dd">350</ix:nonFraction> convertible note financing and in February 2021, the Company completed the IPO, raising net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i3d32c5625af443af9e9ab4f13da85869_D20210201-20210228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNy9mcmFnOmY3YTE1MWJkN2YxZjRkNmM4MWJmMGE4YjE1MGMwZTg1L3RleHRyZWdpb246ZjdhMTUxYmQ3ZjFmNGQ2YzgxYmYwYThiMTUwYzBlODVfODUw_22f869d4-5d3e-45b5-ae1f-537096fee807">15,500</ix:nonFraction>. As of June&#160;30, 2021, the Company had cash and cash equivalents of approximately $<ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNy9mcmFnOmY3YTE1MWJkN2YxZjRkNmM4MWJmMGE4YjE1MGMwZTg1L3RleHRyZWdpb246ZjdhMTUxYmQ3ZjFmNGQ2YzgxYmYwYThiMTUwYzBlODVfOTIz_8395bef1-7f98-48ce-9ea3-24a2c83215b2">10,460</ix:nonFraction>, which management expects will provide funding for its ongoing business activities into the third quarter of 2022. However, the Company has based this estimate on assumptions that may prove erroneous, and it could use capital resources sooner than it expects, therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year of the date that these financial statements are being issued.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company&#8217;s objective is to develop and commercialize biopharmaceutical products that treat central nervous system disorders, but there can be no assurances that the Company will be successful in this regard. Therefore, the Company intends to raise capital through additional issuances of common stock and /or short-term notes. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_40"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80MC9mcmFnOjQ3MzZlYjcxZDlkOTRjNGU5MjhkMzZlYzEwN2JiODc3L3RleHRyZWdpb246NDczNmViNzFkOWQ5NGM0ZTkyOGQzNmVjMTA3YmI4NzdfMjc0ODc3OTA3NzkyOA_29b8196c-a4aa-4bc7-b00d-e3f33f85b414" continuedAt="i6d54a6a384b744f6bfe278387a7db2e3" escape="true">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i6d54a6a384b744f6bfe278387a7db2e3" continuedAt="i582730a7d8c14f7b863979c6246b13f4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80MC9mcmFnOjQ3MzZlYjcxZDlkOTRjNGU5MjhkMzZlYzEwN2JiODc3L3RleHRyZWdpb246NDczNmViNzFkOWQ5NGM0ZTkyOGQzNmVjMTA3YmI4NzdfNTQ5NzU1ODE0ODIzOA_dad13655-f9e7-4395-991b-7654d1508ca1" escape="true">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December 31, 2020 balance sheet was derived from audited financial statements.</ix:nonNumeric> </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of June&#160;30, 2021, and the results of operations and stockholders&#8217; equity (deficit) for the three and six months ended June&#160;30, 2021 and 2020 and cash flows for the six months ended June&#160;30, 2021 and 2020. Results of operations for the three and six months ended June&#160;30, 2021, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2021. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2020 included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 29, 2021. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recapitalization</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the  IPO (Note 6), the Company effected a one-for-40 reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Quarterly Report on Form 10-Q give retroactive effect to the reverse split.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80MC9mcmFnOjQ3MzZlYjcxZDlkOTRjNGU5MjhkMzZlYzEwN2JiODc3L3RleHRyZWdpb246NDczNmViNzFkOWQ5NGM0ZTkyOGQzNmVjMTA3YmI4NzdfNTQ5NzU1ODE0ODIzOQ_c1ac1b70-a37a-48ed-9593-c7458eca3190" continuedAt="i92548d1afd3542cea32942a73e7dde68" escape="true">Use of Estimates</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i92548d1afd3542cea32942a73e7dde68">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</ix:continuation> </span></div><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80MC9mcmFnOjQ3MzZlYjcxZDlkOTRjNGU5MjhkMzZlYzEwN2JiODc3L3RleHRyZWdpb246NDczNmViNzFkOWQ5NGM0ZTkyOGQzNmVjMTA3YmI4NzdfNTQ5NzU1ODE0ODI0MA_f5f6a70a-59d4-438f-8fc1-f5091bb5fd43" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80MC9mcmFnOjQ3MzZlYjcxZDlkOTRjNGU5MjhkMzZlYzEwN2JiODc3L3RleHRyZWdpb246NDczNmViNzFkOWQ5NGM0ZTkyOGQzNmVjMTA3YmI4NzdfNTQ5NzU1ODE0ODI0MQ_93f4d4fd-bb35-449b-82ee-34b30513d4b9" continuedAt="ie9299849950e4b6bb3c629981435c245" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on these financial statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The </span></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i582730a7d8c14f7b863979c6246b13f4"><ix:continuation id="ie9299849950e4b6bb3c629981435c245">amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.</ix:continuation></ix:continuation></span></div><div id="ie97965356b784378b02d7326d25aa562_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RleHRyZWdpb246MWNjYmE1YjBjZTc1NGVmMjg5ODg4OWJmZDIwYzJkYzJfMjc0ODc3OTA2OTU0NA_154d4fc5-451f-4e50-8597-c52e552ad9e6" continuedAt="i246534d2f8914cec928ad6b82d3a39af" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="i246534d2f8914cec928ad6b82d3a39af"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RleHRyZWdpb246MWNjYmE1YjBjZTc1NGVmMjg5ODg4OWJmZDIwYzJkYzJfMjc0ODc3OTA2OTU0NQ_e7be63f8-3ec0-457a-92d2-4d94189ff024" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfMS0xLTEtMS0w_ad0caea1-d9e5-42d1-9658-e3f069617197">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfMS0zLTEtMS0w_cb55e9f3-f54a-49f2-b671-5363e1f00220">259</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfMi0xLTEtMS02NjI_a0706a1d-fcdb-40b6-8a89-e968a21aa112">144</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfMi0zLTEtMS0w_26878f0a-2903-43d0-a9a7-2ad4cb590400">156</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfMy0xLTEtMS02NjI_5f6f5478-fab2-4c1a-ac2d-506adb376117">196</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfMy0zLTEtMS0w_d1ad8b5c-3573-4796-97b7-6403a8a16cd3">342</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" name="ck0001824293:AccruedLicensingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfNC0xLTEtMS0w_ed2c2c71-7660-4ba0-9258-c21f2331bb6d">71</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="ck0001824293:AccruedLicensingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfNC0zLTEtMS0w_a103ea61-9571-4984-bfb5-3c092d68957a">81</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfNS0xLTEtMS02NzI_96b2cc70-e18f-4ad0-828c-a44c169cd9d5">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfNS0zLTEtMS0w_0d9e3b2c-5efc-4b70-8525-531fb2338706">9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfNy0xLTEtMS0w_3ed5fdb2-e794-4cb2-b4e5-cdae0b310194">694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfNy0zLTEtMS0w_b55f1ee6-0e1e-45d6-9a43-2903cfc615a0">847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie97965356b784378b02d7326d25aa562_46"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfMjc0ODc3OTA3MTIwNg_b41d7077-289f-4863-8908-814d18788a02" continuedAt="i29d1c66737fe4adab5950c83a2fb0fb8" escape="true">PPP NOTE AND CONVERTIBLE NOTES</ix:nonNumeric></span></div><ix:continuation id="i29d1c66737fe4adab5950c83a2fb0fb8"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company issued a promissory note under the PPP (the PPP Note) totaling $<ix:nonFraction unitRef="usd" contextRef="i81624bcf1ddd410e8384985a52ed244e_I20200531" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfMTIx_e904f2f7-a602-4503-ad99-48626de6bec0">61</ix:nonFraction>. The PPP Note had a stated interest rate of <ix:nonFraction unitRef="number" contextRef="i81624bcf1ddd410e8384985a52ed244e_I20200531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfMTY4_dfb105ad-5756-431f-967e-02fcb0b7d58b">1</ix:nonFraction>% and had a <ix:nonNumeric contextRef="i727458f1ed4c4be384fc367ff6dbf535_D20200501-20200531" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfNTQ5NzU1ODE0MDcxNQ_564a8b0c-bac6-4b99-9070-c29482c3f80c">two-year</ix:nonNumeric> maturity. Payments were required to be made over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfNTQ5NzU1ODE0MDcxNg_347c90b0-2a8b-4e03-a46b-c55366ecabe5">1.5-year</span> period beginning November 1, 2020 unless forgiven. In January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As a result, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1, disclosed in the amount of $<ix:nonFraction unitRef="usd" contextRef="ic49837a0734b43478ec5edc5f65ef833_D20210101-20210131" decimals="-3" name="ck0001824293:ForgivenessOfDebtInstrument" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfNTQz_426967a3-4c36-4c3f-b24d-cb8916fb469b">61</ix:nonFraction> included in other income on the accompanying Statements of Operations. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;11, 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes, for cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="ice4617251d084359a4b1673e32105777_D20210111-20210111" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfOTc3_1a408564-58ec-4464-84e0-757c7c38ad55">350</ix:nonFraction>. The 2021 Convertible Notes bore an interest rate of <ix:nonFraction unitRef="number" contextRef="i99c9d5a032e74fedb51994d35e423ac4_I20210111" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfMTAzMQ_c5b5688a-4509-4a4e-868b-a629a2701ca9">7.0</ix:nonFraction>% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into <ix:nonFraction unitRef="shares" contextRef="i8bc882349d4b44458f3fcac805712aaa_D20210201-20210228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfMTE0OQ_038ed841-95a5-47ad-9931-d1e637b14fb5">54,906</ix:nonFraction> shares of the Company&#8217;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#8217;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</span></div></ix:continuation><div id="ie97965356b784378b02d7326d25aa562_49"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfNTQ5NzU1ODE0MDM4MQ_a457847d-50d7-4319-8a4e-f9c7a91d25c8" continuedAt="i3cc64d4814a34faa9f7cc51504f56dfc" escape="true">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</ix:nonNumeric></span></div><ix:continuation id="i3cc64d4814a34faa9f7cc51504f56dfc" continuedAt="i44a29f9a7aec4d918e98ad4ce7318420"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;12, 2021, the Company completed the IPO of <ix:nonFraction unitRef="shares" contextRef="i8d10d62088b94b7ca91599063bdd7713_D20210212-20210212" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfOTI_d65358d4-7490-4cd6-a7b9-a944c57ad66b">2,250,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia5a7c424887d4d268f63dad57f3d0c22_I20210212" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfMTQ4_79dd22eb-e5ac-4553-8f6a-07a1860e9026">8.00</ix:nonFraction> per share. The gross proceeds from the IPO, before deducting underwriting discounts, commissions and other offering expenses payable by the Company, were $<ix:nonFraction unitRef="usd" contextRef="i8d10d62088b94b7ca91599063bdd7713_D20210212-20210212" decimals="-3" format="ixt:numdotdecimal" name="ck0001824293:ProceedsFromIssuanceInitialPublicOfferingGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfMzA1_f0ed298a-42f1-47d7-804a-333ee086342c">18,000</ix:nonFraction>. Underwriting discounts and expenses totaled $<ix:nonFraction unitRef="usd" contextRef="i8d10d62088b94b7ca91599063bdd7713_D20210212-20210212" decimals="-3" format="ixt:numdotdecimal" name="ck0001824293:StockIssuanceCostsDiscountsAndCommissions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfMzUz_5fb58fe7-358a-4082-94d6-ad7bb3d56359">1,600</ix:nonFraction> and the Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="idb6e392c488e43689ffc16945c65d467_D20210212-20210212" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfMzk1_7c90f028-44a1-46c4-a971-91d16785d795">905</ix:nonFraction> of additional expenses related to completing the IPO, of which $<ix:nonFraction unitRef="usd" contextRef="if9d38d7df6fa442f80a3d6ebe4c56f9c_D20200101-20201231" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfNDYx_7390f4c7-18ea-429a-80b8-6eaff7324f15">494</ix:nonFraction> were incurred as of December&#160;31, 2020 and included prepaid expenses and other current assets on the Company&#8217;s balance sheet; thus aggregate net proceeds were approximately $<ix:nonFraction unitRef="usd" contextRef="i8d10d62088b94b7ca91599063bdd7713_D20210212-20210212" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfNjEz_6ea6daa4-3537-46ac-bc0b-779567b03f68">15,500</ix:nonFraction>. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, the Company granted the underwriters warrants (the Underwriters' Warrants) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="id368a2d31edc42a0b69cd67c1ee5bee0_I20210212" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfODkw_eb39ed39-3986-4541-b2aa-2cd1fff71e83">112,500</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id368a2d31edc42a0b69cd67c1ee5bee0_I20210212" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfOTQw_4c926dec-8612-41df-bf4a-e5246917d1f2">10.00</ix:nonFraction> per share. The Underwriters&#8217; Warrants have a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfOTg4_8a453afd-a308-407d-aa87-5aea5009f0de">five</span>-year term and are not exercisable prior to August 12, 2021. All of the Underwriters&#8217; Warrants were outstanding as of June&#160;30, 2021. The warrants were </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><ix:continuation id="i44a29f9a7aec4d918e98ad4ce7318420"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">classified as equity and the fair value of $<ix:nonFraction unitRef="usd" contextRef="i4b87e9f4d00f4885821da6e21e067a39_D20210212-20210212" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfMTE3Mw_7355bc04-ec01-4b78-9c4f-20756d661fbe">399</ix:nonFraction> is reflected as additional paid-in capital. <ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfMjc0ODc3OTA3MDgyMg_3d51174d-9a3f-47fe-b9a7-0aea0e688f88" continuedAt="i780cb9cc5d914a0b92be4bded13325b2" escape="true">The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</ix:nonNumeric></span></div><div style="margin-top:8pt"><ix:continuation id="i780cb9cc5d914a0b92be4bded13325b2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba0a050f6bca41bc803a3fd1b6bef4b6_I20210630" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RhYmxlOmUyYjQ5MWIzNjhjNTRmMzA5ZjgwZTE2M2Y0MWY1YWE3L3RhYmxlcmFuZ2U6ZTJiNDkxYjM2OGM1NGYzMDlmODBlMTYzZjQxZjVhYTdfMC0xLTEtMS0w_9d3ddffa-f605-433f-aed6-21d7e7c0c9ca">85.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3621a5e4b5684da1868630577f530cf2_I20210630" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RhYmxlOmUyYjQ5MWIzNjhjNTRmMzA5ZjgwZTE2M2Y0MWY1YWE3L3RhYmxlcmFuZ2U6ZTJiNDkxYjM2OGM1NGYzMDlmODBlMTYzZjQxZjVhYTdfMS0xLTEtMS0w_d227a8fd-2399-46c3-bb80-e73110314b81">2.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i782b28a8f85447788786cb2c7f4d69fb_I20210630" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RhYmxlOmUyYjQ5MWIzNjhjNTRmMzA5ZjgwZTE2M2Y0MWY1YWE3L3RhYmxlcmFuZ2U6ZTJiNDkxYjM2OGM1NGYzMDlmODBlMTYzZjQxZjVhYTdfMi0xLTEtMS0w_d1a05490-91b8-4a8a-b3af-20c8d6155b5d">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id40c60f62dab45c18759442084ff92e9_I20210630" decimals="5" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RhYmxlOmUyYjQ5MWIzNjhjNTRmMzA5ZjgwZTE2M2Y0MWY1YWE3L3RhYmxlcmFuZ2U6ZTJiNDkxYjM2OGM1NGYzMDlmODBlMTYzZjQxZjVhYTdfMy0xLTEtMS0w_9d987973-82e3-47f6-8d5f-957a357d9f28">0.155</ix:nonFraction>&#160;%</span></td></tr></table></ix:continuation></div></ix:continuation><div id="ie97965356b784378b02d7326d25aa562_52"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RleHRyZWdpb246ZWQwOGY1Nzg0YTQ1NDE3N2E1ZTBkN2IxOTVhODJiNGNfMjc0ODc3OTA3NjUxNw_576f4a25-88ed-4d46-a478-66a633ca4fa9" continuedAt="i88da8d4fe09a494e80e39bf310642fc6" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i88da8d4fe09a494e80e39bf310642fc6" continuedAt="i621eb5a96177433c90a289ff63a9a0b1"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RleHRyZWdpb246ZWQwOGY1Nzg0YTQ1NDE3N2E1ZTBkN2IxOTVhODJiNGNfMjc0ODc3OTA3NjUxOA_d979b873-039c-4847-9a83-75e5bf23d03a" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded  stock-based compensation related to stock options issued under the Company&#8217;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2021 and 2020  :</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c7675abef34248a1f00e6bcf04c49d_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMi0xLTEtMS0w_19190420-b99e-4c34-a074-314e63ba6dd6">18</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ce2baeed89423c922e27b6c8e36bba_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMi0zLTEtMS0w_d3169c87-485c-4d0b-9e0e-f80d0f103d62">18</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if64b7ec5ca7045d089a7f58dd9d61741_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMi01LTEtMS0w_7e6bf543-5f70-4b93-a2a7-5b655745af61">39</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887713052e054612a1e185929791f55d_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMi03LTEtMS0w_cf3660a6-6f15-47d6-afb6-fcdcec78f20b">53</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04385040180f467690e4c12dc8d54a53_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMy0xLTEtMS0w_461c21e7-1421-4b2b-a348-70e7530aa77d">120</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2622def42a4874aedf69d387f68fb9_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMy0zLTEtMS0w_ecd28484-ba4f-4c8b-862c-93446a8ac889">10</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06e1e9850961407ca3e9d3986c0b7169_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMy01LTEtMS0w_8ae90f41-a7f0-4dcc-8677-644e86d04ec2">267</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0864fed0eeb54c0887a8eeeaa3029b17_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMy03LTEtMS0w_b372b4f0-56ba-43f5-ac47-1d46387e7e20">10</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfNC0xLTEtMS0w_c004031d-96f4-445c-a8a9-c1f67ab68e20">138</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfNC0zLTEtMS0w_ec025c48-4e27-4abf-ba74-b4ea0983c7c9">28</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfNC01LTEtMS0w_91e621ca-25b0-41d5-98a2-55deeef588ea">306</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfNC03LTEtMS0w_066b9437-6fb8-4309-9928-4ea67d8a5734">63</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Plan, under which the Company may issue stock options, restricted stock and other equity-based awards. The Company has also granted certain stock options outside of the 2018  Plan. Stock options granted by the Company generally have a contractual life of up to <ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RleHRyZWdpb246ZWQwOGY1Nzg0YTQ1NDE3N2E1ZTBkN2IxOTVhODJiNGNfMjc0ODc3OTA3NjUyMg_4e63db4f-8ec6-46c6-8758-07310cf63775">10</ix:nonNumeric> years. As of June&#160;30, 2021, all equity awards granted from the 2018 Plan were in the form of stock options.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period or for certain performance-based awards. The Company records the expense for these awards if it concludes that it is probable that the performance condition will be achieved.</span></div><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RleHRyZWdpb246ZWQwOGY1Nzg0YTQ1NDE3N2E1ZTBkN2IxOTVhODJiNGNfMjc0ODc3OTA3NjUxOQ_1ca51233-ac01-4f81-8002-40022739650d" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfMS0xLTEtMS05Mzg_2fa35e0b-7212-4bc4-865d-f6a34f939ecd">266,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic895252214e44777813c5b78a8d4444f_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfMS0zLTEtMS05Mzg_e0abd091-f521-446c-847e-307ff56fc11d">2.94</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic5f07cccdbc84951b24e82c3340132e0_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfMS01LTEtMS05Mzg_9d12457b-e80d-46d5-aa68-8f5f28f07b99">8.22</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfMi0xLTEtMS05Mzg_fa6c53a0-55fb-4779-aff7-b8466b2aa7ee">397,240</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfMi0zLTEtMS05Mzg_0f5f2a71-f9cf-4654-a966-3a50eee2534b">3.87</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 4pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfNS0xLTEtMS05Mzg_001add63-4329-402d-b22e-829380551b5d">663,490</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfNS0zLTEtMS05Mzg_d1c43f9b-93b2-4470-bae1-ae99c8e10d3e">3.50</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfNS01LTEtMS05Mzg_5981d394-7190-43ae-a811-3cd6e55cfe23">9.07</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfNi0xLTEtMS05Mzg_4e1a7f8e-e2dd-4950-9ecd-bc7545a43a7b">206,380</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfNi0zLTEtMS05Mzg_e4a50a1b-97de-4264-8f68-f66507f2a1d2">2.83</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfNi01LTEtMS05Mzg_ec143d34-962f-4036-8213-4d385effe660">8.00</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="i621eb5a96177433c90a289ff63a9a0b1" continuedAt="i3fb512441bd64cb1a66bf749c350c18f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RleHRyZWdpb246ZWQwOGY1Nzg0YTQ1NDE3N2E1ZTBkN2IxOTVhODJiNGNfMjc0ODc3OTA3NjUyMA_54c095fd-e58b-42b0-893f-3c80ff3f35d3" continuedAt="iee75c59150a74d689b28dd5ce3290ea2" escape="true">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</ix:nonNumeric></span></div><div style="margin-top:8pt"><ix:continuation id="iee75c59150a74d689b28dd5ce3290ea2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfMi0xLTEtMS0w_3480b097-3e94-4440-b2e2-efe93e4d12b2">83.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfMi0zLTEtMS0w_c53e8226-714b-4c4a-807b-9bdac4c77bd8">85.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfMy0xLTEtMS0w_d6b97558-58ae-4cd6-9c32-ed9a96d6167c">5.90</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfMy0zLTEtMS0w_aa5f345a-9bfd-4514-be3f-36981ab4a2d4">5.80</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfNC0xLTEtMS0w_cd24c0c8-20c6-43fa-a8e2-a095f6ba8c21">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfNC0zLTEtMS0w_67acba45-ffe5-4013-b19d-ea68210bb7fa">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfNS0xLTEtMS0w_b457586a-6662-458e-acda-d071d1fad103">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfNS0zLTEtMS0w_c57b16ac-dca7-4d56-9eaa-4936f33c2f84">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfNi0xLTEtMS0w_5d0a4ea2-2712-403e-8655-c9318991acdd">3.87</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa79d0de6ea5497ebb25e7f4d8686d52_I20200630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfNi0zLTEtMS0w_c66c2ef6-3a76-4c1e-90cf-cc7e25965053">3.28</ix:nonFraction></span></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3fb512441bd64cb1a66bf749c350c18f">At June&#160;30, 2021, the unrecognized compensation cost related to unvested stock options expected to vest was $<ix:nonFraction unitRef="usd" contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RleHRyZWdpb246ZWQwOGY1Nzg0YTQ1NDE3N2E1ZTBkN2IxOTVhODJiNGNfMTQ5OA_cf7cf057-5f4d-42e9-89ae-7d3e994d837e">1,046</ix:nonFraction>. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of <ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RleHRyZWdpb246ZWQwOGY1Nzg0YTQ1NDE3N2E1ZTBkN2IxOTVhODJiNGNfMTY5MQ_2233bc7d-9706-4bea-bbe8-59d8e9d72784">2.94</ix:nonNumeric> years.</ix:continuation> </span></div><div id="ie97965356b784378b02d7326d25aa562_55"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81NS9mcmFnOjQ5YTg5OWRjZDQ1ZDQyODQ4YmM0NTkyOGUzNzk2ODk2L3RleHRyZWdpb246NDlhODk5ZGNkNDVkNDI4NDhiYzQ1OTI4ZTM3OTY4OTZfMjc0ODc3OTA3MDkyMA_553ee718-3144-42dd-a995-4a050bfbf342" continuedAt="i0746d186f6b14bd0a50ad297cfc52886" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><ix:continuation id="i0746d186f6b14bd0a50ad297cfc52886"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into a license agreement with Medice which grants Medice an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR throughout Europe. Medice is responsible for obtaining regulatory approval of ADAIR in the licensed territory. Under the license agreement, Medice paid Vallon a $<ix:nonFraction unitRef="usd" contextRef="i8af83bde4e7d4b5986d02a1be122c2df_D20200101-20200131" decimals="-3" name="ck0001824293:RelatedPartyTransactionLicenseAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81NS9mcmFnOjQ5YTg5OWRjZDQ1ZDQyODQ4YmM0NTkyOGUzNzk2ODk2L3RleHRyZWdpb246NDlhODk5ZGNkNDVkNDI4NDhiYzQ1OTI4ZTM3OTY4OTZfMzkx_028fe0b2-7635-403e-bc75-9dc0348c27be">100</ix:nonFraction> upfront payment and is required to pay milestone payments upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds. Medice will also pay tiered royalties on annual net sales of ADAIR at rates in the low double-digits. The initial term of the license agreement will expire <ix:nonNumeric contextRef="i8af83bde4e7d4b5986d02a1be122c2df_D20200101-20200131" format="ixt-sec:durwordsen" name="ck0001824293:RelatedPartyTransactionLicenseAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81NS9mcmFnOjQ5YTg5OWRjZDQ1ZDQyODQ4YmM0NTkyOGUzNzk2ODk2L3RleHRyZWdpb246NDlhODk5ZGNkNDVkNDI4NDhiYzQ1OTI4ZTM3OTY4OTZfNTQ5NzU1ODE0MDM2MQ_8e00b22b-7a28-4b3e-b3cd-749cb24a0f8e">five years</ix:nonNumeric> after the date on which Medice first obtains regulatory approval in any country, territory or region in the licensed territory.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i3d756267a38641f49152d284b506e41c_D20210101-20210131" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81NS9mcmFnOjQ5YTg5OWRjZDQ1ZDQyODQ4YmM0NTkyOGUzNzk2ODk2L3RleHRyZWdpb246NDlhODk5ZGNkNDVkNDI4NDhiYzQ1OTI4ZTM3OTY4OTZfMTIzNg_39488e22-8a4f-4b7d-af5f-bbab03c3b882">350</ix:nonFraction>. The 2021 Convertible Notes bore an interest rate of <ix:nonFraction unitRef="number" contextRef="i78d2a9fcaf4742528def995407f4d94d_I20210131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81NS9mcmFnOjQ5YTg5OWRjZDQ1ZDQyODQ4YmM0NTkyOGUzNzk2ODk2L3RleHRyZWdpb246NDlhODk5ZGNkNDVkNDI4NDhiYzQ1OTI4ZTM3OTY4OTZfMTI5MA_6d9d7da9-a2f3-4c76-8f76-a853910032b8">7.0</ix:nonFraction>% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into <ix:nonFraction unitRef="shares" contextRef="i3d756267a38641f49152d284b506e41c_D20210101-20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81NS9mcmFnOjQ5YTg5OWRjZDQ1ZDQyODQ4YmM0NTkyOGUzNzk2ODk2L3RleHRyZWdpb246NDlhODk5ZGNkNDVkNDI4NDhiYzQ1OTI4ZTM3OTY4OTZfMTQwOA_b0c8b917-628f-4d77-9185-b166b2f1ee82">54,906</ix:nonFraction> shares of the Company&#8217;s common stock upon completion of the IPO.</span></div></ix:continuation><div id="ie97965356b784378b02d7326d25aa562_61"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82MS9mcmFnOjU1NzUxNWQ5NGZkYTRkOTRiNzZkOTYzMThmOTE2ODliL3RleHRyZWdpb246NTU3NTE1ZDk0ZmRhNGQ5NGI3NmQ5NjMxOGY5MTY4OWJfMjc0ODc3OTA4MDYyNw_52488f6a-d2e9-4472-841d-f536684c7b50" continuedAt="i20d4584f9d4d4c44bea6ab441cac1c44" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i20d4584f9d4d4c44bea6ab441cac1c44"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Impact</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to the Company&#8217;s operations and business plan. The Company has closely monitored recent COVID-19 developments, including states&#8217; lifting COVID-19 safety measures, drop in vaccination rates, and spread of various coronavirus strains such as the Delta variant. In light of these developments, the full impact of the COVID-19 pandemic on the Company&#8217;s business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#8217;s future impact on its clinical trial enrollment, clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with most of its employees and consultants working remotely. The Company will continue to actively monitor the COVID-19 outbreak and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that the Company determines are in the best interests of its employees and other third parties with whom the Company does business.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_64"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RleHRyZWdpb246ODQ4M2FmMjM1MzQ5NDQ5ZmE4NTYxMzIyZTI4NDIzZjlfMjc0ODc3OTA2OTk1MA_98ddc618-8ab9-4871-937b-7532a8ae1feb" continuedAt="i07e660db7dc2495ea9b18adac4b29d9b" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i07e660db7dc2495ea9b18adac4b29d9b"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative liability identified in the 2021 Convertible Notes was a Level 3 fair value measurement. As of February&#160;12, 2021, the embedded derivative was remeasured based upon the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i60901d5d21aa4ec69b330ba52b51042b_I20210212" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RleHRyZWdpb246ODQ4M2FmMjM1MzQ5NDQ5ZmE4NTYxMzIyZTI4NDIzZjlfMjQ2_cd7221f8-0223-4c38-87ae-d2e3380bfd82">8.00</ix:nonFraction> per share upon closing of the IPO. As such, an expense of $<ix:nonFraction unitRef="usd" contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RleHRyZWdpb246ODQ4M2FmMjM1MzQ5NDQ5ZmE4NTYxMzIyZTI4NDIzZjlfMzA3_28f8b81a-c940-434b-ba08-b51ac62a97a0">89</ix:nonFraction> was recorded during the six months ended June&#160;30, 2021.</span></div><ix:nonNumeric contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RleHRyZWdpb246ODQ4M2FmMjM1MzQ5NDQ5ZmE4NTYxMzIyZTI4NDIzZjlfMjc0ODc3OTA2OTk1MQ_06459136-8cb3-4d43-93fd-9d4ae8418fa6" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the six months ended June&#160;30, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance as of January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47a4058978b54caa86791e0df0e0a693_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RhYmxlOmFiZjgyOTFmYThlMjRhNThiZWIxZWNmODZlMTMwNWYwL3RhYmxlcmFuZ2U6YWJmODI5MWZhOGUyNGE1OGJlYjFlY2Y4NmUxMzA1ZjBfMC0xLTEtMS0w_3f2ccef2-63fe-4e31-a4f2-0b27dc8e36f4">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions during the six months ended June 30, 2021</span></td><td colspan="3" style="padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie57e0b7edd14462ebede9f2bd8aad12c_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RhYmxlOmFiZjgyOTFmYThlMjRhNThiZWIxZWNmODZlMTMwNWYwL3RhYmxlcmFuZ2U6YWJmODI5MWZhOGUyNGE1OGJlYjFlY2Y4NmUxMzA1ZjBfMS0xLTEtMS0w_bc9e4b6d-060f-4a2e-8b17-d0ab32d9cf70">89</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer out of Level 3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie57e0b7edd14462ebede9f2bd8aad12c_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RhYmxlOmFiZjgyOTFmYThlMjRhNThiZWIxZWNmODZlMTMwNWYwL3RhYmxlcmFuZ2U6YWJmODI5MWZhOGUyNGE1OGJlYjFlY2Y4NmUxMzA1ZjBfMi0xLTEtMS0w_938ddad2-94ab-4b8c-bebe-04a2bf0864bf">89</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2021</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c968c9ac274451f8c6acd6b1628a443_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RhYmxlOmFiZjgyOTFmYThlMjRhNThiZWIxZWNmODZlMTMwNWYwL3RhYmxlcmFuZ2U6YWJmODI5MWZhOGUyNGE1OGJlYjFlY2Y4NmUxMzA1ZjBfMy0xLTEtMS0w_3521392b-578d-4d15-b7d8-ff3dd5f5f16a">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_67"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Quarterly Report, and the audited financial statements (and notes thereto), and management&#8217;s discussion and analysis of financial condition and results of operations for the year ended December 31, 2020, included in our Annual Report on Form 10-K that was filed with the SEC on March 29, 2021. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Quarterly Report, our actual results could differ materially from the results described in, or implied by, these forward-looking statements.</span></div><div id="ie97965356b784378b02d7326d25aa562_70"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel medications for CNS disorders with a focus on abuse-deterrent medications. Our lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#174;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. According to the US Department of Health and Human Services&#8217; 2018 National Survey on Drug Use and Health, over 5 million adolescents and adults misuse prescription stimulant medications on an annual basis. The misuse and abuse of prescription stimulants has substantial medical risk, including risk of irregular heartbeat, heart attack, seizures, hallucinations, hostile behavior and stroke, as well as increased risk of addiction. ADAIR is designed to deter attempts to crush and snort and to provide barriers to injection while still providing the expected therapeutic benefit when taken orally.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are developing ADAIR for registration with the U.S. Food and Drug Administration through the&#160;Section 505(b)(2) regulatory pathway, which is expected to obviate the need for large Phase 2 and Phase 3 efficacy and safety studies. In July 2018, our Investigational New Drug (IND) application for ADAIR was approved by the FDA. We have completed three Phase 1 trials of ADAIR including a proof-of-concept intranasal human abuse potential study. We recently completed a 13-week preclinical toxicology study on the final formulation of ADAIR that showed no safety findings of concern. We are currently conducting a pivotal intranasal abuse study which we expect to complete by the end of 2021.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we entered into a license agreement with Medice, which grants Medice an exclusive license to develop, use, manufacture, market and sell ADAIR throughout Europe. Under the license agreement, Medice paid us a $0.1 million upfront payment and will pay milestone payments of up to $6.3&#160;million in aggregate upon achieving certain regulatory and sales milestones. We are also entitled to low-double digit tiered royalties on net sales of ADAIR. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to ADAIR, we have begun formulation development work on our second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin&#174;), for the treatment of ADHD. We also plan to utilize the Section 505(b)(2) regulatory pathway for registration of ADMIR . </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we plan to use our abuse deterrent platform technology to develop other products that have potential for abuse in their current forms and will continue business development activities and seek partnering, licensing, merger and acquisition opportunities or other transactions to further develop our pipeline and drug-development capabilities.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to our operations and business plan. We have closely monitored recent COVID-19 developments, including states&#8217; lifting COVID-19 safety measures, drop in vaccination rates, and spread of various coronavirus strains such as the Delta variant. In light of these developments, the full impact of the COVID-19 pandemic on our business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#8217;s future impact on our clinical trial enrollment, clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, we are conducting business as usual, with necessary or advisable modifications to employee travel and with most of our employees and consultants working remotely. We will continue to actively monitor the COVID-19 outbreak and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_82"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Revenues - Related Party</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from the sale of any products, and we do not expect to generate significant revenues unless or until we obtain regulatory approval of and commercialize ADAIR. Substantially all of our revenue to date has been generated by the Medice license agreement from which we received a $0.1 million license fee during the six months ended June&#160;30, 2020. We do not expect to generate any additional revenue from the Medice license agreement in the near future. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses have consisted primarily of in-process research and development expenses, costs incurred in preparing for and conducting the development program for ADAIR, working on commercial manufacturing of ADAIR and developing formulations for ADMIR. Research and development costs are expensed as incurred. These expenses include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">employee -related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, stock-based compensation, overhead related expenses and travel related expenses for our research and development personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">expenses incurred under agreements with contract research organizations (CROs), as well as consultants that support the implementation of our clinical and non-clinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">manufacturing and packaging costs in connection with conducting clinical trials and for stability and other studies required to support the NDA filing as well as manufacturing drug product for commercial launch;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">formulation, research and development expenses related to ADMIR; and other products we may choose to develop; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">costs for sponsored research.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically use our employee, consultant and infrastructure resources across our research and development programs. Although we track certain outsourced development costs by product candidate, we do not allocate personnel costs or other internal costs to specific product candidates.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to incur research and development expenses for the foreseeable future as we expect to continue the development of ADAIR and our other product candidates. At this time, due to the inherently unpredictable nature of preclinical and clinical development and the early stage of our other product candidates, we are unable to estimate with any certainty the costs we will incur and the timelines we will require in our continued development efforts.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation and consulting related expenses for executives and other administrative personnel, professional fees and other corporate expenses, including legal and accounting fees, travel expenses, facilities-related expenses, and consulting services relating to our formation and corporate matters.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future as we support our continued research and development activities and operate as a public company. These increases will likely include increased costs related to the hiring of personnel, including compensation and employee-related expenses, including stock-based compensation, and fees to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors and officers insurance, increased legal and accounting costs and investor relations costs. In addition, if ADAIR obtains regulatory approval for marketing, we expect that we would incur expenses associated with building a </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization team if we have not sold or licensed the rights to commercialize ADAIR to a third party in territories not under the license agreement with Medice.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income consists of income recognized as a result of the extinguishment of the promissory note issued to us under the Paycheck Protection Program (PPP) as a result of the forgiveness of the note. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revaluation of Derivative Instruments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a Convertible Promissory Note Purchase Agreement pursuant to which we issued $350,000 in convertible promissory notes (the 2021 Convertible Notes). The 2021 Convertible Notes automatically converted into 54,906 shares of our common stock concurrently with the closing of the IPO. We identified the mandatory conversion into shares our common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. We evaluated the fair value of the derivative liability at issuance. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest (Income) Expense, net</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest (income) expense consists of interest earned on our cash and cash equivalents held with institutional banks and interest expense is primarily related to our finance lease of equipment utilized in the commercial scale manufacturing of ADAIR.</span></div><div id="ie97965356b784378b02d7326d25aa562_85"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June&#160;30, 2021 and 2020 </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue-from related party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,310)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,312)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,147)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $1.2 million and $0.8 million for the three months ended June&#160;30, 2021 and 2020, respectively. The $0.4 million increase in research and development expenses was primarily due to an increase of $0.5 million in expenses related to the registration development program of ADAIR offset by a decrease of&#160;$0.1 million in expenses related to the formulation work for ADMIR. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $1.1 million and $0.3 million for the three months ended June&#160;30, 2021 and 2020, respectively. The $0.8 million increase was primarily related to increased costs for directors and officers insurance of $0.4 million, personnel expenses, including stock compensation, of $0.2 million, and public company expenses of $0.2 million.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net was $2,000 and $12,000 for the three months ended June&#160;30, 2021 and 2020, respectively.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six Months Ended June&#160;30, 2021 and 2020</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue-from related party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,694</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,912</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,395</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,912)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,295)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,950)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,308)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenue &#8211; From Related Party</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing revenues were $0.1 million for the six months ended June&#160;30, 2020 as a result of the upfront payment received under the terms of the Medice license agreement. No licensing revenues were recognized during the six months ended June&#160;30, 2021.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $3.0 million and $1.7 million for the six months ended June&#160;30, 2021 and 2020, respectively. The $1.3 million increase in research and development expenses was primarily due to increases of $1.4 million in expenses related to the registration development program of ADAIR offset by a decrease of&#160;$0.1 million in expenses related to the formulation work for ADMIR. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $1.9 million and $0.7 million for the six months ended June&#160;30, 2021 and 2020, respectively. The $1.2 million increase was primarily related to increased costs for directors and officers insurance of $0.6 million, personnel expense, including non-cash stock compensation, of $0.4 million, and public company expenses of $0.2 million.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company issued a promissory note under the PPP totaling $61,000. As of December 31, 2020, the Company had utilized the entire proceeds from such note for payroll costs (greater than 75%), costs related to health care benefits and rent payments and in January 2021, the Company was notified that the note along with accumulated interest had been forgiven. As the PPP note was forgiven, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revaluation of Derivative Liability</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, pursuant to ASC-815, we revalued the embedded derivative liability associated with the 2021 Convertible Notes, resulting in $89,000 in the fair value of the derivative liability associated with the 2021 Convertible Notes.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net was $10,000 and $13,000 for the six months ended June&#160;30, 2021 and 2020, respectively.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_88"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred losses and expect to continue to incur losses for the foreseeable future. We incurred net losses of $4.9 million and $2.3 million for the six months ended June&#160;30, 2021 and 2020, respectively. As of June&#160;30, 2021, we had an accumulated deficit of $17.5 million.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a PPP promissory note. As of June&#160;30, 2021, we had $10.5 million in cash and cash equivalents. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,834)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,791</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,351&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,822)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2021 and 2020, $5.4 million and $1.8 million were used in operating activities, respectively. The $3.6 million increase was primarily due to a $2.6 million increase in our net loss as well as increases in prepaid expenses, accounts payable and accrued expenses of $1.3 million, offset by $0.2 million increase in non-cash stock compensation expense. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $2,000 for the six months ended June&#160;30, 2020, which was related to the purchase of computer equipment.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $14,000 during the six-month period ended June&#160;30, 2020, which was related to proceeds received from a PPP note of $61,000 offset by payments related to our finance lease of $47,000. Net cash provided by financing activities was $15.8 million for the six months ended June&#160;30, 2021 and was primarily related to the net proceeds from our IPO and 2021 Convertible Notes financings.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Convertible Note Financing</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including SALMON Pharma GmbH (Salmon Pharma), an affiliate of Medice, and David Baker, our Chief Executive Officer, pursuant to which we issued convertible promissory notes (the 2021 Convertible Notes) for cash proceeds of $350,000. The 2021 Convertible Notes bear an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes were convertible into shares of our capital stock offered to investors in any subsequent equity financing after the date of their issuance in which we issued any of our equity securities (a Qualified Financing) and were convertible at a twenty percent discount to the price per share offered in such Qualified Financing. Such Qualified Financing included the initial public offering of our common stock, consummated on February 12, 2021; therefore, the 2021 Convertible Notes converted into an aggregate of 54,906 shares of our common stock immediately prior to the closing of the IPO, as agreed upon among the parties thereto.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is difficult to predict future liquidity requirements, we expect that our existing cash and cash equivalents will provide funding for our ongoing business activities into the third quarter of 2022; however, we have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect therefore there is substantial doubt about our ability to continue as a going concern. We expect to continue to incur significant and increasing operating losses at least for the </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreseeable future. We do not expect to generate product revenue unless and until we successfully complete development, obtain regulatory approval for, and successfully commercialize ADAIR, or any other future products, including ADMIR. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of planned clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will increase substantially as we:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">conduct clinical trials and non-clinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">scale up manufacturing capabilities with third-party contract manufacturer(s);</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">conduct ongoing stability studies of ADAIR;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">seek to identify, acquire, develop and commercialize additional products, such as ADMIR;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">integrate acquired technologies into a comprehensive regulatory and product development strategy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">hire scientific, clinical, quality control and administrative personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">add operational, financial and management information systems and personnel, including personnel to support our drug development efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">seek regulatory approvals for any products that successfully complete clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any drug candidates for which we may obtain regulatory approval, including through the license agreement with Medice; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">operate as a public company.</span></div><div id="ie97965356b784378b02d7326d25aa562_91"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div id="ie97965356b784378b02d7326d25aa562_94"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s critical accounting policies are described in Note B, &#8220;Summary of Significant Accounting Policies,&#8221; in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 29, 2021. There have been no material changes to the significant accounting policies during the six months ended June 30, 2021, except for items mentioned in Note 3 of the unaudited interim financial statements in this Quarterly Report on Form 10-Q.</span></div><div id="ie97965356b784378b02d7326d25aa562_97"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reduced disclosure about our executive compensation arrangements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">no non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken advantage of reduced reporting requirements in this report and may continue to do so until such time that we are no longer an emerging growth company. We will remain an &#8220;emerging growth company&#8221; until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more, (b) December 31, 2026, the last day of the fiscal year </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following the fifth anniversary of the completion of the our IPO, (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></div><div id="ie97965356b784378b02d7326d25aa562_100"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable to a smaller reporting company.</span></div><div id="ie97965356b784378b02d7326d25aa562_103"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) or 15d-15(e)) as of June&#160;30, 2021. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the evaluation of our disclosure controls and procedures as of June&#160;30, 2021, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures, as defined above, are effective.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are taking actions to remediate the material weaknesses relating to our internal controls over financial reporting as described in our Annual Report on Form 10-K. Except as otherwise disclosed herein, there have been no changes in our internal control over financial reporting during the three months ended June&#160;30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_106"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="ie97965356b784378b02d7326d25aa562_109"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Regardless of the outcome, litigation can have a material adverse effect on us because of defense and settlement costs, diversion of management resources, and other factors.</span></div><div id="ie97965356b784378b02d7326d25aa562_112"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, except as set forth below.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health crises such as pandemics or similar outbreaks could materially and adversely affect our preclinical and clinical trials, business, financial condition and results of operations.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2020, the World Health Organization declared COVID-19 a global pandemic and the United States declared a national emergency with respect to COVID-19. The COVID-19 pandemic continues affect the U.S. and global economies and may affect our operations and certain other third parties on which we rely, including by causing disruptions in the supply of our product candidates and the conduct of future clinical trials. Moreover, the COVID-19 pandemic may adversely affect the operations of the FDA and other health authorities, resulting in delays of reviews and approvals with respect to our product candidates. While the potential economic impact brought by, and the duration of the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. In addition, the loss of any of our employees as a result of COVID-19, or another pandemic, may adversely affect our operations. The ultimate impact of the COVID-19 pandemic is highly uncertain, and we do not yet know the full extent of potential delays or impacts that COVID-19 may have on our business, financing or clinical trial activities.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some examples of potential disruptions that may result from the COVID-19 pandemic, include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in enrolling patients in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state or local governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical study endpoints;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff and unforeseen circumstances at CROs and vendors, including any delays caused by the COVID-19 outbreak;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on employee or other resources that would otherwise be focused on the conduct of our clinical trials and pre-clinical work, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures or mass transit disruptions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 global pandemic remains a public health threat and its ultimate impact on our business and the global economy is uncertain. The extent to which the outbreak may affect our clinical trials, business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions, actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States, and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, and the ongoing worldwide vaccine rollout. Future developments in these and other areas present material uncertainty and risk with respect to our clinical trials, business, financial condition and results of operations.</span></div><div id="ie97965356b784378b02d7326d25aa562_115"></div><div style="margin-top:12pt"><span><br/></span></div><div id="ie97965356b784378b02d7326d25aa562_118"></div><div style="margin-top:12pt"><span><br/></span></div><div id="ie97965356b784378b02d7326d25aa562_121"></div><div style="margin-top:12pt"><span><br/></span></div><div id="ie97965356b784378b02d7326d25aa562_124"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_127"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex3-1.htm">Amended and Restated Certificate of Incorporation of Vallon Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on February 16, 2021).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex3-3.htm">Amended and Restated Bylaws of Vallon Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.3 to the Current Report on form 8-K, filed with the SEC on February 16, 2021).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex3-2.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Vallon Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K, filed with the SEC on February 16, 2021).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex311_ceo302cert.htm">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex312_cfo302cert.htm">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex321_ceosection906cert.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex322_cfosection906cert.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Instance Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, exhibits are filed herewith.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.34pt">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent specifically incorporated by reference into such filing.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ie97965356b784378b02d7326d25aa562_130"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie97965356b784378b02d7326d25aa562_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VALLON PHARMACEUTICALS, INC.</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 10, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title: Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex311_ceo302cert.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie4adc843e84a49dbb93c0e0d17312de8_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, David Baker, certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q of Vallon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"></td><td style="width:31.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;10, 2021</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; David Baker</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">David Baker</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex312_cfo302cert.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3b24e3caf36949d286c846c9dee5af6c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly, certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q of Vallon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:24.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;10, 2021</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex321_ceosection906cert.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i165cc3190f0c48988148cda59d141d61_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, David Baker, President and Chief Executive Officer of Vallon Pharmaceuticals, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2021 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;10, 2021</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; David Baker</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">David Baker</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex322_cfosection906cert.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0c5ca590b5174e5c9389128ed0156ab7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly,  Chief Financial Officer of Vallon Pharmaceuticals, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2021 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;10, 2021</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ck0001824293-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:545a0cb1-db3f-4c1d-8b23-fea1d98a8647,g:1675d0ed-3cfa-4512-b65d-428038bee998-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ck0001824293="http://www.vallon-pharma.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vallon-pharma.com/20210630">
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.vallon-pharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.vallon-pharma.com/role/BalanceSheets">
        <link:definition>1001002 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.vallon-pharma.com/role/BalanceSheetsParenthetical">
        <link:definition>1402401 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofOperations" roleURI="http://www.vallon-pharma.com/role/StatementsofOperations">
        <link:definition>1003003 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofChangesinStockholdersEquityDeficit" roleURI="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit">
        <link:definition>1004004 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlows" roleURI="http://www.vallon-pharma.com/role/StatementsofCashFlows">
        <link:definition>1005005 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESS" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS">
        <link:definition>2101101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails">
        <link:definition>2402402 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITY" roleURI="http://www.vallon-pharma.com/role/LIQUIDITY">
        <link:definition>2103102 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITYDetails" roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails">
        <link:definition>2404403 - Disclosure - LIQUIDITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2105103 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2206201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>2407404 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES">
        <link:definition>2108104 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables">
        <link:definition>2309301 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESDetails" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails">
        <link:definition>2410405 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PPPNOTEANDCONVERTIBLENOTES" roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES">
        <link:definition>2111105 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PPPNOTEANDCONVERTIBLENOTESDetails" roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails">
        <link:definition>2412406 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT">
        <link:definition>2113106 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITTables" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables">
        <link:definition>2314302 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails">
        <link:definition>2415407 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails">
        <link:definition>2416408 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2117107 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2318303 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>2419409 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2420410 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails">
        <link:definition>2421411 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails">
        <link:definition>2422412 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2123108 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>2424413 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2125109 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2126110 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2327304 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails">
        <link:definition>2428414 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails">
        <link:definition>2429415 - Disclosure - FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" abstract="false" name="AccruedGeneralAndAdministrativeExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtInstrumentPaymentTerm" abstract="false" name="DebtInstrumentPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment" abstract="false" name="RelatedPartyTransactionLicenseAgreementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ForgivenessOfDebtInstrument" abstract="false" name="ForgivenessOfDebtInstrument" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" abstract="true" name="ConvertiblePromissoryNotePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" abstract="false" name="RelatedPartyTransactionLicenseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" abstract="false" name="ProceedsFromIssuanceInitialPublicOfferingGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AccruedLicensingFeesCurrent" abstract="false" name="AccruedLicensingFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" abstract="true" name="AffiliateOfMediceAndDavidBakerCEOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsOfferingExpenses" abstract="false" name="StockIssuanceCostsOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsDiscountsAndCommissions" abstract="false" name="StockIssuanceCostsDiscountsAndCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_MediceMember" abstract="true" name="MediceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_PaycheckProtectionProgramCARESActMember" abstract="true" name="PaycheckProtectionProgramCARESActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ck0001824293-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:545a0cb1-db3f-4c1d-8b23-fea1d98a8647,g:1675d0ed-3cfa-4512-b65d-428038bee998-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_794c3070-8251-45aa-8225-1bcfe74d0e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8afda5c1-454c-4771-a599-1055ecc91e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_794c3070-8251-45aa-8225-1bcfe74d0e36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8afda5c1-454c-4771-a599-1055ecc91e6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_799eac9c-2899-47ea-9501-d5b88a3d3000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_794c3070-8251-45aa-8225-1bcfe74d0e36" xlink:to="loc_us-gaap_AssetsCurrent_799eac9c-2899-47ea-9501-d5b88a3d3000" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b31c964f-dcdf-4f7f-a449-a2251a1a30d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_794c3070-8251-45aa-8225-1bcfe74d0e36" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b31c964f-dcdf-4f7f-a449-a2251a1a30d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_67789241-af24-4c27-89af-f3d4e4ca992f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dcfc0764-9b94-4ad7-8a30-92de518457b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67789241-af24-4c27-89af-f3d4e4ca992f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dcfc0764-9b94-4ad7-8a30-92de518457b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_be0459e4-b6b5-4338-a9fa-7a6ceef3143c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67789241-af24-4c27-89af-f3d4e4ca992f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_be0459e4-b6b5-4338-a9fa-7a6ceef3143c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5b3a1222-fcff-45f0-a80b-b21218b2dc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2f1daa1b-2465-418f-a721-3a5dd0d100e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5b3a1222-fcff-45f0-a80b-b21218b2dc4c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2f1daa1b-2465-418f-a721-3a5dd0d100e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c77a791c-dccb-4aa4-aa85-f53c13e4568c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5b3a1222-fcff-45f0-a80b-b21218b2dc4c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c77a791c-dccb-4aa4-aa85-f53c13e4568c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0bb11410-3140-4d71-9ffc-c79a36097b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5b3a1222-fcff-45f0-a80b-b21218b2dc4c" xlink:to="loc_us-gaap_AccountsPayableCurrent_0bb11410-3140-4d71-9ffc-c79a36097b4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_85c89b1e-6bd0-4e83-ad16-133774ca0e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5b3a1222-fcff-45f0-a80b-b21218b2dc4c" xlink:to="loc_us-gaap_NotesPayableCurrent_85c89b1e-6bd0-4e83-ad16-133774ca0e66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_98d68c77-999b-42fc-b24b-a213c3365e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8b0020f5-4346-4710-9ea0-c66559cbea6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_98d68c77-999b-42fc-b24b-a213c3365e3f" xlink:to="loc_us-gaap_Liabilities_8b0020f5-4346-4710-9ea0-c66559cbea6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_06875715-1828-48ea-b77e-f88b76bcc976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_98d68c77-999b-42fc-b24b-a213c3365e3f" xlink:to="loc_us-gaap_StockholdersEquity_06875715-1828-48ea-b77e-f88b76bcc976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bc7aef50-4a76-4632-ad1b-9a5f35f075e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_98d68c77-999b-42fc-b24b-a213c3365e3f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bc7aef50-4a76-4632-ad1b-9a5f35f075e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0d26571a-4e3c-4cb7-85c8-e5ba9ae8873a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_303b637c-141a-4788-87ba-cd71ab36f88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0d26571a-4e3c-4cb7-85c8-e5ba9ae8873a" xlink:to="loc_us-gaap_LongTermNotesPayable_303b637c-141a-4788-87ba-cd71ab36f88a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f9ec4a28-6193-448c-8047-8008f5a82530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0d26571a-4e3c-4cb7-85c8-e5ba9ae8873a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f9ec4a28-6193-448c-8047-8008f5a82530" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_aeaf4f60-971a-4832-b509-b5873caa6c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0d26571a-4e3c-4cb7-85c8-e5ba9ae8873a" xlink:to="loc_us-gaap_LiabilitiesCurrent_aeaf4f60-971a-4832-b509-b5873caa6c76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c8849805-c532-41b7-9870-f9534d07d3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_48488673-3d78-4e7e-8dc3-d2ac4833e75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c8849805-c532-41b7-9870-f9534d07d3aa" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_48488673-3d78-4e7e-8dc3-d2ac4833e75c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_c1a2f67a-9556-415b-a892-18bc4de8619b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c8849805-c532-41b7-9870-f9534d07d3aa" xlink:to="loc_us-gaap_CommonStockValueOutstanding_c1a2f67a-9556-415b-a892-18bc4de8619b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d54dfbf1-1641-4aa3-b998-d11f1ac16adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c8849805-c532-41b7-9870-f9534d07d3aa" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d54dfbf1-1641-4aa3-b998-d11f1ac16adf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofOperations" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#StatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_51c8e315-6753-47a9-ba56-703bd613f8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_c3e6d558-f79a-4efa-8989-7dd5baf710b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_51c8e315-6753-47a9-ba56-703bd613f8ec" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_c3e6d558-f79a-4efa-8989-7dd5baf710b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1996af06-5a30-4c1e-b79d-115a5d4d3f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_51c8e315-6753-47a9-ba56-703bd613f8ec" xlink:to="loc_us-gaap_OperatingIncomeLoss_1996af06-5a30-4c1e-b79d-115a5d4d3f8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_e2bc798b-a27b-4e80-8ec4-87a12ef4eb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_51c8e315-6753-47a9-ba56-703bd613f8ec" xlink:to="loc_us-gaap_OtherNonoperatingIncome_e2bc798b-a27b-4e80-8ec4-87a12ef4eb4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_d735b9c9-f8d4-4f27-9148-6da8845195bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_51c8e315-6753-47a9-ba56-703bd613f8ec" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_d735b9c9-f8d4-4f27-9148-6da8845195bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_895dfa3f-e90f-4b26-b253-1c8c0d6d715f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8a4bf8fc-40d2-4e07-8bab-dddac23032e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_895dfa3f-e90f-4b26-b253-1c8c0d6d715f" xlink:to="loc_us-gaap_OperatingExpenses_8a4bf8fc-40d2-4e07-8bab-dddac23032e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e8f239d9-fef9-420d-a329-4f4ebb35bde6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_895dfa3f-e90f-4b26-b253-1c8c0d6d715f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e8f239d9-fef9-420d-a329-4f4ebb35bde6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ca3fe301-a17a-4146-99cf-40e9b4d64547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b5071773-33d1-4946-a764-113c1a7e111b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ca3fe301-a17a-4146-99cf-40e9b4d64547" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b5071773-33d1-4946-a764-113c1a7e111b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3753a49c-90e7-4ded-a11e-b04f1da7ecd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ca3fe301-a17a-4146-99cf-40e9b4d64547" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3753a49c-90e7-4ded-a11e-b04f1da7ecd3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#StatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69a2073b-6e80-47f3-820c-2b9cec28dbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_63719ee8-d3bb-4d8f-b266-7fbfd2a153a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69a2073b-6e80-47f3-820c-2b9cec28dbb4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_63719ee8-d3bb-4d8f-b266-7fbfd2a153a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ca42d198-1f18-4050-b67c-ecbb46d9227f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69a2073b-6e80-47f3-820c-2b9cec28dbb4" xlink:to="loc_us-gaap_NetIncomeLoss_ca42d198-1f18-4050-b67c-ecbb46d9227f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6aa4ebc9-f42e-49cf-9e1e-11e897fe5029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69a2073b-6e80-47f3-820c-2b9cec28dbb4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6aa4ebc9-f42e-49cf-9e1e-11e897fe5029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_b87e7ed7-07f5-4d87-914c-89caf8e56de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69a2073b-6e80-47f3-820c-2b9cec28dbb4" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_b87e7ed7-07f5-4d87-914c-89caf8e56de9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_dbec8423-926e-4812-bb1f-bd2529c12f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69a2073b-6e80-47f3-820c-2b9cec28dbb4" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_dbec8423-926e-4812-bb1f-bd2529c12f60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ac9c4313-6cb5-4edf-8618-22583dd65b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69a2073b-6e80-47f3-820c-2b9cec28dbb4" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ac9c4313-6cb5-4edf-8618-22583dd65b42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument_bfab1c09-436f-42c0-9549-14b037497986" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69a2073b-6e80-47f3-820c-2b9cec28dbb4" xlink:to="loc_ck0001824293_ForgivenessOfDebtInstrument_bfab1c09-436f-42c0-9549-14b037497986" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1d035d73-e614-42f4-af19-2fb784f297e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69a2073b-6e80-47f3-820c-2b9cec28dbb4" xlink:to="loc_us-gaap_ShareBasedCompensation_1d035d73-e614-42f4-af19-2fb784f297e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_43e916ce-8725-4f8a-ac3f-1c54f6b3211d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69a2073b-6e80-47f3-820c-2b9cec28dbb4" xlink:to="loc_us-gaap_OtherNoncashExpense_43e916ce-8725-4f8a-ac3f-1c54f6b3211d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ae515c29-ca68-4fd6-bbb1-566892c162dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6e6d9103-7318-4d46-ae1a-32709ccdcfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ae515c29-ca68-4fd6-bbb1-566892c162dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6e6d9103-7318-4d46-ae1a-32709ccdcfc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cd886924-daad-4387-afb1-e88cba06b32b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ae515c29-ca68-4fd6-bbb1-566892c162dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cd886924-daad-4387-afb1-e88cba06b32b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2b5c183-752c-43ad-84dc-b8e32e1c94d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ae515c29-ca68-4fd6-bbb1-566892c162dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2b5c183-752c-43ad-84dc-b8e32e1c94d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43dd6279-df3e-4f0c-8a7e-f1c5ab7c0cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2a57b51c-43b1-408f-89af-dbbaac54ed44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43dd6279-df3e-4f0c-8a7e-f1c5ab7c0cb2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2a57b51c-43b1-408f-89af-dbbaac54ed44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af962189-c70b-4584-b8ef-58dc35b2f84e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_9881d146-0520-41bc-bf13-8566c80f5098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af962189-c70b-4584-b8ef-58dc35b2f84e" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_9881d146-0520-41bc-bf13-8566c80f5098" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_5526aa70-f6af-49fa-8224-590cffa26912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af962189-c70b-4584-b8ef-58dc35b2f84e" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_5526aa70-f6af-49fa-8224-590cffa26912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_7d423322-4926-4d3e-904c-46a7c66bfcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af962189-c70b-4584-b8ef-58dc35b2f84e" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_7d423322-4926-4d3e-904c-46a7c66bfcb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_55216886-1a97-41b8-813e-53a9dc5903b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af962189-c70b-4584-b8ef-58dc35b2f84e" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_55216886-1a97-41b8-813e-53a9dc5903b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#ACCRUEDEXPENSESDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_83cdbc8d-82c1-482a-b5da-691db4c3f74c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_985c1ac9-b28f-45b8-ba27-1ed22a700e23" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_83cdbc8d-82c1-482a-b5da-691db4c3f74c" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_985c1ac9-b28f-45b8-ba27-1ed22a700e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedLicensingFeesCurrent_714acf9c-27dc-49ce-b477-fe440a2b37e3" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AccruedLicensingFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_83cdbc8d-82c1-482a-b5da-691db4c3f74c" xlink:to="loc_ck0001824293_AccruedLicensingFeesCurrent_714acf9c-27dc-49ce-b477-fe440a2b37e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_49892833-9e07-4ea3-afcb-04948c72afeb" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_83cdbc8d-82c1-482a-b5da-691db4c3f74c" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_49892833-9e07-4ea3-afcb-04948c72afeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5ecf0d33-cc9e-4ef4-baf6-7ede3522242d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_83cdbc8d-82c1-482a-b5da-691db4c3f74c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5ecf0d33-cc9e-4ef4-baf6-7ede3522242d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d800037f-1975-4f4f-84af-ffdc89f53055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_83cdbc8d-82c1-482a-b5da-691db4c3f74c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d800037f-1975-4f4f-84af-ffdc89f53055" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ck0001824293-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:545a0cb1-db3f-4c1d-8b23-fea1d98a8647,g:1675d0ed-3cfa-4512-b65d-428038bee998-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#StatementsofChangesinStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="extended" id="i56095ac0428048dea1b84ae30c3bfdbd_StatementsofChangesinStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_34995986-6a70-4721-8740-1a920630aebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_34995986-6a70-4721-8740-1a920630aebb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_37abcb76-c12c-4418-a6be-bec802fe9b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockholdersEquity_37abcb76-c12c-4418-a6be-bec802fe9b6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_15c2e638-f4ac-4cb0-83ab-43adf73b9421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_15c2e638-f4ac-4cb0-83ab-43adf73b9421" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9957b614-2028-4252-9a86-45a69807d6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9957b614-2028-4252-9a86-45a69807d6ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0be8426b-bd22-455c-98cb-85a835a31d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0be8426b-bd22-455c-98cb-85a835a31d1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_82dc4483-cd7e-46a4-9b60-be3a03d3b6df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_82dc4483-cd7e-46a4-9b60-be3a03d3b6df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_fc651c46-d6d6-45f7-a824-a72a33a666c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_fc651c46-d6d6-45f7-a824-a72a33a666c1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_923d46e2-b166-4c7b-82e0-6e727159c877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_923d46e2-b166-4c7b-82e0-6e727159c877" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_4d9b234e-0c79-4a9e-85c8-68c7afb5f92e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_4d9b234e-0c79-4a9e-85c8-68c7afb5f92e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2f3fe13b-4c1e-4df8-84d3-7281f25384af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2f3fe13b-4c1e-4df8-84d3-7281f25384af" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5e1e9ba7-3414-4220-b3f5-2a2a34fd70f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_NetIncomeLoss_5e1e9ba7-3414-4220-b3f5-2a2a34fd70f1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bbfa4e13-034c-46fd-bc88-36c2b854e4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8e1b6bb1-27cf-467b-a217-0d7658f21693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e6070886-e2e6-438a-a43b-4aeeea567cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StatementTable_e6070886-e2e6-438a-a43b-4aeeea567cbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d89ad35b-a2e4-4a78-9d62-6e4a26e713ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e6070886-e2e6-438a-a43b-4aeeea567cbb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d89ad35b-a2e4-4a78-9d62-6e4a26e713ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d89ad35b-a2e4-4a78-9d62-6e4a26e713ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d89ad35b-a2e4-4a78-9d62-6e4a26e713ce" xlink:to="loc_us-gaap_EquityComponentDomain_d89ad35b-a2e4-4a78-9d62-6e4a26e713ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1cb56d3a-740d-4535-a7bd-b4b0c798bed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d89ad35b-a2e4-4a78-9d62-6e4a26e713ce" xlink:to="loc_us-gaap_EquityComponentDomain_1cb56d3a-740d-4535-a7bd-b4b0c798bed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dcd059e0-5dc9-40c4-b38a-daeab840c344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1cb56d3a-740d-4535-a7bd-b4b0c798bed4" xlink:to="loc_us-gaap_CommonStockMember_dcd059e0-5dc9-40c4-b38a-daeab840c344" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d27d0d95-c0ad-4ab6-8e33-d4197e9d5e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1cb56d3a-740d-4535-a7bd-b4b0c798bed4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d27d0d95-c0ad-4ab6-8e33-d4197e9d5e8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a1c50c23-32dd-4ae5-9e51-c552e61a6357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1cb56d3a-740d-4535-a7bd-b4b0c798bed4" xlink:to="loc_us-gaap_RetainedEarningsMember_a1c50c23-32dd-4ae5-9e51-c552e61a6357" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="extended" id="ifbefffe5101246e2bc4b85b571f8317a_ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b9882081-a53d-4795-beda-38e589825fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b9882081-a53d-4795-beda-38e589825fc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_388489a0-568b-4daa-939a-9fd7e1d01424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_388489a0-568b-4daa-939a-9fd7e1d01424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9fec916a-455b-48d1-bd0c-2d7134f51ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9fec916a-455b-48d1-bd0c-2d7134f51ecb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_61f7210f-869f-42ab-a75e-3ef56954e9f4" xlink:href="ck0001824293-20210630.xsd#ck0001824293_StockIssuanceCostsDiscountsAndCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_61f7210f-869f-42ab-a75e-3ef56954e9f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_8902b67d-f3df-47f2-8cdb-e05c661d65db" xlink:href="ck0001824293-20210630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_8902b67d-f3df-47f2-8cdb-e05c661d65db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_61d24d2d-4100-4376-9734-59a8acb46b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_61d24d2d-4100-4376-9734-59a8acb46b96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3de558cb-d200-44ec-923e-69055e580d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3de558cb-d200-44ec-923e-69055e580d0c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate_72e4f9c9-a71f-44e8-a8d0-352efde1b009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentRate_72e4f9c9-a71f-44e8-a8d0-352efde1b009" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b92d1663-42ef-454a-b32a-cc245911efc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b92d1663-42ef-454a-b32a-cc245911efc4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a419bca7-dadd-43b8-bb54-23c0f5075ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a419bca7-dadd-43b8-bb54-23c0f5075ecb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b2e5d187-6eb1-43fb-9c79-3ce7b2815532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a419bca7-dadd-43b8-bb54-23c0f5075ecb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b2e5d187-6eb1-43fb-9c79-3ce7b2815532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b2e5d187-6eb1-43fb-9c79-3ce7b2815532_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b2e5d187-6eb1-43fb-9c79-3ce7b2815532" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b2e5d187-6eb1-43fb-9c79-3ce7b2815532_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_00cc6354-3064-4961-9c0a-5ed1a073bacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b2e5d187-6eb1-43fb-9c79-3ce7b2815532" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_00cc6354-3064-4961-9c0a-5ed1a073bacc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_e56a98a2-8046-4ff3-9618-1adb15dc003a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_00cc6354-3064-4961-9c0a-5ed1a073bacc" xlink:to="loc_us-gaap_IPOMember_e56a98a2-8046-4ff3-9618-1adb15dc003a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c90f33c9-04cf-4af9-a6ce-99bc31ba16dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a419bca7-dadd-43b8-bb54-23c0f5075ecb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c90f33c9-04cf-4af9-a6ce-99bc31ba16dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c90f33c9-04cf-4af9-a6ce-99bc31ba16dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c90f33c9-04cf-4af9-a6ce-99bc31ba16dc" xlink:to="loc_us-gaap_RelatedPartyDomain_c90f33c9-04cf-4af9-a6ce-99bc31ba16dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8ef540a9-9284-4b7f-be94-c255b55823d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c90f33c9-04cf-4af9-a6ce-99bc31ba16dc" xlink:to="loc_us-gaap_RelatedPartyDomain_8ef540a9-9284-4b7f-be94-c255b55823d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_b2edea79-750e-4dde-b19c-cc95e395efc2" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8ef540a9-9284-4b7f-be94-c255b55823d9" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_b2edea79-750e-4dde-b19c-cc95e395efc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_111dca61-3269-4bd5-a789-8c04962d0f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a419bca7-dadd-43b8-bb54-23c0f5075ecb" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_111dca61-3269-4bd5-a789-8c04962d0f82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_111dca61-3269-4bd5-a789-8c04962d0f82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_111dca61-3269-4bd5-a789-8c04962d0f82" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_111dca61-3269-4bd5-a789-8c04962d0f82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_84047c20-a1cb-4bc9-be6c-a73f35eb2873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_111dca61-3269-4bd5-a789-8c04962d0f82" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_84047c20-a1cb-4bc9-be6c-a73f35eb2873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_a681bc01-cf8a-4e64-8339-6123462fa735" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_84047c20-a1cb-4bc9-be6c-a73f35eb2873" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_a681bc01-cf8a-4e64-8339-6123462fa735" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#PPPNOTEANDCONVERTIBLENOTESDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="extended" id="ibacd7eea05344624bb135747e11b6d74_PPPNOTEANDCONVERTIBLENOTESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_22380847-d51c-477d-99ff-10ff1f34ba82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_22380847-d51c-477d-99ff-10ff1f34ba82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a466b9e6-b319-4fa3-a71e-ec10944249ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a466b9e6-b319-4fa3-a71e-ec10944249ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_9c6dfee0-c5e1-45d2-90dd-45ec503635de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_us-gaap_DebtInstrumentTerm_9c6dfee0-c5e1-45d2-90dd-45ec503635de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentPaymentTerm_551915e5-9e79-48fa-a4a7-64c59371d898" xlink:href="ck0001824293-20210630.xsd#ck0001824293_DebtInstrumentPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_ck0001824293_DebtInstrumentPaymentTerm_551915e5-9e79-48fa-a4a7-64c59371d898" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument_60b21faa-db61-476a-960d-d94040127cc6" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_ck0001824293_ForgivenessOfDebtInstrument_60b21faa-db61-476a-960d-d94040127cc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_60b0325a-0eca-4e2f-bddb-269e9111cd84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_60b0325a-0eca-4e2f-bddb-269e9111cd84" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_52a34bc7-05f2-48a5-bac6-f2f0c81b54b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2bde8589-27ff-4d2b-b713-6e577109618e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2bde8589-27ff-4d2b-b713-6e577109618e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42681872-a893-40ee-8814-61a91cbfc6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42681872-a893-40ee-8814-61a91cbfc6f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_67730733-8473-4ca7-9451-a19d7e83eb50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42681872-a893-40ee-8814-61a91cbfc6f7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_67730733-8473-4ca7-9451-a19d7e83eb50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_67730733-8473-4ca7-9451-a19d7e83eb50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_67730733-8473-4ca7-9451-a19d7e83eb50" xlink:to="loc_us-gaap_RelatedPartyDomain_67730733-8473-4ca7-9451-a19d7e83eb50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7d199521-5bd0-4a40-8fba-fafa058ad82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_67730733-8473-4ca7-9451-a19d7e83eb50" xlink:to="loc_us-gaap_RelatedPartyDomain_7d199521-5bd0-4a40-8fba-fafa058ad82c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_aaa4b990-aa7f-4f31-ae27-0f03f1262615" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7d199521-5bd0-4a40-8fba-fafa058ad82c" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_aaa4b990-aa7f-4f31-ae27-0f03f1262615" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_48f47369-1f19-4dc2-a468-fd16d8063653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42681872-a893-40ee-8814-61a91cbfc6f7" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_48f47369-1f19-4dc2-a468-fd16d8063653" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_48f47369-1f19-4dc2-a468-fd16d8063653_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_48f47369-1f19-4dc2-a468-fd16d8063653" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_48f47369-1f19-4dc2-a468-fd16d8063653_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3f734247-d9bb-4828-87a1-be2659526e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_48f47369-1f19-4dc2-a468-fd16d8063653" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3f734247-d9bb-4828-87a1-be2659526e0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_d8f55781-33a5-47d3-9056-f9903d5b2450" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3f734247-d9bb-4828-87a1-be2659526e0d" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_d8f55781-33a5-47d3-9056-f9903d5b2450" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1cd51978-4bae-4f30-aeb0-21a64ef35577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42681872-a893-40ee-8814-61a91cbfc6f7" xlink:to="loc_us-gaap_DebtInstrumentAxis_1cd51978-4bae-4f30-aeb0-21a64ef35577" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1cd51978-4bae-4f30-aeb0-21a64ef35577_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1cd51978-4bae-4f30-aeb0-21a64ef35577" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1cd51978-4bae-4f30-aeb0-21a64ef35577_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2980b4e9-d32f-4e12-8374-a678fca1c253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1cd51978-4bae-4f30-aeb0-21a64ef35577" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2980b4e9-d32f-4e12-8374-a678fca1c253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_fae96b4b-f76c-4ae4-9462-ff01a0e0da08" xlink:href="ck0001824293-20210630.xsd#ck0001824293_PaycheckProtectionProgramCARESActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2980b4e9-d32f-4e12-8374-a678fca1c253" xlink:to="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_fae96b4b-f76c-4ae4-9462-ff01a0e0da08" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#STOCKHOLDERSEQUITYDEFICITDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails" xlink:type="extended" id="i3eb2a829699f46eaa433f6c37b1ac4b3_STOCKHOLDERSEQUITYDEFICITDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8b66a769-ebfb-443d-aae0-bebda791387d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8b66a769-ebfb-443d-aae0-bebda791387d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_42d1f5fc-39da-42eb-8355-b1f994044abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_42d1f5fc-39da-42eb-8355-b1f994044abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_015ff2f6-3cb7-4fbe-be7e-0a10bb8c0708" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_015ff2f6-3cb7-4fbe-be7e-0a10bb8c0708" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_b51863ce-f0a1-4a0e-b975-aab283feccfd" xlink:href="ck0001824293-20210630.xsd#ck0001824293_StockIssuanceCostsDiscountsAndCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_b51863ce-f0a1-4a0e-b975-aab283feccfd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_cb1c0a95-a0f1-4860-8181-1db3b7902009" xlink:href="ck0001824293-20210630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_cb1c0a95-a0f1-4860-8181-1db3b7902009" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ac056d90-eafc-4d8c-9d0d-cb3a5005994a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ac056d90-eafc-4d8c-9d0d-cb3a5005994a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7e24fb46-8024-4fd7-8af6-3c599ae3dce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7e24fb46-8024-4fd7-8af6-3c599ae3dce9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26972298-9a59-43cd-bc68-86318aa7272f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26972298-9a59-43cd-bc68-86318aa7272f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_d2907f4c-7cf4-48d4-b302-c24e1cbb4887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_d2907f4c-7cf4-48d4-b302-c24e1cbb4887" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1307e5ec-8dac-4a8b-9ef7-10db0b65b99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1307e5ec-8dac-4a8b-9ef7-10db0b65b99b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ce5037e9-2184-48ae-921e-46cb6c7c6297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ce5037e9-2184-48ae-921e-46cb6c7c6297" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0378f470-eeb6-4a33-b61c-40d44cf338e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ce5037e9-2184-48ae-921e-46cb6c7c6297" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0378f470-eeb6-4a33-b61c-40d44cf338e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0378f470-eeb6-4a33-b61c-40d44cf338e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0378f470-eeb6-4a33-b61c-40d44cf338e7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0378f470-eeb6-4a33-b61c-40d44cf338e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7a2ba766-aa29-4e67-b4c1-23fcf5d55900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0378f470-eeb6-4a33-b61c-40d44cf338e7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7a2ba766-aa29-4e67-b4c1-23fcf5d55900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_f9e1193b-4114-401b-a36d-e919e87f831e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7a2ba766-aa29-4e67-b4c1-23fcf5d55900" xlink:to="loc_us-gaap_IPOMember_f9e1193b-4114-401b-a36d-e919e87f831e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_6bbe1c3f-aee2-4e5a-8538-314bda61e530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7a2ba766-aa29-4e67-b4c1-23fcf5d55900" xlink:to="loc_us-gaap_OverAllotmentOptionMember_6bbe1c3f-aee2-4e5a-8538-314bda61e530" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended" id="i93bf43e18cbf4c9683b1ff8a8878d068_STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0a512f5a-ea6b-4522-a0c0-a06b012c41a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_b5068c37-4c78-44e9-9645-cfad67c1f5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0a512f5a-ea6b-4522-a0c0-a06b012c41a4" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_b5068c37-4c78-44e9-9645-cfad67c1f5a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d61014c3-9d29-4da8-8764-d1e0002a2b74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0a512f5a-ea6b-4522-a0c0-a06b012c41a4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d61014c3-9d29-4da8-8764-d1e0002a2b74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_de1a4bee-4a25-4dc0-9f86-01237e4f5346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d61014c3-9d29-4da8-8764-d1e0002a2b74" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_de1a4bee-4a25-4dc0-9f86-01237e4f5346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_de1a4bee-4a25-4dc0-9f86-01237e4f5346_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_de1a4bee-4a25-4dc0-9f86-01237e4f5346" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_de1a4bee-4a25-4dc0-9f86-01237e4f5346_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d3fa968b-6c16-4936-bfdf-bf994116a758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_de1a4bee-4a25-4dc0-9f86-01237e4f5346" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d3fa968b-6c16-4936-bfdf-bf994116a758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_1584b2bd-e72c-4b53-856b-791ece13deab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d3fa968b-6c16-4936-bfdf-bf994116a758" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_1584b2bd-e72c-4b53-856b-791ece13deab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_08cadda5-f0eb-4f96-935a-08f7a9d1a31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d3fa968b-6c16-4936-bfdf-bf994116a758" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_08cadda5-f0eb-4f96-935a-08f7a9d1a31a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_b9e9360f-47f1-4f43-bf4c-05e1e2fe86f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d3fa968b-6c16-4936-bfdf-bf994116a758" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_b9e9360f-47f1-4f43-bf4c-05e1e2fe86f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a5af562f-8bec-42db-a060-acaa698cac42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d3fa968b-6c16-4936-bfdf-bf994116a758" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a5af562f-8bec-42db-a060-acaa698cac42" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i3b63917ede5b4117b428b5c18a555fb9_STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0e645082-15ef-4aad-8e37-5632aaad0d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_48a319ac-b69b-4902-a6ab-50c588191f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0e645082-15ef-4aad-8e37-5632aaad0d17" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_48a319ac-b69b-4902-a6ab-50c588191f01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9a8093a4-3dd3-4b7a-bcb8-cace9aeee654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0e645082-15ef-4aad-8e37-5632aaad0d17" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9a8093a4-3dd3-4b7a-bcb8-cace9aeee654" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8b9fcf6c-3549-492a-8f54-96333ec8b769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9a8093a4-3dd3-4b7a-bcb8-cace9aeee654" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8b9fcf6c-3549-492a-8f54-96333ec8b769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8b9fcf6c-3549-492a-8f54-96333ec8b769_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8b9fcf6c-3549-492a-8f54-96333ec8b769" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8b9fcf6c-3549-492a-8f54-96333ec8b769_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f24c8dec-4a97-4672-8ba5-7593449baa74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8b9fcf6c-3549-492a-8f54-96333ec8b769" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f24c8dec-4a97-4672-8ba5-7593449baa74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_809eab55-a9fb-4acd-a3b4-e517410ab387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f24c8dec-4a97-4672-8ba5-7593449baa74" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_809eab55-a9fb-4acd-a3b4-e517410ab387" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d7f37eab-94e1-4618-a57a-a4bf7119c840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f24c8dec-4a97-4672-8ba5-7593449baa74" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d7f37eab-94e1-4618-a57a-a4bf7119c840" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="i3ef6677ee9c6439fa9e6f896274d48b3_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_93ec151b-f608-4dd8-97a8-c0679cf6c8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment_7fb3a980-675c-4d41-8701-417272f2a085" xlink:href="ck0001824293-20210630.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_93ec151b-f608-4dd8-97a8-c0679cf6c8ff" xlink:to="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment_7fb3a980-675c-4d41-8701-417272f2a085" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_4520a46f-30cb-4d80-86ac-f1428764db71" xlink:href="ck0001824293-20210630.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_93ec151b-f608-4dd8-97a8-c0679cf6c8ff" xlink:to="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_4520a46f-30cb-4d80-86ac-f1428764db71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_f7a1f9e6-66ba-4de9-8703-8ac92aaacf87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_93ec151b-f608-4dd8-97a8-c0679cf6c8ff" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_f7a1f9e6-66ba-4de9-8703-8ac92aaacf87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1325a6d-ae39-4de5-9fce-bb7274a9fb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_93ec151b-f608-4dd8-97a8-c0679cf6c8ff" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1325a6d-ae39-4de5-9fce-bb7274a9fb4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_beff6128-3236-462a-97d7-0b6153830439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_93ec151b-f608-4dd8-97a8-c0679cf6c8ff" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_beff6128-3236-462a-97d7-0b6153830439" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_62b4a730-1a45-4359-9a77-ded9c28482f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_93ec151b-f608-4dd8-97a8-c0679cf6c8ff" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_62b4a730-1a45-4359-9a77-ded9c28482f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c94e4808-d1d5-4580-abbe-26f19eec510f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_62b4a730-1a45-4359-9a77-ded9c28482f5" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c94e4808-d1d5-4580-abbe-26f19eec510f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c94e4808-d1d5-4580-abbe-26f19eec510f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c94e4808-d1d5-4580-abbe-26f19eec510f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c94e4808-d1d5-4580-abbe-26f19eec510f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_bf45643f-7ceb-47ce-a358-86bb6a199ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c94e4808-d1d5-4580-abbe-26f19eec510f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_bf45643f-7ceb-47ce-a358-86bb6a199ecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_7cb2131a-0785-48ea-8494-83164e93f625" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_bf45643f-7ceb-47ce-a358-86bb6a199ecc" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_7cb2131a-0785-48ea-8494-83164e93f625" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_288133d1-1a15-457f-b499-8df74c5698fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_62b4a730-1a45-4359-9a77-ded9c28482f5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_288133d1-1a15-457f-b499-8df74c5698fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_288133d1-1a15-457f-b499-8df74c5698fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_288133d1-1a15-457f-b499-8df74c5698fc" xlink:to="loc_us-gaap_RelatedPartyDomain_288133d1-1a15-457f-b499-8df74c5698fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e80540f9-872d-47d7-a5fd-c57c3d5080f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_288133d1-1a15-457f-b499-8df74c5698fc" xlink:to="loc_us-gaap_RelatedPartyDomain_e80540f9-872d-47d7-a5fd-c57c3d5080f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_d9db3a53-f722-4851-a6d3-a6c67da9847c" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e80540f9-872d-47d7-a5fd-c57c3d5080f4" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_d9db3a53-f722-4851-a6d3-a6c67da9847c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_MediceMember_eefc8571-913d-435d-b55f-9868b31a00e8" xlink:href="ck0001824293-20210630.xsd#ck0001824293_MediceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e80540f9-872d-47d7-a5fd-c57c3d5080f4" xlink:to="loc_ck0001824293_MediceMember_eefc8571-913d-435d-b55f-9868b31a00e8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="extended" id="i82b45aedb6454aea96c3340c795570a7_FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c05c6173-cdc9-4dec-a8cd-da59daa08caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9ebefd83-d399-4629-8315-47fe9fb336fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c05c6173-cdc9-4dec-a8cd-da59daa08caa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9ebefd83-d399-4629-8315-47fe9fb336fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_a0a68b9d-5e38-4d21-8971-5c8789f7125b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c05c6173-cdc9-4dec-a8cd-da59daa08caa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_a0a68b9d-5e38-4d21-8971-5c8789f7125b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_06289a33-e4bc-4ff4-b436-83dfb113bbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c05c6173-cdc9-4dec-a8cd-da59daa08caa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_06289a33-e4bc-4ff4-b436-83dfb113bbe7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e9a4b2b7-8a55-4d1e-b921-3c575b59fd66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd4d5fee-1081-4cd3-91fd-83fe754649e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c05c6173-cdc9-4dec-a8cd-da59daa08caa" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd4d5fee-1081-4cd3-91fd-83fe754649e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_99597f36-b5fb-4aa9-b86a-284a58b41959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd4d5fee-1081-4cd3-91fd-83fe754649e4" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_99597f36-b5fb-4aa9-b86a-284a58b41959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_99597f36-b5fb-4aa9-b86a-284a58b41959_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_99597f36-b5fb-4aa9-b86a-284a58b41959" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_99597f36-b5fb-4aa9-b86a-284a58b41959_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9b7484d5-d234-4136-a587-35126158ffa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_99597f36-b5fb-4aa9-b86a-284a58b41959" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9b7484d5-d234-4136-a587-35126158ffa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_6d9cea5c-a431-4c10-97a6-d3f75e8a6195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9b7484d5-d234-4136-a587-35126158ffa0" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_6d9cea5c-a431-4c10-97a6-d3f75e8a6195" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ck0001824293-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:545a0cb1-db3f-4c1d-8b23-fea1d98a8647,g:1675d0ed-3cfa-4512-b65d-428038bee998-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment_46734212-a505-4328-8b88-09c7e461c3ae_terseLabel_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received under license agreement</link:label>
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment_label_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, License Agreement, Upfront Payment</link:label>
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, License Agreement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment" xlink:href="ck0001824293-20210630.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment" xlink:to="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_8d031cbb-a035-4669-b2ee-55f242ccfef1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_6392a51e-95ca-4307-b9ab-a835e46aae84_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_20d7e1c7-bca4-45af-ae9e-25271d07854c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_77be5488-446d-44f4-8837-b7dc76647c0d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5612e0db-9bb8-482f-a78f-2d61ff3842cc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c98a8527-7499-4420-bc0e-f26f73faa02d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_04d99f68-70d8-416c-9949-166fbed28761_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_319a94bf-f2ed-4647-ab4c-cf46b3d9359c_terseLabel_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, term</link:label>
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_label_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, License Agreement, Term</link:label>
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_documentation_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, License Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:href="ck0001824293-20210630.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:to="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_09c1f6a8-0b07-428d-8e2f-5703202e911f_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of option on grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0d3dabd9-12d2-4c8b-a5d1-1fd6546e6b21_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6aa4a1fa-f652-4547-a25d-b9eaae0d4482_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_5a885f8b-bbc4-4f1e-bc76-1b8233e5c629_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_223ff04f-291d-4aee-8953-74c16bd6e04f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock awards, contractual life (up to)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_f9b80c77-423d-4e19-bed2-ba1768fe2d94_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b3ea13e3-37f0-497c-87e6-881c49475667_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c70a448d-4873-40b2-9e6e-46e0e2f2d226_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_aa326357-3d7f-43b8-a361-de4abbabffbc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_45c7dd6b-2217-44b5-983a-7f9c440fcc34_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_cbde9ac3-4b63-4734-8a22-f6033812096e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity for the Liability Measured at Estimated Fair Value Using Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_003a9e5c-c8b8-49d9-b0e9-75e0c2d3f4b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_19819ba6-4659-41ad-bef6-df6a45929c1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_d153d91e-40f6-44d9-acc5-ed92aebb679f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_802374d9-2426-448a-b49c-036dd63c650f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_ce56a193-19ed-47f7-8fe5-ef8eaa7bca12_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0e4aad7a-cd8e-46a9-bb6e-c7a9ef1ac5c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b65636c5-3924-4bf0-a9cb-cd9354a6a68f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0462fbbc-7d26-4ef6-9f3d-a115aca064e0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c87b89be-a2ac-435b-83de-1cc6853e99d0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_90cb90b8-b6f6-4f16-859d-654224a5b8d7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedLicensingFeesCurrent_13beaa25-97c7-4bda-84d2-43b1ea32c5c7_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing related</link:label>
    <link:label id="lab_ck0001824293_AccruedLicensingFeesCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Licensing Fees, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedLicensingFeesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Licensing Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedLicensingFeesCurrent" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AccruedLicensingFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedLicensingFeesCurrent" xlink:to="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b293eb5c-dd2d-467b-b6df-41e24af4d70a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ac55de58-f5c9-4284-a40e-5a571673e117_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_38706bb1-8ad2-442d-9fcd-ebd0479178ff_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_323be8f9-61ab-4320-afc8-df4531f081ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_05048517-88e8-43cc-802b-c4feb81d7b29_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Underwriters Warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_a5197f88-65a1-47c3-94db-20818fd33c64_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant issued reflected in additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_5076ba53-16fd-4ff2-99a0-0518f7a8da59_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8883ecf5-bda4-43d5-81ed-e7e4c7ed3f34_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_e5738444-ea2f-4ec9-9937-23e0bea75b63_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2777908a-8431-4c14-9cc4-8cecdfce1f9d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_50bc5158-81cd-4f3a-894c-c685a25d735d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_3749474f-bb96-42c2-b71f-51cfb2f620ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b77936fb-fbef-49d8-8365-e3cd4b2e1e38_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_14fc5255-0ba7-4f83-99a2-88fffa776cfa_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_MediceMember_c3989ed7-f2c8-48f0-bae9-6279fc1f4ce5_terseLabel_en-US" xlink:label="lab_ck0001824293_MediceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medice</link:label>
    <link:label id="lab_ck0001824293_MediceMember_label_en-US" xlink:label="lab_ck0001824293_MediceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medice [Member]</link:label>
    <link:label id="lab_ck0001824293_MediceMember_documentation_en-US" xlink:label="lab_ck0001824293_MediceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_MediceMember" xlink:href="ck0001824293-20210630.xsd#ck0001824293_MediceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_MediceMember" xlink:to="lab_ck0001824293_MediceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c76e424f-7d75-48e0-bf07-854b27f291a7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_49071963-b3d5-4a9e-a82b-bdcd440440f3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes, converted, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_20a615a6-8fa9-4c3b-b5ba-754c6a207d19_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable, non-current</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_0c3064a2-4b11-4249-951d-babf56be9989_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense recognized on embedded derivative</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_ee5f09f6-c1de-48d1-9da7-bd2123d8c002_terseLabel_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note Purchase Agreement</link:label>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_label_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note Purchase Agreement [Member]</link:label>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_documentation_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:to="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_a549fc09-f159-429d-b688-0a7646697797_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7650e348-815a-482f-8907-174c9d9c5122_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f2f8341e-eec4-43f6-8bc8-be348b036ce1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term&#160;(years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b6f1c40a-71ad-4ba9-a3d8-a790cd7a13bb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f6ade4fe-f4b2-4f4c-b4f3-dd792c1d3d58_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8b1b0ffa-b994-4bb8-8b64-18421d62d2a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2206aea8-f825-4299-bc5f-4e5fb2f28e58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">44377</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1be9952b-f7f3-4c33-a331-dce65b3d68b2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ce41c6b9-e4cd-41d1-b36e-79863dfa1db7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_db112661-f3d4-4848-935c-f26e73f323de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_277dc547-1024-416f-8192-f8b2b3928b88_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_1bb34d59-2e46-494a-892e-ac76bf098fc4_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_578620dc-da79-4dd4-a693-e377bc615de7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_911ac6fa-ea87-4f94-a2a6-159ac9c914be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_16afca51-b3c0-4bf5-a2aa-6232664e73d8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_5e97f475-a48c-47fc-b5ea-9cdf31fdafaf_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity of Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_801e14b1-a85d-420a-8b4a-20c5d07ba682_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_727ee013-f89d-456f-9435-5444a71763fb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_c9f13324-c114-49f4-b3b3-fcd81f973460_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2279376a-fc44-48b4-b607-91745cdfe8aa_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5a0e6a78-eba4-4241-b3cd-b22a0a1642c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6785756a-b947-4dab-9a6c-3b3b487438bf_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19f3f9f0-0516-4481-99c5-eeb1cd8315eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c00e07e3-50a9-47dc-84e7-bb0713e34972_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b413931e-142d-4eaa-8ec6-15b87934a1f0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1ca52371-d9cc-4a4b-bf05-c54c7830c78f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e31ec916-fa8a-4e52-be14-d88714e8d858_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_47c6d6a8-1775-4c5c-908d-d984139f7be7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bab7a653-24a5-434a-8780-7076ade01a24_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_fe441433-a950-4e08-9fe9-6ed99438204b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_fbbfe39c-13b3-4139-9e1b-8a5448d516c0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_75fe52aa-01a4-4532-8701-d1fffb2614c3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_033cd874-bfa0-497b-84e1-6307c79b39b2_terseLabel_en-US" xlink:label="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from stock offering</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_label_en-US" xlink:label="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering, Gross</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_documentation_en-US" xlink:label="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:to="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f2c38a3b-f8b8-4a1c-ad1a-4a0b6d2d89e5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_cfa0d58f-ea67-4843-b385-3109dc25a80d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_196b0c90-e5e3-4d90-8e3e-517cae75ad35_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance as of January 1, 2021</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_46cdc641-12fa-4f9a-9917-db06bb187ddc_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of June 30, 2021</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_49a09c9e-e0e3-4934-9fd6-a378cc289c7d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5d648b38-2708-49d7-9f77-ae44b3da25c1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c2c73dfd-337d-45c0-9e98-c839ca732192_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3063b4d7-4c92-4ae6-95bb-174b43f3a9c4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_ab7411ea-ab3e-48ab-8b1b-747a4108a6f2_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs, discounts and commissions</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Discounts And Commissions</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Discounts And Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:href="ck0001824293-20210630.xsd#ck0001824293_StockIssuanceCostsDiscountsAndCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:to="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2e926732-9e13-4946-a3dd-98bd7a439194_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_6e8d80bb-2ba4-4cd8-8107-e92e847b69a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer out of Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9a3aac6a-7479-44eb-9c57-d0893c53b2ba_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d12e7e9c-791d-4262-9db9-8cbe72a6a97b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_888ac948-3391-4e3d-b119-82b94bf64977_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_6a1a6ede-92bd-4edb-bd7f-8c5e08c1563e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentRate_b3939cc4-b4ab-448d-aabc-3b0c0d5c76a2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Converted debt, discount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentRate_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_054ae627-11ad-4dba-b9a1-16223e9e3c01_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a72f03d4-b18f-45e9-8b13-cf6a0ec103bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_344935c9-efd3-4086-89f3-880bd1bb1d32_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_23fc1e55-3228-4b97-afc4-d758d68a59fb_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_df9a8c3b-b2e9-4803-8817-1be079cfa8a1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_31eb86d6-ade1-4062-b863-e41f5c75309c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0f9ea686-1591-429c-8616-5abc5fd7d00a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_ced63c0b-1154-41db-9702-891065a22813_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7668031d-26ff-4341-a751-55ae3297d3ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_fcb7401a-2434-41e7-9827-30993736b057_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashExpense_ffa08c2f-d375-4c0f-886c-bcdecffd51a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest, depreciation and other expense</link:label>
    <link:label id="lab_us-gaap_OtherNoncashExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_872c2fe7-4ea1-461d-8043-1b8df400eac5_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_5a5607d2-4bcc-4883-922a-a05037958292_verboseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional offering expense</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:href="ck0001824293-20210630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:to="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f77f1628-78c0-4d7f-8120-a3619d999681_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_9409394a-88c9-425d-8361-4be2f4e7c9db_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1e345bc0-be17-4f79-9de0-4e169d45e077_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock, net of offering expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_03745d83-e085-49ba-a1f7-96293460df9a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_2b922247-3818-461b-90be-f8812d6f7e2a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from convertible notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_f61baf7e-b7c3-4ca7-94ff-2b99586d4108_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIQUIDITY</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_854632b1-c85f-4e74-bdb1-2325861349a6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e1b1c74b-4533-44c9-8aeb-febe55dbf9f2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a8e271c7-e40d-45e1-8ec4-cbae9155640d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_45f8b15a-56ba-4848-978f-8c275455cf56_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PaycheckProtectionProgramCARESActMember_8c06ef9f-b933-4c2e-885e-72e229742173_terseLabel_en-US" xlink:label="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:label id="lab_ck0001824293_PaycheckProtectionProgramCARESActMember_label_en-US" xlink:label="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act [Member]</link:label>
    <link:label id="lab_ck0001824293_PaycheckProtectionProgramCARESActMember_documentation_en-US" xlink:label="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:href="ck0001824293-20210630.xsd#ck0001824293_PaycheckProtectionProgramCARESActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:to="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_b08b0e1f-4baa-425c-8789-06abada371ee_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:to="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bff9631e-dc6d-4ef8-b9ae-325195c9e972_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_b207839a-911e-463a-a32e-ac48fd4ff777_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from PPP loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_987e32e7-1aa5-49df-98b1-f88b0df62092_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_ff7ccada-7873-453c-8ddc-897081c7fae9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, maturity</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ca77af41-5de0-4a70-b25d-e7b5c79800c2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8ef61dca-459c-47a8-be23-b443ea8dfda4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_9ea8ca78-0048-449f-87ed-7b088c8b1c1f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_54e4d2c9-8ecd-453e-baa5-a47f60e59b03_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ec6edcd1-4ceb-408c-bb78-143945dd2039_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_ad70ef47-b047-40c8-8f96-2558b11a441e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for IPO, net of issuance expenses</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_6878a9b9-4b5d-4e31-9de1-be918a1c6008_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7061c5e5-b115-4b21-a80c-e774190869da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_e9669091-77e0-40ed-8e3a-1a494021fbc3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP NOTE AND CONVERTIBLE NOTES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f5a49396-ecff-4fa5-8d30-163065372275_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_26935067-be27-4427-90cf-0ba82c3da046_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e2c73f00-9f8f-4ae1-9d62-c553f2125eb3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_85e2c3d6-ff09-4f4f-b21e-5597b769c885_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2ebac75b-c7bd-4916-84af-1aa2a56964d7_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9dfe527d-a96b-42bb-8912-3dd02b8e7a4b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b8186f03-db99-471c-be04-519b1b64bd74_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_eaeae0df-2d6c-4aee-9f14-b0b26e9b1862_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1b2fa4e0-6342-4efb-9cc0-ec0a89b5dc66_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for IPO, net of issuance expenses (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d4c3fb7d-1104-4297-9b5a-db499e005156_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_93e7508b-2f3c-43d0-99f2-ff90a9e0a908_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bc17eef4-d92d-49ea-bce3-9080900025d1_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_e91ee8c2-3e46-4add-83e7-670768dbe4f1_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_92c556d0-6d67-480e-ae61-771e4f9d345e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation, weighted average amortization period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3fa42d39-5fa1-4118-8f14-201a96142b8c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_4afd3149-9082-4653-b17a-ea98b72e1a76_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0dcb7d05-6ab8-4653-8039-edba2a4e3cdc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a94f5553-51e6-4ea9-b8bf-e8f62f920df0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6658912a-a9ac-4599-8e06-e5972ff5e50e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Balance Ending (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_7d535eec-e300-4227-aa2c-08e2b65c8ed7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of finance lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_2a5171bb-8f2b-4ad9-ad5e-7174a1d79ae1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_35707a9e-e1bf-42a1-935e-224ccdec0377_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_885c6e36-163f-4661-b7c4-82bbc0348c8f_negatedLabel_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of PPP note</link:label>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_de8df487-d75b-4287-a637-8ad4408f8149_terseLabel_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of PPP note</link:label>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_label_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness Of Debt Instrument</link:label>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_documentation_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness Of Debt Instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ForgivenessOfDebtInstrument" xlink:to="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_158d3b3d-68e4-4c28-b7f2-3276f4142b94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ee4cdafb-309d-4b48-981f-e81dee898b7c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fabcc5f9-b9f7-485b-b5b7-c11fb9c70f81_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a565ed46-82d3-43a1-8cdf-7aace73feb83_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89108d5b-31ab-4262-885d-56711c7d39f1_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d8707de0-0fb0-4b6f-860e-0e93ec10d21a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_db7aa44c-51f9-4cea-8ab2-af6035175f63_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_93f3a197-0d65-4494-8282-8f393d91cda5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtInstrumentPaymentTerm_80122eba-40e8-4c78-842c-7eed2ac8fdab_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, payment term</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentPaymentTerm_label_en-US" xlink:label="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Term</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentPaymentTerm_documentation_en-US" xlink:label="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentPaymentTerm" xlink:href="ck0001824293-20210630.xsd#ck0001824293_DebtInstrumentPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtInstrumentPaymentTerm" xlink:to="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_424a8ed9-2d90-45e8-a2f2-6b1674c686d9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bbd99c53-b9b2-4156-8398-457abdd98c1d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a3a4f52f-97a1-4d6c-84db-b523e1d19e5a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d58eff82-4178-46f6-aa5e-8c6806347cb8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cb6d493f-80e9-488c-ad9d-99d9ac6abaf8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_58137230-ef54-46a9-a459-fe79830e882a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_de4e0782-294c-46eb-81a0-e5adff7b00dd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0346e008-7066-4947-90cb-590a92d37331_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_bb1a8b03-8cbe-4d36-8392-6f4068c894ee_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1e9f4249-05d9-4801-b485-4feae094cc67_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenue-related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_060fae60-8eac-40ae-911b-dc84f0a64ed9_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters' Allotment</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_63414489-6908-4c56-8c73-5c3566b52fd9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e9f491d4-b531-4986-a161-5787ecc717e3_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9b616b91-69a1-4b5c-bfeb-7031a6729509_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_49850129-5986-4381-93d5-32298fe4b9e9_terseLabel_en-US" xlink:label="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salmon Pharma, Affiliate of Medice and David Baker, CEO</link:label>
    <link:label id="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_label_en-US" xlink:label="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliate of Medice and David Baker, CEO [Member]</link:label>
    <link:label id="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_documentation_en-US" xlink:label="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliate of Medice and David Baker, CEO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:to="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_a55ad59a-a55c-4c61-a107-40b633536968_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_0f07a18d-0cdb-4c4f-8baf-af45ab12e84a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_ad0268e5-0623-4b99-a1cb-1d48daa0c9f1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7d7605f3-72fe-466f-bd95-184ae26aa2e3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1820185-229b-4d87-bf6c-fff572dc26c6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1510324f-a366-4d6c-80b1-2617a18fda34_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_fc917364-698a-4979-bc16-c0dc5702ba61_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c34cb530-e2f3-450c-b742-42133e48d0df_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_a895687d-e206-40c5-87ca-13041ecc1469_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_836f03ce-ae35-4ea8-972d-7599a2565d39_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a9962e3a-6e6c-43f4-9c59-daccd343dd84_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_03117dfc-0e8a-4953-8696-27f2b61901dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_fd2f4968-bb4b-4384-92c2-a10aba21c8f8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional&#160;Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_10cc9cba-047d-474c-a1cd-d2cb81fa4ea3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c1860964-62a8-400b-afcc-8e5abb7ddfc8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_db849400-f38b-4510-a7e7-12aa3eb0c384_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_a8fc375b-b21f-44ff-97c9-e6fa1d7124f6_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of derivative liability</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_658b32e8-4c57-4027-aef0-dc87da8cd3fa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of derivative liability</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_021ed053-32e1-46c4-95de-3e5a76b1434d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_87a0c2d9-2b38-4f49-a4c3-00153cfc1b85_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8a01b8e1-64ae-45bd-871e-2b2e3ce30e83_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_fb730142-f720-41c7-96b4-bd9e56714502_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_efafb845-72e9-441e-8754-93c70cf7f864_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_60c93d5c-964d-4958-a721-b25beebbd243_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_64ad5fbd-fac6-4862-8adc-f3842c148e3e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ad35b59f-3e9b-4c50-955f-a388b8ba54ed_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b5c63111-17f7-4702-b02c-69993db0b2df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3218470e-4368-4e49-8fa8-410f326dadee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9ce4b182-f3bf-4b7c-9fd1-75d861ec8bda_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_1775b463-b4cf-45cf-8eee-cb35ffbaa604_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_4bc8ee91-5799-49ce-a47a-93b2dc4e1429_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9923f370-930f-4e44-a49b-1b1136b48e3a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_13ce6270-14ef-4085-a068-d47536151224_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_4f49b840-62ae-48ee-ad79-7396827061b5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_a2e7d9ae-8e83-4cf1-a425-adcaeabc5b04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_f8af44a7-0159-4454-a73a-34751d383486_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e671486e-9ce3-4c13-b2e8-79f2ede6b585_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_c52a3eca-56bd-4c69-8d45-04c98fb54b08_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_221ce4d7-0178-4b78-b637-950ef3fcc2f2_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_72f20563-0421-4e0d-b851-406b22af5d19_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_089f8349-d0dd-4871-9123-e0703efe6ee9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_62dbad17-5529-445d-99d0-9b3b2662fc48_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_b2787b71-a6ba-445a-9375-08296dc78ee6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible notes to common stock</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a1287d90-b665-4c45-aa60-9ea0ecc33a02_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3c26aa1c-b5b0-4e90-8c3a-5b263477fbf0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_4657dbea-c216-46ca-bdfe-c03796fd9177_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable, current</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3cfc6b42-0e28-4db3-a649-73e8866d24d6_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ck0001824293-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:545a0cb1-db3f-4c1d-8b23-fea1d98a8647,g:1675d0ed-3cfa-4512-b65d-428038bee998-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/Cover" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9430e528-789c-436c-adc8-5f6e20f4e016" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_DocumentType_9430e528-789c-436c-adc8-5f6e20f4e016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_a1f7e036-2cd9-4f2d-a117-b4c00073edb2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_DocumentQuarterlyReport_a1f7e036-2cd9-4f2d-a117-b4c00073edb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2d9111c8-6cd6-4dc3-9866-8f8d3a7fc31f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_DocumentPeriodEndDate_2d9111c8-6cd6-4dc3-9866-8f8d3a7fc31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c6573387-71b7-4f99-bc35-b8e7c1417ce7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_DocumentTransitionReport_c6573387-71b7-4f99-bc35-b8e7c1417ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8dd9600a-20ec-4754-819e-b12d5eca641c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityFileNumber_8dd9600a-20ec-4754-819e-b12d5eca641c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4081135b-563a-4844-aa9f-19cda29f54a7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityRegistrantName_4081135b-563a-4844-aa9f-19cda29f54a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_dca4d487-ff77-47c5-8bb0-f51d32b5f380" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_dca4d487-ff77-47c5-8bb0-f51d32b5f380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_030cbf80-a4af-4fa2-84db-36b8d6b4c554" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityTaxIdentificationNumber_030cbf80-a4af-4fa2-84db-36b8d6b4c554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8cf9f3e1-87c4-4b06-961e-ba6a6ecefe7d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityAddressPostalZipCode_8cf9f3e1-87c4-4b06-961e-ba6a6ecefe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b98c8ed3-cd48-44eb-a7c6-1e9a65c1d16e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityAddressAddressLine1_b98c8ed3-cd48-44eb-a7c6-1e9a65c1d16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_f604c495-db25-4e31-8029-065ca6bd83c5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityAddressAddressLine2_f604c495-db25-4e31-8029-065ca6bd83c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1d7b58ce-4770-4729-af4b-a9682a241245" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityAddressCityOrTown_1d7b58ce-4770-4729-af4b-a9682a241245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_678e893a-a722-4c71-8c1e-b6ec2100dad6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityAddressStateOrProvince_678e893a-a722-4c71-8c1e-b6ec2100dad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1874c43a-d09d-4577-8c52-acbaaa0bf881" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_CityAreaCode_1874c43a-d09d-4577-8c52-acbaaa0bf881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5327e214-274f-4490-bb96-40572e89c126" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_LocalPhoneNumber_5327e214-274f-4490-bb96-40572e89c126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cbf89dad-b623-4ff9-a679-3b82f13cbc4e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_Security12bTitle_cbf89dad-b623-4ff9-a679-3b82f13cbc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_022fc189-3ec4-4d62-a31d-eb795c5222c3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_TradingSymbol_022fc189-3ec4-4d62-a31d-eb795c5222c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_bb713f10-8de4-40de-b7b6-bf29969cbef3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityCurrentReportingStatus_bb713f10-8de4-40de-b7b6-bf29969cbef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4fa86dc4-9c56-4a15-b5cc-99802e9c6dbe" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityInteractiveDataCurrent_4fa86dc4-9c56-4a15-b5cc-99802e9c6dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d1bb32d8-7da8-466d-bce3-c39aff15973a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityFilerCategory_d1bb32d8-7da8-466d-bce3-c39aff15973a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_bfcc069c-f879-4cbf-bc77-d9709fd7040d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntitySmallBusiness_bfcc069c-f879-4cbf-bc77-d9709fd7040d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e1a3b3e0-c81f-4787-af36-81b9601219b1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityEmergingGrowthCompany_e1a3b3e0-c81f-4787-af36-81b9601219b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_758b0ccc-274a-40c3-82ed-a14c374876a1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityShellCompany_758b0ccc-274a-40c3-82ed-a14c374876a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1cb1878a-5d98-4b15-ad9c-8c03d2c93a8f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1cb1878a-5d98-4b15-ad9c-8c03d2c93a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a7091793-3ad1-4631-8bf8-6141bede53fd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityCentralIndexKey_a7091793-3ad1-4631-8bf8-6141bede53fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_7fd90e63-4694-437e-a7a5-a428e51c3ff6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_CurrentFiscalYearEndDate_7fd90e63-4694-437e-a7a5-a428e51c3ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c0caa3ce-3e2f-4ad4-85a8-8224a92af185" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_DocumentFiscalYearFocus_c0caa3ce-3e2f-4ad4-85a8-8224a92af185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_cc4d2c2c-70f3-49f7-832d-cd0ec98b9dd5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_DocumentFiscalPeriodFocus_cc4d2c2c-70f3-49f7-832d-cd0ec98b9dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_14256de9-2a14-48b5-ae21-1856f445c763" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_AmendmentFlag_14256de9-2a14-48b5-ae21-1856f445c763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8b072485-86ec-42c0-9f2c-d1f8e62db5c6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_SecurityExchangeName_8b072485-86ec-42c0-9f2c-d1f8e62db5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_e7d864cb-bbcf-4ba9-8ef3-8d474e76a936" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ceb41a74-464e-44e2-9b45-13ead05ea48d" xlink:to="loc_dei_EntityExTransitionPeriod_e7d864cb-bbcf-4ba9-8ef3-8d474e76a936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4f90b6c3-a061-4c64-97cb-59e1efcc947f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4f6a87c6-78d2-4e85-bc4f-e5eba7b62060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4f90b6c3-a061-4c64-97cb-59e1efcc947f" xlink:to="loc_us-gaap_AssetsAbstract_4f6a87c6-78d2-4e85-bc4f-e5eba7b62060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1206d5d0-cde5-45ea-86ea-3f8f53f3aa3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4f6a87c6-78d2-4e85-bc4f-e5eba7b62060" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1206d5d0-cde5-45ea-86ea-3f8f53f3aa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1942d1b-5692-4b66-b4c3-e6147cb72e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1206d5d0-cde5-45ea-86ea-3f8f53f3aa3b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1942d1b-5692-4b66-b4c3-e6147cb72e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ac499ddd-ea48-43e8-b5c3-2736befbb5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1206d5d0-cde5-45ea-86ea-3f8f53f3aa3b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ac499ddd-ea48-43e8-b5c3-2736befbb5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8d5fb23b-8b0a-4488-90d4-88dba5770b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1206d5d0-cde5-45ea-86ea-3f8f53f3aa3b" xlink:to="loc_us-gaap_AssetsCurrent_8d5fb23b-8b0a-4488-90d4-88dba5770b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4d004a21-dc99-44fa-81df-55fcf5b6c91b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4f6a87c6-78d2-4e85-bc4f-e5eba7b62060" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4d004a21-dc99-44fa-81df-55fcf5b6c91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_305f35c8-7bb1-419b-b20e-d669a544b972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4f6a87c6-78d2-4e85-bc4f-e5eba7b62060" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_305f35c8-7bb1-419b-b20e-d669a544b972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c786d49f-8151-4537-a252-23e2968689e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4f6a87c6-78d2-4e85-bc4f-e5eba7b62060" xlink:to="loc_us-gaap_Assets_c786d49f-8151-4537-a252-23e2968689e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ebadac8f-dd17-4592-a6e8-c5bfd0c22814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4f90b6c3-a061-4c64-97cb-59e1efcc947f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ebadac8f-dd17-4592-a6e8-c5bfd0c22814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7ef325aa-eab1-41d2-a837-af2249bf39ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ebadac8f-dd17-4592-a6e8-c5bfd0c22814" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7ef325aa-eab1-41d2-a837-af2249bf39ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_39efdb14-691e-4127-870c-5f6b7966ba2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ef325aa-eab1-41d2-a837-af2249bf39ab" xlink:to="loc_us-gaap_AccountsPayableCurrent_39efdb14-691e-4127-870c-5f6b7966ba2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b88ad18a-a999-4061-a2fb-e6968797ba74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ef325aa-eab1-41d2-a837-af2249bf39ab" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b88ad18a-a999-4061-a2fb-e6968797ba74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_8beba5f9-c1d3-47fa-a385-0f6235af42cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ef325aa-eab1-41d2-a837-af2249bf39ab" xlink:to="loc_us-gaap_NotesPayableCurrent_8beba5f9-c1d3-47fa-a385-0f6235af42cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_02cf40d0-4be9-4612-bc32-5179ea14833f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ef325aa-eab1-41d2-a837-af2249bf39ab" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_02cf40d0-4be9-4612-bc32-5179ea14833f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_aa025617-f890-464e-94c0-a9b8956b7a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ef325aa-eab1-41d2-a837-af2249bf39ab" xlink:to="loc_us-gaap_LiabilitiesCurrent_aa025617-f890-464e-94c0-a9b8956b7a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_7d360746-deca-4fe2-ae2f-cdc496509c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ebadac8f-dd17-4592-a6e8-c5bfd0c22814" xlink:to="loc_us-gaap_LongTermNotesPayable_7d360746-deca-4fe2-ae2f-cdc496509c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2f6efe9c-5e99-481e-b9f7-e233f31912a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ebadac8f-dd17-4592-a6e8-c5bfd0c22814" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2f6efe9c-5e99-481e-b9f7-e233f31912a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7c28a50b-3097-4268-a95d-57554799ccb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ebadac8f-dd17-4592-a6e8-c5bfd0c22814" xlink:to="loc_us-gaap_Liabilities_7c28a50b-3097-4268-a95d-57554799ccb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2bafe9b6-7803-4088-abef-8893521bc36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ebadac8f-dd17-4592-a6e8-c5bfd0c22814" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2bafe9b6-7803-4088-abef-8893521bc36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_d9fdcd2b-f36a-482d-bf4e-4cdcb6d78cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ebadac8f-dd17-4592-a6e8-c5bfd0c22814" xlink:to="loc_us-gaap_StockholdersEquityAbstract_d9fdcd2b-f36a-482d-bf4e-4cdcb6d78cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_1e6a10d9-c8e2-44ea-9156-28a2361f4d95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d9fdcd2b-f36a-482d-bf4e-4cdcb6d78cc4" xlink:to="loc_us-gaap_CommonStockValueOutstanding_1e6a10d9-c8e2-44ea-9156-28a2361f4d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3cfef2f1-2a8d-4194-890e-8a2782ffb53b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d9fdcd2b-f36a-482d-bf4e-4cdcb6d78cc4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3cfef2f1-2a8d-4194-890e-8a2782ffb53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9547af81-dff8-49f6-9f09-190621bac139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d9fdcd2b-f36a-482d-bf4e-4cdcb6d78cc4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9547af81-dff8-49f6-9f09-190621bac139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7b1c939d-bdb6-4ddf-86e4-d0f1f365bb11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d9fdcd2b-f36a-482d-bf4e-4cdcb6d78cc4" xlink:to="loc_us-gaap_StockholdersEquity_7b1c939d-bdb6-4ddf-86e4-d0f1f365bb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c8fc6a7e-49f7-4f27-a1f9-7305a3dd5dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d9fdcd2b-f36a-482d-bf4e-4cdcb6d78cc4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c8fc6a7e-49f7-4f27-a1f9-7305a3dd5dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_aa00780b-096e-48bc-a8be-7a8731dc4b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8caeed4e-92dc-4632-a560-b3f913eaa3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aa00780b-096e-48bc-a8be-7a8731dc4b2c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8caeed4e-92dc-4632-a560-b3f913eaa3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2a336ee0-6dd4-4bef-a61f-eee5e9e9d57e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aa00780b-096e-48bc-a8be-7a8731dc4b2c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2a336ee0-6dd4-4bef-a61f-eee5e9e9d57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_319219b3-3bca-40d6-aa1a-8d94ae6a424c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aa00780b-096e-48bc-a8be-7a8731dc4b2c" xlink:to="loc_us-gaap_CommonStockSharesIssued_319219b3-3bca-40d6-aa1a-8d94ae6a424c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_aa621089-1622-4bf3-baca-6ddf5c1ef143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aa00780b-096e-48bc-a8be-7a8731dc4b2c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_aa621089-1622-4bf3-baca-6ddf5c1ef143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofOperations" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#StatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_153812d0-f2dd-4da7-a6f0-2d0bcf12b988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_561fa78f-2328-4a17-8fdd-178bd156a436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_153812d0-f2dd-4da7-a6f0-2d0bcf12b988" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_561fa78f-2328-4a17-8fdd-178bd156a436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_40ca7503-3251-47e5-b5ef-1989f2bb5a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_153812d0-f2dd-4da7-a6f0-2d0bcf12b988" xlink:to="loc_us-gaap_OperatingExpensesAbstract_40ca7503-3251-47e5-b5ef-1989f2bb5a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_69a954e1-131d-4898-a53e-1bb6ac0408e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40ca7503-3251-47e5-b5ef-1989f2bb5a6b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_69a954e1-131d-4898-a53e-1bb6ac0408e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d6235087-f34a-4e2c-baff-c7a2d217c2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40ca7503-3251-47e5-b5ef-1989f2bb5a6b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d6235087-f34a-4e2c-baff-c7a2d217c2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3cd4f5b2-9738-4701-87c6-c0b82bbaa5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40ca7503-3251-47e5-b5ef-1989f2bb5a6b" xlink:to="loc_us-gaap_OperatingExpenses_3cd4f5b2-9738-4701-87c6-c0b82bbaa5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ce460ce8-3b1a-4a15-87e5-63b602e20b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_153812d0-f2dd-4da7-a6f0-2d0bcf12b988" xlink:to="loc_us-gaap_OperatingIncomeLoss_ce460ce8-3b1a-4a15-87e5-63b602e20b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_5eead536-ed29-41bc-b013-9f657b2a5e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_153812d0-f2dd-4da7-a6f0-2d0bcf12b988" xlink:to="loc_us-gaap_OtherNonoperatingIncome_5eead536-ed29-41bc-b013-9f657b2a5e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_67ac51ff-16af-4420-b89d-fd97fe10a6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_153812d0-f2dd-4da7-a6f0-2d0bcf12b988" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_67ac51ff-16af-4420-b89d-fd97fe10a6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_f6899b50-09e5-46ed-a4a1-28bed9bf75a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_153812d0-f2dd-4da7-a6f0-2d0bcf12b988" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_f6899b50-09e5-46ed-a4a1-28bed9bf75a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_25de9fe6-9323-4e71-a57e-6bbd6f45571a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_153812d0-f2dd-4da7-a6f0-2d0bcf12b988" xlink:to="loc_us-gaap_NetIncomeLoss_25de9fe6-9323-4e71-a57e-6bbd6f45571a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_519b31ca-7c9e-4a4a-b4c8-5aaea4f498f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_153812d0-f2dd-4da7-a6f0-2d0bcf12b988" xlink:to="loc_us-gaap_EarningsPerShareBasic_519b31ca-7c9e-4a4a-b4c8-5aaea4f498f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5cc89db3-7d7b-4b36-8f51-bd1bc6b30070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_153812d0-f2dd-4da7-a6f0-2d0bcf12b988" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5cc89db3-7d7b-4b36-8f51-bd1bc6b30070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d67da869-b037-4257-acf0-9724bbec4d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_153812d0-f2dd-4da7-a6f0-2d0bcf12b988" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d67da869-b037-4257-acf0-9724bbec4d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2eb53e74-382b-4c72-a075-e70f0970278b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_153812d0-f2dd-4da7-a6f0-2d0bcf12b988" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2eb53e74-382b-4c72-a075-e70f0970278b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#StatementsofChangesinStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e7be5bc2-2ccd-4c02-adf0-d257e63943fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e6070886-e2e6-438a-a43b-4aeeea567cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e7be5bc2-2ccd-4c02-adf0-d257e63943fa" xlink:to="loc_us-gaap_StatementTable_e6070886-e2e6-438a-a43b-4aeeea567cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d89ad35b-a2e4-4a78-9d62-6e4a26e713ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e6070886-e2e6-438a-a43b-4aeeea567cbb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d89ad35b-a2e4-4a78-9d62-6e4a26e713ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1cb56d3a-740d-4535-a7bd-b4b0c798bed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d89ad35b-a2e4-4a78-9d62-6e4a26e713ce" xlink:to="loc_us-gaap_EquityComponentDomain_1cb56d3a-740d-4535-a7bd-b4b0c798bed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dcd059e0-5dc9-40c4-b38a-daeab840c344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1cb56d3a-740d-4535-a7bd-b4b0c798bed4" xlink:to="loc_us-gaap_CommonStockMember_dcd059e0-5dc9-40c4-b38a-daeab840c344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d27d0d95-c0ad-4ab6-8e33-d4197e9d5e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1cb56d3a-740d-4535-a7bd-b4b0c798bed4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d27d0d95-c0ad-4ab6-8e33-d4197e9d5e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a1c50c23-32dd-4ae5-9e51-c552e61a6357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1cb56d3a-740d-4535-a7bd-b4b0c798bed4" xlink:to="loc_us-gaap_RetainedEarningsMember_a1c50c23-32dd-4ae5-9e51-c552e61a6357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e6070886-e2e6-438a-a43b-4aeeea567cbb" xlink:to="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_34995986-6a70-4721-8740-1a920630aebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_34995986-6a70-4721-8740-1a920630aebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_37abcb76-c12c-4418-a6be-bec802fe9b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockholdersEquity_37abcb76-c12c-4418-a6be-bec802fe9b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_15c2e638-f4ac-4cb0-83ab-43adf73b9421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_15c2e638-f4ac-4cb0-83ab-43adf73b9421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9957b614-2028-4252-9a86-45a69807d6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9957b614-2028-4252-9a86-45a69807d6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0be8426b-bd22-455c-98cb-85a835a31d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0be8426b-bd22-455c-98cb-85a835a31d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_82dc4483-cd7e-46a4-9b60-be3a03d3b6df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_82dc4483-cd7e-46a4-9b60-be3a03d3b6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_fc651c46-d6d6-45f7-a824-a72a33a666c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_fc651c46-d6d6-45f7-a824-a72a33a666c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_923d46e2-b166-4c7b-82e0-6e727159c877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_923d46e2-b166-4c7b-82e0-6e727159c877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_4d9b234e-0c79-4a9e-85c8-68c7afb5f92e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_4d9b234e-0c79-4a9e-85c8-68c7afb5f92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2f3fe13b-4c1e-4df8-84d3-7281f25384af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2f3fe13b-4c1e-4df8-84d3-7281f25384af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5e1e9ba7-3414-4220-b3f5-2a2a34fd70f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_NetIncomeLoss_5e1e9ba7-3414-4220-b3f5-2a2a34fd70f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bbfa4e13-034c-46fd-bc88-36c2b854e4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bbfa4e13-034c-46fd-bc88-36c2b854e4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8e1b6bb1-27cf-467b-a217-0d7658f21693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_292254f3-015a-439b-b81a-64ef9bf4ad3c" xlink:to="loc_us-gaap_StockholdersEquity_8e1b6bb1-27cf-467b-a217-0d7658f21693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#StatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6713c898-71c1-48bb-b7ce-4bb63c200744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_509f2acb-5493-440e-b0f4-08f0bb28e6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6713c898-71c1-48bb-b7ce-4bb63c200744" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_509f2acb-5493-440e-b0f4-08f0bb28e6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b10be115-9fd7-4969-b54a-8cebe1ffb70b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_509f2acb-5493-440e-b0f4-08f0bb28e6c8" xlink:to="loc_us-gaap_NetIncomeLoss_b10be115-9fd7-4969-b54a-8cebe1ffb70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4a735a9-9406-4aa7-bd5b-57c4acd28e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_509f2acb-5493-440e-b0f4-08f0bb28e6c8" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4a735a9-9406-4aa7-bd5b-57c4acd28e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_51350a21-bc20-42cd-9d5d-5595c200c359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4a735a9-9406-4aa7-bd5b-57c4acd28e96" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_51350a21-bc20-42cd-9d5d-5595c200c359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9a6f4307-854e-401b-aae3-cda4e4ff13fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4a735a9-9406-4aa7-bd5b-57c4acd28e96" xlink:to="loc_us-gaap_ShareBasedCompensation_9a6f4307-854e-401b-aae3-cda4e4ff13fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_f8a8cbc8-3d88-4ee0-8efb-8dc6a3214e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4a735a9-9406-4aa7-bd5b-57c4acd28e96" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_f8a8cbc8-3d88-4ee0-8efb-8dc6a3214e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument_1cda3d79-e35b-4ba1-8b5c-a086de805e0f" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4a735a9-9406-4aa7-bd5b-57c4acd28e96" xlink:to="loc_ck0001824293_ForgivenessOfDebtInstrument_1cda3d79-e35b-4ba1-8b5c-a086de805e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_4ce51272-4463-455f-bd58-716743dd0c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4a735a9-9406-4aa7-bd5b-57c4acd28e96" xlink:to="loc_us-gaap_OtherNoncashExpense_4ce51272-4463-455f-bd58-716743dd0c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_398c997e-33e7-41d8-adf0-28bf4d424786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4a735a9-9406-4aa7-bd5b-57c4acd28e96" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_398c997e-33e7-41d8-adf0-28bf4d424786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b2d08da8-8ff1-4b66-a74b-8a8ee7076305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_398c997e-33e7-41d8-adf0-28bf4d424786" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b2d08da8-8ff1-4b66-a74b-8a8ee7076305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a603c75b-24da-4cd1-b970-02f36686b6da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_398c997e-33e7-41d8-adf0-28bf4d424786" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a603c75b-24da-4cd1-b970-02f36686b6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8f9489e0-86a5-4efb-b4db-cae194012a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_398c997e-33e7-41d8-adf0-28bf4d424786" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8f9489e0-86a5-4efb-b4db-cae194012a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7bddb291-aa84-4fdc-ad0c-678282ee8d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4a735a9-9406-4aa7-bd5b-57c4acd28e96" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7bddb291-aa84-4fdc-ad0c-678282ee8d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce1ea4ab-9a9b-40e2-abad-f86715dcf7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6713c898-71c1-48bb-b7ce-4bb63c200744" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce1ea4ab-9a9b-40e2-abad-f86715dcf7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fe43b1ed-9597-4e27-86df-385bdf903930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce1ea4ab-9a9b-40e2-abad-f86715dcf7e7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fe43b1ed-9597-4e27-86df-385bdf903930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f4e363f9-54cf-4daf-ba12-f759ab61c91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce1ea4ab-9a9b-40e2-abad-f86715dcf7e7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f4e363f9-54cf-4daf-ba12-f759ab61c91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_577ca574-ab83-480e-9b08-f03dfc52c21e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6713c898-71c1-48bb-b7ce-4bb63c200744" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_577ca574-ab83-480e-9b08-f03dfc52c21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_bd998920-6884-4e02-8512-2f400414aa84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_577ca574-ab83-480e-9b08-f03dfc52c21e" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_bd998920-6884-4e02-8512-2f400414aa84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_f9697efc-e736-4cfc-8b14-d883fbb68c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_577ca574-ab83-480e-9b08-f03dfc52c21e" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_f9697efc-e736-4cfc-8b14-d883fbb68c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_e8fe1e4c-5a90-41fe-ac53-65e6ef88e22f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_577ca574-ab83-480e-9b08-f03dfc52c21e" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_e8fe1e4c-5a90-41fe-ac53-65e6ef88e22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_c5432357-39eb-482b-ad1f-ad88c08a47e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_577ca574-ab83-480e-9b08-f03dfc52c21e" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_c5432357-39eb-482b-ad1f-ad88c08a47e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c0965518-214a-4a92-8822-119e869eedc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_577ca574-ab83-480e-9b08-f03dfc52c21e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c0965518-214a-4a92-8822-119e869eedc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d6f6dd3f-b6d8-4f50-8abc-627af137baf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6713c898-71c1-48bb-b7ce-4bb63c200744" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d6f6dd3f-b6d8-4f50-8abc-627af137baf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb295b44-aacb-474d-bd8f-96d9703d950e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6713c898-71c1-48bb-b7ce-4bb63c200744" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb295b44-aacb-474d-bd8f-96d9703d950e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45abe308-4dc5-4bf0-bba3-99fd262ff913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6713c898-71c1-48bb-b7ce-4bb63c200744" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45abe308-4dc5-4bf0-bba3-99fd262ff913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9357d460-5079-405e-b475-23eb9e9eee7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6713c898-71c1-48bb-b7ce-4bb63c200744" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9357d460-5079-405e-b475-23eb9e9eee7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0aee56bc-7479-4936-be9d-4ea27797d1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9357d460-5079-405e-b475-23eb9e9eee7b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0aee56bc-7479-4936-be9d-4ea27797d1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4449a11d-fb1c-40d0-a26b-14be762fe19f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_463ce835-2b19-4a1b-b365-181640b04f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4449a11d-fb1c-40d0-a26b-14be762fe19f" xlink:to="loc_us-gaap_NatureOfOperations_463ce835-2b19-4a1b-b365-181640b04f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a72968d-f626-43c4-9841-942395d5d5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a419bca7-dadd-43b8-bb54-23c0f5075ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a72968d-f626-43c4-9841-942395d5d5e1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a419bca7-dadd-43b8-bb54-23c0f5075ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b2e5d187-6eb1-43fb-9c79-3ce7b2815532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a419bca7-dadd-43b8-bb54-23c0f5075ecb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b2e5d187-6eb1-43fb-9c79-3ce7b2815532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_00cc6354-3064-4961-9c0a-5ed1a073bacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b2e5d187-6eb1-43fb-9c79-3ce7b2815532" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_00cc6354-3064-4961-9c0a-5ed1a073bacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_e56a98a2-8046-4ff3-9618-1adb15dc003a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_00cc6354-3064-4961-9c0a-5ed1a073bacc" xlink:to="loc_us-gaap_IPOMember_e56a98a2-8046-4ff3-9618-1adb15dc003a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c90f33c9-04cf-4af9-a6ce-99bc31ba16dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a419bca7-dadd-43b8-bb54-23c0f5075ecb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c90f33c9-04cf-4af9-a6ce-99bc31ba16dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8ef540a9-9284-4b7f-be94-c255b55823d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c90f33c9-04cf-4af9-a6ce-99bc31ba16dc" xlink:to="loc_us-gaap_RelatedPartyDomain_8ef540a9-9284-4b7f-be94-c255b55823d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_b2edea79-750e-4dde-b19c-cc95e395efc2" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8ef540a9-9284-4b7f-be94-c255b55823d9" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_b2edea79-750e-4dde-b19c-cc95e395efc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_111dca61-3269-4bd5-a789-8c04962d0f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a419bca7-dadd-43b8-bb54-23c0f5075ecb" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_111dca61-3269-4bd5-a789-8c04962d0f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_84047c20-a1cb-4bc9-be6c-a73f35eb2873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_111dca61-3269-4bd5-a789-8c04962d0f82" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_84047c20-a1cb-4bc9-be6c-a73f35eb2873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_a681bc01-cf8a-4e64-8339-6123462fa735" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_84047c20-a1cb-4bc9-be6c-a73f35eb2873" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_a681bc01-cf8a-4e64-8339-6123462fa735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a419bca7-dadd-43b8-bb54-23c0f5075ecb" xlink:to="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b9882081-a53d-4795-beda-38e589825fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b9882081-a53d-4795-beda-38e589825fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_388489a0-568b-4daa-939a-9fd7e1d01424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_388489a0-568b-4daa-939a-9fd7e1d01424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9fec916a-455b-48d1-bd0c-2d7134f51ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9fec916a-455b-48d1-bd0c-2d7134f51ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_61f7210f-869f-42ab-a75e-3ef56954e9f4" xlink:href="ck0001824293-20210630.xsd#ck0001824293_StockIssuanceCostsDiscountsAndCommissions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_61f7210f-869f-42ab-a75e-3ef56954e9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_8902b67d-f3df-47f2-8cdb-e05c661d65db" xlink:href="ck0001824293-20210630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_8902b67d-f3df-47f2-8cdb-e05c661d65db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_61d24d2d-4100-4376-9734-59a8acb46b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_61d24d2d-4100-4376-9734-59a8acb46b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3de558cb-d200-44ec-923e-69055e580d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3de558cb-d200-44ec-923e-69055e580d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate_72e4f9c9-a71f-44e8-a8d0-352efde1b009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentRate_72e4f9c9-a71f-44e8-a8d0-352efde1b009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b92d1663-42ef-454a-b32a-cc245911efc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd4e5fa1-47ef-419d-90b6-14c7fcf0251b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b92d1663-42ef-454a-b32a-cc245911efc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#LIQUIDITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ece15097-f777-467f-9285-63df2e89382d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_7ed13cfd-4a1c-4d10-ac3e-fb1e520d0229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ece15097-f777-467f-9285-63df2e89382d" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_7ed13cfd-4a1c-4d10-ac3e-fb1e520d0229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#LIQUIDITYDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_136b729c-4755-4a3a-95ef-2808380e1ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_579b35ab-daf3-4191-8dd2-5825da398291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_136b729c-4755-4a3a-95ef-2808380e1ad6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_579b35ab-daf3-4191-8dd2-5825da398291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_fa6f6f55-6085-4081-87e9-5007cd2e3cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_136b729c-4755-4a3a-95ef-2808380e1ad6" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_fa6f6f55-6085-4081-87e9-5007cd2e3cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5ccb2744-5005-45b6-87b1-85dbd73a8106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_136b729c-4755-4a3a-95ef-2808380e1ad6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5ccb2744-5005-45b6-87b1-85dbd73a8106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_000858d8-98be-4561-a9e5-51e17a1da46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_136b729c-4755-4a3a-95ef-2808380e1ad6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_000858d8-98be-4561-a9e5-51e17a1da46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_786c5390-d408-4df9-bf89-b3985632efb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1939b498-661a-4b9f-a030-3c38bb5223a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_786c5390-d408-4df9-bf89-b3985632efb7" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1939b498-661a-4b9f-a030-3c38bb5223a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ffdf2b7b-7c1e-4e72-acc0-8c839772fe1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a2198410-a2a8-4533-ab9c-b42a8d0e7604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ffdf2b7b-7c1e-4e72-acc0-8c839772fe1c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a2198410-a2a8-4533-ab9c-b42a8d0e7604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_72d036db-99cc-4fde-aa70-03032a60473b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ffdf2b7b-7c1e-4e72-acc0-8c839772fe1c" xlink:to="loc_us-gaap_UseOfEstimates_72d036db-99cc-4fde-aa70-03032a60473b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_92a2ed12-12db-4702-ba6e-bd3f1423401d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ffdf2b7b-7c1e-4e72-acc0-8c839772fe1c" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_92a2ed12-12db-4702-ba6e-bd3f1423401d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fdb4a5cb-39d9-4d8c-a4fc-42125c73ae73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ffdf2b7b-7c1e-4e72-acc0-8c839772fe1c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fdb4a5cb-39d9-4d8c-a4fc-42125c73ae73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0f0d04fd-b8ca-4031-8c7b-39af12273093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_54d349b1-ab61-43d8-813c-5799df1914a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f0d04fd-b8ca-4031-8c7b-39af12273093" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_54d349b1-ab61-43d8-813c-5799df1914a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_da3c01f5-9a03-4818-836b-52873ec0f750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_acb4a4b2-caec-41cb-bcf0-f33bffa4a405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_da3c01f5-9a03-4818-836b-52873ec0f750" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_acb4a4b2-caec-41cb-bcf0-f33bffa4a405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_26b1cc01-0969-4ff1-a58f-f71ac5c66287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_67443b98-9a9e-4a4a-b6e6-f7f9761a21ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_26b1cc01-0969-4ff1-a58f-f71ac5c66287" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_67443b98-9a9e-4a4a-b6e6-f7f9761a21ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#ACCRUEDEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a107107f-e5fa-4b3f-a3d2-7c837cd3f632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_b5426384-c418-4c1d-962d-40f048612026" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a107107f-e5fa-4b3f-a3d2-7c837cd3f632" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_b5426384-c418-4c1d-962d-40f048612026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_512d2011-515a-4556-8d5d-004bedf24e63" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a107107f-e5fa-4b3f-a3d2-7c837cd3f632" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_512d2011-515a-4556-8d5d-004bedf24e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fcf521ba-79d8-4ccb-9af3-5b2bd8bde56b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a107107f-e5fa-4b3f-a3d2-7c837cd3f632" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fcf521ba-79d8-4ccb-9af3-5b2bd8bde56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedLicensingFeesCurrent_af31ba1f-1c16-4a12-be0a-c47f145958a7" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AccruedLicensingFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a107107f-e5fa-4b3f-a3d2-7c837cd3f632" xlink:to="loc_ck0001824293_AccruedLicensingFeesCurrent_af31ba1f-1c16-4a12-be0a-c47f145958a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ab511009-e27a-491e-9de5-d5a4f71ff1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a107107f-e5fa-4b3f-a3d2-7c837cd3f632" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ab511009-e27a-491e-9de5-d5a4f71ff1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4429463a-b06b-4b2c-a789-568d46199d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a107107f-e5fa-4b3f-a3d2-7c837cd3f632" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4429463a-b06b-4b2c-a789-568d46199d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#PPPNOTEANDCONVERTIBLENOTES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f46d2c65-1f28-4447-9b83-c5a77a4341f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_181f450f-084d-437d-bb62-dc8899ca6143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f46d2c65-1f28-4447-9b83-c5a77a4341f0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_181f450f-084d-437d-bb62-dc8899ca6143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#PPPNOTEANDCONVERTIBLENOTESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_76da6e09-eeb6-4356-95d8-45b77acb51b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42681872-a893-40ee-8814-61a91cbfc6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_76da6e09-eeb6-4356-95d8-45b77acb51b6" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42681872-a893-40ee-8814-61a91cbfc6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_67730733-8473-4ca7-9451-a19d7e83eb50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42681872-a893-40ee-8814-61a91cbfc6f7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_67730733-8473-4ca7-9451-a19d7e83eb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7d199521-5bd0-4a40-8fba-fafa058ad82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_67730733-8473-4ca7-9451-a19d7e83eb50" xlink:to="loc_us-gaap_RelatedPartyDomain_7d199521-5bd0-4a40-8fba-fafa058ad82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_aaa4b990-aa7f-4f31-ae27-0f03f1262615" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7d199521-5bd0-4a40-8fba-fafa058ad82c" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_aaa4b990-aa7f-4f31-ae27-0f03f1262615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_48f47369-1f19-4dc2-a468-fd16d8063653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42681872-a893-40ee-8814-61a91cbfc6f7" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_48f47369-1f19-4dc2-a468-fd16d8063653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3f734247-d9bb-4828-87a1-be2659526e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_48f47369-1f19-4dc2-a468-fd16d8063653" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3f734247-d9bb-4828-87a1-be2659526e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_d8f55781-33a5-47d3-9056-f9903d5b2450" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3f734247-d9bb-4828-87a1-be2659526e0d" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_d8f55781-33a5-47d3-9056-f9903d5b2450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1cd51978-4bae-4f30-aeb0-21a64ef35577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42681872-a893-40ee-8814-61a91cbfc6f7" xlink:to="loc_us-gaap_DebtInstrumentAxis_1cd51978-4bae-4f30-aeb0-21a64ef35577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2980b4e9-d32f-4e12-8374-a678fca1c253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1cd51978-4bae-4f30-aeb0-21a64ef35577" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2980b4e9-d32f-4e12-8374-a678fca1c253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_fae96b4b-f76c-4ae4-9462-ff01a0e0da08" xlink:href="ck0001824293-20210630.xsd#ck0001824293_PaycheckProtectionProgramCARESActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2980b4e9-d32f-4e12-8374-a678fca1c253" xlink:to="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_fae96b4b-f76c-4ae4-9462-ff01a0e0da08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42681872-a893-40ee-8814-61a91cbfc6f7" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_22380847-d51c-477d-99ff-10ff1f34ba82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_22380847-d51c-477d-99ff-10ff1f34ba82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a466b9e6-b319-4fa3-a71e-ec10944249ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a466b9e6-b319-4fa3-a71e-ec10944249ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_9c6dfee0-c5e1-45d2-90dd-45ec503635de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_us-gaap_DebtInstrumentTerm_9c6dfee0-c5e1-45d2-90dd-45ec503635de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentPaymentTerm_551915e5-9e79-48fa-a4a7-64c59371d898" xlink:href="ck0001824293-20210630.xsd#ck0001824293_DebtInstrumentPaymentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_ck0001824293_DebtInstrumentPaymentTerm_551915e5-9e79-48fa-a4a7-64c59371d898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument_60b21faa-db61-476a-960d-d94040127cc6" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_ck0001824293_ForgivenessOfDebtInstrument_60b21faa-db61-476a-960d-d94040127cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_60b0325a-0eca-4e2f-bddb-269e9111cd84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_60b0325a-0eca-4e2f-bddb-269e9111cd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_52a34bc7-05f2-48a5-bac6-f2f0c81b54b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2bde8589-27ff-4d2b-b713-6e577109618e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fa78327d-e3c9-4338-9840-ae52d503e0e1" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2bde8589-27ff-4d2b-b713-6e577109618e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#STOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_17d55a55-79de-4b0d-968b-66dd648205c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d3373794-74b8-4980-9418-455198be9980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_17d55a55-79de-4b0d-968b-66dd648205c6" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d3373794-74b8-4980-9418-455198be9980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#STOCKHOLDERSEQUITYDEFICITTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_09f2ff8e-7da9-4ce8-85f9-f7ecdafaabf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ebc33261-60ad-40b4-bc5d-3fa7da090778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_09f2ff8e-7da9-4ce8-85f9-f7ecdafaabf0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ebc33261-60ad-40b4-bc5d-3fa7da090778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#STOCKHOLDERSEQUITYDEFICITDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8ac3fae4-b031-4912-8982-8d16d0fc2382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ce5037e9-2184-48ae-921e-46cb6c7c6297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8ac3fae4-b031-4912-8982-8d16d0fc2382" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ce5037e9-2184-48ae-921e-46cb6c7c6297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0378f470-eeb6-4a33-b61c-40d44cf338e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ce5037e9-2184-48ae-921e-46cb6c7c6297" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0378f470-eeb6-4a33-b61c-40d44cf338e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7a2ba766-aa29-4e67-b4c1-23fcf5d55900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0378f470-eeb6-4a33-b61c-40d44cf338e7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7a2ba766-aa29-4e67-b4c1-23fcf5d55900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_f9e1193b-4114-401b-a36d-e919e87f831e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7a2ba766-aa29-4e67-b4c1-23fcf5d55900" xlink:to="loc_us-gaap_IPOMember_f9e1193b-4114-401b-a36d-e919e87f831e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_6bbe1c3f-aee2-4e5a-8538-314bda61e530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7a2ba766-aa29-4e67-b4c1-23fcf5d55900" xlink:to="loc_us-gaap_OverAllotmentOptionMember_6bbe1c3f-aee2-4e5a-8538-314bda61e530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ce5037e9-2184-48ae-921e-46cb6c7c6297" xlink:to="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8b66a769-ebfb-443d-aae0-bebda791387d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8b66a769-ebfb-443d-aae0-bebda791387d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_42d1f5fc-39da-42eb-8355-b1f994044abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_42d1f5fc-39da-42eb-8355-b1f994044abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_015ff2f6-3cb7-4fbe-be7e-0a10bb8c0708" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_015ff2f6-3cb7-4fbe-be7e-0a10bb8c0708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_b51863ce-f0a1-4a0e-b975-aab283feccfd" xlink:href="ck0001824293-20210630.xsd#ck0001824293_StockIssuanceCostsDiscountsAndCommissions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_b51863ce-f0a1-4a0e-b975-aab283feccfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_cb1c0a95-a0f1-4860-8181-1db3b7902009" xlink:href="ck0001824293-20210630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_cb1c0a95-a0f1-4860-8181-1db3b7902009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ac056d90-eafc-4d8c-9d0d-cb3a5005994a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ac056d90-eafc-4d8c-9d0d-cb3a5005994a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7e24fb46-8024-4fd7-8af6-3c599ae3dce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7e24fb46-8024-4fd7-8af6-3c599ae3dce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26972298-9a59-43cd-bc68-86318aa7272f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26972298-9a59-43cd-bc68-86318aa7272f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_d2907f4c-7cf4-48d4-b302-c24e1cbb4887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_d2907f4c-7cf4-48d4-b302-c24e1cbb4887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1307e5ec-8dac-4a8b-9ef7-10db0b65b99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89d8b702-96ba-4f24-9f95-60be4127f0fe" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1307e5ec-8dac-4a8b-9ef7-10db0b65b99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3a98e44a-136d-475c-b9cf-bf59fb3bf1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d61014c3-9d29-4da8-8764-d1e0002a2b74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3a98e44a-136d-475c-b9cf-bf59fb3bf1a2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d61014c3-9d29-4da8-8764-d1e0002a2b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_de1a4bee-4a25-4dc0-9f86-01237e4f5346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d61014c3-9d29-4da8-8764-d1e0002a2b74" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_de1a4bee-4a25-4dc0-9f86-01237e4f5346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d3fa968b-6c16-4936-bfdf-bf994116a758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_de1a4bee-4a25-4dc0-9f86-01237e4f5346" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d3fa968b-6c16-4936-bfdf-bf994116a758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_1584b2bd-e72c-4b53-856b-791ece13deab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d3fa968b-6c16-4936-bfdf-bf994116a758" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_1584b2bd-e72c-4b53-856b-791ece13deab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_08cadda5-f0eb-4f96-935a-08f7a9d1a31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d3fa968b-6c16-4936-bfdf-bf994116a758" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_08cadda5-f0eb-4f96-935a-08f7a9d1a31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_b9e9360f-47f1-4f43-bf4c-05e1e2fe86f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d3fa968b-6c16-4936-bfdf-bf994116a758" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_b9e9360f-47f1-4f43-bf4c-05e1e2fe86f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a5af562f-8bec-42db-a060-acaa698cac42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d3fa968b-6c16-4936-bfdf-bf994116a758" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a5af562f-8bec-42db-a060-acaa698cac42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0a512f5a-ea6b-4522-a0c0-a06b012c41a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d61014c3-9d29-4da8-8764-d1e0002a2b74" xlink:to="loc_us-gaap_ClassOfStockLineItems_0a512f5a-ea6b-4522-a0c0-a06b012c41a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_b5068c37-4c78-44e9-9645-cfad67c1f5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0a512f5a-ea6b-4522-a0c0-a06b012c41a4" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_b5068c37-4c78-44e9-9645-cfad67c1f5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c27d3b45-02ff-4ffa-8517-ba611a8cd514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a29389cd-b03b-4782-9557-48f645b3b815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c27d3b45-02ff-4ffa-8517-ba611a8cd514" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a29389cd-b03b-4782-9557-48f645b3b815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e23d89d3-fd7c-4993-91dc-1116c67c7b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_179b9b2c-24b4-4c5a-ae11-6e48411b8b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e23d89d3-fd7c-4993-91dc-1116c67c7b47" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_179b9b2c-24b4-4c5a-ae11-6e48411b8b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_281634ce-7bd2-4a74-ab5a-2a526e82ee7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e23d89d3-fd7c-4993-91dc-1116c67c7b47" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_281634ce-7bd2-4a74-ab5a-2a526e82ee7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0caa49b3-7225-4e40-a613-b417f9c9f91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e23d89d3-fd7c-4993-91dc-1116c67c7b47" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0caa49b3-7225-4e40-a613-b417f9c9f91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ae7d638-e6a4-492d-97e3-a1d66e564dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9a8093a4-3dd3-4b7a-bcb8-cace9aeee654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ae7d638-e6a4-492d-97e3-a1d66e564dee" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9a8093a4-3dd3-4b7a-bcb8-cace9aeee654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8b9fcf6c-3549-492a-8f54-96333ec8b769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9a8093a4-3dd3-4b7a-bcb8-cace9aeee654" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8b9fcf6c-3549-492a-8f54-96333ec8b769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f24c8dec-4a97-4672-8ba5-7593449baa74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8b9fcf6c-3549-492a-8f54-96333ec8b769" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f24c8dec-4a97-4672-8ba5-7593449baa74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_809eab55-a9fb-4acd-a3b4-e517410ab387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f24c8dec-4a97-4672-8ba5-7593449baa74" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_809eab55-a9fb-4acd-a3b4-e517410ab387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d7f37eab-94e1-4618-a57a-a4bf7119c840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f24c8dec-4a97-4672-8ba5-7593449baa74" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d7f37eab-94e1-4618-a57a-a4bf7119c840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0e645082-15ef-4aad-8e37-5632aaad0d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9a8093a4-3dd3-4b7a-bcb8-cace9aeee654" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0e645082-15ef-4aad-8e37-5632aaad0d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_48a319ac-b69b-4902-a6ab-50c588191f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0e645082-15ef-4aad-8e37-5632aaad0d17" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_48a319ac-b69b-4902-a6ab-50c588191f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ece8840f-4aa4-488f-ab56-571b45783ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ad7bc18c-88cc-4183-b9ab-3bda8b364cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ece8840f-4aa4-488f-ab56-571b45783ba6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ad7bc18c-88cc-4183-b9ab-3bda8b364cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d4bee5e4-a98a-4cde-b5d8-f3fff417c4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ece8840f-4aa4-488f-ab56-571b45783ba6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d4bee5e4-a98a-4cde-b5d8-f3fff417c4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d32c1b7f-89cd-4d18-b919-8f222c59141d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ece8840f-4aa4-488f-ab56-571b45783ba6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d32c1b7f-89cd-4d18-b919-8f222c59141d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_174e3b35-54fe-409a-bb0f-9920689774a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_31a85384-1365-4cad-8343-e249ee12987b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_174e3b35-54fe-409a-bb0f-9920689774a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_31a85384-1365-4cad-8343-e249ee12987b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2c0a3429-4eea-4e41-a8a5-ab077ec868ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_31a85384-1365-4cad-8343-e249ee12987b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2c0a3429-4eea-4e41-a8a5-ab077ec868ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_379e1075-4e30-42e0-9fbf-15b6ca838f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_31a85384-1365-4cad-8343-e249ee12987b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_379e1075-4e30-42e0-9fbf-15b6ca838f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_965ba56e-0c41-4767-8ce2-b6cc5b7afdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_31a85384-1365-4cad-8343-e249ee12987b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_965ba56e-0c41-4767-8ce2-b6cc5b7afdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6e7e2aa5-fc4b-4452-b046-d77b29ad0bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_31a85384-1365-4cad-8343-e249ee12987b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6e7e2aa5-fc4b-4452-b046-d77b29ad0bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0791171d-088b-4016-8f0d-449e6ac3aa67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_174e3b35-54fe-409a-bb0f-9920689774a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0791171d-088b-4016-8f0d-449e6ac3aa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7b677c76-1037-4bd0-8045-85970c47571e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0791171d-088b-4016-8f0d-449e6ac3aa67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7b677c76-1037-4bd0-8045-85970c47571e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a71caa89-5534-4832-b163-8ed3f0de113f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0791171d-088b-4016-8f0d-449e6ac3aa67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a71caa89-5534-4832-b163-8ed3f0de113f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2752df79-676e-4a99-b0e9-a3e20e1a2ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0791171d-088b-4016-8f0d-449e6ac3aa67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2752df79-676e-4a99-b0e9-a3e20e1a2ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_17b20f49-3c31-47db-a449-73177a04d459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0791171d-088b-4016-8f0d-449e6ac3aa67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_17b20f49-3c31-47db-a449-73177a04d459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c61fe68-4f33-4f5e-99aa-297af27d153d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_174e3b35-54fe-409a-bb0f-9920689774a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c61fe68-4f33-4f5e-99aa-297af27d153d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_269aa9fc-b5ad-4880-bea8-100efe951c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c61fe68-4f33-4f5e-99aa-297af27d153d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_269aa9fc-b5ad-4880-bea8-100efe951c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_776eefcd-fe2b-4ed7-be82-dfc6e8846be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c61fe68-4f33-4f5e-99aa-297af27d153d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_776eefcd-fe2b-4ed7-be82-dfc6e8846be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c387b3de-06c0-430e-9280-2e9b75cda451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c61fe68-4f33-4f5e-99aa-297af27d153d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c387b3de-06c0-430e-9280-2e9b75cda451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2be5f521-71ce-4877-bdee-8093773f3060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c71f7c3b-2635-4fe5-bc80-ec32672f417a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2be5f521-71ce-4877-bdee-8093773f3060" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c71f7c3b-2635-4fe5-bc80-ec32672f417a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9f184973-47c2-4e31-ac27-70cbd5c48b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2be5f521-71ce-4877-bdee-8093773f3060" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9f184973-47c2-4e31-ac27-70cbd5c48b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ec5125da-dcf2-4542-90f9-fcc54bc32a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2be5f521-71ce-4877-bdee-8093773f3060" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ec5125da-dcf2-4542-90f9-fcc54bc32a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f315467c-7a08-4c21-9b24-93e136c1db84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2be5f521-71ce-4877-bdee-8093773f3060" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f315467c-7a08-4c21-9b24-93e136c1db84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7fc5f77b-dfc5-49ff-96ef-7c82948cb931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2be5f521-71ce-4877-bdee-8093773f3060" xlink:to="loc_us-gaap_SharePrice_7fc5f77b-dfc5-49ff-96ef-7c82948cb931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f3e9226b-ace5-490f-a9eb-5db5d1ada940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_93775a50-1fab-41c9-95b3-1eeeff6f0131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f3e9226b-ace5-490f-a9eb-5db5d1ada940" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_93775a50-1fab-41c9-95b3-1eeeff6f0131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_8df63d0c-d026-4c42-8f8c-c16108a20c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_62b4a730-1a45-4359-9a77-ded9c28482f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_8df63d0c-d026-4c42-8f8c-c16108a20c03" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_62b4a730-1a45-4359-9a77-ded9c28482f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c94e4808-d1d5-4580-abbe-26f19eec510f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_62b4a730-1a45-4359-9a77-ded9c28482f5" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c94e4808-d1d5-4580-abbe-26f19eec510f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_bf45643f-7ceb-47ce-a358-86bb6a199ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c94e4808-d1d5-4580-abbe-26f19eec510f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_bf45643f-7ceb-47ce-a358-86bb6a199ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_7cb2131a-0785-48ea-8494-83164e93f625" xlink:href="ck0001824293-20210630.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_bf45643f-7ceb-47ce-a358-86bb6a199ecc" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_7cb2131a-0785-48ea-8494-83164e93f625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_288133d1-1a15-457f-b499-8df74c5698fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_62b4a730-1a45-4359-9a77-ded9c28482f5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_288133d1-1a15-457f-b499-8df74c5698fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e80540f9-872d-47d7-a5fd-c57c3d5080f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_288133d1-1a15-457f-b499-8df74c5698fc" xlink:to="loc_us-gaap_RelatedPartyDomain_e80540f9-872d-47d7-a5fd-c57c3d5080f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_d9db3a53-f722-4851-a6d3-a6c67da9847c" xlink:href="ck0001824293-20210630.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e80540f9-872d-47d7-a5fd-c57c3d5080f4" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_d9db3a53-f722-4851-a6d3-a6c67da9847c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_MediceMember_eefc8571-913d-435d-b55f-9868b31a00e8" xlink:href="ck0001824293-20210630.xsd#ck0001824293_MediceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e80540f9-872d-47d7-a5fd-c57c3d5080f4" xlink:to="loc_ck0001824293_MediceMember_eefc8571-913d-435d-b55f-9868b31a00e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_93ec151b-f608-4dd8-97a8-c0679cf6c8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_62b4a730-1a45-4359-9a77-ded9c28482f5" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_93ec151b-f608-4dd8-97a8-c0679cf6c8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment_7fb3a980-675c-4d41-8701-417272f2a085" xlink:href="ck0001824293-20210630.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_93ec151b-f608-4dd8-97a8-c0679cf6c8ff" xlink:to="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment_7fb3a980-675c-4d41-8701-417272f2a085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_4520a46f-30cb-4d80-86ac-f1428764db71" xlink:href="ck0001824293-20210630.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_93ec151b-f608-4dd8-97a8-c0679cf6c8ff" xlink:to="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_4520a46f-30cb-4d80-86ac-f1428764db71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_f7a1f9e6-66ba-4de9-8703-8ac92aaacf87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_93ec151b-f608-4dd8-97a8-c0679cf6c8ff" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_f7a1f9e6-66ba-4de9-8703-8ac92aaacf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1325a6d-ae39-4de5-9fce-bb7274a9fb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_93ec151b-f608-4dd8-97a8-c0679cf6c8ff" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1325a6d-ae39-4de5-9fce-bb7274a9fb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_beff6128-3236-462a-97d7-0b6153830439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_93ec151b-f608-4dd8-97a8-c0679cf6c8ff" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_beff6128-3236-462a-97d7-0b6153830439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6fc0bc0-ec58-4fe3-a035-3555afa8b79e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cc92825f-303d-43b6-931f-577922c8239e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6fc0bc0-ec58-4fe3-a035-3555afa8b79e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cc92825f-303d-43b6-931f-577922c8239e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2d534664-9e02-4cb2-8d76-c4ea68346a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e6517e72-cea0-4d71-a50a-8cd78fec2e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2d534664-9e02-4cb2-8d76-c4ea68346a6e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e6517e72-cea0-4d71-a50a-8cd78fec2e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_13b2c211-a797-41a9-a256-45dc033e20fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_07cd8333-cd19-4e3c-9085-f4df621b31a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_13b2c211-a797-41a9-a256-45dc033e20fb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_07cd8333-cd19-4e3c-9085-f4df621b31a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#FAIRVALUEMEASUREMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_229af802-f437-410b-9202-2efb0a531694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_e76651fd-661c-4f80-a8dd-cae9b6f9149e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_229af802-f437-410b-9202-2efb0a531694" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_e76651fd-661c-4f80-a8dd-cae9b6f9149e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_45a82ff3-f8d0-4d04-b67c-07d94f9706a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_229af802-f437-410b-9202-2efb0a531694" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_45a82ff3-f8d0-4d04-b67c-07d94f9706a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20210630.xsd#FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dc681082-45d0-435d-9ee7-614dbb6feb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd4d5fee-1081-4cd3-91fd-83fe754649e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dc681082-45d0-435d-9ee7-614dbb6feb8b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd4d5fee-1081-4cd3-91fd-83fe754649e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_99597f36-b5fb-4aa9-b86a-284a58b41959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd4d5fee-1081-4cd3-91fd-83fe754649e4" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_99597f36-b5fb-4aa9-b86a-284a58b41959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9b7484d5-d234-4136-a587-35126158ffa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_99597f36-b5fb-4aa9-b86a-284a58b41959" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9b7484d5-d234-4136-a587-35126158ffa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_6d9cea5c-a431-4c10-97a6-d3f75e8a6195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9b7484d5-d234-4136-a587-35126158ffa0" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_6d9cea5c-a431-4c10-97a6-d3f75e8a6195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c05c6173-cdc9-4dec-a8cd-da59daa08caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd4d5fee-1081-4cd3-91fd-83fe754649e4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c05c6173-cdc9-4dec-a8cd-da59daa08caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9ebefd83-d399-4629-8315-47fe9fb336fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c05c6173-cdc9-4dec-a8cd-da59daa08caa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9ebefd83-d399-4629-8315-47fe9fb336fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_a0a68b9d-5e38-4d21-8971-5c8789f7125b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c05c6173-cdc9-4dec-a8cd-da59daa08caa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_a0a68b9d-5e38-4d21-8971-5c8789f7125b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_06289a33-e4bc-4ff4-b436-83dfb113bbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c05c6173-cdc9-4dec-a8cd-da59daa08caa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_06289a33-e4bc-4ff4-b436-83dfb113bbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e9a4b2b7-8a55-4d1e-b921-3c575b59fd66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c05c6173-cdc9-4dec-a8cd-da59daa08caa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e9a4b2b7-8a55-4d1e-b921-3c575b59fd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ck0001824293-20210630_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ck0001824293-20210630_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7OP/_P!A^P_]*(Z_M5'2OS/C[^+1]'^:/ILA^"?J@HHHK\_/>"BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M':Z'>'Q3\/II3)?>$=2G(M'+'+26\F&:VE//S("K9RR/@8_IB_8*_;E\%_\
M!0_]G#2_B5X':\CTV\E>SO+*\4+=:9=Q[?,MY0I(W#<K @D,KJPZU_)C^R-^
MQK\1?VY/B]9^"?AKX=NM>UBX*M/(!LM=-B)P9[B4_+%&OJ>3C"AF(!_J<_X)
M,?\ !.FP_P""8?[(5C\.X-5.N:Q?7TFN:_?J&6&YU"6.*-_)5N5B6.")%S@D
M)N(!8BOS?C:A@(VG&RK-ZI=5W?Z/=^?3Z3):E=Z/X//OY'K7Q+_93^%WQH\0
M6NK>,?AMX!\6:K9,KV][K/AZTO[B!E^Z4DEC9E(P,$'C%=KI&CV?A[3(+'3[
M6VL;.U01PV]O$(XHE'1550 !["K-%?GLIR:46]$>_9;GXA_\%F/^#E_5O"/C
M#Q1\(_V?UDTR^T6\FTC6?&MQ&&D6:)BDT>GQG(&&!7[0X.<,8UQLE/XB^)/$
MNI>,O$%YJVL:A?:MJFI3-<7=Y>3M/<74K'+/)(Q+,Q))))))K],_^"[G_!"S
MQU^RW\4?&7QE\$0W/B[X6>(-1GUK4/*4R7_A>2>1I95G0#YK8,QVS#.U3MDP
M0'D_+ZOVKANA@8813P5G=*[ZWZI_Y;=CXS,JE=U6JWR[6\@KI/A%\8?%/P#^
M(NE^+O!>O:IX9\2:+,)[/4-/G,,T+=QD=5(R&4Y5E)!!!(KFZ*]Z45)<LE=,
MX%)IW1_1;_P1_P#^#DSPO^U;_9?P]^-TVF^"_B1*4M;'6LB#2/$;G 4$GBVN
M&/&P_NW/W2I81CV__@JU_P $(/AC_P %*[*;Q#9M%X!^*<:CR_$EE;"2/40H
MP([V$%1,,<"0$2+A?F91L/\ +1964VIWL-O;PRW%Q<.L<44:%GD<G 50.223
M@ =:_KK_ ."/V@_$[PO_ ,$W/A5I_P 8(]0A\>6>EO'=1:AG[;#;B>7[(D^[
MYO-6U\@,&^8$8;Y@U?F7$66QRFK'&X"?(V[<O^7EW3TV/ILOQ+Q<'1KJ]NO]
M=3\7?"W_  :2_M$7_P 2+?3=8\3_  UTWPX;C9<:S:W]Q=LD/=X[<PQL[8Z(
MS(,]6 YK]G_^"=W_  2>^$/_  34\&?9/ ^B_;?$MU&%U+Q/J2K-JFH' RN_
M&(HN.(HPJ]SN;+'Z7KY2_P""TW[:/C#]@?\ X)_^*/B)X%L+.[\16MS::?!<
M7<7G0:8+B41?:63(#E20%!^7>ZY!&0?#Q&=9AFDH86<OB:5EHFWW.VG@\/A4
MZJ6VM]_N.F_X*"_\%/\ X3?\$V?A]_:_Q UQ6UB\B9]*\.V!6;5=6(X_=Q9&
MV//!E<J@Z9)P#\H?L>_\'3/P+_:1^)EMX6\6:/X@^%=QJ3^79:EJ\\-QI;N<
M )+.A!A8DG!9/+P#EU. ?YUOB_\ &/Q5\?\ XCZKXN\::]J?B;Q+K<QGO=0O
MYC+-,QZ#)X55& J* JJ J@  #FJ^SPW ^%C0Y:\FYOJM$O1=?GOY'CU,\JN=
MX+W>Q_<%#.ES"LD;+)'(H964Y5@>A!]*=7\X7_!$S_@X5UG]BI]+^&/Q?NM0
M\0?"52MMI^HX:XOO"2\ !0,O-:*/^60RR#_5Y $9_HG\"^.M&^)W@W2_$7AW
M5+'6M"UJVCO+"_LYEFM[N%U#)(CKPRD$'(KX'-\FQ&7U>2JM'L^C_P"#W1[V
M$QE/$1YH;]5V-:BBBO).H**** "BBB@ HHHH **** "BBB@ HHHH **** "O
M'_V_/V5+']MO]CCX@_#"^\E7\5:3+#8SRIN6TO4Q+:S8R/N3I&Q&1D C/->P
M45I3J2IS52&C3NO5$RBI)Q>S/XB_%?A;4/ WBG4M%U:TFL-5T>ZEL;VVE&)+
M>:)RDD;#U5E(/N*SZ_1[_@YY_8O7]F7_ (*&3>,M,M?(\-_&"U.NQ%0!&FH1
ME8[Z,<=2QBF.<\W77L/SAK]\R_&1Q6&AB(_:5_GU7R>A\'B*+I594WT"OT&_
MX-J?VR?^&6O^"D>BZ!J%XMOX;^+$'_",7@D<+&MVS;[*3G^+SAY(]KEJ_/FK
M6A:Y>>&-;L]2T^YFL]0T^=+FVN(6VR02HP9'4CHP8 @]B*,?A(XK#SP\]I*W
M^3^3U##UG2J*HNC/[>J*\=_X)^_M5V?[;7[&GP]^)UHUN)?%&D12W\,+;EM;
MY,Q74(.!]R=)%' R #WKV*OP.K3E3FZ<]&G9^J/O(R4DI+8****S*"BBB@!'
M=8T9F(55&22> *_D2_X*]_MAM^W)_P %"?B)XZM[HW6@?;SI.@$/OC&GVO[F
M%D]%DVM-@?Q3-7]$W_!>?]L?_AC#_@FGXZU2RNQ:^)/&$7_"*:'B4QR">[5E
MDD0@$AHK<3R@_P!Z-1D9!K^4.OT?@7+])XR2_NK\W^GXGSN>8CX:*]7^@444
M5^BGSIZ)^R5^SKJW[6_[3'@?X:Z)N74/&6KP::)0N[[+$S9EG([K%$'D(]$-
M?V1_##X<:/\ !WX;:!X2\/VB6.A>&=.@TK3[=>D%O#&L<:_@JBOPP_X-%OV,
MO^$J^*OCKX[:I;[K/PK"?"^AEL%3>SHDMU(.,AHX#$@.1D73=>W[V5^3\;9A
M[;%K#1VIK\7O]RM^)]9DN'Y*/M'O+\@HK@?VH/VE_"?['WP*U_XC>.+F^L_"
M_AJ));V:TLI;R50\B1(!'&I;EW49.%7.6( )'X]?M5_\'@)9;FP^"OPNVY#+
M%K'C"XZ'. 19V[>G()GZGE>.?GLOR?&8W_=X76S>R7S9WXC&4J/\1V/W#KCO
MBQ^T/X!^ VDR7WCCQOX1\'V<0!:;6M7M[!!D@#F5UY)( '<D 5_*[^T=_P %
MQ/VI/VGGNHM<^+7B+1],N&S_ &=X=9=%MT7^YFW"2.OM([D]R:^5]8UF\\0Z
MI<7VH75S?7MTYDFN+B5I99F/5F9B2Q/J37UN%X#JO7$54O)*_P"+M^IY57/H
M+^'&_KI_F?U8_%#_ (.!/V0_A1<>3>?&31]4N#G":)I]YJBG&/\ EI!"\8ZC
MJPSSCH<>.^-?^#K;]E?PM"[6*_$KQ(RLJA--T".-G!&2P^TSPC Z')!ST!'-
M?S3T5[%/@; 1^.4G\TOT_4XY9Y7>R2^__,_HR_XB\?V;/^A(^.'_ ()]+_\
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M.<Y ?X/_ .#M']F'Q-K M;W1?BYX=A*Y^UZAH=H\(.X#&+>[E?."3]S&%/?
M/\V]%>M_J3EO+;WO6_\ P+''_;6(O?3[C^MO]GC_ (+:?LN?M.WT%EX9^+_A
MNVU2XD$,=CKGFZ+<22'HB"Z6,2$]O++9/'7BOJ:WN([NWCEBD22*10Z.AW*Z
MGD$'N#ZU_#]7U-^P3_P6,^.G_!/35[.+PAXLN=5\)0R*9_"VLNUWI<R \K&K
M'=;DC^*%D.<9W 8KQL?P):+E@ZE_*7^:_P OF=N'SR[M6C\U_D?UO45\C?\
M!+'_ (+&?#7_ (*B^")%T1F\,^/])@676?"M[,'GMQP#-;R8 N(-W&\!67(W
MHFY<_7-? 8C#U:%1TJT>62W3/>IU(SCS0=T%%%%8EA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#;1^$%_P"!_B1X<LO$6@7PW*DR[9K*7!"SP2#YHI5R<.I!P2#D$@_S7_\
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M,?PK-HULUIXP^+-];^9IWAN*;Y+,-]V>]=<F*/G<$X>3&%P,NOSM_P %K/\
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M,-V 0@C!;=^@'C[Q_H?PK\%ZGXC\2ZMI^@Z#HMNUW?ZA?3K!;VD2C+.[L0%
M]ZXW]K#]KKX?_L2_!O4/'7Q'\06N@Z#8_(F\[KB^F()6""/[TLK8.%7L"3@
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M.!6#PD,.NBU]=W^)\'BZ[K5I5._Y= J6RLIM3O8;>WAEN+BX=8XHHT+/(Y.
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M6W1!114ME93:G>PV]O#+<7%PZQQ11H6>1R<!5 Y)). !UKV3C(J*_1?]B_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#A_CW^S/\/?VI?"4.A?$;P;X=\::3:W NX+;5[%+I;>8
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M2["> X4J3QG-?GKP>(5+V[@^3O9V^_8^@]M#FY+J_:^I^&G_  =I:MXPN/\
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M2/\ DU/X9?\ 8J:7_P"D<5?GO'WP4?67Z'T.0[S^7ZGH5%%%?FI]&%?SF_\
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M_P#8;U?_ -*WK]":_/;_ (-?_P#E$7X1_P"PWJ__ *5O7Z$U^#YU_P C"O\
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M *5O7Z$5^>__  ; ?\HBO"/_ &&M7_\ 2MZ_0BOP?.O^1A7_ ,<OS9]W@_\
M=X>B_(****\LZ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHKQ7_ (* _MC:3^PS^S#KWCK4#;S:A$GV/1+*
M1L?VC?R*WDQ8ZE1AG?'(2-SVKIP>$K8JO##4%S3FTDN[9CB<13P]*5>L[1BF
MV^R1\%_\'#W_  49_L/2_P#A0O@^_P 7E\B7/BZY@EPT,)P\5CD<@OQ)(./D
MV+R'8#\_/^":_P"W#J7[!7[3NE>+8OM%SX=O<:?XAL(V_P"/NR=AN91T,D9
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MU;'JG+X:FGSZ?CI\SR\VP_M*',MXZ_YG\]-%%%?L1\>?5G_!%/\ ;&'[$/\
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M>A^9M%%%?LQ\:%?UA?\ ! ;P2WP__P""0'P1L6:1S<:7=:EEUVG%W?W5T!]
M)@ >X -?R?PPO<3+'&K222$*JJ,LQ/0 5_9W^Q[\&O\ AG;]D_X:> _F,G@_
MPQIVD2LP^:22"VCC=C[LZL3CC)KX+CVM;#TJ7>3?W*WZGO9##]Y*?E;[_P#A
MC?\ C=_R1CQ=_P!@6\_]$/7\4=?VN?&[_DC'B[_L"WG_ *(>OXHZPX ^&O\
M]N_^W&F??8^?Z!1117Z(?.G[8?\ !FU_R.'[0'_7GH/_ *'J%?NI7X5_\&;7
M_(X?M ?]>>@_^AZA7[J5^+\6_P#(UJ_]N_\ I*/LLI_W6/S_ #84445\V>D%
M%%% 'P9_P<N_\H=/B9_U^:-_Z=+6OY;J_J1_X.7?^4.GQ,_Z_-&_].EK7\MU
M?K' O^X3_P ;_P#28GRF>?[PO1?FPHHHK[0\8_I\_P"#8#_E$5X1_P"PUJ__
M *5O7Z$5^>__  ; ?\HBO"/_ &&M7_\ 2MZ_0BOP?.O^1A7_ ,<OS9]W@_\
M=X>B_(****\LZ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'9.S\[-!1117.;!1110 4444 %%%% !1110 4444 %<E\>O@QHO[1?P4\5^
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M**BO))?D*=24W>3;]0HHJ;3]/N-7OX+6U@FNKJZD6*&&)"\DKL<*JJ.2Q)
M'))K4@AK]5?^#=__ ((G7'[6?CO2_C9\3-,*?"WPW=^=HVGW"X_X2B]A<8+*
M?O6D3CYL\2.NSE1(*[3_ (([_P#!LYKGQ3U'2/B1^T5I]WX>\*KLN[#P;+F'
M4=6Z,IO1]ZWA]8CB5NA\L#YOWOT#P_8^%-$M-,TNRM=.TVPB6"VM;:)8H;>-
M1A41% "J ,  8%?GW$O%48Q>$P3NWHY+IY+S\^G37;Z#+<K;:JUEZ+_,N*NU
M< 8 X ':BBBOS0^D.7^-W_)&/%W_ &!;S_T0]?Q1U_:Y\;O^2,>+O^P+>?\
MHAZ_BCK](X ^&O\ ]N_^W'SN??8^?Z!1117Z(?.G[8?\&;7_ ".'[0'_ %YZ
M#_Z'J%?NI7X5_P#!FU_R.'[0'_7GH/\ Z'J%?NI7XOQ;_P C6K_V[_Z2C[+*
M?]UC\_S84445\V>D%%%% 'P9_P '+O\ RAT^)G_7YHW_ *=+6OY;J_J1_P"#
MEW_E#I\3/^OS1O\ TZ6M?RW5^L<"_P"X3_QO_P!)B?*9Y_O"]%^;"BBBOM#Q
MC^GS_@V _P"417A'_L-:O_Z5O7Z$5^>__!L!_P HBO"/_8:U?_TK>OT(K\'S
MK_D85_\ '+\V?=X/_=X>B_(****\LZ0HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "N!_:L\%77Q*_9=^)/AVRF-O>:_
MX6U338)0I8QR36DL:M@$$X+ X!%=]16M"M*E4C5CO%IKY.YG5IJI!TY;-6^\
M_DA@@DNITBB1I))&"HBC<S$\  =R:_HL_8)^"'AO_@E9_P $[+>\\:W5OHDU
MK:-XC\77KJ6:.ZE5<Q *"SM&OEP*JY+,O )?GX+_ & _^"7-T_\ P6 \;6NM
M:')#X'^$.N3ZM;^9"5M[DM(9-,C7(PWR,DQ R,18/!&>@_X.0?VYVUOQ+I?P
M+\/7W^AZ7Y>K>*3$W^LN&&ZVM6(/1$/FLI!!,D)R"A%?T?Q=C'Q-F.%R# R_
M=M*K4:Z1:NEZV?I>4>Q^(\-X3_5_ XG.<7']XFZ<$^K3L_DVO6T6?HI^Q%_P
M4-^''[?WAW6K[P'=:DDWA^X$%]8:G;K;W<*L6\J7:K.#')L8J0V>""%((KX%
M_P"#A_\ X)S^;%_POKPA8?,GEVOB^V@C^\.$AOL#T^6.0_\ 7-NS&OS]_P""
M=W[:.J?L)?M/Z'XVL_.N-'8_8==L(S_Q_P!C(1YB\_QH0LB'CYHU!."0?Z3-
M+U/PU\?/A7#=6[:?XD\)>+M-#H2HEMM0M)X^A!ZJR-@@^N#7QN=Y;7X'SVEC
ML#>5"7=[K[4&^_5.W9ZM,^GRG'T>+,HJ83%V56.]NC^S-+MT>O=;-'\H->S?
ML(?L4^)OV[_V@--\%Z DEO9\7.L:H8]T6DV8(#RMZL<A47.69@.!DCZ<_:D_
MX-]_C'X3_:)OM-^&>A0>)? >IW?F:7J4FJ6\!TZ!V_U5RLKJ^Z+)!9%;>J@C
MYB4'ZM?\$V_V!-!_X)]_L_6WANR,.H>)=4*WGB+5E4YO[K;C:F>1#&,JB\<9
M8C<[9_2>*O$[+\+E:K994C4K5%[J33<;[N2Z-=GN^EKGPG#O .,KY@Z>84W&
ME3?O/92MTB^J?5K9>=CU+]GWX!^&/V8OA!HG@?P?IZZ=H.A0>3"G625CR\LC
M?Q2.Q+,W<D]!@5\!_P#!63_@N;=_LO?$6;X<_":'1]4\3::,:YJ][&;BWTR0
M]+:) 0'F Y=FRJ9"X9MVST'_ (+3?\%38_V+_ANW@GP9?0M\4/%%L0DB-N;P
M_:MD&Y8=I6Y$0/0_.00H#?@A>7LVHWDUQ<2R3W%PYDEED8L\C$Y+$GDDGDDU
M\-X<<!?VG)YUG*YH2;<5*_OM[REW5]N[U>BU^NXYXQ_L^*RO+'RS25VK>ZND
M5V=ON6VKT_9+_@EG_P %ZM1^.7Q2M?A_\:/[#T^_UIUAT37K2$VL4UP2 MM<
M)DJK.2=CKM&["D?,#7ZE5_(_7[9?\$1?^"NZ?'72-/\ A#\2]4"^-M/B$6A:
MM=2 ?V]$HP('/&;E%Z$Y,BC/W@=VGB5X<0PT'FN40M!?'!=/[T5V_F73?:]L
M^ ^.)8B7]GYE.\W\$GU_NOS[/KMO:_Z74445^$GZX%%%% !1110 4444 <I\
M;_@AX5_:0^%6M>"?&VBV?B#PQX@MS;7UC<KE)%/((/574@,KJ0RLH(((!K^7
M[_@LC_P1N\5?\$OOBK]LL_MGB#X3^(+AAH6NE,M;,<M]CN]HPLZ@'#<+*H++
M@AT3^JRN5^-_P0\*_M'_  JUKP3XVT6S\0>&/$%N;:^L;E<I(IY!!ZJZD!E=
M2&5@""" :]S(\\JY=5NM8/=?JO,X<=@88B%GH^C/XI:Z/X1?"/Q-\>OB7HO@
MWP;HM]XB\3>(KE;/3]/LTW2W$A_15 !9F8A5569B%!(_8GXX_P#!GMX@D^)-
MQ)\-_BUHB^$;B<O#!XBLI1J%C$02$+P@I.P.!NQ%D$G&1@_H)_P20_X(H> O
M^"6?AV]U**\'C3XE:U'Y-_XEN+00?9X,@_9K6+<WDQ$@%CN+2, 6.%1%_0L;
MQE@:=#GP[YIO96:^_P!/^&[G@4<GKRJ<M167?_(R_P#@BW_P1<\,_P#!,/X9
MC6M:%CXB^,/B*V":SK*+NBTV,X8V-F6&5B! WO@-*R@G"A$3[HHHK\IQ>+JX
MFJZU9WD_Z^X^II4HTX*$%9(****YS0**** "BBB@ HHKS+]KG]K/PC^Q9\$=
M4\=>,KMHK"Q CMK6'#76IW#?ZNWA4D;G8CZ*H9F(521MAL/5Q%6-"A%RE)I)
M+=M[(RK5J=&G*K5:48J[;V21R7_!0O\ ;\\+?\$_/@A/XEUKR]1UZ^W0:%HB
M3!)M5N!CZE8DR&=\':, 99E4_EO\-/\ @Y5^+^F?%"TO/%GA_P 'ZIX3DN/]
M,TZPLY+:YCA)Y\F5I6^=>HWA@V,'&=P^.?VS?VQO%W[</QPU#QMXNN,23?N;
M#3XG8VNDVP^Y!$#V'5FZLQ9CR:\GK^H^%_"S+<+E_)FE-5*TU[S_ );](VVM
MW6K?E8_G_B#Q#QU?&\V73<*4=O[WF[]^W;SN?U;_  4^-'AO]H;X6Z+XR\(Z
ME'JWA_7K<7-I<("I(/!5E/*NK JRGE6!!Z5^4_\ P7O_ ."5Z^'[C4/CM\/=
M-;['</YOB_3;=,B!R<?V@BCHK''F@< _/T+D?.G_  1R_P""H=W^PK\5/^$;
M\2W$MQ\+_%5RO]HH2S?V-<$!1>QJ,\8"K(H&64 CE #^_O\ Q+/'7A?_ )<M
M6T;6+7_9GM[VWE3\5='1O<$'TK\HQN%S#@7/(UJ-Y4I;=IPOK%_WE^#M*UG8
M_1L+B,%Q;E#I5=)K?O"5M)+R?XJZ/Y+J]>_8<_9 \0?MP?M%Z'X$T)7ABNI!
M/JE_MRFF62$>=.W;('"@_>=D7C.1]<?M_?\ ! [XE^!/CO>W?P;\-R>+/ NN
MS-<6=O%>P17&B,QR;:02NFZ-23L<9^0 .=PRWZ.?\$D_^"<EK_P3^^ 9AU5+
M6Z^(/BC9<^(+N(AUAQGR[2-N\<8)R?XG9CTV@?KG$GB9EV'R?ZWEU13JU%:,
M;J\6]W);KE[/=VMIJ?FV0\ XVKF?U?'4W&G!WD[:22V47UOY;*][/0^@/A[X
M#\*_LP?!+3M!TM;?0O"/@O2_*1II,):VT*$O)(YZG 9W<\DEB>IKRO\ 9!_X
M*;?"']NCQ7KGA_P'K5W=:KHL1N);2_LFM9+JVW!#/$K?>C#,H.<,N]<J,BOC
M?_@XE_X*$#P7X/B^!7A6^*ZMK\27GBB>"3#6MGG=%:9!X:4@,X_YYA005E-?
MEM^QW^TYK'['G[1WA?X@Z+ODFT*Z#75J'*K?VK_)/ WL\98 G.&VMC(%?FO#
MGAE5S;)JN9XF4E6J7=-7WZWE?5\[VU5E[VMS[O/./*>79I3R^C%.E&RF^WE&
MVGNK??MI8]:_X*__ +$8_8D_;!U;3M+MFA\'>*@VM: 0H$<$4C'S+88  \F3
M<H'41F,GDU]D_P#!K?X8O$_X7-K31E=/D_LFRCD/_+25?M;N!_NJR$_[X]Z^
M@/\ @L=^SKI?_!0/_@GGI_Q!\%Q_VSJGAFT3Q3H,T";I;RPEC5KF$  G+1!9
M-@Y+VZ+ZBM#_ (-]O@<_PB_X)YZ7JUU;R6]]X\U2YUUQ(,-Y.5MX?^ F. ./
M:3/>O4SCB_Z[P.Z6(?[_ )HTI)[WB^:[7G&.K[W.#+>&?JG%BJT%^ZY95(VV
MU7*U\G+1=K'W!1117X.?K@4444 %%%% !1110 4444 %%%% !1110 5^?G_!
M?W_@DKKW_!3KX.^#+CP'_8\/Q"\%:E(+=]2N6MX+C3[A )XF90WS"2*!U)!Q
MAP,;C7Z!T5U8/&5<+6C7HNTH[&=:C&K!TY[,_FE_XA3/VJ/^J;?^% __ ,9H
M_P"(4S]JC_JFW_A0/_\ &:_I:HKZ3_77,O[OW?\ !/-_L7#>?WG\TO\ Q"F?
MM4?]4V_\*!__ (S7[4?\$7?^">=Q_P $V?V(-)\$ZU_9TWC/5+VXUGQ'<V3F
M2&6ZD(1$1R 66.".%,X )5F &ZOK*BO.S+B+&8ZE[&NURWOHK'1ALOHT)<\-
MPHHHKPCN"BBB@ HHHH *X7]HO]FGP+^UK\*M1\$_$7PSIOBGPUJBXEM;M3F-
MNTD4BD/%(O\ #)&RLO8BNZHJH3E"2E%V:ZB:35F?A!^W%_P:/:_I.IW6L?L_
M^,;/5]-D9I!X=\42_9[N ?,=L-VB^7+_  J!*L>!R78U^;7QL_X)4_M'_L\7
MLD/BSX+_ ! LXX@6>ZM-*?4;-0.O^D6WF0_^/U_8)17UV"XTQU%<M6TUYZ/[
MU^J/*K9-0F[QO'TV/XA=9T6\\.ZG-8ZA:75C>6[;9;>XB:*6(]<,K $'ZUJ>
M _A9XH^*=[);>&/#>O>([B(J'BTO3Y;QT+9V@B-21G:V/7:?0U_;-17J/C^7
M+I0U_P 7_P!K^IR_V"KZST]/^"?R<?L\_P#!"#]JK]I"YM&TWX2Z]X=TZZ;#
M:AXGVZ+# N2-[).5F9>/X(V)!! (YK]/?V&?^#2GP;X N;'7/CQXLD\<7\>V
M1_#VA&2STM6P,K)<';/,H.?N"'.!G/(K]BJ*\7'<89AB%RP:@O[N_P![U^ZQ
MV4,HP]-W?O/S_P C!^&?PN\-_!CP1I_AKPCH6D^&_#^E1B&TT_3;5+>WMU'9
M44 <]2>I/)R:V-2TVWUG3KBSO+>&ZM+J-H9X)D$D<R,"&5E/#*02"#P0:FHK
MY9R;=WN>IY'XA_\ !4K_ (-7;C6]?U3QO^S3-8PB[=KFX\#:A<BWCC8@DBPN
M'^506QB&9E5=QQ(%"H/R-^.G[#/QD_9GO[N#Q[\,/''A=;$D27-[I$RV9 Y+
M)<!3$Z_[2.1[U_9=17U^7\9XS#P5.JE42[Z/[^OS5_,\C$9/1J/FC[K_  ^X
M_A[KTSP7^Q;\8_B01_PCOPF^)FO;NG]G>%[ZZS_W[B/J*_LXHKTJG'TW\%%+
MUE?]$<T<AC]J?X?\$\#_ ."6?@_Q)\._^"=7P;\.^+M'OO#_ (D\/^%[33+[
M3[R,1SVKP)Y05@"<':@/K@C/->^445\#6J.I4E4?5M_>>]&/+%170Y7XU_!#
MPG^T;\,]5\&^.-!T[Q+X9UJ(PW=A>Q[XY!V8'JKJ>5=2&4@$$$9K\._V_O\
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M_P"7RL<F*P5*NOWBU[]3^,WXP?L/_&3]G^YO(_&OPM\?>&5L=WG3W^A7,5L
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M]S+.(L7@*3HT+6;OJKZV2_0X<3E]&O+GJ7OL?S2_\0IG[5'_ %3;_P *!_\
MXS1_Q"F?M4?]4V_\*!__ (S7]+5%>E_KKF7]W[O^"<_]BX;S^\^3?^"*?[&O
MC+]@K]@;0?AOX\&E?\)%INI7]U+_ &=<FXMRDT[2)ARJG.T\C'!KZRHHKY?$
M8B=>K*M/>3;?JSTZ=-0BH1V6@4445B6%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 <;^T5\8K7]GOX#>,?'-Y"
M;FW\)Z/=:H8 =IN#%$SK&#V+L H/JU?RW_%'XE:Q\8_B1KGBSQ!=->:UXBOI
MM0O9CGYY9'+-@=E&< =@ .U?TX_MM?"._P#CS^R'\2?!^E;6U;Q!X>O+2Q4M
MM62X,3&)2<' 9PH)]":_ETO+.;3KR:WN(9(+BW<QRQ2*5>-@<%2#R"#P0:_H
MCP/HX?V&*JK^)>*?=1LVOO=_N78_%?%JI6]IAZ?V+2?ES:?DOS(Z_73_ (-N
M/VWM2U6?6/@7K;SW5I8VLVN^'IV.1:()$%Q:^NTM()5]#YN>H%?D77Z3_P#!
MMA^S=K7BW]IW7/B=):M'X9\):9-ID=TV0)K^XV 1IV;;#O9O[N^/CY@1][XE
M8?"U>'L0\5;W5>+[3O[MO-WMZ-GQO =;$4\ZHK#W]YVE_AZW]-_5(_;FO'/V
M^OVKH?V*?V4?%GQ#>T34+S28$AT^T<D)<7<SK%"&QSL#L&;&#M5L<XKV.OF/
M_@L#^S/K7[5G[!?B[PYX:MFOO$-BT&KV%HOWKM[>0.\2^KM'Y@4=VVCO7\H9
M%2PU3,J%/&.U)SBI=/=;5[OHK;OH?T9FU2O#!5IX57J*,G'UL[?B?SN?%CXJ
M^(/CA\1]8\6^*=2FU?Q!KURUU>W<N-TKGC@#A5  4*  J@    5SU275K+8W
M,D,T<D,T+%)(W4JR,#@@@\@@\8-1U_<U*G"$%"FDHI626R2V2\C^1ZE2<YN=
M1W;=VWNWUN%6-)U:ZT'5+:^L;FXL[ZSE6>WN()#'+!(I#*Z,N"K @$$'((S5
M>BM&DU9F:;3NC^A;_@BQ_P %#=0_;O\ V>+ZW\4&.3QQX$D@L=5N$P/[2BD1
MC!=E0 %=_+E5@.-T988#!1]E5^;G_!N#^R7KWP8^ WBKXA>(+.XT]OB1)9G2
M8)AM9["!962XV]0LK3MMSU6-6'# G](Z_BGC?#X*AGF)HY?;V:EI;9.RYDO)
M2NEVV/ZLX5K8JME-"IC?XC6M]VKNS?FU9L****^5/H HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** *?B+7[3PIX?OM4U"9;>QTVWDNKF5ND<<:EF
M8_1037\V/_!1W_@H1XF_X*#?&Z77-2,VG^%]*>2#P]HVX;=/MR1\SXX:9]JE
MV]0 /E45_2!\2/!R?$3X=Z]X?DF:WCUS3KC3VE4?-&)8FC+#W&[-?RV_M!_
M'Q1^R_\ %[6O _C'3VTW7M#F\J9,[HYE/*2QM_%&ZD,K=P>QR!^Y>">%P4\5
MB*U2SK12Y;[J+NI-+[DWT3MUU_)_%;$8N&&HTZ=U2DWS6V;5N5/\6EUMY'%T
M445_1Q^%A7ZY?\&ZO_!0G5M:U:7X"^*+B2^M;>TFU#PK=2MF2V6/#361[LFT
MM(G=0LBYV[ OY&U^BW_!N?\ LF:Y\0/VL/\ A:\UG-;^%_ -M<P0W;95;J_N
M(&@$*?WML,LC-_=S'_>%?#>(^'P57A_$/&V]U7B^JG]FWFWIZ-GV' M?%4\Y
MHK"W]YVDNG+UOZ;KS2/W*KRK]MS]IVS_ &.?V6?&'Q&N[=;QO#]F#:6K$@75
MU*ZPP1D@$A6ED0,0.%R>U>JU\]?\%4_V<]:_:I_8,\?^#?#B--K]Q;0WVGVX
MQF[EMKB.X\@9(&Z01%%R0 S*3QFOY*R6GAZF84*>,=J3G%2>WNN2OKTTN?T=
MF=2O#!U9X97J*,G%?WK.WXG\X7Q1^)NN?&;XBZUXK\27\VIZ[X@NY+V]N93D
MR2.<G'HHZ!1PJ@ 8  K!IT\$EK.\4J-')&Q5T8;64C@@CL13:_NNG3A""A35
MDE9);)=+'\B5)RG-RF[MN[OO<_:3_@VL_:QO/'OP>\4?";59)IYO!4BZII$K
MG.VSN&(DA]<),"P_Z[D<!0*_3ROR+_X-A?@?J]O?_$CXC7$30Z'<0P>'[-V'
M_'U,&$\V/9%\H9[F3V-?KI7\>^)5'#T^(\3'#6M=-V_F<4Y?C>_G<_IW@:I6
MGD="5?>S2OV3:C^%K>04445\(?6!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%?GA_P %L_\ @IG\3/V"/'W@/3O 3: +
M;Q%I]U<W8U&Q-RV^.1%7:=RX&&.>M>OD>2XG-L9' X2W/*]KNRT3;UUZ(\[-
MLTH9=A98S$WY(VO97>K27XL_0^BOQU_X)]?\%O\ XW_M+?ME^ ? OB1_"/\
M8?B/4&MKS[+I1BFV"*1_E;S#@Y4=J_8JNOB3AC&Y'B(X;&VYI1YERNZM=KLN
MQS9'GV%S:B\1A+\J=G=6ULG^H4445\Z>T%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_L$_L1>)OV\OC[I_@_08Y+?3XR+G6]5*9ATFT!PTC=B[?=1.K,1T 8C^D/\
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MN>(O^_5O_P#&Z/\ A\/^TQ_T5SQ%_P!^K?\ ^-U^FW_$,O\  ?\ Z&WXN?\
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MX$A/'W8O,/2OBG4=/N-(U">TNX)K6ZM9&BFAF0I)$ZG#*RGD,"""#R"*Z*O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU9^C3MY6ZG].\&Y]4S;+EB*RM.+<7V;23NO6_P!]PHHHKX<^K"BBB@ HHHH
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M+E(EBG?N%5HBF>@,X!ZBOQ0K^GO!S*\)2RAXZG9U:C:D^J2>D?+2TO.Z[(_
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M !1110!_*'\8O^2N^*O^PQ=_^CGK]F/^#8[_ ),Z\=?]CE)_Z0VE?C/\8O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT.,N,L+D&$]I/WJLO@AW?=]HKJ_DM3AX5X7Q&<XCEC[M./Q2[>2[M_ANR_\
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M%OX!\!^)/%4T9VI=:G/'I=J_^TH ED(]F5"?;K7T64\)9QF6N"P\I+O:T?\
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M8-N-6NF^T?>?X72^;1^RM%?SS^//^"]?[3?C6XW6_C;3_#L/_/#2]$M%4_\
M I8Y'_\ 'N_TKS[4?^"LO[2&JW'F2?&#QBK8VXAN%A7_ +Y10/QQFOK:/@KG
M,E>I5IQ\KR?_ +;;\3YNIXJ95%VA3J/SM%?G*_X']+-%?S4Z1_P5J_:1T2\\
M^'XP>+G<#&+B9+A.H/W9%9>WIZCN:]K^"G_!Q5\?OAQ<VL?B9_#/CZQC;$PO
M].6SNI$]%EMMBJW3YFC;IR">:SQ7@OG=.'-1G3GY)M/\8I?BB\/XI934ERU(
MSCYM)K\&W^!^]=%?#O[&/_!>GX/?M0WMIHOB.27X9^*KHK'';:O.KZ?<R''R
MQ78"KG/ $JQD\ 9)Q7W"CB1 RD,K#((Z$5^:9KDN.RVM[#'4G3EYK?T>S7FF
MS[O+\TPN.I>VPE13CY=/5;I^3%HHHKS#N"BBB@ HHHH **** "BBB@ HHHH
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MZ6M_V[>_ROT/5****_G<_:@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNWR[9$/X#;CZ"OYCZ_3[]H+_ (*(W'P;_P""*GP5^'_A?5"GBCX@Z+/9WES
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MJ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML_AK]+/V=/V</!_[*7PIT_P9X'TB'1]#T\%@H.Z6YD/WI97/,DC8Y8^@ P
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M.B?"K3;G?;VO,=QKKH?EGN>?N@C<D71<@ME@-OJ7_!R+^TQXKUW]IG3?A?\
M:[NR\&Z#I5MJ?V-3MCU&[E,A,[8^^$7"*#PI60CDFOS5K]J\+^ \/0P]/.L7
M:=2:O!=(I[/SD^_3IKJ?E?B#QA6JUIY5AO=A%VD^LGV\H_GZ!1117[8?DYWG
M[-G[2?C#]DSXO:7XW\$:H^F:UIC8(.6@O(21O@F3(\R)\ %3Z @AE5A_15_P
M3F_;NT?_ (*"_L[V_C+3[)])U2QN#INM:<Q++9W:HCG8Q WQLKJRMZ-@\J:_
MFF\-^&]0\8^(++2=)LKK4M4U*=+:UM;:(R37$KD*J(HY9B2  *_HE_X(Z_L+
MZI^PE^R8FC^)&C_X2[Q/?-K6KPQN)$L&:-(X[8,.&V(@+$9&]W )4 U^)>-&
M%RSZE3Q%2RQ-THVW<>M^\5T?1[;N_P"L^%F(Q_UF=&%W0M>5]E+I;S?7NM]D
M?5U%%%?S8?N84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M_*'\8O\ DKOBK_L,7?\ Z.>OJ7_@G)_P6&US_@G9\)M:\)Z9X)TKQ-#K6KMJ
MS7%U?R6[1,88HM@"J01B('/O7RU\8O\ DKOBK_L,7?\ Z.>OIC_@GM_P2 \6
M?\%#OA9K'BKP_P"+/#N@6NC:JVDR0:A%,TDCB&*7<-BD;<2@<\Y!K^UL_64O
M*4L[M['W;WYM^GPZ[G\LY0\S6:2_LG^+>5OAVZ_%H?27_$41XM_Z)+X=_P#!
MS-_\;H_XBB/%O_1)?#O_ (.9O_C=9/\ Q#"?$K_HI'@?_P ![K_XBC_B&$^)
M7_12/ __ (#W7_Q%?F_L_#7^[]]7_,^ZYN///[J1K?\ $41XM_Z)+X=_\',W
M_P ;H_XBB/%O_1)?#O\ X.9O_C=9/_$,)\2O^BD>!_\ P'NO_B*/^(83XE?]
M%(\#_P#@/=?_ !%'L_#7^[]]7_,.;CSS^ZD:C_\ !T/XO*-M^$WAM6QP3K$Q
M /T\NN#\?_\ !RK\<O$D;1:'X?\ A_X;C9<"1+&>ZN%;N0TDVS\#'^==1_Q#
M"?$K_HI'@?\ \![K_P"(KI/#_P#P:XZU->#^U/C'I=M;@C)M/#KS.PYSPUP@
M';UZ^V#4*WAM0?.N1^JJR_!IF<Z?'=5<KYEZ.G'\59GY]_M#_MS_ !=_:M.W
MX@>/O$'B*UW!Q8O*+>Q# Y#"VA"0AAZA,UQ_PA^"GB[X^^,H/#W@OP[JWB;6
M;C[MK86[3,HSC<Y'"(,\LQ"CN17[9?!;_@V_^!OP^O8[KQ1J'BWQW-&03;W=
MVMC9MC_8@"R<^AE(K[:^#_P&\%_L_>&1H_@CPMH?A;3<Y:'3;-(!*?[SE1EV
M_P!IB3[U.8>+V48&C]7R3#W[:*$%\EJ_2R]1X/PUS'&5?;9M7MWU<Y/YO1?>
M_0_/#_@F?_P;_P"G_!_5-.\<?&HV'B#Q%;D3V7AF+$VGZ>_57N'Z3R+_ '!^
M[4CK)P1^G8&T8' '0445^&9]Q%CLXQ/UG'SYGT6RBNR71?B^K9^MY1DN$RRA
M]7P<>5=>[?=OJ_Z04445XAZ@5^-O_!T1_P E:^$O_8(O_P#T=%7[)5^-O_!T
M1_R5KX2_]@B__P#1T5?HOA3_ ,E-0])_^D2/BO$/_D05_P#MS_TN)\1_\$SO
M L?Q'_X* _"#2YANA/BBRNY%X^=;>07#*<]B(B#WP>.:_INK^;7_ ((\_P#*
M2_X1_P#87?\ ])YJ_I*KZ/QNJ2>:T(=%3O\ ?*5_R1X7A1!++:L^KG;[HQ_S
M84445^+GZD%%%% !1110 5^*_P#P<^?\G*?#?_L69?\ TJ>OVHK\5_\ @Y\_
MY.4^&_\ V+,O_I4]?I'A/_R4E'TG_P"DL^'\1?\ D0U?6/\ Z4CYO_X(F_\
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M/#X+R>'])N7UC7]8D2YUW6)(_+;4)E!"*J9.R) S!5R3\S$DEC7:_LF?L?\
M@7]BOX56_A+P)I*6%FN)+R[DQ)>:I-CF:>3 +L><#A5'RJ%4 5XE_P %,O\
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M?6/_ *4CYO\ ^")O_*4/X4?]?=[_ .F^ZK^CBOYQ_P#@B;_RE#^%'_7W>_\
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MJ4I<(\TG=OV=_O1^!\!Q4>)'&.B7/^I^FU%%%?RL?T(%9_BS_D5=3_Z])?\
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M*_%^+/\ D>8S_K[4_P#2Y'ZAPW_R*<+_ ->X?^DH;-,MO$TDC+''&"S,QP%
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MEM\G.P?,F3MW#"5^U7P?^.'@_P#: \'0^(/!/B31_$VCS_=N=/N5F5#_ '7
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MJUN5=^Y^>\*\!O)L8\7[?GO%QMRVW:=[\S[=B:BBBORD_0@HHHH **** "O
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MBL>Z?M/=:M?EW\[/\CY_B;(O[7P3P?/R:IWM?;RNOS/P%_X-\/\ E)=X=_[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>ck0001824293-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ck0001824293="http://www.vallon-pharma.com/20210630"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ck0001824293-20210630.xsd" xlink:type="simple"/>
    <context id="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i34b302c75dba4c628d85244f68002a60_I20210806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="i6b79fcafbff642fa848ff1901341ccd7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic895252214e44777813c5b78a8d4444f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i61ac3f94b5f149979bd71ad52587031e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibe37a5900c304ce28d7ecdea6420b23a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if56d5eae60d046f096e356f7a5042dcb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie3e856b37c19403f8329a07be3454d4e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibafcc59176d54d99a4b6f080f91bebfe_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i50024d555c8a4c84929dda5920ed007b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5765e73948fa479394575bdc1358aa9a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie620d3313620467383dee26f0f0a3c7c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i238b94d82c304fccbc90bb50080061c5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iac63187c14bf4722bde64d421ce98362_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibffb387820b54b48a3579ed3b5009547_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie769608b479948f496d2bb6a432fac37_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ief43562ce2e047b9817ddf36217940df_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaa5c17d856644cd3b88a05d18f8e6bfe_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ife011d6dbed94ffeaeb46db11c3e48e3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iff321e9d1ca24eeb985f787da4129ad1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iaa79d0de6ea5497ebb25e7f4d8686d52_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i31e1e141d8814e4090f2d3e21275625e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i143f796f80894c99aac56a13b900ee21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d46e3841ca64fbb811bcae232cd7200_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd589b362dd643cabf0c87233e57e988_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2d33cef40f034ce2a44f35ae028bb669_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i63727a089ddc482397d5b8b38b53f131_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id6b512a400b941aba498ea638f7583ed_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifea416d58bba48c59aae046eaf6963ee_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5eb9251ed6a246158ebed555043580de_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie850734f1a4c4bdc9dbd84239c0edf92_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i466406119fd042e78b23e14be880ebc6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie683a1421b7e42d5869006a49ce417bb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0c283f6cb704453592615c899f3cf9d8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i86f5891de57c4edfb483409095deae5b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i02909c7ca37a4096874b575c77575a27_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1a315f92ff66436b99d5d04a5d936d46_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3d32c5625af443af9e9ab4f13da85869_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ib40eca850643445aa3fb581f3a267821_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="if3a045458c344fe6b012e31e07176174_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i3d756267a38641f49152d284b506e41c_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i78d2a9fcaf4742528def995407f4d94d_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="ic49837a0734b43478ec5edc5f65ef833_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="idb6e392c488e43689ffc16945c65d467_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="i81624bcf1ddd410e8384985a52ed244e_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i727458f1ed4c4be384fc367ff6dbf535_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ice4617251d084359a4b1673e32105777_D20210111-20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="i99c9d5a032e74fedb51994d35e423ac4_I20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="i8bc882349d4b44458f3fcac805712aaa_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i8d10d62088b94b7ca91599063bdd7713_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="ia5a7c424887d4d268f63dad57f3d0c22_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="if9d38d7df6fa442f80a3d6ebe4c56f9c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id368a2d31edc42a0b69cd67c1ee5bee0_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="i4b87e9f4d00f4885821da6e21e067a39_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="iba0a050f6bca41bc803a3fd1b6bef4b6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3621a5e4b5684da1868630577f530cf2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i782b28a8f85447788786cb2c7f4d69fb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id40c60f62dab45c18759442084ff92e9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i27c7675abef34248a1f00e6bcf04c49d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib5ce2baeed89423c922e27b6c8e36bba_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if64b7ec5ca7045d089a7f58dd9d61741_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i887713052e054612a1e185929791f55d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i04385040180f467690e4c12dc8d54a53_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibc2622def42a4874aedf69d387f68fb9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i06e1e9850961407ca3e9d3986c0b7169_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0864fed0eeb54c0887a8eeeaa3029b17_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic5f07cccdbc84951b24e82c3340132e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8af83bde4e7d4b5986d02a1be122c2df_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:MediceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i60901d5d21aa4ec69b330ba52b51042b_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="i47a4058978b54caa86791e0df0e0a693_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie57e0b7edd14462ebede9f2bd8aad12c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6c968c9ac274451f8c6acd6b1628a443_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80L2ZyYWc6NjY0MWYzZmFlM2Y1NDk4Yjg1MTM2OTdjOTExYTIxNWYvdGFibGU6NzU0MjkwNWYzNmYyNGM4MGE4NGFlNjgxOWM3MmQxY2MvdGFibGVyYW5nZTo3NTQyOTA1ZjM2ZjI0YzgwYTg0YWU2ODE5YzcyZDFjY18yOS0xLTEtMS0xNDM0_45d40320-bb3e-4dd1-a9ca-fcd74eb372f1">0001824293</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80L2ZyYWc6NjY0MWYzZmFlM2Y1NDk4Yjg1MTM2OTdjOTExYTIxNWYvdGFibGU6NzU0MjkwNWYzNmYyNGM4MGE4NGFlNjgxOWM3MmQxY2MvdGFibGVyYW5nZTo3NTQyOTA1ZjM2ZjI0YzgwYTg0YWU2ODE5YzcyZDFjY18zMC0xLTEtMS0xNDM4_92728026-f68b-487a-90b9-08afb6ab95ef">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80L2ZyYWc6NjY0MWYzZmFlM2Y1NDk4Yjg1MTM2OTdjOTExYTIxNWYvdGFibGU6NzU0MjkwNWYzNmYyNGM4MGE4NGFlNjgxOWM3MmQxY2MvdGFibGVyYW5nZTo3NTQyOTA1ZjM2ZjI0YzgwYTg0YWU2ODE5YzcyZDFjY18zMS0xLTEtMS0xNDM4_39cf15f0-1abe-4d2c-9ca5-074ecce0ca2c">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80L2ZyYWc6NjY0MWYzZmFlM2Y1NDk4Yjg1MTM2OTdjOTExYTIxNWYvdGFibGU6NzU0MjkwNWYzNmYyNGM4MGE4NGFlNjgxOWM3MmQxY2MvdGFibGVyYW5nZTo3NTQyOTA1ZjM2ZjI0YzgwYTg0YWU2ODE5YzcyZDFjY18zMi0xLTEtMS0xNDM4_2e1bfceb-5631-4837-a05a-68251a930743">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80L2ZyYWc6NjY0MWYzZmFlM2Y1NDk4Yjg1MTM2OTdjOTExYTIxNWYvdGFibGU6NzU0MjkwNWYzNmYyNGM4MGE4NGFlNjgxOWM3MmQxY2MvdGFibGVyYW5nZTo3NTQyOTA1ZjM2ZjI0YzgwYTg0YWU2ODE5YzcyZDFjY18zMy0xLTEtMS0xNDQx_9bb3b8cc-a9d2-4b08-a150-c5a4bc235d8e">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="idb6e392c488e43689ffc16945c65d467_D20210212-20210212"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81NjkvZnJhZzo2MjkxY2ZkZWZmN2I0M2M5OTE0NzdjNzVkNDY1YzI0Mi90YWJsZTozYjQyM2MxMjIwODM0ZWI1OTE5OWQ3Njc2NWI5YTE1Ny90YWJsZXJhbmdlOjNiNDIzYzEyMjA4MzRlYjU5MTk5ZDc2NzY1YjlhMTU3XzEtMS0xLTEtMTU0OQ_35b1e05b-f729-42d0-904a-3186bb158cb0"
      unitRef="number">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <ck0001824293:DebtInstrumentPaymentTerm
      contextRef="i727458f1ed4c4be384fc367ff6dbf535_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfNTQ5NzU1ODE0MDcxNg_347c90b0-2a8b-4e03-a46b-c55366ecabe5">P1Y6M0D</ck0001824293:DebtInstrumentPaymentTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="id368a2d31edc42a0b69cd67c1ee5bee0_I20210212"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfOTg4_8a453afd-a308-407d-aa87-5aea5009f0de">P5Y0M0D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <dei:DocumentType
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTE0_91123be4-8fc1-4689-8564-30d62fd99c0d">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NTU0YmQxZThkM2U4NGRjYzkxZWM4YWIyYTJjZjFhMzAvdGFibGVyYW5nZTo1NTRiZDFlOGQzZTg0ZGNjOTFlYzhhYjJhMmNmMWEzMF8wLTAtMS0xLTEwMjY_1c06e5e7-74f2-4f0b-b5a4-4dc9b7e9c23b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTU0_9adb1ea0-7f9e-4702-95b9-05a0d5ac59b8">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6ZWJmZmQzMDk5ODRiNDNhNDkyNmEzNzY3Y2IwZjQ5ZWEvdGFibGVyYW5nZTplYmZmZDMwOTk4NGI0M2E0OTI2YTM3NjdjYjBmNDllYV8wLTAtMS0xLTEwMjg_184f7f2f-4616-4da5-a2e5-1cded3e5a632">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTEx_061717eb-8d44-4113-8932-e5e2acc3f637">001-40034</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTEz_465781a4-7e62-4890-b175-208b79788cd0">VALLON PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NjkyOTA5M2RkODQyNDM3MjgyMDJmOWQ3ZTg3ZTI5OTEvdGFibGVyYW5nZTo2OTI5MDkzZGQ4NDI0MzcyODIwMmY5ZDdlODdlMjk5MV8wLTAtMS0xLTEwNDk_277dca42-da1f-419d-afb9-2d6ae5c1dc53">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NjkyOTA5M2RkODQyNDM3MjgyMDJmOWQ3ZTg3ZTI5OTEvdGFibGVyYW5nZTo2OTI5MDkzZGQ4NDI0MzcyODIwMmY5ZDdlODdlMjk5MV8wLTItMS0xLTEwNTE_0e74b148-d037-4096-ba54-4de4d71dd10c">82-4369909</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NjkyOTA5M2RkODQyNDM3MjgyMDJmOWQ3ZTg3ZTI5OTEvdGFibGVyYW5nZTo2OTI5MDkzZGQ4NDI0MzcyODIwMmY5ZDdlODdlMjk5MV8zLTAtMS0xLTExNzMvdGV4dHJlZ2lvbjplNTQ4MTZkMDI5NTU0NzE2ODM2ZGNiYTFiYjU1ODk4Ml8yNzQ4Nzc5MDY5NTEy_691947bb-3040-4bb3-9edf-77e95d61d235">100 N. 18th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NjkyOTA5M2RkODQyNDM3MjgyMDJmOWQ3ZTg3ZTI5OTEvdGFibGVyYW5nZTo2OTI5MDkzZGQ4NDI0MzcyODIwMmY5ZDdlODdlMjk5MV8zLTAtMS0xLTExNzMvdGV4dHJlZ2lvbjplNTQ4MTZkMDI5NTU0NzE2ODM2ZGNiYTFiYjU1ODk4Ml8yNzQ4Nzc5MDY5NTg5_fbda1fe8-067d-4a39-b083-8bb7bad9cd0a">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NjkyOTA5M2RkODQyNDM3MjgyMDJmOWQ3ZTg3ZTI5OTEvdGFibGVyYW5nZTo2OTI5MDkzZGQ4NDI0MzcyODIwMmY5ZDdlODdlMjk5MV8zLTAtMS0xLTExNzMvdGV4dHJlZ2lvbjplNTQ4MTZkMDI5NTU0NzE2ODM2ZGNiYTFiYjU1ODk4Ml8yNzQ4Nzc5MDY5NjI3_c2f9df1f-9710-49b8-9800-270b6c20110f">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NjkyOTA5M2RkODQyNDM3MjgyMDJmOWQ3ZTg3ZTI5OTEvdGFibGVyYW5nZTo2OTI5MDkzZGQ4NDI0MzcyODIwMmY5ZDdlODdlMjk5MV8zLTAtMS0xLTExNzMvdGV4dHJlZ2lvbjplNTQ4MTZkMDI5NTU0NzE2ODM2ZGNiYTFiYjU1ODk4Ml8yNzQ4Nzc5MDY5NjMy_f6617047-cd93-4387-86ea-4b2fb24ec89a">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6NjkyOTA5M2RkODQyNDM3MjgyMDJmOWQ3ZTg3ZTI5OTEvdGFibGVyYW5nZTo2OTI5MDkzZGQ4NDI0MzcyODIwMmY5ZDdlODdlMjk5MV8zLTAtMS0xLTExNzMvdGV4dHJlZ2lvbjplNTQ4MTZkMDI5NTU0NzE2ODM2ZGNiYTFiYjU1ODk4Ml8yNzQ4Nzc5MDY5Njk2_43288622-d3cb-439d-b183-20ac167600d9">19103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8xMDk5NTExNjI5OTU4_9cf46636-2d1b-4d49-9415-5831d2a8126b">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8xMDk5NTExNjI5OTU0_fc7a3f74-60da-4265-a03c-c77a09ec1e78">207-3606</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6Zjc1NjI1OWZjMjcyNDIzODk0NjU5ZjYyNTVhNjkyMWQvdGFibGVyYW5nZTpmNzU2MjU5ZmMyNzI0MjM4OTQ2NTlmNjI1NWE2OTIxZF8xLTAtMS0xLTExODU_6d8ee716-5536-4fb6-a176-91eae53bced6">Common Stock, par value $0.0001per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6Zjc1NjI1OWZjMjcyNDIzODk0NjU5ZjYyNTVhNjkyMWQvdGFibGVyYW5nZTpmNzU2MjU5ZmMyNzI0MjM4OTQ2NTlmNjI1NWE2OTIxZF8xLTItMS0xLTEwMzA_2eda2738-8d0e-4253-8fc9-3dabcef5c999">VLON</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6Zjc1NjI1OWZjMjcyNDIzODk0NjU5ZjYyNTVhNjkyMWQvdGFibGVyYW5nZTpmNzU2MjU5ZmMyNzI0MjM4OTQ2NTlmNjI1NWE2OTIxZF8xLTQtMS0xLTExOTEvdGV4dHJlZ2lvbjphMjQwYzRjMTY3OTE0NDdiYTE5NjYxZmI1MmY2NmYxZl8yNzQ4Nzc5MDY5NDcx_6640ae0c-6190-48d1-84c0-51912dada128">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTM1_16de5ed8-80f4-45c7-93eb-1437055eacbd">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTM2_1184ad98-a402-403f-91df-8430bedad2bc">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6OWEzYWM2YzQ5ODZjNGU4Mjg2MzMyOTAzZDc1N2FiYzMvdGFibGVyYW5nZTo5YTNhYzZjNDk4NmM0ZTgyODYzMzI5MDNkNzU3YWJjM18xLTAtMS0xLTEwNTM_bd085198-8c6c-4cc4-891f-ae822d17167a">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6OWEzYWM2YzQ5ODZjNGU4Mjg2MzMyOTAzZDc1N2FiYzMvdGFibGVyYW5nZTo5YTNhYzZjNDk4NmM0ZTgyODYzMzI5MDNkNzU3YWJjM18xLTMtMS0xLTEwNTc_987451c2-dc42-4736-b67a-d7211b53abd1">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGFibGU6OWEzYWM2YzQ5ODZjNGU4Mjg2MzMyOTAzZDc1N2FiYzMvdGFibGVyYW5nZTo5YTNhYzZjNDk4NmM0ZTgyODYzMzI5MDNkNzU3YWJjM18yLTEtMS0xLTEwNTU_1c4e1d45-eebc-47be-8689-54db846dfee2">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNzg0_940b20aa-f74e-4b2c-96cf-707977682966">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTc0_59330821-3894-4dc8-bd9b-3916df99824e">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i34b302c75dba4c628d85244f68002a60_I20210806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xL2ZyYWc6NGE3Y2YzZGMwMDY0NGRiNDhkNTEzNDgxODczNWY4ZmIvdGV4dHJlZ2lvbjo0YTdjZjNkYzAwNjQ0ZGI0OGQ1MTM0ODE4NzM1ZjhmYl8yNzQ4Nzc5MDcxNTI0_7e17540c-fac2-425e-baf1-1c8cb28bad4e"
      unitRef="shares">6812836</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMy0xLTEtMS0w_340be2b5-a91a-4d82-8574-28d21c87fefb"
      unitRef="usd">10460000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMy0zLTEtMS0w_41073bac-7f32-453b-af61-4ab932fa8dd1"
      unitRef="usd">109000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNC0xLTEtMS00OA_6dba0616-2cf5-4a12-9180-71d69aeaffda"
      unitRef="usd">944000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNC0zLTEtMS0w_3dca3f74-5ca7-4067-badb-abe865c1f79d"
      unitRef="usd">565000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNS0xLTEtMS0xMDI0_50b2bbda-8673-4655-b6f9-ef850bc67ea9"
      unitRef="usd">11404000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNS0zLTEtMS0w_629691f8-a294-4831-a1be-086046d2c1f7"
      unitRef="usd">674000</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNi0xLTEtMS0w_d523feda-3b6e-43e8-b8d1-2435d7b95541"
      unitRef="usd">243000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNi0zLTEtMS0w_a32a29d7-b436-4730-a515-252beb6de06f"
      unitRef="usd">279000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNy0xLTEtMS01Mg_8adca70b-446e-4941-9b2b-ed35654963a8"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfNy0zLTEtMS0w_1d13893e-9d2c-4968-a0eb-572d4b27f21a"
      unitRef="usd">2000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfOC0xLTEtMS0w_fd8bd3b6-1ec3-4238-bc2d-47d2432ca043"
      unitRef="usd">11647000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfOC0zLTEtMS0w_89b0c0fc-69da-428f-a427-4fda8df08565"
      unitRef="usd">955000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTItMS0xLTEtMA_686beeb4-55f9-481d-b7de-895d750e3644"
      unitRef="usd">886000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTItMy0xLTEtMA_fc63d4da-60c3-4fae-b350-eab3b435b7ea"
      unitRef="usd">1226000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTMtMS0xLTEtNTc_683ad932-ea49-4743-9658-de1aaa529391"
      unitRef="usd">694000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTMtMy0xLTEtMA_6d20b9a3-cb61-400a-bb33-db7c78e13513"
      unitRef="usd">847000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTQtMS0xLTEtMA_0ffbd79c-097e-422c-9e32-6e9a6609e892"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTQtMy0xLTEtMA_b8f458ba-4adc-4900-9a04-8963091a999b"
      unitRef="usd">47000</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTUtMS0xLTEtNjE_da238913-5641-46a1-86d8-429a8d16ab00"
      unitRef="usd">91000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTUtMy0xLTEtMA_56a90e2a-3885-4bda-abe8-a338de76cd07"
      unitRef="usd">105000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTYtMS0xLTEtMA_afc2ed09-14c9-43dd-891b-a3cf7a71533a"
      unitRef="usd">1671000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTYtMy0xLTEtMA_8fa93354-467b-4f7c-b473-f794550b6e49"
      unitRef="usd">2225000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTctMS0xLTEtMA_ffda80ec-10ae-443d-850e-ed4430c5aed8"
      unitRef="usd">0</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTctMy0xLTEtMA_bc6e31f1-147f-4366-a9c2-b02d1e55daec"
      unitRef="usd">14000</us-gaap:LongTermNotesPayable>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTgtMS0xLTEtNjU_2328f5e1-36d0-48a0-8fec-8c39d79a8e84"
      unitRef="usd">123000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTgtMy0xLTEtMA_1b5339b0-0809-4c08-aa20-53d777b39aca"
      unitRef="usd">170000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTktMS0xLTEtMA_00f4e713-833b-4d7e-b35c-d52d8bd131c6"
      unitRef="usd">1794000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMTktMy0xLTEtMA_6e03b646-66f0-44fb-8f50-fa0e23d60290"
      unitRef="usd">2409000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjEtMS0xLTEtMTk5NA_3cd7b6f9-f878-4b9e-9ac2-0eebcc401516"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjEtMy0xLTEtMTk5Ng_b426df9e-72fd-4be4-b2b2-c1beb1e8a3b2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2XzE4_4bf1bb38-9875-4f39-8d47-928ac41ec3d8"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2XzE4_b27b3166-dfbe-4a57-8d66-76c645957377"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2XzMy_143265dc-17f2-4ded-a936-7d7d733c265f"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2XzMy_20837609-4414-4c33-958e-8ba71632c6d9"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2Xzcw_26422d54-e86a-41b0-9a55-7cc8e28663e6"
      unitRef="shares">6812836</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2Xzcw_a665de09-c25a-432c-a390-50c2d3d957bb"
      unitRef="shares">6812836</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2Xzc3_87e7fe20-74d1-453e-97c1-b7fcb2a38a53"
      unitRef="shares">4506216</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmEyZTg3OTZlMGExZTQ3ZmZiZWRkNmQzYWQ1M2RiYWE2Xzc3_fa55df69-b22f-40fe-8f9f-8c829efd792f"
      unitRef="shares">4506216</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMS0xLTEtMA_e69a35cb-5d0d-4a2f-849c-56db7fb705ee"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMy0xLTEtMA_be1e8d79-1690-4d9e-aab8-58acf7f892a7"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjMtMS0xLTEtNzM_1e3e46dd-c2ce-4b6d-834c-2bb31633613f"
      unitRef="usd">27402000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjUtMy0xLTEtMA_b72cab36-4da0-4944-af14-849fb163bbb0"
      unitRef="usd">11145000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjQtMS0xLTEtNzc_ee157762-70f5-4b8b-9ce0-5b70f4653284"
      unitRef="usd">-17549000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjYtMy0xLTEtMA_184b09cc-f5b6-4edd-a5e0-e8cf30c518d4"
      unitRef="usd">-12599000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjUtMS0xLTEtMTI3Mw_8517c0bf-2b0f-43e9-8d7d-d3f9f58a8afe"
      unitRef="usd">9853000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjctMy0xLTEtMA_e605f179-7fe7-4417-9745-33318b3fa886"
      unitRef="usd">-1454000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjgtMS0xLTEtMA_c167cde0-0363-4cbd-a89a-35ce245c493a"
      unitRef="usd">11647000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8xOS9mcmFnOjM1YzNkMGZlNzdmYTQyMGRhYzM4NjY4ZWIyZjViNmExL3RhYmxlOmE0ZWUwY2YwZjVmMjRkMDM5NGY3NTAyZTkyODdiODJhL3RhYmxlcmFuZ2U6YTRlZTBjZjBmNWYyNGQwMzk0Zjc1MDJlOTI4N2I4MmFfMjgtMy0xLTEtMA_0394d09c-e228-4df9-90ef-7e82060c2963"
      unitRef="usd">955000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMy0xLTEtMS0w_31dd145e-8b03-4514-a4ac-fd316120eb8a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMy0zLTEtMS0w_8f107906-5a7f-49d7-95b2-72f3020ae0ad"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMy01LTEtMS0xMjE_d17953a7-ff51-4013-b292-ad0148a0fcd2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMy03LTEtMS0w_638a1d02-e9ec-488a-b260-caed544b4d70"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNS0xLTEtMS0xNTE_a8bb2bff-5ea7-4a9a-bcc6-61cde0dff1fe"
      unitRef="usd">1202000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNS0zLTEtMS0w_6eba41bd-f28a-4b47-9b9d-e72c55c299dd"
      unitRef="usd">808000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNS01LTEtMS0xMTQ_f4e786f3-2f9f-4e1f-83cd-080fb8d80e2c"
      unitRef="usd">2974000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNS03LTEtMS0w_65c61d64-7c2c-4061-bdf5-5343819a31e1"
      unitRef="usd">1694000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNi0xLTEtMS0xNTE_435ee7a1-be0b-4ed8-84a8-937925fdda76"
      unitRef="usd">1108000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNi0zLTEtMS0w_c8a8e258-5ef8-4340-9d1a-0b1768ae8017"
      unitRef="usd">327000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNi01LTEtMS0xMTA_635309eb-bcc6-411d-baa9-e4edfb5f194e"
      unitRef="usd">1938000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNi03LTEtMS0w_fdd676db-8251-4eec-a8ce-bdfd88059e06"
      unitRef="usd">701000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNy0xLTEtMS0w_84ed2c4b-ecb7-4210-8380-2f29b2cd55e6"
      unitRef="usd">2310000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNy0zLTEtMS0w_3a94669b-7adb-45c2-8e03-b50484fe0398"
      unitRef="usd">1135000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNy01LTEtMS0w_66e0065d-80d8-41e4-bb56-6581b9405590"
      unitRef="usd">4912000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfNy03LTEtMS0w_2a421e3a-6b55-4e2e-8faf-60f0122071a7"
      unitRef="usd">2395000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOC0xLTEtMS0w_68a42e63-4f6c-4dd0-ace9-9ba04706b601"
      unitRef="usd">-2310000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOC0zLTEtMS0w_c6ec917b-24fa-4d62-b265-edfca0cb31fb"
      unitRef="usd">-1135000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOC01LTEtMS0w_45b4e906-cc9f-4655-8ec5-b62f14d39ceb"
      unitRef="usd">-4912000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOC03LTEtMS0w_85226b68-4619-474f-8bd2-deec0a0a562d"
      unitRef="usd">-2295000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOS0xLTEtMS0w_dfe5e5bd-cd3f-4e8d-a124-760fb4a9b79a"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOS0zLTEtMS0w_5fbe1348-b18c-4147-b0cc-ba6679d8a6e7"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOS01LTEtMS0w_59017b5f-6481-4c3f-b83b-f028f5b2d822"
      unitRef="usd">61000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfOS03LTEtMS0w_b0b1aaca-7ce2-44b1-a867-9c68a2c40da5"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTAtMS0xLTEtMA_ae891dea-6042-4395-9416-3953c44577c5"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTAtMy0xLTEtMA_08e1039c-599a-4e34-a01d-6626c81d18cb"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTAtNS0xLTEtMA_d84c5ced-67a9-4f08-99a3-1806c7a434ed"
      unitRef="usd">-89000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTAtNy0xLTEtMA_2a2cc0e3-ea42-40bb-87f3-1ae9ee48d9fc"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTEtMS0xLTEtMTQ3_e3e941bc-b310-4b02-8446-ea8a19f12862"
      unitRef="usd">-2000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTEtMy0xLTEtMA_0564110d-910a-4717-acf3-029ee1321cd9"
      unitRef="usd">-12000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTEtNS0xLTEtMTM5_e0126353-c037-4512-86fd-aaead25f5ab6"
      unitRef="usd">-10000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTEtNy0xLTEtMA_2809b4d2-1e06-4396-8a23-12e29643e296"
      unitRef="usd">-13000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTItMS0xLTEtMA_dc1d292a-a5e7-4298-bef8-d1f6f6c91f17"
      unitRef="usd">-2312000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTItMy0xLTEtMA_18494711-6d4d-4c44-b158-f983b43d5a10"
      unitRef="usd">-1147000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTItNS0xLTEtMA_273e7158-3694-421c-9994-ac147644b316"
      unitRef="usd">-4950000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTItNy0xLTEtMA_01ac486a-d122-486a-859a-99ab9301a764"
      unitRef="usd">-2308000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtMS0xLTEtMA_267c2318-b4df-4709-8195-6344eae8894f"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtMS0xLTEtMA_61374a24-4bb0-4be1-9660-aba80734d0b2"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtMy0xLTEtMA_80b75de7-444b-441e-8da8-d5a70d5ac39e"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtMy0xLTEtMA_918165d0-7c95-4aeb-8b66-ac7b640871a9"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtNS0xLTEtMA_594b3605-106b-4dcd-aef7-730a8d7af326"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtNS0xLTEtMA_91623ebc-749c-4fee-b3c3-24c95408f7ec"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtNy0xLTEtMA_3eebce8c-a18c-4a9d-8dda-4d936a070e7b"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTMtNy0xLTEtMA_b378dcee-3be4-4d46-b2c5-a69f1a6cf892"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtMS0xLTEtNTk5_94ae9fda-98fc-472d-a005-bf862bdd7244"
      unitRef="shares">6812836</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtMS0xLTEtNTk5_a68c1300-148f-418f-9c10-1f0052b5c424"
      unitRef="shares">6812836</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtMy0xLTEtMA_93e75d4b-3457-475a-92d5-075ce7ca13f7"
      unitRef="shares">4506216</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtMy0xLTEtMA_ad1abc61-fc8c-4bf6-afdc-f3eee52f10d3"
      unitRef="shares">4506216</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtNS0xLTEtNjA1_66288e3f-1fc6-4638-ad6b-defa9cbd5b51"
      unitRef="shares">6264854</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtNS0xLTEtNjA1_ce919846-783f-4cbe-a43e-80bf15c97a5e"
      unitRef="shares">6264854</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtNy0xLTEtMA_5bbd37b1-7f4a-498e-817b-112dbe2e79f2"
      unitRef="shares">4506216</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yMi9mcmFnOjI1NTcwNTE2ZmY1ZTRmZmZiMTg4ODk5MTk5OWUxYTU4L3RhYmxlOmY3YTFkMWNjYmMzNzQwYzc5NzgwYTY5Zjg5ZjU4ZGNhL3RhYmxlcmFuZ2U6ZjdhMWQxY2NiYzM3NDBjNzk3ODBhNjlmODlmNThkY2FfMTQtNy0xLTEtMA_b2cedd9f-b925-459e-a2ba-30219142cb0b"
      unitRef="shares">4506216</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i61ac3f94b5f149979bd71ad52587031e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfMi0xLTEtMS0w_00f4044e-38a8-49bf-80f3-75abdce04fce"
      unitRef="shares">4506216</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibe37a5900c304ce28d7ecdea6420b23a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfMi01LTEtMS0w_aa2e4beb-d474-4dd1-aacc-66ce160cd7c4"
      unitRef="usd">10991000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if56d5eae60d046f096e356f7a5042dcb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfMi03LTEtMS0w_3d932c05-17f3-431a-ac2d-3d462492718c"
      unitRef="usd">-7777000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie3e856b37c19403f8329a07be3454d4e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfMi05LTEtMS0w_5b0480b8-4ee6-4d7e-a90a-5ecda46240da"
      unitRef="usd">3214000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibafcc59176d54d99a4b6f080f91bebfe_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfMy01LTEtMS0w_4e812cf1-9fdd-46ef-b786-38a2ada4cca0"
      unitRef="usd">35000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i50024d555c8a4c84929dda5920ed007b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfMy05LTEtMS0w_c361636a-ed59-46ef-9fa3-5a47d768ae7c"
      unitRef="usd">35000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i5765e73948fa479394575bdc1358aa9a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNC03LTEtMS0w_49ac8970-9ea9-46f1-9865-0bd3679afdf6"
      unitRef="usd">-1161000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i50024d555c8a4c84929dda5920ed007b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNC05LTEtMS0w_f55ecb74-2026-4a41-a968-15b5a420a70c"
      unitRef="usd">-1161000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie620d3313620467383dee26f0f0a3c7c_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNS0xLTEtMS0w_124d1236-1ba1-4133-a8de-0cea110e046b"
      unitRef="shares">4506216</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i238b94d82c304fccbc90bb50080061c5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNS01LTEtMS0w_324694ed-6044-4736-8f16-8c5b4b5f8ba7"
      unitRef="usd">11026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac63187c14bf4722bde64d421ce98362_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNS03LTEtMS0w_f52d9cfb-8bec-4e2b-9e61-24a8ac1095e9"
      unitRef="usd">-8938000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibffb387820b54b48a3579ed3b5009547_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNS05LTEtMS0w_7d63134c-5072-4c83-a363-5ca770b54073"
      unitRef="usd">2088000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie769608b479948f496d2bb6a432fac37_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNy01LTEtMS0w_21f48517-0881-46be-a9aa-12a29413ae34"
      unitRef="usd">28000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfNy05LTEtMS0w_ff7c2ba1-99a4-4a42-a4da-67f044a16fed"
      unitRef="usd">28000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ief43562ce2e047b9817ddf36217940df_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfOC03LTEtMS0w_5caba09a-a016-4614-91ab-540677866bfc"
      unitRef="usd">-1147000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfOC05LTEtMS0w_f8a9086b-2671-44da-97c7-d7e85f095cfe"
      unitRef="usd">-1147000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaa5c17d856644cd3b88a05d18f8e6bfe_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfOS0xLTEtMS0w_a57ed225-f5b9-4391-9cf2-b1a1062d45ad"
      unitRef="shares">4506216</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ife011d6dbed94ffeaeb46db11c3e48e3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfOS01LTEtMS0w_e84f97b8-2d1f-4d6c-b785-83da12b75f86"
      unitRef="usd">11054000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff321e9d1ca24eeb985f787da4129ad1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfOS03LTEtMS0w_415ffe7a-4e91-4a64-8557-1ad7b6068852"
      unitRef="usd">-10085000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa79d0de6ea5497ebb25e7f4d8686d52_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjU0YTYxZWE4OTg5NjQyNjhiYzc1NjI1MzZmMDFhZTNjL3RhYmxlcmFuZ2U6NTRhNjFlYTg5ODk2NDI2OGJjNzU2MjUzNmYwMWFlM2NfOS05LTEtMS0w_40508f80-6edc-43e0-b262-fc8639777ef2"
      unitRef="usd">969000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i31e1e141d8814e4090f2d3e21275625e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMi0xLTEtMS0w_522e2279-54da-4261-bb93-52cd4006f882"
      unitRef="shares">4506216</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i143f796f80894c99aac56a13b900ee21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMi01LTEtMS0w_31db3e4a-66cb-40eb-8f02-34bf27ad9719"
      unitRef="usd">11145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6d46e3841ca64fbb811bcae232cd7200_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMi03LTEtMS0w_a3af10d3-eee3-4753-a9d9-8e7b68b8986a"
      unitRef="usd">-12599000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMi05LTEtMS0w_cc435fa7-a0a8-4f66-8c47-c5a6aae52c6d"
      unitRef="usd">-1454000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="icd589b362dd643cabf0c87233e57e988_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMy0xLTEtMS0w_d2868603-c62a-4dea-9669-2ac66d25fbdd"
      unitRef="shares">54906</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i2d33cef40f034ce2a44f35ae028bb669_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMy01LTEtMS0w_5262fdaa-59cf-4443-811a-bea8ed0f1f5c"
      unitRef="usd">439000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i63727a089ddc482397d5b8b38b53f131_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMy05LTEtMS0w_2d6c3630-cc93-4b0c-b6b3-260fe04f1f22"
      unitRef="usd">439000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="icd589b362dd643cabf0c87233e57e988_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNC0xLTEtMS0w_e485d005-d58c-4e2f-987c-3ac840b28e34"
      unitRef="shares">2250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2d33cef40f034ce2a44f35ae028bb669_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNC01LTEtMS0w_c51ade59-ef0d-45ab-8c07-350b136514b5"
      unitRef="usd">15104000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i63727a089ddc482397d5b8b38b53f131_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNC05LTEtMS0w_f0969801-0c4b-4153-bf3c-10c54ab7d3c9"
      unitRef="usd">15104000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="icd589b362dd643cabf0c87233e57e988_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNS0xLTEtMS0w_45cdf56a-a7c1-4d8d-a74b-cc3000882a9f"
      unitRef="shares">1714</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i2d33cef40f034ce2a44f35ae028bb669_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNS01LTEtMS0w_a787fe6b-5402-4497-9f15-a0154187e3a6"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i63727a089ddc482397d5b8b38b53f131_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNS05LTEtMS0w_3453702c-9567-428e-9075-e656d02ba616"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i2d33cef40f034ce2a44f35ae028bb669_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNi01LTEtMS0w_54d159e3-e6a8-4cbb-9f8b-f82eeeb0920e"
      unitRef="usd">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i63727a089ddc482397d5b8b38b53f131_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNi05LTEtMS0w_f63d7a73-4395-40c2-b1d5-b88cbffc0307"
      unitRef="usd">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2d33cef40f034ce2a44f35ae028bb669_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNy01LTEtMS0w_7bac4acb-2188-4895-af3d-e6b9fa0620dd"
      unitRef="usd">168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i63727a089ddc482397d5b8b38b53f131_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfNy05LTEtMS0w_5bbee011-a1d6-4574-a3de-6097f4b34309"
      unitRef="usd">168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="id6b512a400b941aba498ea638f7583ed_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfOC03LTEtMS0w_d01d0a73-778b-4a21-abbe-7fcd7f85ae26"
      unitRef="usd">-2638000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i63727a089ddc482397d5b8b38b53f131_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfOC05LTEtMS0w_c67a477f-4eab-42d3-8ce3-b430d1cd966d"
      unitRef="usd">-2638000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifea416d58bba48c59aae046eaf6963ee_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfOS0xLTEtMS0w_475647fa-c2b3-4eec-aa31-69e422bf90ea"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5eb9251ed6a246158ebed555043580de_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfOS01LTEtMS0w_69213538-3530-440e-93a3-2941d824bfdf"
      unitRef="usd">27264000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie850734f1a4c4bdc9dbd84239c0edf92_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfOS03LTEtMS0w_ced44101-45fa-46c9-b0b8-b5e5d87e166e"
      unitRef="usd">-15237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i466406119fd042e78b23e14be880ebc6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfOS05LTEtMS0w_f84986db-4b20-4cb4-8606-fa702f8571d7"
      unitRef="usd">12027000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie683a1421b7e42d5869006a49ce417bb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTAtNS0xLTEtMjMx_b1ed3e42-b0e1-4534-bf2b-6c018869927b"
      unitRef="usd">138000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTAtOS0xLTEtMjQx_4d864871-94fd-4f35-8419-d97cac2cc6e8"
      unitRef="usd">138000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i0c283f6cb704453592615c899f3cf9d8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTEtNy0xLTEtMjM2_fd7d46ed-4002-41d1-9338-152886d1038a"
      unitRef="usd">-2312000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTEtOS0xLTEtMjQy_a44e6acc-a1c2-4c18-8022-bc647b45e70f"
      unitRef="usd">-2312000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i86f5891de57c4edfb483409095deae5b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTMtMS0xLTEtMA_7f208f0b-0971-4ef6-9b6e-97864422a67e"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i02909c7ca37a4096874b575c77575a27_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTMtNS0xLTEtMA_f45535df-00bf-472f-beda-53b51c11c14a"
      unitRef="usd">27402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1a315f92ff66436b99d5d04a5d936d46_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTMtNy0xLTEtMA_65e50153-79a7-4339-87a4-c8fbd8ef29e6"
      unitRef="usd">-17549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yNS9mcmFnOjYwZjkzNjIzZWQwMzQwNTM5NmU5ZjE5MzlkNzE2M2Y2L3RhYmxlOjQzZmM0MTczZDE5OTRjZDY5ZmJiY2Q2MWQ0MTk4MGE5L3RhYmxlcmFuZ2U6NDNmYzQxNzNkMTk5NGNkNjlmYmJjZDYxZDQxOTgwYTlfMTMtOS0xLTEtMA_225c6075-8ff8-4bbd-a6fc-f84e1d419da7"
      unitRef="usd">9853000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMy0xLTEtMS0w_cef1b213-4809-4fc2-a62b-3ecff5500443"
      unitRef="usd">-4950000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMy0zLTEtMS0w_e1ad6834-0738-41bb-b287-295528785104"
      unitRef="usd">-2308000</us-gaap:NetIncomeLoss>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfNS0xLTEtMS0w_81494815-80e5-4e66-9b06-3cc09e3e5cec"
      unitRef="usd">36000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfNS0zLTEtMS0w_ccdbe690-b6c8-42bb-a2c3-1551782335d8"
      unitRef="usd">37000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfNi0xLTEtMS0xODg_05e806b1-6e6a-4f76-86f2-dd516a6d25c5"
      unitRef="usd">306000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfNi0zLTEtMS0w_bcc33416-0d9f-4bbf-96bd-c3deff807489"
      unitRef="usd">63000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfNy0xLTEtMS0w_c48296f9-891f-4c2b-9bf8-6639e6c67540"
      unitRef="usd">-89000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfNy0zLTEtMS0w_9fb13b2a-db57-4941-90d5-b5375379e129"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <ck0001824293:ForgivenessOfDebtInstrument
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfOC0xLTEtMS0w_b879b61c-fbf5-489f-b24c-2c54cae74573"
      unitRef="usd">61000</ck0001824293:ForgivenessOfDebtInstrument>
    <ck0001824293:ForgivenessOfDebtInstrument
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfOC0zLTEtMS0w_3d528cbc-c90d-4200-83a2-90aa55f918a5"
      unitRef="usd">0</ck0001824293:ForgivenessOfDebtInstrument>
    <us-gaap:OtherNoncashExpense
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfOS0xLTEtMS0xODg_09f921b8-cf46-4317-a5d2-662b47d40457"
      unitRef="usd">2000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfOS0zLTEtMS0w_390342f5-9b6d-46f4-b69d-c298cdd879fa"
      unitRef="usd">1000</us-gaap:OtherNoncashExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTEtMS0xLTEtMTkz_97b110c3-e454-438c-bc18-506db62eaf3c"
      unitRef="usd">379000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTEtMy0xLTEtMA_05f4d7e7-a0d4-44d0-9ecf-8f0e5e62ca56"
      unitRef="usd">17000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTItMS0xLTEtMTkz_66443332-0019-4348-8728-25d0673c6b69"
      unitRef="usd">-330000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTItMy0xLTEtMA_8bcc55c7-2319-4164-9498-206e55f6eca5"
      unitRef="usd">262000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTMtMS0xLTEtMTkz_0b3915ef-5910-43a6-84c2-3a4504ea98be"
      unitRef="usd">-153000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTMtMy0xLTEtMA_59472807-1b4f-413e-9c2a-ed0210448848"
      unitRef="usd">128000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTQtMS0xLTEtMA_5ba852e4-1c2c-419c-acb1-6b3a95ec9285"
      unitRef="usd">-5440000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTQtMy0xLTEtMA_a48e2b0f-fc24-45fc-8e06-8ec386fc0239"
      unitRef="usd">-1834000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTctMS0xLTEtMA_8a259192-31b1-4014-a8a2-17c300dd573b"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTctMy0xLTEtMA_1d9e7f8e-ab99-4f32-ba5f-1e368ed5eb9c"
      unitRef="usd">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTgtMS0xLTEtMA_077b1e22-a2df-479c-b02e-e8e0489d9370"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMTgtMy0xLTEtMA_251d180f-e987-403b-b256-9e791ed07aae"
      unitRef="usd">-2000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjEtMS0xLTEtMA_6730d0aa-7978-4040-9af8-50e341f9f67f"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjEtMy0xLTEtMA_ba79a2a9-dcf8-48db-a4b0-b8d33f58ba10"
      unitRef="usd">61000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjItMS0xLTEtMA_7c7a7c76-14db-451d-af73-c949123d60a6"
      unitRef="usd">15503000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjItMy0xLTEtMA_d52a2583-8d6d-420c-b114-7392a799fcfe"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjMtMS0xLTEtMA_2413ae75-bd8f-456c-bd5a-03de20a5af3b"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjMtMy0xLTEtMA_17ac1c98-2d4f-4410-881c-f2a21ce69e8a"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjQtMS0xLTEtMTk3_47ba46c5-e271-43a0-a0e1-b97391c3a5ac"
      unitRef="usd">62000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjQtMy0xLTEtMA_240f3bd3-ed10-4ac1-b1ab-fe67ef859c8a"
      unitRef="usd">47000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjUtMS0xLTEtMA_f3710ef9-1e6b-4302-be5e-49079fccb018"
      unitRef="usd">15791000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjUtMy0xLTEtMA_20eeadce-0aa4-483f-a485-32bf2ffe7614"
      unitRef="usd">14000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjctMS0xLTEtMTQ3MQ_72096782-772e-45ec-a7e4-a98c299e7ec0"
      unitRef="usd">10351000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjctMy0xLTEtMA_06e29ed0-56d7-4976-ab0a-dc474446c80c"
      unitRef="usd">-1822000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjgtMS0xLTEtMA_bf907819-079a-433c-85f5-7a7e1b1b7c8b"
      unitRef="usd">109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie3e856b37c19403f8329a07be3454d4e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjgtMy0xLTEtMA_d0afd6b8-dea1-418f-a867-15d4f8f084aa"
      unitRef="usd">3821000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjktMS0xLTEtMA_016fdc4f-2f86-4618-8bb3-1b637e72559c"
      unitRef="usd">10460000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa79d0de6ea5497ebb25e7f4d8686d52_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMjktMy0xLTEtMA_4cb92757-6bc4-49ef-b611-2764d95af13e"
      unitRef="usd">1999000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMzMtMS0xLTEtMA_d0a95aac-48e8-4e97-bba8-d5cf10b67877"
      unitRef="usd">350000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8yOC9mcmFnOjA1Njc2N2IyODlhNDQ5NDQ5ODY0NjVlMWM4ZjlkZjY3L3RhYmxlOjM2MWI4NmM2OWNmZDQxZjc5YTFkMGY4ZjQyZDU0YmNlL3RhYmxlcmFuZ2U6MzYxYjg2YzY5Y2ZkNDFmNzlhMWQwZjhmNDJkNTRiY2VfMzMtMy0xLTEtMA_66af227c-972e-4856-8745-f617a0a6438b"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:NatureOfOperations
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMjc0ODc3OTA3NjUwNw_3d671f84-20e0-446d-9322-b0fcf5e178fe">ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vallon Pharmaceuticals, Inc. (Vallon or the Company), based in Philadelphia, PA was incorporated in Delaware on January 11, 2018, which is the date of inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company&#x2019;s lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#xae;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The Company plans to develop other abuse-deterrent products, which have potential for abuse in their current forms, beginning with the development of ADMIR, an abuse deterrent formulation of Ritalin, for which the Company is conducting formulation development work.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company completed an initial public offering (IPO) of its common stock, selling 2,250,000 shares at $8.00 per share. As a result of the IPO, the Company received approximately $15,500 in net proceeds, after deducting discounts and commissions of approximately $1,600 and estimated offering expenses of approximately $905 payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, our Chief Executive Officer, pursuant to which we issued convertible promissory notes (the 2021 Convertible Notes) for cash proceeds of $350. The 2021 Convertible Notes bear an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes were convertible into shares of our capital stock offered to investors in any subsequent equity financing after the date of their issuance in which we issued any of our equity securities (a Qualified Financing) and were convertible at a twenty percent (20%) discount to the price per share offered in such Qualified Financing. Such Qualified Financing included the IPO and as a result, the 2021 Convertible Notes converted into an aggregate of 54,906 shares of our common stock immediately prior to the closing of IPO.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3d32c5625af443af9e9ab4f13da85869_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfOTcy_7c4cc056-cf71-4c59-b7d1-0e5b2476c0e5"
      unitRef="shares">2250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ib40eca850643445aa3fb581f3a267821_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfOTg1_5954f8f9-dce3-4ba5-b403-51c698b7b9be"
      unitRef="usdPerShare">8.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i3d32c5625af443af9e9ab4f13da85869_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMTA1OA_c1e63987-df1f-4039-9b4f-31b5d4c3d4c7"
      unitRef="usd">15500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsDiscountsAndCommissions
      contextRef="i3d32c5625af443af9e9ab4f13da85869_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMTEzNw_0debbb7f-a78b-4f79-8fa4-213275024703"
      unitRef="usd">1600000</ck0001824293:StockIssuanceCostsDiscountsAndCommissions>
    <ck0001824293:StockIssuanceCostsOfferingExpenses
      contextRef="if3a045458c344fe6b012e31e07176174_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMTE4OQ_169f5748-0cf2-4977-b66f-3fa33a8d0719"
      unitRef="usd">905000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i3d756267a38641f49152d284b506e41c_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMTUzNQ_17c12f28-2984-4a3d-a64c-f272dae51766"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i78d2a9fcaf4742528def995407f4d94d_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMTU5MQ_316bbf3c-41b9-4071-a533-8ec9d94bee43"
      unitRef="number">0.070</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="i3d756267a38641f49152d284b506e41c_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMTk0OQ_70d21f7d-0d54-4070-89c1-33769a9c087a"
      unitRef="number">0.20</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i3d756267a38641f49152d284b506e41c_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNC9mcmFnOmMzMGIyM2NhNmRiZjRjNDQ4OThkYjA5NTlhYWExMzFmL3RleHRyZWdpb246YzMwYjIzY2E2ZGJmNGM0NDg5OGRiMDk1OWFhYTEzMWZfMjEzOQ_c157c2a0-101f-475b-83d2-c7fae0d2bca7"
      unitRef="shares">54906</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNy9mcmFnOmY3YTE1MWJkN2YxZjRkNmM4MWJmMGE4YjE1MGMwZTg1L3RleHRyZWdpb246ZjdhMTUxYmQ3ZjFmNGQ2YzgxYmYwYThiMTUwYzBlODVfMjc0ODc3OTA3MTc4OA_6919c9a5-fd91-43bf-8bd3-2f3f10453ff1">LIQUIDITY&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception and has incurred $17,549 in accumulated deficit through June&#160;30, 2021. The Company has financed its working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a Paycheck Protection Program (PPP) promissory note.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company completed a $350 convertible note financing and in February 2021, the Company completed the IPO, raising net proceeds of $15,500. As of June&#160;30, 2021, the Company had cash and cash equivalents of approximately $10,460, which management expects will provide funding for its ongoing business activities into the third quarter of 2022. However, the Company has based this estimate on assumptions that may prove erroneous, and it could use capital resources sooner than it expects, therefore, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year of the date that these financial statements are being issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company&#x2019;s objective is to develop and commercialize biopharmaceutical products that treat central nervous system disorders, but there can be no assurances that the Company will be successful in this regard. Therefore, the Company intends to raise capital through additional issuances of common stock and /or short-term notes. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNy9mcmFnOmY3YTE1MWJkN2YxZjRkNmM4MWJmMGE4YjE1MGMwZTg1L3RleHRyZWdpb246ZjdhMTUxYmQ3ZjFmNGQ2YzgxYmYwYThiMTUwYzBlODVfNDY4_231cadbc-79f2-4996-9a1b-5498b6444748"
      unitRef="usd">-17549000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ic49837a0734b43478ec5edc5f65ef833_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNy9mcmFnOmY3YTE1MWJkN2YxZjRkNmM4MWJmMGE4YjE1MGMwZTg1L3RleHRyZWdpb246ZjdhMTUxYmQ3ZjFmNGQ2YzgxYmYwYThiMTUwYzBlODVfNzU0_81e793fa-8ca2-4fe9-ae61-fd93ac4723dd"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i3d32c5625af443af9e9ab4f13da85869_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNy9mcmFnOmY3YTE1MWJkN2YxZjRkNmM4MWJmMGE4YjE1MGMwZTg1L3RleHRyZWdpb246ZjdhMTUxYmQ3ZjFmNGQ2YzgxYmYwYThiMTUwYzBlODVfODUw_22f869d4-5d3e-45b5-ae1f-537096fee807"
      unitRef="usd">15500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml8zNy9mcmFnOmY3YTE1MWJkN2YxZjRkNmM4MWJmMGE4YjE1MGMwZTg1L3RleHRyZWdpb246ZjdhMTUxYmQ3ZjFmNGQ2YzgxYmYwYThiMTUwYzBlODVfOTIz_8395bef1-7f98-48ce-9ea3-24a2c83215b2"
      unitRef="usd">10460000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80MC9mcmFnOjQ3MzZlYjcxZDlkOTRjNGU5MjhkMzZlYzEwN2JiODc3L3RleHRyZWdpb246NDczNmViNzFkOWQ5NGM0ZTkyOGQzNmVjMTA3YmI4NzdfMjc0ODc3OTA3NzkyOA_29b8196c-a4aa-4bc7-b00d-e3f33f85b414">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December 31, 2020 balance sheet was derived from audited financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of June&#160;30, 2021, and the results of operations and stockholders&#x2019; equity (deficit) for the three and six months ended June&#160;30, 2021 and 2020 and cash flows for the six months ended June&#160;30, 2021 and 2020. Results of operations for the three and six months ended June&#160;30, 2021, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2021. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2020 included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 29, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recapitalization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the closing of the  IPO (Note 6), the Company effected a one-for-40 reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Quarterly Report on Form 10-Q give retroactive effect to the reverse split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s results of operations could either benefit from, or be adversely affected by, any such change in estimate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are recorded as a cumulative adjustment in the period the estimates are revised. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The &lt;/span&gt;&lt;/div&gt;amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80MC9mcmFnOjQ3MzZlYjcxZDlkOTRjNGU5MjhkMzZlYzEwN2JiODc3L3RleHRyZWdpb246NDczNmViNzFkOWQ5NGM0ZTkyOGQzNmVjMTA3YmI4NzdfNTQ5NzU1ODE0ODIzOA_dad13655-f9e7-4395-991b-7654d1508ca1">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December 31, 2020 balance sheet was derived from audited financial statements.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80MC9mcmFnOjQ3MzZlYjcxZDlkOTRjNGU5MjhkMzZlYzEwN2JiODc3L3RleHRyZWdpb246NDczNmViNzFkOWQ5NGM0ZTkyOGQzNmVjMTA3YmI4NzdfNTQ5NzU1ODE0ODIzOQ_c1ac1b70-a37a-48ed-9593-c7458eca3190">Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</us-gaap:UseOfEstimates>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80MC9mcmFnOjQ3MzZlYjcxZDlkOTRjNGU5MjhkMzZlYzEwN2JiODc3L3RleHRyZWdpb246NDczNmViNzFkOWQ5NGM0ZTkyOGQzNmVjMTA3YmI4NzdfNTQ5NzU1ODE0ODI0MA_f5f6a70a-59d4-438f-8fc1-f5091bb5fd43">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are recorded as a cumulative adjustment in the period the estimates are revised. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80MC9mcmFnOjQ3MzZlYjcxZDlkOTRjNGU5MjhkMzZlYzEwN2JiODc3L3RleHRyZWdpb246NDczNmViNzFkOWQ5NGM0ZTkyOGQzNmVjMTA3YmI4NzdfNTQ5NzU1ODE0ODI0MQ_93f4d4fd-bb35-449b-82ee-34b30513d4b9">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The &lt;/span&gt;&lt;/div&gt;amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RleHRyZWdpb246MWNjYmE1YjBjZTc1NGVmMjg5ODg4OWJmZDIwYzJkYzJfMjc0ODc3OTA2OTU0NA_154d4fc5-451f-4e50-8597-c52e552ad9e6">ACCRUED EXPENSES&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RleHRyZWdpb246MWNjYmE1YjBjZTc1NGVmMjg5ODg4OWJmZDIwYzJkYzJfMjc0ODc3OTA2OTU0NQ_e7be63f8-3ec0-457a-92d2-4d94189ff024">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfMS0xLTEtMS0w_ad0caea1-d9e5-42d1-9658-e3f069617197"
      unitRef="usd">283000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfMS0zLTEtMS0w_cb55e9f3-f54a-49f2-b671-5363e1f00220"
      unitRef="usd">259000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfMi0xLTEtMS02NjI_a0706a1d-fcdb-40b6-8a89-e968a21aa112"
      unitRef="usd">144000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfMi0zLTEtMS0w_26878f0a-2903-43d0-a9a7-2ad4cb590400"
      unitRef="usd">156000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfMy0xLTEtMS02NjI_5f6f5478-fab2-4c1a-ac2d-506adb376117"
      unitRef="usd">196000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfMy0zLTEtMS0w_d1ad8b5c-3573-4796-97b7-6403a8a16cd3"
      unitRef="usd">342000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ck0001824293:AccruedLicensingFeesCurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfNC0xLTEtMS0w_ed2c2c71-7660-4ba0-9258-c21f2331bb6d"
      unitRef="usd">71000</ck0001824293:AccruedLicensingFeesCurrent>
    <ck0001824293:AccruedLicensingFeesCurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfNC0zLTEtMS0w_a103ea61-9571-4984-bfb5-3c092d68957a"
      unitRef="usd">81000</ck0001824293:AccruedLicensingFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfNS0xLTEtMS02NzI_96b2cc70-e18f-4ad0-828c-a44c169cd9d5"
      unitRef="usd">0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfNS0zLTEtMS0w_0d9e3b2c-5efc-4b70-8525-531fb2338706"
      unitRef="usd">9000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfNy0xLTEtMS0w_3ed5fdb2-e794-4cb2-b4e5-cdae0b310194"
      unitRef="usd">694000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80My9mcmFnOjFjY2JhNWIwY2U3NTRlZjI4OTg4ODliZmQyMGMyZGMyL3RhYmxlOjU5NzNiOTRjZDI3NDRjOWZiMWNiNGY4M2FiOTZkYjE3L3RhYmxlcmFuZ2U6NTk3M2I5NGNkMjc0NGM5ZmIxY2I0ZjgzYWI5NmRiMTdfNy0zLTEtMS0w_b55f1ee6-0e1e-45d6-9a43-2903cfc615a0"
      unitRef="usd">847000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfMjc0ODc3OTA3MTIwNg_b41d7077-289f-4863-8908-814d18788a02">PPP NOTE AND CONVERTIBLE NOTES&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company issued a promissory note under the PPP (the PPP Note) totaling $61. The PPP Note had a stated interest rate of 1% and had a two-year maturity. Payments were required to be made over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfNTQ5NzU1ODE0MDcxNg_347c90b0-2a8b-4e03-a46b-c55366ecabe5"&gt;1.5-year&lt;/span&gt; period beginning November 1, 2020 unless forgiven. In January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As a result, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1, disclosed in the amount of $61 included in other income on the accompanying Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January&#160;11, 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#x2019;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes, for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#x2019;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#x2019;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i81624bcf1ddd410e8384985a52ed244e_I20200531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfMTIx_e904f2f7-a602-4503-ad99-48626de6bec0"
      unitRef="usd">61000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i81624bcf1ddd410e8384985a52ed244e_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfMTY4_dfb105ad-5756-431f-967e-02fcb0b7d58b"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="i727458f1ed4c4be384fc367ff6dbf535_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfNTQ5NzU1ODE0MDcxNQ_564a8b0c-bac6-4b99-9070-c29482c3f80c">P2Y</us-gaap:DebtInstrumentTerm>
    <ck0001824293:ForgivenessOfDebtInstrument
      contextRef="ic49837a0734b43478ec5edc5f65ef833_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfNTQz_426967a3-4c36-4c3f-b24d-cb8916fb469b"
      unitRef="usd">61000</ck0001824293:ForgivenessOfDebtInstrument>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ice4617251d084359a4b1673e32105777_D20210111-20210111"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfOTc3_1a408564-58ec-4464-84e0-757c7c38ad55"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i99c9d5a032e74fedb51994d35e423ac4_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfMTAzMQ_c5b5688a-4509-4a4e-868b-a629a2701ca9"
      unitRef="number">0.070</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i8bc882349d4b44458f3fcac805712aaa_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfMTE0OQ_038ed841-95a5-47ad-9931-d1e637b14fb5"
      unitRef="shares">54906</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfNTQ5NzU1ODE0MDM4MQ_a457847d-50d7-4319-8a4e-f9c7a91d25c8">STOCKHOLDERS&#x2019; EQUITY (DEFICIT)&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;12, 2021, the Company completed the IPO of 2,250,000 shares of common stock at a public offering price of $8.00 per share. The gross proceeds from the IPO, before deducting underwriting discounts, commissions and other offering expenses payable by the Company, were $18,000. Underwriting discounts and expenses totaled $1,600 and the Company incurred approximately $905 of additional expenses related to completing the IPO, of which $494 were incurred as of December&#160;31, 2020 and included prepaid expenses and other current assets on the Company&#x2019;s balance sheet; thus aggregate net proceeds were approximately $15,500. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the IPO, the Company granted the underwriters warrants (the Underwriters' Warrants) to purchase an aggregate of 112,500 shares of common stock at an exercise price of $10.00 per share. The Underwriters&#x2019; Warrants have a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfOTg4_8a453afd-a308-407d-aa87-5aea5009f0de"&gt;five&lt;/span&gt;-year term and are not exercisable prior to August 12, 2021. All of the Underwriters&#x2019; Warrants were outstanding as of June&#160;30, 2021. The warrants were &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;classified as equity and the fair value of $399 is reflected as additional paid-in capital. The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.155&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8d10d62088b94b7ca91599063bdd7713_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfOTI_d65358d4-7490-4cd6-a7b9-a944c57ad66b"
      unitRef="shares">2250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia5a7c424887d4d268f63dad57f3d0c22_I20210212"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfMTQ4_79dd22eb-e5ac-4553-8f6a-07a1860e9026"
      unitRef="usdPerShare">8.00</us-gaap:SaleOfStockPricePerShare>
    <ck0001824293:ProceedsFromIssuanceInitialPublicOfferingGross
      contextRef="i8d10d62088b94b7ca91599063bdd7713_D20210212-20210212"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfMzA1_f0ed298a-42f1-47d7-804a-333ee086342c"
      unitRef="usd">18000000</ck0001824293:ProceedsFromIssuanceInitialPublicOfferingGross>
    <ck0001824293:StockIssuanceCostsDiscountsAndCommissions
      contextRef="i8d10d62088b94b7ca91599063bdd7713_D20210212-20210212"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfMzUz_5fb58fe7-358a-4082-94d6-ad7bb3d56359"
      unitRef="usd">1600000</ck0001824293:StockIssuanceCostsDiscountsAndCommissions>
    <ck0001824293:StockIssuanceCostsOfferingExpenses
      contextRef="idb6e392c488e43689ffc16945c65d467_D20210212-20210212"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfMzk1_7c90f028-44a1-46c4-a971-91d16785d795"
      unitRef="usd">905000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:StockIssuanceCostsOfferingExpenses
      contextRef="if9d38d7df6fa442f80a3d6ebe4c56f9c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfNDYx_7390f4c7-18ea-429a-80b8-6eaff7324f15"
      unitRef="usd">494000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8d10d62088b94b7ca91599063bdd7713_D20210212-20210212"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfNjEz_6ea6daa4-3537-46ac-bc0b-779567b03f68"
      unitRef="usd">15500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="id368a2d31edc42a0b69cd67c1ee5bee0_I20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfODkw_eb39ed39-3986-4541-b2aa-2cd1fff71e83"
      unitRef="shares">112500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id368a2d31edc42a0b69cd67c1ee5bee0_I20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfOTQw_4c926dec-8612-41df-bf4a-e5246917d1f2"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i4b87e9f4d00f4885821da6e21e067a39_D20210212-20210212"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfMTE3Mw_7355bc04-ec01-4b78-9c4f-20756d661fbe"
      unitRef="usd">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfMjc0ODc3OTA3MDgyMg_3d51174d-9a3f-47fe-b9a7-0aea0e688f88">The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.155&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="iba0a050f6bca41bc803a3fd1b6bef4b6_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RhYmxlOmUyYjQ5MWIzNjhjNTRmMzA5ZjgwZTE2M2Y0MWY1YWE3L3RhYmxlcmFuZ2U6ZTJiNDkxYjM2OGM1NGYzMDlmODBlMTYzZjQxZjVhYTdfMC0xLTEtMS0w_9d3ddffa-f605-433f-aed6-21d7e7c0c9ca"
      unitRef="number">0.850</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i3621a5e4b5684da1868630577f530cf2_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RhYmxlOmUyYjQ5MWIzNjhjNTRmMzA5ZjgwZTE2M2Y0MWY1YWE3L3RhYmxlcmFuZ2U6ZTJiNDkxYjM2OGM1NGYzMDlmODBlMTYzZjQxZjVhYTdfMS0xLTEtMS0w_d227a8fd-2399-46c3-bb80-e73110314b81"
      unitRef="number">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i782b28a8f85447788786cb2c7f4d69fb_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RhYmxlOmUyYjQ5MWIzNjhjNTRmMzA5ZjgwZTE2M2Y0MWY1YWE3L3RhYmxlcmFuZ2U6ZTJiNDkxYjM2OGM1NGYzMDlmODBlMTYzZjQxZjVhYTdfMi0xLTEtMS0w_d1a05490-91b8-4a8a-b3af-20c8d6155b5d"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="id40c60f62dab45c18759442084ff92e9_I20210630"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RhYmxlOmUyYjQ5MWIzNjhjNTRmMzA5ZjgwZTE2M2Y0MWY1YWE3L3RhYmxlcmFuZ2U6ZTJiNDkxYjM2OGM1NGYzMDlmODBlMTYzZjQxZjVhYTdfMy0xLTEtMS0w_9d987973-82e3-47f6-8d5f-957a357d9f28"
      unitRef="number">0.00155</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RleHRyZWdpb246ZWQwOGY1Nzg0YTQ1NDE3N2E1ZTBkN2IxOTVhODJiNGNfMjc0ODc3OTA3NjUxNw_576f4a25-88ed-4d46-a478-66a633ca4fa9">STOCK-BASED COMPENSATION&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded  stock-based compensation related to stock options issued under the Company&#x2019;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2021 and 2020  :&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Plan, under which the Company may issue stock options, restricted stock and other equity-based awards. The Company has also granted certain stock options outside of the 2018  Plan. Stock options granted by the Company generally have a contractual life of up to 10 years. As of June&#160;30, 2021, all equity awards granted from the 2018 Plan were in the form of stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period or for certain performance-based awards. The Company records the expense for these awards if it concludes that it is probable that the performance condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397,240&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 4pt 0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,490&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,380&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.90&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;At June&#160;30, 2021, the unrecognized compensation cost related to unvested stock options expected to vest was $1,046. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 2.94 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RleHRyZWdpb246ZWQwOGY1Nzg0YTQ1NDE3N2E1ZTBkN2IxOTVhODJiNGNfMjc0ODc3OTA3NjUxOA_d979b873-039c-4847-9a83-75e5bf23d03a">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded  stock-based compensation related to stock options issued under the Company&#x2019;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2021 and 2020  :&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i27c7675abef34248a1f00e6bcf04c49d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMi0xLTEtMS0w_19190420-b99e-4c34-a074-314e63ba6dd6"
      unitRef="usd">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib5ce2baeed89423c922e27b6c8e36bba_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMi0zLTEtMS0w_d3169c87-485c-4d0b-9e0e-f80d0f103d62"
      unitRef="usd">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if64b7ec5ca7045d089a7f58dd9d61741_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMi01LTEtMS0w_7e6bf543-5f70-4b93-a2a7-5b655745af61"
      unitRef="usd">39000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i887713052e054612a1e185929791f55d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMi03LTEtMS0w_cf3660a6-6f15-47d6-afb6-fcdcec78f20b"
      unitRef="usd">53000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i04385040180f467690e4c12dc8d54a53_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMy0xLTEtMS0w_461c21e7-1421-4b2b-a348-70e7530aa77d"
      unitRef="usd">120000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibc2622def42a4874aedf69d387f68fb9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMy0zLTEtMS0w_ecd28484-ba4f-4c8b-862c-93446a8ac889"
      unitRef="usd">10000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i06e1e9850961407ca3e9d3986c0b7169_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMy01LTEtMS0w_8ae90f41-a7f0-4dcc-8677-644e86d04ec2"
      unitRef="usd">267000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0864fed0eeb54c0887a8eeeaa3029b17_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfMy03LTEtMS0w_b372b4f0-56ba-43f5-ac47-1d46387e7e20"
      unitRef="usd">10000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iff765d30586a42d785391d5ce396cfdd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfNC0xLTEtMS0w_c004031d-96f4-445c-a8a9-c1f67ab68e20"
      unitRef="usd">138000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ida292cc7bec44c8384928d3cca65bd6b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfNC0zLTEtMS0w_ec025c48-4e27-4abf-ba74-b4ea0983c7c9"
      unitRef="usd">28000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfNC01LTEtMS0w_91e621ca-25b0-41d5-98a2-55deeef588ea"
      unitRef="usd">306000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjk4NjA5Nzc1NjBjMjRhNjFiNDhiOGNmNWY2NTMyODk5L3RhYmxlcmFuZ2U6OTg2MDk3NzU2MGMyNGE2MWI0OGI4Y2Y1ZjY1MzI4OTlfNC03LTEtMS0w_066b9437-6fb8-4309-9928-4ea67d8a5734"
      unitRef="usd">63000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RleHRyZWdpb246ZWQwOGY1Nzg0YTQ1NDE3N2E1ZTBkN2IxOTVhODJiNGNfMjc0ODc3OTA3NjUyMg_4e63db4f-8ec6-46c6-8758-07310cf63775">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RleHRyZWdpb246ZWQwOGY1Nzg0YTQ1NDE3N2E1ZTBkN2IxOTVhODJiNGNfMjc0ODc3OTA3NjUxOQ_1ca51233-ac01-4f81-8002-40022739650d">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397,240&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 4pt 0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,490&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,380&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfMS0xLTEtMS05Mzg_2fa35e0b-7212-4bc4-865d-f6a34f939ecd"
      unitRef="shares">266250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic895252214e44777813c5b78a8d4444f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfMS0zLTEtMS05Mzg_e0abd091-f521-446c-847e-307ff56fc11d"
      unitRef="usdPerShare">2.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic5f07cccdbc84951b24e82c3340132e0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfMS01LTEtMS05Mzg_9d12457b-e80d-46d5-aa68-8f5f28f07b99">P8Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfMi0xLTEtMS05Mzg_fa6c53a0-55fb-4779-aff7-b8466b2aa7ee"
      unitRef="shares">397240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfMi0zLTEtMS05Mzg_0f5f2a71-f9cf-4654-a966-3a50eee2534b"
      unitRef="usdPerShare">3.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfNS0xLTEtMS05Mzg_001add63-4329-402d-b22e-829380551b5d"
      unitRef="shares">663490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfNS0zLTEtMS05Mzg_d1c43f9b-93b2-4470-bae1-ae99c8e10d3e"
      unitRef="usdPerShare">3.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfNS01LTEtMS05Mzg_5981d394-7190-43ae-a811-3cd6e55cfe23">P9Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfNi0xLTEtMS05Mzg_4e1a7f8e-e2dd-4950-9ecd-bc7545a43a7b"
      unitRef="shares">206380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfNi0zLTEtMS05Mzg_e4a50a1b-97de-4264-8f68-f66507f2a1d2"
      unitRef="usdPerShare">2.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOmIxNTExYmQ5NTNjMTQyNDY4ZjMzMzIyNzVhYWRiYzZlL3RhYmxlcmFuZ2U6YjE1MTFiZDk1M2MxNDI0NjhmMzMzMjI3NWFhZGJjNmVfNi01LTEtMS05Mzg_ec143d34-962f-4036-8213-4d385effe660">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RleHRyZWdpb246ZWQwOGY1Nzg0YTQ1NDE3N2E1ZTBkN2IxOTVhODJiNGNfMjc0ODc3OTA3NjUyMA_54c095fd-e58b-42b0-893f-3c80ff3f35d3">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.90&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfMi0xLTEtMS0w_3480b097-3e94-4440-b2e2-efe93e4d12b2"
      unitRef="number">0.8350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfMi0zLTEtMS0w_c53e8226-714b-4c4a-807b-9bdac4c77bd8"
      unitRef="number">0.8500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfMy0xLTEtMS0w_d6b97558-58ae-4cd6-9c32-ed9a96d6167c">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfMy0zLTEtMS0w_aa5f345a-9bfd-4514-be3f-36981ab4a2d4">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfNC0xLTEtMS0w_cd24c0c8-20c6-43fa-a8e2-a095f6ba8c21"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfNC0zLTEtMS0w_67acba45-ffe5-4013-b19d-ea68210bb7fa"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfNS0xLTEtMS0w_b457586a-6662-458e-acda-d071d1fad103"
      unitRef="number">0.0099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="idd126fcd5baa42fd8c6e6dd9a2f19d59_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfNS0zLTEtMS0w_c57b16ac-dca7-4d56-9eaa-4936f33c2f84"
      unitRef="number">0.0043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfNi0xLTEtMS0w_5d0a4ea2-2712-403e-8655-c9318991acdd"
      unitRef="usdPerShare">3.87</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="iaa79d0de6ea5497ebb25e7f4d8686d52_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RhYmxlOjNmMDQwNDJmYTQyMzRmY2ZhZjI1MTJkOTNjMDk1OGU4L3RhYmxlcmFuZ2U6M2YwNDA0MmZhNDIzNGZjZmFmMjUxMmQ5M2MwOTU4ZThfNi0zLTEtMS0w_c66c2ef6-3a76-4c1e-90cf-cc7e25965053"
      unitRef="usdPerShare">3.28</us-gaap:SharePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i6b79fcafbff642fa848ff1901341ccd7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RleHRyZWdpb246ZWQwOGY1Nzg0YTQ1NDE3N2E1ZTBkN2IxOTVhODJiNGNfMTQ5OA_cf7cf057-5f4d-42e9-89ae-7d3e994d837e"
      unitRef="usd">1046000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81Mi9mcmFnOmVkMDhmNTc4NGE0NTQxNzdhNWUwZDdiMTk1YTgyYjRjL3RleHRyZWdpb246ZWQwOGY1Nzg0YTQ1NDE3N2E1ZTBkN2IxOTVhODJiNGNfMTY5MQ_2233bc7d-9706-4bea-bbe8-59d8e9d72784">P2Y11M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81NS9mcmFnOjQ5YTg5OWRjZDQ1ZDQyODQ4YmM0NTkyOGUzNzk2ODk2L3RleHRyZWdpb246NDlhODk5ZGNkNDVkNDI4NDhiYzQ1OTI4ZTM3OTY4OTZfMjc0ODc3OTA3MDkyMA_553ee718-3144-42dd-a995-4a050bfbf342">RELATED PARTY TRANSACTIONS&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the Company entered into a license agreement with Medice which grants Medice an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR throughout Europe. Medice is responsible for obtaining regulatory approval of ADAIR in the licensed territory. Under the license agreement, Medice paid Vallon a $100 upfront payment and is required to pay milestone payments upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds. Medice will also pay tiered royalties on annual net sales of ADAIR at rates in the low double-digits. The initial term of the license agreement will expire five years after the date on which Medice first obtains regulatory approval in any country, territory or region in the licensed territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#x2019;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#x2019;s common stock upon completion of the IPO.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <ck0001824293:RelatedPartyTransactionLicenseAgreementUpfrontPayment
      contextRef="i8af83bde4e7d4b5986d02a1be122c2df_D20200101-20200131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81NS9mcmFnOjQ5YTg5OWRjZDQ1ZDQyODQ4YmM0NTkyOGUzNzk2ODk2L3RleHRyZWdpb246NDlhODk5ZGNkNDVkNDI4NDhiYzQ1OTI4ZTM3OTY4OTZfMzkx_028fe0b2-7635-403e-bc75-9dc0348c27be"
      unitRef="usd">100000</ck0001824293:RelatedPartyTransactionLicenseAgreementUpfrontPayment>
    <ck0001824293:RelatedPartyTransactionLicenseAgreementTerm
      contextRef="i8af83bde4e7d4b5986d02a1be122c2df_D20200101-20200131"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81NS9mcmFnOjQ5YTg5OWRjZDQ1ZDQyODQ4YmM0NTkyOGUzNzk2ODk2L3RleHRyZWdpb246NDlhODk5ZGNkNDVkNDI4NDhiYzQ1OTI4ZTM3OTY4OTZfNTQ5NzU1ODE0MDM2MQ_8e00b22b-7a28-4b3e-b3cd-749cb24a0f8e">P5Y</ck0001824293:RelatedPartyTransactionLicenseAgreementTerm>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i3d756267a38641f49152d284b506e41c_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81NS9mcmFnOjQ5YTg5OWRjZDQ1ZDQyODQ4YmM0NTkyOGUzNzk2ODk2L3RleHRyZWdpb246NDlhODk5ZGNkNDVkNDI4NDhiYzQ1OTI4ZTM3OTY4OTZfMTIzNg_39488e22-8a4f-4b7d-af5f-bbab03c3b882"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i78d2a9fcaf4742528def995407f4d94d_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81NS9mcmFnOjQ5YTg5OWRjZDQ1ZDQyODQ4YmM0NTkyOGUzNzk2ODk2L3RleHRyZWdpb246NDlhODk5ZGNkNDVkNDI4NDhiYzQ1OTI4ZTM3OTY4OTZfMTI5MA_6d9d7da9-a2f3-4c76-8f76-a853910032b8"
      unitRef="number">0.070</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i3d756267a38641f49152d284b506e41c_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml81NS9mcmFnOjQ5YTg5OWRjZDQ1ZDQyODQ4YmM0NTkyOGUzNzk2ODk2L3RleHRyZWdpb246NDlhODk5ZGNkNDVkNDI4NDhiYzQ1OTI4ZTM3OTY4OTZfMTQwOA_b0c8b917-628f-4d77-9185-b166b2f1ee82"
      unitRef="shares">54906</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82MS9mcmFnOjU1NzUxNWQ5NGZkYTRkOTRiNzZkOTYzMThmOTE2ODliL3RleHRyZWdpb246NTU3NTE1ZDk0ZmRhNGQ5NGI3NmQ5NjMxOGY5MTY4OWJfMjc0ODc3OTA4MDYyNw_52488f6a-d2e9-4472-841d-f536684c7b50">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Impact&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to the Company&#x2019;s operations and business plan. The Company has closely monitored recent COVID-19 developments, including states&#x2019; lifting COVID-19 safety measures, drop in vaccination rates, and spread of various coronavirus strains such as the Delta variant. In light of these developments, the full impact of the COVID-19 pandemic on the Company&#x2019;s business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#x2019;s future impact on its clinical trial enrollment, clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with most of its employees and consultants working remotely. The Company will continue to actively monitor the COVID-19 outbreak and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that the Company determines are in the best interests of its employees and other third parties with whom the Company does business.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RleHRyZWdpb246ODQ4M2FmMjM1MzQ5NDQ5ZmE4NTYxMzIyZTI4NDIzZjlfMjc0ODc3OTA2OTk1MA_98ddc618-8ab9-4871-937b-7532a8ae1feb">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the embedded derivative liability identified in the 2021 Convertible Notes was a Level 3 fair value measurement. As of February&#160;12, 2021, the embedded derivative was remeasured based upon the conversion price of $8.00 per share upon closing of the IPO. As such, an expense of $89 was recorded during the six months ended June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the six months ended June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance as of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions during the six months ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfer out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i60901d5d21aa4ec69b330ba52b51042b_I20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RleHRyZWdpb246ODQ4M2FmMjM1MzQ5NDQ5ZmE4NTYxMzIyZTI4NDIzZjlfMjQ2_cd7221f8-0223-4c38-87ae-d2e3380bfd82"
      unitRef="usdPerShare">8.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RleHRyZWdpb246ODQ4M2FmMjM1MzQ5NDQ5ZmE4NTYxMzIyZTI4NDIzZjlfMzA3_28f8b81a-c940-434b-ba08-b51ac62a97a0"
      unitRef="usd">-89000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RleHRyZWdpb246ODQ4M2FmMjM1MzQ5NDQ5ZmE4NTYxMzIyZTI4NDIzZjlfMjc0ODc3OTA2OTk1MQ_06459136-8cb3-4d43-93fd-9d4ae8418fa6">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the six months ended June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance as of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions during the six months ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfer out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i47a4058978b54caa86791e0df0e0a693_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RhYmxlOmFiZjgyOTFmYThlMjRhNThiZWIxZWNmODZlMTMwNWYwL3RhYmxlcmFuZ2U6YWJmODI5MWZhOGUyNGE1OGJlYjFlY2Y4NmUxMzA1ZjBfMC0xLTEtMS0w_3f2ccef2-63fe-4e31-a4f2-0b27dc8e36f4"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="ie57e0b7edd14462ebede9f2bd8aad12c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RhYmxlOmFiZjgyOTFmYThlMjRhNThiZWIxZWNmODZlMTMwNWYwL3RhYmxlcmFuZ2U6YWJmODI5MWZhOGUyNGE1OGJlYjFlY2Y4NmUxMzA1ZjBfMS0xLTEtMS0w_bc9e4b6d-060f-4a2e-8b17-d0ab32d9cf70"
      unitRef="usd">89000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="ie57e0b7edd14462ebede9f2bd8aad12c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RhYmxlOmFiZjgyOTFmYThlMjRhNThiZWIxZWNmODZlMTMwNWYwL3RhYmxlcmFuZ2U6YWJmODI5MWZhOGUyNGE1OGJlYjFlY2Y4NmUxMzA1ZjBfMi0xLTEtMS0w_938ddad2-94ab-4b8c-bebe-04a2bf0864bf"
      unitRef="usd">89000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6c968c9ac274451f8c6acd6b1628a443_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml82NC9mcmFnOjg0ODNhZjIzNTM0OTQ0OWZhODU2MTMyMmUyODQyM2Y5L3RhYmxlOmFiZjgyOTFmYThlMjRhNThiZWIxZWNmODZlMTMwNWYwL3RhYmxlcmFuZ2U6YWJmODI5MWZhOGUyNGE1OGJlYjFlY2Y4NmUxMzA1ZjBfMy0xLTEtMS0w_3521392b-578d-4d15-b7d8-ff3dd5f5f16a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466676813032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VALLON PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4369909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 N. 18th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">207-3606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VLON<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001824293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466676611208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,460<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">565<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">11,404<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">11,647<span></span>
</td>
<td class="nump">955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">886<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,671<span></span>
</td>
<td class="nump">2,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">2,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">27,402<span></span>
</td>
<td class="nump">11,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(17,549)<span></span>
</td>
<td class="num">(12,599)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">9,853<span></span>
</td>
<td class="num">(1,454)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 11,647<span></span>
</td>
<td class="nump">$ 955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466676590984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue-related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,202<span></span>
</td>
<td class="nump">808<span></span>
</td>
<td class="nump">2,974<span></span>
</td>
<td class="nump">1,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="nump">1,938<span></span>
</td>
<td class="nump">701<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,310<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">4,912<span></span>
</td>
<td class="nump">2,395<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,310)<span></span>
</td>
<td class="num">(1,135)<span></span>
</td>
<td class="num">(4,912)<span></span>
</td>
<td class="num">(2,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Revaluation of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,312)<span></span>
</td>
<td class="num">$ (1,147)<span></span>
</td>
<td class="num">$ (4,950)<span></span>
</td>
<td class="num">$ (2,308)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in usd per share)</a></td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in usd per share)</a></td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="nump">6,264,854<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="nump">6,264,854<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466676156456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional&#160;Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 3,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,991<span></span>
</td>
<td class="num">$ (7,777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,161)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">2,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,026<span></span>
</td>
<td class="num">(8,938)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">3,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,991<span></span>
</td>
<td class="num">(7,777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2020</a></td>
<td class="nump">969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,054<span></span>
</td>
<td class="num">(10,085)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2020</a></td>
<td class="nump">2,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,026<span></span>
</td>
<td class="num">(8,938)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,147)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,054<span></span>
</td>
<td class="num">(10,085)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Dec. 31, 2020</a></td>
<td class="nump">4,506,216<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="num">$ (1,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,145<span></span>
</td>
<td class="num">(12,599)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for convertible notes</a></td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for IPO, net of issuance expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for IPO, net of issuance expenses</a></td>
<td class="nump">15,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Underwriters Warrants</a></td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,638)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 12,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,264<span></span>
</td>
<td class="num">(15,237)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Dec. 31, 2020</a></td>
<td class="nump">4,506,216<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="num">$ (1,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,145<span></span>
</td>
<td class="num">(12,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Jun. 30, 2021</a></td>
<td class="nump">4,506,216<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 9,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,402<span></span>
</td>
<td class="num">(17,549)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2021</a></td>
<td class="nump">12,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,264<span></span>
</td>
<td class="num">(15,237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,312)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Jun. 30, 2021</a></td>
<td class="nump">4,506,216<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 9,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,402<span></span>
</td>
<td class="num">$ (17,549)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466676774920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Net Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,950)<span></span>
</td>
<td class="num">$ (2,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use asset</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Revaluation of derivative liability</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ForgivenessOfDebtInstrument', window );">Forgiveness of PPP note</a></td>
<td class="num">(61)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest, depreciation and other expense</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(379)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(330)<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(153)<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(5,440)<span></span>
</td>
<td class="num">(1,834)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from PPP loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from common stock, net of offering expenses</a></td>
<td class="nump">15,503<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease liability</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">15,791<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">10,351<span></span>
</td>
<td class="num">(1,822)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at beginning of period</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">3,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at end of period</a></td>
<td class="nump">10,460<span></span>
</td>
<td class="nump">1,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes to common stock</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ForgivenessOfDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness Of Debt Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ForgivenessOfDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466756442264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">4,506,216<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466763727704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text">ORGANIZATION AND DESCRIPTION OF BUSINESS<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vallon Pharmaceuticals, Inc. (Vallon or the Company), based in Philadelphia, PA was incorporated in Delaware on January 11, 2018, which is the date of inception.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company&#8217;s lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#174;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The Company plans to develop other abuse-deterrent products, which have potential for abuse in their current forms, beginning with the development of ADMIR, an abuse deterrent formulation of Ritalin, for which the Company is conducting formulation development work.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company completed an initial public offering (IPO) of its common stock, selling 2,250,000 shares at $8.00 per share. As a result of the IPO, the Company received approximately $15,500 in net proceeds, after deducting discounts and commissions of approximately $1,600 and estimated offering expenses of approximately $905 payable by the Company.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, our Chief Executive Officer, pursuant to which we issued convertible promissory notes (the 2021 Convertible Notes) for cash proceeds of $350. The 2021 Convertible Notes bear an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes were convertible into shares of our capital stock offered to investors in any subsequent equity financing after the date of their issuance in which we issued any of our equity securities (a Qualified Financing) and were convertible at a twenty percent (20%) discount to the price per share offered in such Qualified Financing. Such Qualified Financing included the IPO and as a result, the 2021 Convertible Notes converted into an aggregate of 54,906 shares of our common stock immediately prior to the closing of IPO.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466672277880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY</a></td>
<td class="text">LIQUIDITY<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception and has incurred $17,549 in accumulated deficit through June&#160;30, 2021. The Company has financed its working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a Paycheck Protection Program (PPP) promissory note.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company completed a $350 convertible note financing and in February 2021, the Company completed the IPO, raising net proceeds of $15,500. As of June&#160;30, 2021, the Company had cash and cash equivalents of approximately $10,460, which management expects will provide funding for its ongoing business activities into the third quarter of 2022. However, the Company has based this estimate on assumptions that may prove erroneous, and it could use capital resources sooner than it expects, therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year of the date that these financial statements are being issued.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company&#8217;s objective is to develop and commercialize biopharmaceutical products that treat central nervous system disorders, but there can be no assurances that the Company will be successful in this regard. Therefore, the Company intends to raise capital through additional issuances of common stock and /or short-term notes. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466673508472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December 31, 2020 balance sheet was derived from audited financial statements. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of June&#160;30, 2021, and the results of operations and stockholders&#8217; equity (deficit) for the three and six months ended June&#160;30, 2021 and 2020 and cash flows for the six months ended June&#160;30, 2021 and 2020. Results of operations for the three and six months ended June&#160;30, 2021, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2021. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2020 included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 29, 2021. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recapitalization</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the  IPO (Note 6), the Company effected a one-for-40 reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Quarterly Report on Form 10-Q give retroactive effect to the reverse split.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on these financial statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The </span></div>amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466672245672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466673530360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP NOTE AND CONVERTIBLE NOTES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">PPP NOTE AND CONVERTIBLE NOTES</a></td>
<td class="text">PPP NOTE AND CONVERTIBLE NOTES<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company issued a promissory note under the PPP (the PPP Note) totaling $61. The PPP Note had a stated interest rate of 1% and had a two-year maturity. Payments were required to be made over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80Ni9mcmFnOmNmNTRjNzFhYzk1YTQ0Y2RiMWNlNmY1ZjgwNDY0YjFjL3RleHRyZWdpb246Y2Y1NGM3MWFjOTVhNDRjZGIxY2U2ZjVmODA0NjRiMWNfNTQ5NzU1ODE0MDcxNg_347c90b0-2a8b-4e03-a46b-c55366ecabe5">1.5-year</span> period beginning November 1, 2020 unless forgiven. In January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As a result, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1, disclosed in the amount of $61 included in other income on the accompanying Statements of Operations. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;11, 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes, for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#8217;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#8217;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466672265368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY (DEFICIT)<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;12, 2021, the Company completed the IPO of 2,250,000 shares of common stock at a public offering price of $8.00 per share. The gross proceeds from the IPO, before deducting underwriting discounts, commissions and other offering expenses payable by the Company, were $18,000. Underwriting discounts and expenses totaled $1,600 and the Company incurred approximately $905 of additional expenses related to completing the IPO, of which $494 were incurred as of December&#160;31, 2020 and included prepaid expenses and other current assets on the Company&#8217;s balance sheet; thus aggregate net proceeds were approximately $15,500. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, the Company granted the underwriters warrants (the Underwriters' Warrants) to purchase an aggregate of 112,500 shares of common stock at an exercise price of $10.00 per share. The Underwriters&#8217; Warrants have a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5Nzk2NTM1NmI3ODQzNzhiMDJkNzMyNmQyNWFhNTYyL3NlYzplOTc5NjUzNTZiNzg0Mzc4YjAyZDczMjZkMjVhYTU2Ml80OS9mcmFnOjk2MTc5NzAyYjFkNzQ5MGI4YmM3NzIxMjAxNjJiM2U4L3RleHRyZWdpb246OTYxNzk3MDJiMWQ3NDkwYjhiYzc3MjEyMDE2MmIzZThfOTg4_8a453afd-a308-407d-aa87-5aea5009f0de">five</span>-year term and are not exercisable prior to August 12, 2021. All of the Underwriters&#8217; Warrants were outstanding as of June&#160;30, 2021. The warrants were </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">classified as equity and the fair value of $399 is reflected as additional paid-in capital. The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.155&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466673528920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded  stock-based compensation related to stock options issued under the Company&#8217;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2021 and 2020  :</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Plan, under which the Company may issue stock options, restricted stock and other equity-based awards. The Company has also granted certain stock options outside of the 2018  Plan. Stock options granted by the Company generally have a contractual life of up to 10 years. As of June&#160;30, 2021, all equity awards granted from the 2018 Plan were in the form of stock options.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period or for certain performance-based awards. The Company records the expense for these awards if it concludes that it is probable that the performance condition will be achieved.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,250</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.22</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,240</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 4pt 0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,490</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.07</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,380</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.83</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.707%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.90</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.28</span></td></tr></table></div>At June&#160;30, 2021, the unrecognized compensation cost related to unvested stock options expected to vest was $1,046. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 2.94 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466672288584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into a license agreement with Medice which grants Medice an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR throughout Europe. Medice is responsible for obtaining regulatory approval of ADAIR in the licensed territory. Under the license agreement, Medice paid Vallon a $100 upfront payment and is required to pay milestone payments upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds. Medice will also pay tiered royalties on annual net sales of ADAIR at rates in the low double-digits. The initial term of the license agreement will expire five years after the date on which Medice first obtains regulatory approval in any country, territory or region in the licensed territory.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#8217;s common stock upon completion of the IPO.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466672194216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Impact</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to the Company&#8217;s operations and business plan. The Company has closely monitored recent COVID-19 developments, including states&#8217; lifting COVID-19 safety measures, drop in vaccination rates, and spread of various coronavirus strains such as the Delta variant. In light of these developments, the full impact of the COVID-19 pandemic on the Company&#8217;s business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#8217;s future impact on its clinical trial enrollment, clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with most of its employees and consultants working remotely. The Company will continue to actively monitor the COVID-19 outbreak and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that the Company determines are in the best interests of its employees and other third parties with whom the Company does business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466672286600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative liability identified in the 2021 Convertible Notes was a Level 3 fair value measurement. As of February&#160;12, 2021, the embedded derivative was remeasured based upon the conversion price of $8.00 per share upon closing of the IPO. As such, an expense of $89 was recorded during the six months ended June&#160;30, 2021.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the six months ended June&#160;30, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance as of January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions during the six months ended June 30, 2021</span></td><td colspan="3" style="padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer out of Level 3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2021</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466756566008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December 31, 2020 balance sheet was derived from audited financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on these financial statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The </span></div>amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466673497592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466673668872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text">The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.155&#160;%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466756247880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded  stock-based compensation related to stock options issued under the Company&#8217;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2021 and 2020  :</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Activity of Stock Options Granted</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,250</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.22</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,240</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 4pt 0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,490</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.07</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,380</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.83</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.707%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.90</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.28</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466672244552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Activity for the Liability Measured at Estimated Fair Value Using Unobservable Inputs</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the six months ended June&#160;30, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance as of January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions during the six months ended June 30, 2021</span></td><td colspan="3" style="padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer out of Level 3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2021</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466669327832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="nump">$ 905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember', window );">Salmon Pharma, Affiliate of Medice and David Baker, CEO | Convertible Promissory Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Converted debt, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes, converted, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsDiscountsAndCommissions', window );">Stock issuance costs, discounts and commissions</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Discounts And Commissions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466673765704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,460<span></span>
</td>
<td class="nump">$ 1,999<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 3,821<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466673800616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466756319560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development</a></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent', window );">General and administrative</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_AccruedLicensingFeesCurrent', window );">Licensing related</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 694<span></span>
</td>
<td class="nump">$ 847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued General and Administrative Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedLicensingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Licensing Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedLicensingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466665656840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP NOTE AND CONVERTIBLE NOTES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ForgivenessOfDebtInstrument', window );">Forgiveness of PPP note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001824293_PaycheckProtectionProgramCARESActMember', window );">Paycheck Protection Program, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_DebtInstrumentPaymentTerm', window );">Debt instrument, payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember', window );">Salmon Pharma, Affiliate of Medice and David Baker, CEO | Convertible Promissory Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes interest rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes, converted, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtInstrumentPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Payment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtInstrumentPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ForgivenessOfDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness Of Debt Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ForgivenessOfDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001824293_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001824293_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466665709224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Additional offering expense</a></td>
<td class="nump">$ 905<span></span>
</td>
<td class="nump">$ 905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issued reflected in additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">2,250,000<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Gross proceeds from stock offering</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsDiscountsAndCommissions', window );">Stock issuance costs, discounts and commissions</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Additional offering expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' Allotment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="nump">112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants outstanding, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issued reflected in additional paid-in capital</a></td>
<td class="nump">$ 399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance Initial Public Offering, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Discounts And Commissions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466677557416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.00155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466775113688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466672190904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock awards, contractual life (up to)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 1,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, weighted average amortization period</a></td>
<td class="text">2 years 11 months 8 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466756063656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Activity of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">266,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">397,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">663,490<span></span>
</td>
<td class="nump">266,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Ending Balance (in shares)</a></td>
<td class="nump">206,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning Balance (in usd per share)</a></td>
<td class="nump">$ 2.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">3.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending Balance (in usd per share)</a></td>
<td class="nump">3.50<span></span>
</td>
<td class="nump">$ 2.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Ending Balance (in usd per share)</a></td>
<td class="nump">$ 2.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term&#160;(years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Beginning Balance (years)</a></td>
<td class="text">9 years 25 days<span></span>
</td>
<td class="text">8 years 2 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Ending Balance (years)</a></td>
<td class="text">9 years 25 days<span></span>
</td>
<td class="text">8 years 2 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Balance Ending (years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466774445704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">83.50%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.99%<span></span>
</td>
<td class="nump">0.43%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of option on grant date (in dollars per share)</a></td>
<td class="nump">$ 3.87<span></span>
</td>
<td class="nump">$ 3.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466665700200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_MediceMember', window );">Medice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment', window );">Upfront payment received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm', window );">License agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember', window );">Convertible Promissory Note Purchase Agreement | Salmon Pharma, Affiliate of Medice and David Baker, CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes interest rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes, converted, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, License Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_RelatedPartyTransactionLicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, License Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_MediceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_MediceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466756433096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Expense recognized on embedded derivative</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140466672048408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details) - Embedded Derivative Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance as of January 1, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">44377</a></td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfer out of Level 3</a></td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of June 30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>48
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M'V<D89)L69AQ\K/1,R"])5"^Y<4M5IM6J8/BY@[IWPOB#5F^12L1UM$V"+Q
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M@"O)8C.T.%$BR?<35T(I$>6'/H>27NH'X/Y:"'4XT2\HMZ0G_P)02P,$%
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M!?E>T1W.U".<M:I#Q2:4WEF[)0S"6"6VZY;$935K;(Y0A@W*<!3E R<EIAM
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M26S^X+6@T/#-1*K*7[*IL%'0([-":9'5P? $69)7_^RM-F(O 'CP *\.\.R
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M GT.\CS(!*Q5!RCU-;5FHZ9>15AB)NR8)10!J.FVUU ]1DV9"IC$#$S3(HH
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MS#AX7F4-6I4S,OC9,= ]% 4D'YS1,B]3N(%^D-AB[BS7M2("U-S BGUB<9"
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M&F!V*-23NRJ& 8\6/2CK"?M"I#IC88A8QK(JX?6)S/)&9T//S68J4[7>7;'
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MO.IYH%I!MX:1M1/15AJ2I-L6] :BL@%TGDMICH8MT+VJTY]02P,$%     @
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M8(#]S$"E9A(.V'VW3?X!4$L#!!0    ( "Q!"E-5O/%;100  & )   9
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M@X^3'NAFGC<+JTH_0S?*TD3VCSE] J%V!G2>*F7W"Q>@_:B:_P-02P,$%
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M(,4U*X6=J^H:]_7T'%^BA/%?J.K87B^ I#16Y7LP*<BYK/_L:7\.+P#GT1N
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MPY.\)XXX 5CU*P [ =AE ;4$4"L+J"> >EF DP"<LH!& FB4!3030+,LH)4
M6O'I'HXC/LL1D:37X6P/7$LK;7H0!T2,5D=((QV["\G56ZIPLC=[>>I/)W_U
MOTYF4^A/1S :+X8ODWD\GSW"X'4QF8X7"[@;H20T$/?P*[PN1G#WZ1X^@0%B
M33@*H!&\1E2*JEI4XZ]KMA4D\D3'D(JEWLMP$T:# R/["J-'7#Z 95?!-FTK
M!SXLAO]&(@6WKL)')7:W6U?AXQ*[UZ[O_G@#OM5P\RK\J3S<S($_%\-'Z*;D
MS^"&"JLTMNPTMNQ87^V*OF% A #FPT(R]PW^_EV]AXG$4/Q3H+V6:J_%VNO7
M(M?WD=-H!?BN$KG W% [J&C$*G0:W_7:IM,Q=J<!42R3X59/N=4+N<TY<Q$]
M 3YG(;@LVB&7=!D@1$SF,AW7+UC4'#/+]+&$S-.EC)EOBY/:XA3:LB!!J(K,
M7'WG(:E"W_=I0(E$?;!?T*,N@OK0841VU(,!>4->A>%X!O_"\,1NY9&0"L'X
M=Y@J%\!\R]VUJCG07W%$50QE04@T4JJ-GQ!PS51[\W\^U&'S]H&-BV4R3%LI
MTU8AT^$Y-Y62):HT+8&KD\MC6JRP^6":O^1%[0_#,O:T4WO:9>Q!3]U*EK(*
M'A4NVYZ'S(%1L2;;O$'),H^%T_PQ)U<_8@*]:EH6A=@JVG>J)!Y6[G-+TF$G
MYR0&G'K;;)Q%RDVQK"4G5P"KT)+)?%;DD6.ZMWY&OK>."=\JSO@J$\591\3J
MBWTZ2'2=.LNV'5/]SM)_"<$LWV,1L(JK0(9O%39<Y\H-\@/MV("M\(XK^79<
M)O36N05%(EGNQZ1O%6?]J6J;-IF$)TZMR67J7-"P'.?2W[?$LHR/N=]J%'L[
MC@K]P9%(^=EE0M]&/U*%B(N4RT)=A533E'\Q;5Q2:UP:<$,JR_]87:SB\E+F
M/O-L75:+>KM^MK5QT@[H!O0+X2L:"0C05RCSH:E.@!]ZNL-$LDW<(2R95/U&
M/%RK/ABY%E#O?:;R6S+134?:6??^ U!+ P04    "  L00I3YFN8/O "  !_
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R-EEUOVC 4AO^*%?6B
ME=KF Y*6"I H%(UIU5AI-TW3+DQR(%8=F]H.=/OULYTTI1 R;L!VSO/F/3[)
M<;H;+IYE"J#0:T:9[#FI4JL;UY5Q"AF6EWP%3%]9<)%AI:=BZ<J5 )Q8**-N
MX'F1FV'"G'[7KDU%O\MS10F#J4 RSS(L_MP"Y9N>XSMO"P]DF2JSX/:[*[R$
M&:BGU53HF5NI)"0#)@EG2,"BYPS\FW%DXFW =P(;N35&)I,YY\]F,DEZCF<,
M 858&06L_]8P!$J-D+;Q4FHZU2T-N#U^4Q_;W'4N<RQAR.D/DJBTYUP[*($%
MSJEZX)M/4.83&KV84VE_T::,]1P4YU+QK(2U@XRPXA^_EONP!6B=>B H@>!8
MH%4"K5V@?0!HET#[6" L@?!8("H!6TRWV"R[TR.L<+\K^ 8)$ZW5S,"6R])Z
M@PDS#]9,"7V5:$[UOTR^/4U&D\>?Z'0$"A,JS] %>IJ-T.G)&3I!A*''E.<2
MLT1V7:7O:#@W+M5O"_7@@+J/[CE3J41W+(&DAA\V\U$#[^I,JW2#MW1O@T;!
MSYA=HI9_C@(O\.O\_ ?/#>X=Q$?'XUX-?M>,CR"NS-?AXZ-QO].PEZWJT6E9
MO=8!O:]BB1GYBTV'.$=#SB2G),%%PV )F@J0P%2QP!=H3!AF,<$4S?0BZ.ZD
M)/HUF$LE='_YW>"H73EJ6T?M XX&<9QG.=7BB>DN)":JKL:%2&1%3.-=]R_\
MJ["M]V2]78RZL"#LO(=]\!A6'L-&CU/!8X!$HH7@&8HY6X-09$X!,:Z@]AT+
M]XRT0N^CV6$1$S;%C/9UO/I<HBJ7J#&7(9:I+75L!O"2DS6FIJQUNQ[MW=WW
MVM&NQYJH3F>W,G52.S'C_9C6M7EG/^3K;C7.#,32'G%25R5GJF@JU6IUB@[L
MX;&S/O1O1L5A^"Y3',WW6"P)DXC"0DMZEU>Z"J(X[HJ)XBO;GN=<Z69OAZG^
M0@!A O3U!=?/13DQ-ZB^.?K_ %!+ P04    "  L00I3+NF:D P"  #H P
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q]4]&.VC 0_!4K3SVIPB$<
MO=XI1 H!KI%*B BTJJH^F+ 0"R=.;4.N?U_;"1&5CK[$7GMG9B?K]1LN3K(
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M7<] 8D+%#7J+'E8S='UU@ZX0*='WG.T%+C,QLJ4RUG([K4WN*Q/O@LFG?3E
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M#D3V=9!-%%^FE],95W3538<+^J)"H0WHO<])7C[1]]WB&ZW['U!+ P04
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MU7\/X'J">K]F3!X&.D#];V;\+U!+ P04    "  L00I3+>O@71 #  "9"
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MFETBD/E5,%]HL<YN(@NAZ5Z3/:[H^HS2&-#[2%!XQ<)<;LH+^> [4$L#!!0
M   ( "Q!"E/Z.Q\@@0(  (\%   9    >&PO=V]R:W-H965T<R]S:&5E=#,T
M+GAM;'U446_:,!#^*Z>H#ZW4$0C0=56(1(%JK4950>D>ICV8Y"!6$SNS'>CV
MZW=V0D8[X"6QS_=]]]W9=^%6JE>=(AIXRS.A!UYJ3''C^SI.,6>Z)0L4=+*2
M*F>&MFKMZT(A2QPHS_R@W;[R<\:%%X7.]J2B4)8FXP*?%.@RSYGZ?8N9W Z\
MCK<SS/@Z-=;@1V'!UCA'LRB>%.W\AB7A.0K-I0"%JX$W[-R,^M;?.;QPW.J]
M-=A,EE*^VLU],O#:5A!F&!O+P.BWP1%FF24B&;]J3J\):8'[ZQW[G<N=<EDR
MC2.9?>>)20?>M0<)KEB9F9G<?L4Z'R<PEIEV7]C6OFT/XE(;F==@4I!S4?W9
M6UV'/0#Q' 8$-2#X".@= 71K0-<E6BES:8V985&HY!:4]28VNW"U<6C*A@M[
MBW.CZ)03SD1WP_L9O R_+28PG0SGB]ED.GE\GL,G>&1*,5MC.!^C83S3%V1=
MS,=P?G8!9^"#3IE"#5S 0G"C+\E(Z^=4EIJ)1(>^(8$VC!_78FXK,<$1,5<P
ME<*D&B8BP>0]WJ?$FNR"77:WP4G"AU*TH-N^A* == [H&9V&W^&R!9W@$/R=
MG&Y3[*[CZQ[C8US!"\M*A#'7<29U:0OX8[C41M&#_GDB1J^)T7,Q>D=BC*38
MH')-5B@>T^W1G90Z@0)5=6,7API1D5XY4MOYF^@Z]#<'=/0;'?V3.B9O-&@T
M4J?'<BWX'TR )&&^Q(3NECI-\8U[7H>>2?]_-5\^R/'WWGR.:NU&@898EL)4
MS[^Q-M-FZ)K,_^=>C:HI4VLN-&2X(FB[]9G"JZK]JXV1A>N@I334CVZ9TL1$
M91WH?"6EV6UL@&8&1W\!4$L#!!0    ( "Q!"E,(4<O0OP(  &@&   9
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M'>M;2-U?DKI,!>H.^Z_CB\MNL;K9U76H^Y)VSLGZL!E]V$A__1U02P,$%
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M]L/R>7/R00TX6SA@W?\"4$L#!!0    ( "Q!"E/?(2<;D@$  /D5   3
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MR7$/DN,!) <?H01!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M
M(:M (:M (:M (:M (:M (:M (:M (6N*0M84A:PI"EE3%+*F*&1-_Y.L'UHO
M__IG9+LFM53-P9]U?WQG7U!+ 0(4 Q0    ( "Q!"E,'04UB@0   +$    0
M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M+$$*4ZWLNW3M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ +$$*4YE<G",0!@  G"<  !,
M ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  L00I3>_BB
M6&T%  ">%@  &               @($,"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ +$$*4^XI1M&6!   R!$  !@
M ("!KPT  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( "Q!
M"E,M*:III00  ,@2   8              " @7L2  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    "  L00I3\[[^'R<&  "<(0  &
M        @(%6%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ +$$*4\B'E*V(!0  %14  !@              ("!LQT  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( "Q!"E-E11K.?0(  +L&   8
M              " @7$C  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    "  L00I3YX( Q!P&  "<#0  &               @($D)@  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ +$$*4SFB_;_^!0
MLPT  !@              ("!=BP  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( "Q!"E/:T]LOR0D  + 8   8              " @:HR
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  L00I3T1?R
MCHL"  !A!0  &0              @(&I/   >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( "Q!"E-B?4[U1P0  ,,)   9
M  " @6L_  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M+$$*4U6\\5M%!   8 D  !D              ("!Z4,  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    "  L00I3GV((_]\%  ! #@  &0
M            @(%E2   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( "Q!"E-D@,?/?00  $4*   9              " @7M.  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ +$$*4_)HX)P(!0
M5PL  !D              ("!+U,  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    "  L00I3[+YK\"0#   4!P  &0              @(%N
M6   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( "Q!"E,R
M5RX'3 @  $D4   9              " @<E;  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ +$$*4Q/LZ!2< @  904  !D
M     ("!3&0  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "Q!"E/F:Y@^\ (  '\(   9              "
M@39V  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ +$$*
M4R[IFI , @  Z ,  !D              ("!77D  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    "  L00I3+8H,IJX"  !J!P  &0
M        @(&@>P  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( "Q!"E-QSX;CUP,  *\-   9              " @85^  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ +$$*4\/R9D;E P  I0T
M !D              ("!DX(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    "  L00I39<"S(;L"   X"   &0              @(&OA@
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( "Q!"E--A+J*
M*@,  )X*   9              " @:&)  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ +$$*4R[$YY.5 @  [P4  !D
M ("! HT  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  L
M00I32@_+?XD#  #9#   &0              @('.CP  >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "Q!"E,MZ^!=$ ,  )D(   9
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M;',O+G)E;'-02P$"% ,4    "  L00I3"#G;WI4#  #,%P  #P
M    @ %PI   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ +$$*4TN*H MS
M 0  <!4  !H              ( !,J@  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ +$$*4]\A)QN2 0  ^14  !,
M ( !W:D  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "L *P"D"P  H*L
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>75</ContextCount>
  <ElementCount>225</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>16</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003003 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementsofOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004004 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit</Role>
      <ShortName>Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005005 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementsofCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1402401 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108104 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111105 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES</Role>
      <ShortName>PPP NOTE AND CONVERTIBLE NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113106 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2117107 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2123108 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125109 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126110 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2206201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2327304 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - LIQUIDITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITYDetails</Role>
      <ShortName>LIQUIDITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/LIQUIDITY</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails</Role>
      <ShortName>PPP NOTE AND CONVERTIBLE NOTES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ck0001824293-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ck0001824293-20210630.htm">ck0001824293-20210630.htm</File>
    <File>ck0001824293-20210630.xsd</File>
    <File>ck0001824293-20210630_cal.xml</File>
    <File>ck0001824293-20210630_def.xml</File>
    <File>ck0001824293-20210630_lab.xml</File>
    <File>ck0001824293-20210630_pre.xml</File>
    <File>ex311_ceo302cert.htm</File>
    <File>ex312_cfo302cert.htm</File>
    <File>ex321_ceosection906cert.htm</File>
    <File>ex322_cfosection906cert.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ck0001824293-20210630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>54
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ck0001824293-20210630.htm": {
   "axisCustom": 0,
   "axisStandard": 8,
   "contextCount": 75,
   "dts": {
    "calculationLink": {
     "local": [
      "ck0001824293-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ck0001824293-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ck0001824293-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ck0001824293-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ck0001824293-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ck0001824293-20210630.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 231,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://www.vallon-pharma.com/20210630": 1,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 8
   },
   "keyCustom": 10,
   "keyStandard": 215,
   "memberCustom": 4,
   "memberStandard": 12,
   "nsprefix": "ck0001824293",
   "nsuri": "http://www.vallon-pharma.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.vallon-pharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108104 - Disclosure - ACCRUED EXPENSES",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111105 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES",
     "role": "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES",
     "shortName": "PPP NOTE AND CONVERTIBLE NOTES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113106 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117107 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123108 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125109 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126110 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2206201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - ACCRUED EXPENSES (Tables)",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Tables)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i6b79fcafbff642fa848ff1901341ccd7_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Balance Sheets",
     "role": "http://www.vallon-pharma.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i6b79fcafbff642fa848ff1901341ccd7_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327304 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "idb6e392c488e43689ffc16945c65d467_D20210212-20210212",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:StockIssuanceCostsOfferingExpenses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i3d756267a38641f49152d284b506e41c_D20210101-20210131",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtConversionConvertedInstrumentRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i6b79fcafbff642fa848ff1901341ccd7_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - LIQUIDITY (Details)",
     "role": "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
     "shortName": "LIQUIDITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i6b79fcafbff642fa848ff1901341ccd7_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - ACCRUED EXPENSES (Details)",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
     "shortName": "ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i6b79fcafbff642fa848ff1901341ccd7_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "ic49837a0734b43478ec5edc5f65ef833_D20210101-20210131",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:ForgivenessOfDebtInstrument",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)",
     "role": "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
     "shortName": "PPP NOTE AND CONVERTIBLE NOTES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "ic49837a0734b43478ec5edc5f65ef833_D20210101-20210131",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:ForgivenessOfDebtInstrument",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "idb6e392c488e43689ffc16945c65d467_D20210212-20210212",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:StockIssuanceCostsOfferingExpenses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i8d10d62088b94b7ca91599063bdd7713_D20210212-20210212",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ck0001824293:ProceedsFromIssuanceInitialPublicOfferingGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "iba0a050f6bca41bc803a3fd1b6bef4b6_I20210630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "iba0a050f6bca41bc803a3fd1b6bef4b6_I20210630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "iff765d30586a42d785391d5ce396cfdd_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "iff765d30586a42d785391d5ce396cfdd_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "iff765d30586a42d785391d5ce396cfdd_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003003 - Statement - Statements of Operations",
     "role": "http://www.vallon-pharma.com/role/StatementsofOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "iff765d30586a42d785391d5ce396cfdd_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "ic895252214e44777813c5b78a8d4444f_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Activity of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "ic49837a0734b43478ec5edc5f65ef833_D20210101-20210131",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i8af83bde4e7d4b5986d02a1be122c2df_D20200101-20200131",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ck0001824293:RelatedPartyTransactionLicenseAgreementUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i60901d5d21aa4ec69b330ba52b51042b_I20210212",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details)",
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i60901d5d21aa4ec69b330ba52b51042b_I20210212",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i47a4058978b54caa86791e0df0e0a693_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)",
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i47a4058978b54caa86791e0df0e0a693_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i61ac3f94b5f149979bd71ad52587031e_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004004 - Statement - Statements of Changes in Stockholders' Equity (Deficit)",
     "role": "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit",
     "shortName": "Statements of Changes in Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i50024d555c8a4c84929dda5920ed007b_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005005 - Statement - Statements of Cash Flows",
     "role": "http://www.vallon-pharma.com/role/StatementsofCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i6b79fcafbff642fa848ff1901341ccd7_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1402401 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i6b79fcafbff642fa848ff1901341ccd7_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - LIQUIDITY",
     "role": "http://www.vallon-pharma.com/role/LIQUIDITY",
     "shortName": "LIQUIDITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20210630.htm",
      "contextRef": "i9b95a919a9834042ab82dd251d29ab12_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 16,
   "tag": {
    "ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued General and Administrative Expenses, Current",
        "label": "Accrued General and Administrative Expenses, Current",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "AccruedGeneralAndAdministrativeExpensesCurrent",
     "nsuri": "http://www.vallon-pharma.com/20210630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AccruedLicensingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Licensing Fees, Current",
        "label": "Accrued Licensing Fees, Current",
        "terseLabel": "Licensing related"
       }
      }
     },
     "localname": "AccruedLicensingFeesCurrent",
     "nsuri": "http://www.vallon-pharma.com/20210630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research and Development Costs, Current",
        "label": "Accrued Research and Development Costs, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.vallon-pharma.com/20210630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliate of Medice and David Baker, CEO",
        "label": "Affiliate of Medice and David Baker, CEO [Member]",
        "terseLabel": "Salmon Pharma, Affiliate of Medice and David Baker, CEO"
       }
      }
     },
     "localname": "AffiliateOfMediceAndDavidBakerCEOMember",
     "nsuri": "http://www.vallon-pharma.com/20210630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Promissory Note Purchase Agreement",
        "label": "Convertible Promissory Note Purchase Agreement [Member]",
        "terseLabel": "Convertible Promissory Note Purchase Agreement"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotePurchaseAgreementMember",
     "nsuri": "http://www.vallon-pharma.com/20210630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_DebtInstrumentPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Term",
        "label": "Debt Instrument, Payment Term",
        "terseLabel": "Debt instrument, payment term"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTerm",
     "nsuri": "http://www.vallon-pharma.com/20210630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ck0001824293_ForgivenessOfDebtInstrument": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiveness Of Debt Instrument",
        "label": "Forgiveness Of Debt Instrument",
        "negatedLabel": "Forgiveness of PPP note",
        "terseLabel": "Forgiveness of PPP note"
       }
      }
     },
     "localname": "ForgivenessOfDebtInstrument",
     "nsuri": "http://www.vallon-pharma.com/20210630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_MediceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medice",
        "label": "Medice [Member]",
        "terseLabel": "Medice"
       }
      }
     },
     "localname": "MediceMember",
     "nsuri": "http://www.vallon-pharma.com/20210630",
     "presentation": [
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_PaycheckProtectionProgramCARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act",
        "label": "Paycheck Protection Program, CARES Act [Member]",
        "terseLabel": "Paycheck Protection Program, CARES Act"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMember",
     "nsuri": "http://www.vallon-pharma.com/20210630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance Initial Public Offering, Gross",
        "label": "Proceeds from Issuance Initial Public Offering, Gross",
        "terseLabel": "Gross proceeds from stock offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOfferingGross",
     "nsuri": "http://www.vallon-pharma.com/20210630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_RelatedPartyTransactionLicenseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, License Agreement, Term",
        "label": "Related Party Transaction, License Agreement, Term",
        "terseLabel": "License agreement, term"
       }
      }
     },
     "localname": "RelatedPartyTransactionLicenseAgreementTerm",
     "nsuri": "http://www.vallon-pharma.com/20210630",
     "presentation": [
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, License Agreement, Upfront Payment",
        "label": "Related Party Transaction, License Agreement, Upfront Payment",
        "terseLabel": "Upfront payment received under license agreement"
       }
      }
     },
     "localname": "RelatedPartyTransactionLicenseAgreementUpfrontPayment",
     "nsuri": "http://www.vallon-pharma.com/20210630",
     "presentation": [
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockIssuanceCostsDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs, Discounts And Commissions",
        "label": "Stock Issuance Costs, Discounts And Commissions",
        "terseLabel": "Stock issuance costs, discounts and commissions"
       }
      }
     },
     "localname": "StockIssuanceCostsDiscountsAndCommissions",
     "nsuri": "http://www.vallon-pharma.com/20210630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockIssuanceCostsOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs, Offering Expenses",
        "label": "Stock Issuance Costs, Offering Expenses",
        "terseLabel": "Offering expenses",
        "verboseLabel": "Additional offering expense"
       }
      }
     },
     "localname": "StockIssuanceCostsOfferingExpenses",
     "nsuri": "http://www.vallon-pharma.com/20210630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r26",
      "r278"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r224",
      "r225",
      "r226",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional\u00a0Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r206",
      "r207",
      "r230",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r140",
      "r193",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of Underwriters Warrants",
        "verboseLabel": "Warrant issued reflected in additional paid-in capital"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r207",
      "r221",
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r65",
      "r104",
      "r107",
      "r113",
      "r119",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r236",
      "r238",
      "r252",
      "r276",
      "r278",
      "r293",
      "r303"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r39",
      "r65",
      "r119",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r236",
      "r238",
      "r252",
      "r276",
      "r278"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Accounting"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r24",
      "r57"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r53",
      "r57",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, at end of period",
        "periodStartLabel": "Cash and cash equivalents, at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r53",
      "r253"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants granted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r35",
      "r127",
      "r297",
      "r307"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r128",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r68",
      "r69",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance, shares (in shares)",
        "periodStartLabel": "Beginning Balance, shares (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r58",
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of convertible notes to common stock"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentRate": {
     "auth_ref": [
      "r58",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.",
        "label": "Debt Conversion, Converted Instrument, Rate",
        "terseLabel": "Converted debt, discount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r58",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Convertible notes, converted, shares issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r158",
      "r165",
      "r166",
      "r167",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "PPP NOTE AND CONVERTIBLE NOTES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r64",
      "r66",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r148",
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r169",
      "r170",
      "r171",
      "r172",
      "r261",
      "r294",
      "r295",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r143",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in usd per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r141",
      "r169",
      "r170",
      "r260",
      "r261",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r32",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Convertible notes interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r33",
      "r64",
      "r66",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r148",
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r169",
      "r170",
      "r171",
      "r172",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, maturity"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Embedded Derivative Liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r208",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Activity of Stock Options Granted"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r46",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r81",
      "r83",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r243",
      "r244",
      "r299",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share of common stock, basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r46",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r83",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r243",
      "r244",
      "r299",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share of common stock, diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "negatedTerseLabel": "Expense recognized on embedded derivative"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation, weighted average amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r42",
      "r43",
      "r44",
      "r68",
      "r69",
      "r70",
      "r72",
      "r78",
      "r80",
      "r90",
      "r120",
      "r193",
      "r200",
      "r224",
      "r225",
      "r226",
      "r234",
      "r235",
      "r242",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r310",
      "r311",
      "r312",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r247",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r247",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Activity for the Liability Measured at Estimated Fair Value Using Unobservable Inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "negatedTerseLabel": "Transfer out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "44377"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance as of June 30, 2021",
        "periodStartLabel": "Beginning balance as of January 1, 2021"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r264",
      "r266"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of finance lease liability"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r263",
      "r265",
      "r267"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of finance lease right-of-use asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.vallon-pharma.com/role/StatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedTerseLabel": "Revaluation of derivative liability",
        "terseLabel": "Revaluation of derivative liability"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows",
      "http://www.vallon-pharma.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r300"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29",
      "r65",
      "r108",
      "r119",
      "r129",
      "r130",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r237",
      "r238",
      "r239",
      "r252",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r65",
      "r119",
      "r252",
      "r278",
      "r296",
      "r305"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r65",
      "r119",
      "r129",
      "r130",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r237",
      "r238",
      "r239",
      "r252",
      "r276",
      "r277",
      "r278"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Note payable, non-current"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r93",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r53",
      "r54",
      "r56"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r40",
      "r41",
      "r44",
      "r45",
      "r56",
      "r65",
      "r71",
      "r73",
      "r74",
      "r75",
      "r76",
      "r79",
      "r80",
      "r84",
      "r104",
      "r106",
      "r109",
      "r112",
      "r114",
      "r119",
      "r129",
      "r130",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r244",
      "r252",
      "r298",
      "r308"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vallon-pharma.com/role/StatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Noncash financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Note payable, current"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r104",
      "r106",
      "r109",
      "r112",
      "r114"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r30"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r30",
      "r278"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense",
        "terseLabel": "Non-cash interest, depreciation and other expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters' Allotment"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from common stock, net of offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from PPP loan"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r121",
      "r278",
      "r301",
      "r306"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r205",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r205",
      "r270",
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r205",
      "r270",
      "r273",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r268",
      "r269",
      "r271",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r233",
      "r279",
      "r316"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r200",
      "r227",
      "r278",
      "r304",
      "r313",
      "r314"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r68",
      "r69",
      "r70",
      "r72",
      "r78",
      "r80",
      "r120",
      "r224",
      "r225",
      "r226",
      "r234",
      "r235",
      "r242",
      "r310",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r102",
      "r103",
      "r105",
      "r110",
      "r111",
      "r115",
      "r116",
      "r117",
      "r203",
      "r204",
      "r280"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "License revenue-related party"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r207",
      "r220",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r207",
      "r220",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r36",
      "r62",
      "r91",
      "r92",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r186",
      "r191",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual term\u00a0(years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable, Ending Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable, Ending Balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r212",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Outstanding, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending Balance (in usd per share)",
        "periodStartLabel": "Outstanding, Beginning Balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r208",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of option on grant date (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock awards, contractual life (up to)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r216",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Balance Ending (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Beginning Balance (years)",
        "verboseLabel": "Outstanding, Ending Balance (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r42",
      "r43",
      "r44",
      "r68",
      "r69",
      "r70",
      "r72",
      "r78",
      "r80",
      "r90",
      "r120",
      "r193",
      "r200",
      "r224",
      "r225",
      "r226",
      "r234",
      "r235",
      "r242",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r310",
      "r311",
      "r312",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r90",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r37",
      "r159",
      "r193",
      "r194",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for convertible notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r193",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for IPO, net of issuance expenses (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r38",
      "r193",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r193",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for IPO, net of issuance expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r19",
      "r20",
      "r65",
      "r118",
      "r119",
      "r252",
      "r278"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r63",
      "r178",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r200",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "terseLabel": "LIQUIDITY"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants outstanding, measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants outstanding, term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r82",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r81",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=51888271"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/subtopic&trid=2229187"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r317": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r318": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r319": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r321": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r322": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r323": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>55
<FILENAME>0001824293-21-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001824293-21-000010-xbrl.zip
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MQ<GYP?<*KW_?&=9K?P/0?FQ4+C9'S_P#[XK;![4.J=;VLH.MCTT WHN#VA&
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MDO>]J.^;_C0P0%2<Q#L)<QID]P;./79D&W^8[KO;$S*78>\#DG?SP@A1-Y\
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M^]<43./;><4EF&[;T.&<%6@?^,$"LC[)ABW)- L[M7O#0^GZHP&HS$YW&$Z
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MRT$?K?==L[NG879/@L,--%QJ>'B^+7,='D;$V"YH 4"Q&PA1^-8C+Z@$AR>
M0_7#I;F"=S</A3,:"R(0M6D,H$ H4D1BE! GE/8Z39U>V5"</PP/<_07WZH
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MH-=QP'I@F.[K\7+>XGI8B\WLP]Q-\SW]WD?:VDX+>C,,*:?M4'4YZG> S_7
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M*%&^MNCU2?9\S^NN;>39/@[ O]DY#8E,OUB1DOG%67]2U*"@SF;;;5W19KL
MI5+O/D'O5O<OPZKGT+]#+8VA)DU1[,$EX%J!ZK56($'"_A67IB1L#B:K](Y2
M84L?5WU]85X*1W\*L<A27%]-7*_BB\(;S8EQ**5@(8-9G"!EE$,^H3:.+57*
MN94-B>4;\]I+,7V->%RI<&<EP5?AM]K7PY3[1(J4(1J*TW-/4B29=0A+G!KI
M)/;4AN/357*[/$ IQF_#=)Y"M*J4Y'E(\D3(*K:".,%18JE%' N"C$MC%#/.
M)& T(YX$NUFH^8KQ*Q8#6WRG_I-O^ZYNYCZ]=JVLG?7ZW7R#X[/<^CLFX^UA
MTRS=^A%] )HVKU&G1*=GH%-VW;'G+/8^T0!+'IM0J5 BR;5$BB6*QD!(G>1E
MB,C+W84'0.*U'/LIEAA[PQ[#U!W[4F"G*K!7KKV56GH:2Q3[5"(._AU2CFB$
M#4F$U%YBDJQL,/KB:C$ODM5G^ 2EH"Z::U_*\%1E>,*YWSP4+&98>5/$T#DA
M#H&+IY '_9N:&+P[GD?3%9NOTEU&05X6 WKJJ2BEP$Y58*]\>#""12*<09*&
M3#CO+=+2^N#(.REQK#P&$SG!9($,Y&DNRU.YQN(%=^&+JIR=6XDH4RB0]C:*
M"B^H:W^9.C1"J5X)4T^!J<G-3Q*,!VJY0=Z:!'$@# )7#B.:4F4H*)HXG/9.
M5QF95G[<4E2++"5^YKN,2HE_38F_B@8PK;@0RJ!$@W7"8TN1])@A$V,N>0H?
ME<QC=^QV)<12XG]IB9]E)*&4^!=*/+E:3A0>T#=V2&(G$2>>(V-B@40LB5$<
MQ['"X?!Z1::5AE=*_!N1^%DF$Y02_T*)OPH^4" 6\4PC8>(8<4\]DJE.D< I
M)I3BA(0SO<&J5\NAXW^%_3"?.[U>E'8[K7% 8K*TZ0*<;C2_M8ZG'&TTA3#$
MT\\XND2NG;;MM'R@9(E=3\"NW0\3$0DA@7 ^G&R1"HNX<QAIZQ521F.>8&$$
M)O=%).9^Q-%\USY^39&?0ARB%/DYB/Q$@H+P5I'$(,I3#2(O:-BB&R/O4JNQ
M-8RDYKZ01"GROZ#(3R$048K\'$3^*B;!8\-]*&=D;=BI(,!-D=[&R CP++EC
MRGIS7TRB%/FW$XMXDJ)_>3"BE/HY2/U57$+&E((!+T'@B4(\X2F2QE'DO+=8
MXW#$B@NV/;TC+C%WJ7^57(F%#DGL]AN^&V4YXY<Y$7//B;BOR%E.IFJGW;D.
M525,/06F]B="$"[UL0??$5G'PC9*Z9 FE*-$X-1PK4RBIEX1MEPR65C/9/$J
MKY82/Q6)OXI Q*GQA'&)#)$6<<(39+"UR&@A$N6D%CY9=(F?[Z;J7U+<IQ"'
M* 7[%03[*LX0*TP2$Z=(<$D0MZ#/C60&I9C*-#;4R7#JIGAQ%G8ITV_(;I]R
MUD.IQ5]5V*_""P8;HK75*+&>(LX-05J*!"DKI*:68Z?C1=?BOU[BPY[_H9N#
M/.$A'.P*LYG]R/<@1<W1<>BWSM<I-X3-.,3P26?M$/K<;6]=DF>GW>MW!_F!
MO%7?_]+U_;),\=/*%-<V\\V=HP/JM9= .J^1 $L2<:9BI#@1"#XP\";C)+'3
M0Z^RK,*""O2,(@BE0+^60 \O!1I+3S!3%L5*:<0]XTACXI 05%A)')'6+(9
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M@*>Y"Z 4UM<1U@G76V)EN*.(>"S"HI9 4E-PO:FG2G 6_@9198MA__X*R^W
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MP0Q.1>1FAB!;9>+(20,T2HWV(8#NG.R;]Q>5X]=K+'_8M;V=>"[A+F<H#(M
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M$5EG<M-E1I&S(B$2F=0QB.B,GU48\.(S7EZ6E[ S0[][W+$&C49P+XW@$C?
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MSIA'6B2!%.@8Q!&GO'99N[@XC*A)&GU<UHHL:B$=4YX8CEG2#"P!K%QD7/#
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MVXD7#0B/H?;4)Y']GF?.831NK$&%.Z!"9ZS[T/;>RK;%"DM+ DH^.,2QDPA
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M0@.+#2S.E5K9P.(#P>)$HW1")!*C1#B2//XUY!'@G)6L )^\),+B-^\U5[\
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M+46J4H"#H\/YR?F_HV"H^JSL?X5KX;I_5D[;>[M[[<TO^ZNGBR(G:'_;!&%
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M__;>=+EM)&D7OA6$OYX(^P2AQK[8[^<(M65[-*\EN2VY^]A_.@I 080%$AR
ME"Q?_<G,JL+"1:)D+:2%CIENFP0+M61FY?KDX=]?<-Z71WMG[KS_^NCDU#K8
M.[,/?\ \WL,ZWK^U#O[>-X[09VXAXN 7\^ '-AW*NS$J,S1#P[$,/0I#CG#&
MCLX,W]%MT^&>'3$O23P$@7B0_JN]>.G%RY7B)7)C;D6,\R0('<N.0\OBEA]Y
M<<!M+XJ8K.MW5.N%7KP\BGAI>HHEMNF%<>#K3N#&NI,8D1YR@^MI8"1&:AIV
MXEF_JGBY!Q5V&V7+XVW#30!#/"?R>>S&S#<<-S&"D/FI&R1)F'BF[YA+8S2]
M8'EHP6+6@L4'I3)U'5MW4]_ CC"VSBSFZV[DN:[ON"SU3"S<Z05++U@>4[ $
M 6*[&*[%#=?Q3(N9W S<T K]T$Q=-YE#(NH%R^,(%KL6+'%J>Y[!/-U+3013
M1X2S-/+T-$YB'OM!:AG1L]>N_5.)N]OD&WK/Q[QDN2BP3T;9.*NF)16D/[E\
MO47V-AP[<-'>"(S4\7PO-+@3FU82!XGK,-?N_1T;P-[M?#V0P;%E<E\W'0L+
M?JU(9[83Z+[!?=<V&//]! P2:S$G]VY#"[\Z8T2QY5E6PE/'8D[@.XPGJ8>H
M?'[J!6D4]I;Z1C!&8ZGS.+$")W#TB#FI[L1!I >>%>NA[3@>"U@<! CON:E\
ML17*H.%QDX=P882>Z1A^S&P.+!$&7FQ$ONF%O96Y$4S16)D!XPAI:>K,3\'*
M3&($A?)]W7,<'GB)X?#8>O;:\OR>*WZ"*P(/&Y49G$>N$QM@,;& <\Z8;5AA
M9/J]B;017-&82)'M6Y$##.%Z$=,=.W5U%CN@4B6.!Q<\]SF"^%QW5=Q17%U3
M-;\;;42=(!#Z+:/I,IT4RYJ38H;)J>0TZ8-A=[A-OUZH+$U]STULPPT\YEB)
M'[AV:"9NS.W0B].DC\1O@%0];,-"Q&@-V6:BAU[JZ([CQCJHW:$>FZGGL\@+
MA%2U-RI6ULNF7C;=7#8ES JM./8C'CM@:=J!$UI!8L<Q\]PH\:+>.; 1LJGM
M'# L-W8"W>&6KSLL2O6(^8X>.9P986#'?AR"'?0$1=-VQ^(>2"YMA1EZJS+-
M7B@]M%!JG#.AR3W+C)ENN9&!.-VN'@;,TETWX4#D;A!P]NRUO:3G<2^5>JFT
M)5(I24S+2^/$C1B8<6D2Q![WDB1D5FJ&B1OVSK&-D$J-<\SPO"AT;%_W4@3]
ML8U0#T/LE\69YR<!<WW;>?;:6R=_H(8!J4$_VC 'FUR#/F15W8ZE6V'>[K*"
MY=^=#AH(9BOQ#40G)V"%:I9/";ZV*4JO"\T'\D/1(*S="V;$+D4Q>_?U PW!
MAF#[FHDU#:,$K+>LEV<7K$RJ;H-V7!5P55$O+0:!PK+QW!*Q54"6\*8+.\R6
MIKLCV^ZH!]4PW3:;VJE(N,@O58,(% A()3.6:WF6TLBS">[6G<-.M/K/8">*
ME\FL1 S&!3P*E!W1 NP$(@Z=4OW^'Y?-(Q(O91=W%,1+)FKZ!1K%=DJ7N\*?
M0%!I++-((B?5 QY[B!3HZ8'O!KKAVZ81IY[M^V[;F:[X7V!C[FB[*YI1#(!4
M\QJJGJBY)KBZ?6S-2:H!FX1M*$<X:(>L=S:[252;3T<"WJI:QM%-EZB6K!F0
M%(#-U1OQ(WXDNL9E90=76^Q2(GM#3:D]+\-.<PABJ.!6JB[DA@+ $$ 6!?:8
M$O,ISJ54*W&V50:#5@+;!7O) (MH\ OX$W'F..9R->*[@11]6=62&CC8.8*"
M8W-H.40J7U$AP"I"=M#;A7@;-6A@8E$XQR[AP/CM)=-RQ:9UMKBSXAB!9J@E
M2[TGHGN"W(EK%]Y:W+(EE31/)8(7=VB9!!?8*&*\[HGPYD0R!"9!64H]!O%A
M-L5/,FK '!$\"'V&H[3>BS\1+0"TBPQX+X(1XV'&SWFRLP!*]$!H5BOP@1I!
M74E)_<>\I.XA@B1$T)__@(WIFI9MZXR:1*2!J0>&8>D@B2S+MT//-9*M@ @2
MT#81SXL+8(4)B ."VD$Z1B7T'#E^7NXO%9A+Y*5"Z%D#E^=7!.-Q_1V@D!XR
M9GLF:^]XUGK#WATXR5;A:8AND@*(BT3!_>4T;?Q>_"T;I6BJ44JWS>.#[<R5
MT=&'[.]V[;992[<-U$S0UE"-:QNU"/<OKHCG9-6\F.LE]E1@.([:30:G=0-L
M3?6^_AF_]<V\I]N;BKZT(V\<A*[E6I;I<,1-]P/3CMW(#Q %%/Y)"5-YH0W\
MS3KR7JMJK]*TCX1T;1W^H<2%WHSN"S_G@QWM?S\\>?O]R^A/]_#D\-O!"<QE
M[XOS]=O!CX,?^Y>'/^ ]?W_*OOSXFL_[8+]\>VL>G+S+ONZ=F0?6P??#O7WC
M\-MPA+\\^+9OXYJ^OO_/M\/17^WN"^[!C]-_K)39+L<^WM@]SXEB1P\\-]%3
MC]E.&MHACQ/,W/4&EGNKG/9-+Q+=^IR97S\K9D7OYY\05O<FD=1%OBON\4X#
MZ5Y.W4Q._6C+*6ZP*#%"4T]=K$=SO%@/')_KMN&GJ>NEL6FBG-H)G0<14KU&
ML=0K%[NIX<=QG$1QX(2N&5D.#ZS8MAW#M"UNS$5A!6_>=RSE6B[]I)3M-XVN
M?0*J]B,W>=@6/C7;?!HFIN6X?J3SP$ATQTM<G3$OT(/43:T J",*PV>O@QW+
M6HE'_ZO5A0N_X),K E]J8/QD\MC#6AIT<M6^#,&^+XNJZN_PF\B&K&MKI,R+
M79L9NNNFD0XJ6ZBS-/7U*' \+[(8\SDUD?8'EG.G];-+^.O7L0^>AK)_%X+C
MAM)A9<AOJ7CH-?^[DQH=S=] S8'YH/F'<0H:A>OH+/0\W6:NP3FW7-N)0&KL
M! ]57&P0FW5^\!2<KHJBU]%D?JW>D]35Q7KUV'9DOW<_OW<WX=IM8LYW19GR
M[!<V,]:GHU\=7.A>=^+)W6ISH435=$5;MQW$TW+ZK6GE>Y$?IC%+HS3%1H$L
M<((T-4/#M!TSCA-_>6O6/HRX/4KZX5P8T3!,(&O/UAW;"G7'L!(]LBRN!U9H
M!X;KFM3"V?/L@1-N1ACQUW0&W$AY_/6\!#\A>/J0X!;(G(YC(#%CQT[#2 _M
MR-(=QS?TB'%39SP,XX";1F*C.W'G@?(6?GE3;NN*J/K W_UR8R?PYX:!F=BA
MH_L@;T$-8%QG@6GJ=IQXW'7CE%OVL]?ACN$_E<"?E/24F7\;TV+=(N_YK[99
MN/Q"!D;K^'L#X^;B92YVZ'"3^6G =0[WBNZ$KJ%C:J(>Q;[KN SDC1]A4T)O
M /9&'SOL8X>;:!6T1$)O%=R=H.@F"CK,-9@)5H&?<-VQ/$</4B_04\]S#3^U
M&*BDF"@87(,L\32=R]NJXZ_FK%4ZOMGSUCJ\U='Q>6PZ=F([>NA9J>X8MJ<'
MEFGK3F('+MBUW/,,3.XS%E 8;@K:@G]'XLO&,R9XLU6T)2DV#';"$*AZ4E14
M3?ZRY#GU6VFJ5/_5K?:2NK31_(1%59'/IJM_<N\%8FN6)9O&7*U7Z]_#LI$Y
MIUR/2L[.=);"9%^R_()=5L]^[U8/9V,UN"?W<'[Y*Q>9IO>V2"$9$X0>H#-_
M2: U^!3,B6W,7+1AB>+P_\MXZ(>>:[N@7@2.[0>1826^;7D@$AES/>L?_]GK
M$[+^BE1#Z8,Y1?_S.WN]["3K/7_]/U'Y^^L%'(0V,PC!Y5DFCT @>Z;O.[8=
MAP:S@A!4')N%S(A,H03!;T 4H@"VT\@U+<<QH\1SXLADGA>EOA/&MFO$9I!>
M<_#W2MUW#] S=[W$0Y[,\@[00_L6(;PA>97\Q7*QS;M5-1N)S^@8>Z0'"<:S
M^P_V'PC=--&Y&T2@9$6&'H1VJMMQ %QII[:;V//TQ[GOQFYH@G;F.XD7A)$5
M) 2T;84&9]8\,@0",?R1L_A,A],K<B V45ZM8R4QAFM'1<)S[8)5VJR2N O5
M%)3W*6]AS0B@EA8H3:IQ%@\[V T*ED8@E< 0#7@+#(VO$F@_>5Y<X-\NI(:A
MJVI=UE#*RY4WW[48#DNY_-I=VR+L!]_9<4/G[A$*C!W?N!WPP=7?.?<U6?]!
MX!3"[800>"<!4HZS[]J! $AY6P.DH /U-O[B=8(U:V5L;/SVW<R[?,5JG]26
M&3<AJINU7 DWW$_X5X%64YY-+^^_&'FIYW1CO2"+/L:Q=.3?96F"<V=>QG>@
MYJ#VREN:*^+4(HIG<\J?0".J/8SZ5H<ZOQV.#O;^O#C<^\\(E-C+@Q^?1E^L
MK\.OW_;-@Y/_G!VA:V3OS#QZ_]F9=X,<6%_@=[O&P>CK\'!O_\?A^Z_?OH[>
MC0Z^??Y^,/K3/; .+HY./CM?3X;M.J:+?VPG,"(C]'6;A]A^Q#'TR.*6SE,>
MVMQ)3"L"I2Q8FG8@L%MNV=[H>BF[#>[[?]UKZD4OJ*X25#^)D=T+JBT05$TO
MDMBU>6!9GNZ;#MCHL</TP/ C/8P2%CNQ[T=) (+*;7EK>T&U2E#=6"-,Z9_M
MU @5*Q+>&((=$]C8K03WLFVP^V#8/07#KI*K6Q_S>B@9VNZ"GGA1Z+MNH+L!
MXR!#$T\/8QN4/;@T0R_Q3,^/G[UV=\*K UZWY)9;99C^LAQW*^VEY[BMX+A&
M:V',36W'9:"FI(GNN*:C1QPC"UX8F"QRF)4XR''!&B'FI^+!V<O.LX0CJ#YH
MS'=5)/)+6D!;X:I1Q]G;/S>5)-T^L8GEQ$8<P$EBPQ [93H+N*4SC%QZ$0MB
MRWSVVK@[\V?KC9Q'\,;\\A)G*WPNO<3Y"8G3Z"Z>S^*(.:Z>IMS5$?)0C^"0
M=<Z\ "Z3*/)3UDN<)^M6^9159WI:<NP?->788.WV"MN2??@EQ>=&*VQXH._@
M//?E<?;B\\;B\[BEL$6.Z[N!QW3/\RPP_0*NLSAA>F+X9F*F+#$-&\5G&/ZL
M^+Q"BFR5^+QKOU(O<39<8>LESAU(G':(S(],C\5Z$C-?=Q+7TT/.F.Z$MI?:
M=FRE@8,2QUFL%7JB$N=)^=7>==*&9:YPG2Z<+-'=>M"9U:=N;P>]/WI]Z2]4
M OI0,KV=G^4F!G,XLW3+QX8VALVQH8VKQZ%M!F%H@DJ9W!XNMH>AZB7"&A*!
M,3],C(1[G+E.Z/,HLESNITX2>(&7N)9H3=-+A'N4""TMS_-BBZ>(&.U[NA.;
M7 ^-.-7CV.>6BUUI71LE@A5<+1&Z9:L+!:I-(>O*PM6-:'"[O,[H^NK W>G2
M[NE8JC$;MUI7+S2WUJ@N5U1HS<;8GIHG6K=W+J\SC@KJ7TU57;]=Q7AW<@7K
M]@WP8-[*%K['HOGV<KONL) +)!.N.BFF+&]__P;VX["8?N$P;[5C[>+#FLOM
M[>3RVQ<9GOSI'NW^$Z=^G!JNK[L@+'7'XJ$>A(SK?F+S, 3Y:?O\V6MS8#C>
M K-B"_.LNH(8LRZA19V.Z]1FG2VI[1L5<!7]$",T;>(?*S?LWJA0=#%X5Y3R
M(WQN2[-7?H((O[@'?_YC6;8=Q7ZBA[X!%T;$F1Y%/-#=, EXF/B6CVZ!=J\Q
ME8,B,B5W%F\!;;$,5)1W7E=#[KK/UJD=O=^+9'G3VF!'W 6+_[[G:NY/XC[Y
MR,KIY0G8XI40 -5>5L5Y4<W*C2G5/CR6!/SM3Q<(U#WZ^].WKWM_FO#_2WB7
M\V5T ,1\=@GZS@^<Q]'>F35/P(=[.1#HF?OU_>'9X=Y?\/]]YW!OF'WY\:=Y
M=+(/^LZ!?73RQ3DZ^=HIU08]BDJU79MSWPQTVW0<D*@)B+8P='6'&:X1P85I
M.]9\J;;A.UYB!E[J1:83@4'E&@R.!T1S[%I!X,V7:G]Z^V'WY.V>]G'WT\D7
M[>33[N'Q[IN3_:/#XZNKH9=J(M>^?/-4JOVQ]A\&BR@OJ?VP4(I0X++QI4;E
MCG#!9&.X<YB6@]0>5W"OG):<_+_:138=:@<\@2^TBV$6#X6#J5*?P7KX]SB?
M5=DY5S\?B%_A>\A@POM,N*6J622?J0;X:<+/>5Y,!E@D/]!@J;,407!*^DMY
MQJ<P/JAC/,^UW;W=_4\P)AANI\-B-M7>SLIBPG?41.#^+'DU 4[+L.(<;BRM
MB*:R3W7)3V? E@7L 9M,RN*<Y7A/BC&S,4U53HP2R\L,G]W1/B.P1OO;9F<&
MZL43EB7:7RS/@4;8C?3"@*6!'27<X7[B1&X(UI=A,3/BIF7%5I+.>_/-;K-0
M5!"%[(G/@(3,P'*LT%XE@#Z(!>RJ^7^>I"5,1CKU-T:U>W"A]./L^S^&%:3<
MB"S=]VQ7N&40ND\/D]BPG2"V_ @5NR6I$=I,;"-0 >TCT2N1XG]G62E4.?A*
M [X&G:<8<_4@J() JUJ:E6!07$VH,,1R9@#"11Z.B]EX6EX.&L+5@/AA))):
MJXB;!J,YL'B8\7-JY\Y+G A\-<:.[F-X9<40W +8CE?#(D^JFM\N,I@'T*%8
MWS0C,5(6ERR'/U?HB5X8I>8X)I(+JGIVQ84$"=63[#2;5J@M8R8"*'JRLSS^
M>"D?BHF Z@S;?:7B>RMN6Z+X7A2@M?+QS_ >)E\_,3X#K1C6\]D\VGMK'.P=
M6*#)!MP GK,BW6=6 )HL<IT=)SH:]C \,]( N"[%BT76^,SILX0B151!0"I
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MU_(ZT;Z=P2SN IF9CF6%Q(A*H*_T\L(% ":95$+@#6+?4$Y2(\;Q:8%_CV9
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MN*-11\SYE+>A/T GCD@1AXL?"W!0JV43E(4@HV!*0@C.#S,"%0F$&*Q.X(7
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MB#KKU($+SLY0N^,2#8=$>;'4J5ZM]*H+NFBE4>#/5V<\[* *B&D%2(<H;2_
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M:S P,#$X,C0R.3,M,C R,3 V,S N>'-D[5QM<^(X$OX^OT+'5=W-5:T#!I)
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M#  ,;QKK[8XZSQ$S-#O&V&P-C.'X^WAH</\UY<J<*0(.@B@;:-ZGI2^15E!
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M(_N>EV&&Y+K#W\T(7#2-H3DR[".K]\GB?^F<Y=5=]/2[VP]_ E!+ P04
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M>7*K'U;7,%6+@@6 ^935F[.AK/,K2R='D7F>M2DK/13FGDQA.FL=QZ(E1)G
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M]A[KAM*3D1PPH\(([ !#)89+ZTP&1;E[/)=R ]V&-5>?S*NL8[3';\,&:\!
M,H2:LGDAV7F;+Q+KHL\6E$[0AE*-VK!MVU*/Q*LFUJO&K9?C:3G5ZE5A_-NB
M]3<9U3#?>;][TO7#^+]S58Y2@&@E%\1QC<2WY32TP#"L)JZXBXQGW6;E[8H
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MCXR.C4],3LTO+"XMKZRNK6_@]O8/#H^.\2>G?^VB JBI_NOXEW:Q@W:= 7U
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MG)4HP)EXHA,^.J-AG'0;MD\!*( X!=A&\A(0A#0DD9K@1@$^#FA3@'\J4RA
M@"Y9(9TK3]YQK7L-(UOZ+82NNFC^"%4N,RE*?J@_GT2*2(:18]M@-UL%;Y&^
MGH<Z]/7!$RL*5@BI(; O_O8ILQ4%8Q0@?<W80--O<)W6"(6C#4FX'K-QVC^E
M9=5D]]4@[+#IEC(TP;)H58G,LD<!/L?A1<E=64CR=P7SPU++(H(&YR'\C95
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MRU631%U_)U+M@N O5E*Z!PU2P"8GW*]:;N:NY,9]HE*8'&NA3;:)GZ3F&FH
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M[I!.CZ!KSLN7RB;4.1)#O]/P5G,@E4ZO;:8 >(4@"A"1N>A%C$7R(B9X]BG
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MX?4^68YCO,G6.=F]8\=/O-[*\_+\G[?39L$>)SNN[?6C,-H=:;SP7A3W 4+
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MU09!):&7-T=MM;I+4TT2 I9,G\.0]Z])MYO+^P<ZY&4FX4$V*6;3ACZBK:,
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MGEE5[*:C)FM&D^:VX0N?E\&#:G8O;;ML)5V2=Y*W?4<;S)>DJ4(9E >6U.>
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MSA3B"'J*(I@F1:V+!G)2T^_I?'!5*4WHW-/ AL>6UD%S&O'W?!H-;O[]?#
MS>ON(O:_*8.&TGD:?J&,TE=MSOW:4XM034)G.HK^+A@4RY-\=3P_^U>@#4DO
MU:SGAU_#KAB19FY_L*?F_D?@N41A= 8T3/$4V>@A<3_L*@U\>VA+Q<76K,K(
M2$Y.W])Q,\N+[4.ZC%1B*.C8J J-<:MG )<3(*2W(9CM> 3BH5_0AA=0G]>7
M3[HX>?7!9YG=O"6E8_:E[HY^=LMX=7[<(A6/#8 4(9I@8WFMK];%CI'-9Q1/
MK?,<!^SBG8&G :L/EV5+@J9^O$(_.N=GGF\DVR*L49)^[E)OQ[&;F_#!?K62
MK&MBS0%N@=.UV]NPQ+ZWW;:Z3W:\_34#+,P$QB;CN8Z]?*G&QN(!"X(2 /-$
M5CP@&L%AQ^G,ZX\'VRF*O.3";AB9NE9B8=&)V^[_T26;FAK_H%**X3=QJ018
M!1EWH9@ G4&7],Q**=K/1?.,=046<K6,C0.>.,$U;0&R[O.(-G4G-7)OG=#!
M[A+1KJC61D?LPGRZ$I>^#*338"L!#5& U#MBFHP;SF&:E-!JBF%U$M*D3^$Y
M+B$V!'QOGVA*)4CZV'N6GOA7AH;'9 P$[%Z:';2'4:BZ8E]]7>/MD/4#,P]R
M90SN<O1!QO@WE"@>9!8Z&P^!Q9C\%K!R]RG&D?V;B(T+YQ&OK;X=\X._.X'_
M\.J4A.S:HX\E1=)P4C$M#G6& J=RCFA!J+<&TD:NBEIJ@=G=[60H"9P&$1VR
M8K?!;MKWM>GW,#/)TP335,8M7FW0FD".-IE#'8NKQQ!8!W/N^))1O'9__(4K
M%3H] HN@,F>3*;/7B#4/TAE:0X,8IDE'B]D2N3Z[^7W(:D$[US%!X_X12*>Z
M_0[_*=86[].LYB*YXKCS_25"8W9VEN&HA($]D]*=C<-4Z[<=+3P<!E1K<X^#
M4."@LH')Y5">@.MN($]>""W4NU8\,VFIA^% QLH83JRY<Z J\:+-8)P@%*_P
M,!"FB5(FV\V!(XY G%<Q;&1SO8;1.AWLD\R4U.RQ]A=):V::LM'#<6] DC''
M5&C?J89DJ]G4B :.&L)6>!TTG9RAW2!0-51N);,E_[+#>*"3+=E+;:XJ^DUJ
M47\3;@QA43/<($I5(I@$>LJU;F?5#>Y^?EK]X<K7% =KB@?UW/QX?;ZJJ*$:
MVG+XX(="90D:L5<YX_ZP<XB1*K"!8O1ZOP-LZ0(20V=-(QQ"><@I&J)^\PKU
MSORFPP]9S_^:>\I:6B9=Z2@EH,SU-@AD/OW0%'8FHOU1VR///(VN(Q#,?=,T
M@^W>O8 21I:BTK?_R*@'F<$B48[?J>J$J$PL?#RH,#Y]A=3OX^?SBB)>$7JV
M5 -RD]G)? Y*Y?>FLR6A-<@5RS-;;\I!4^R_7*%S?AB$8D_!U'E =+Z[/0T-
M&5@07 DS&2(DL,]=^8MR^_@Z;.05_?'^GI_4[P/K%#"7_;!RLG#K[]]XWDG2
M[MKT/_ZU#-S;A&I@0?^""A?4\1PG?VDI=4J V0ZIR#\?D7%&+,I7J/PMN:+[
M0FUB23:BB(4E#,!VS,!Q!,#!$WHSV52I*=YB"RTIY(7)A;)_!%Q>]HH.6D+,
M(5?:Z".+\[V2Z&.C6WI4SG4Z&P+@UWZ$'"J4&+^-:\6<G#A3VGT09U-D_:-2
M9-ONUBV#476]GQ8!]-RV)_Q:_%\O4<Z_*E?=RMK*&EU%UG^OL5DWQMV8G9(-
MX;R599HLY8/US(3O55H9(/A')O>I@I^N!>OJF9G??\0(J11C;])B5;[:MDR7
MZ[7 ^T!WQG_CPJZ.%.M_@1LICF>PI1+$O6*0YV*0V&K<S R8T6ON(OA]'S&A
MB20.924W;+VL=CFAYYJ0TV#RM8-=A)J\R[TI"/CY#@"0O,:]L"<W41XR?NPM
M&"N#!A>]'"XZL!_.-M/OJ(J"JO2[39D7H!-A$9?5HH1SDSMF%AS;CD!7ACY0
MQVVB*! 6O6"EUU=6[*+G[AM#-PM\$KK\#UW1*Z8V5^8Q$Y6-4##46?$TE>NW
MHL(,,23\:OMP?FIWWS>-9$GP!;3%"R[#A[8L3T\$K B/Y1TP<05BM6\]2I_+
MJL[PK*DUMS&_0_^4\3[S4=>#6%3ASTG1N-*=4H:PJ1?]I[#]CQ]S*>+Z3'LX
M18=ZE@A[0]4!CU^%"CB:"QFO1==))"D'?=P[7?WW.Z<V*(++VH77-"[\?M2*
M4$TI- PWSC2354Y1I;H1[=^@=-B;"I#01U6#KH&Z Z%"%]E\PL :(J U7UX[
MB7.!3_S1U9BF<4CQ Y02+;M.D9AG4/YP@"YI$:GXV&&^,?IAV4VNO\OY%5./
M0> #SYA8#]B'<LK/!U&/>R65V'^,_G8 _,X,\;6HT&#VQ#9;XAY[Z"6)<L<E
M^.,7/K;OJI7:-\]J,*\(!IR3?'5+\5N. _:?988;UGK#J)1%=_"@IV"5)BT
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M!9#X53!1#H;D5*U'GYP=1LYG5X66+(__ZF+1&?)P21N?\#WCK_E1L'(K=6[
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M8[IP6VK+W?Z55]=X_G>:[XCE'IDMHI0C*=SL5$"_!\U?LP1ZI9Z4+A+N ZD
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M(7TI,E9;@M.O</A*/XN=@M#]2YT/A%3X)#W5$4.[LWH4MFCRIP[&Q>\4@=%
MX839N\U[.X%L9NIEOV;:V[\E](17P=S8_340?_H33[38>=S470=+OK>:@ ?@
MO?N;*Z'A+;,C0R " [YHB0J8 2VY=[<V?\1+=@LGY(K>6N%#:"F%<3^)>57Y
M]NBSY"49(XU+DE?;:CR<%]Q2]#V67V6Z/HJUN!DM2XPN;#^)C#*7AR7"TFDT
MU[%CA7VG*06"))X? SX'$;HYD3NB-Q8D]QAO.>QQS<<9>RN'SL^*?NE:D4YQ
M^'1S),W^1)M1QE ".R3$^4A.0K(B/F&W(2QPSB7_;>ZRH3!%NP_^D-MJ:FEC
MA&!E<>A#,>81B&7!OB-64]SW>XBR\*YB%)^.Z! D"N_0E\]'@)1^,<SJ_TH%
M^'C%O&][8C#D&R? 8%<,H *8Z JF=F<D*8Q('"^%:?FGES,[KGE*"RSP2+AW
M=K]ZIR1_5;3!$%IP\CC>")T!?F .5GGK=U[S4K/7C]&M!O JQ2<_2UC^H^$#
MN8CV4T/+L75J9!5TQ-=MA:0)?EBVZQ/2+32MG?1 3[#"">OJF-\C%@#^P4"Z
MG4.T@D^J4@'=SZD PC#<Q,JVEB;U[]N-'VWOVA_;SE(!J_Z//UOA+Q[EL:]F
M4Z[<(U< -][!,;>H ));*N&ETM$G*J#"APIX24<%X',I69\0#N2@[ZC68WB7
M!O!?T.)O$A5P;H]V^B1TKL&[%-OT\/9K6#!)5 ?\JOK@2P,5L)5W9UY@KG$T
M V8>3 74W L:T58 EUF9@S53!JS[IK.N(GNW(\)D87$?;[_RZ+*,_?H?K29U
M'&DL&J1\[;A.;@&B\RF*!'<T? M%, [:3+YI MUFR8!"X^4?YAVKVPQ\XW>)
MR4@D&?T[/'2L^.-J'UKZIK*<VVY%1Y/)@;J?1M3EO;7RB"VX,@K/[+YM3@58
MS=$@!0,5L*0,_R](Z:!1/QR\6>-*7FRE,(V0DV+WB2,9<'0BO!;Q"O40,<.O
M2X N=97 N_5+-VR/+:@ =\=W2?X99F,2 A7OM[5>/85LRD@ALGL?2SI758).
MQZAJWPR<N/I1,.NY/K>-^,O_'G#\?VD)0+=Y\(G31Q$$MB5A@87;OCXDR:)Y
MKUA \+L8[GN;E[23/C.S5]KN+>(-L3:U^%2L03-VA,-)9;41*_NGD>57"BSL
MB?_P\U\&3QD> K;!XZG;C;@4&IU&MN+PDETG-E.3;;J8S2$3'KG&)U\4%!*,
MNSK=F9E.^VN9#&DT;'ZKWKF2SI(4HC#$G6B]]/"I5<Q7$9PN8CV5;AU#CI6I
MH(AC"X+X53N.X<W!0!Z\5PG4,Z[L2$YR9;AL&:5XDTQ3[#&^0)]M$^N"!P3>
MZK9CFRS5>DB'4%Z*?B$3AZ/]R;:<2&84^[O\#[;+3K ,FB V"=<'-V(79T,<
M"7GBE8:8 B;/#,^T>=5;N92EAYQE;G/GCZ [NZFI;SF/.\0?X1I#(SCP-L?6
M6*(99;MM?GO]%[Z-P8$3=+/P\_%Q7@E%"'FP."EZM-H6<'1"KOQ(3H2["E^,
MU(NX,R&O_)9+4&?T&Y-?B%+5_=@!3;K/;OWG)[T#$H]N_DVEL- 1E3;!C>Y;
MO-C=\Z%>OQ!M>H]_>AU=3#JN65BXM<MUTFJX>E9PSF,7/,C'<TWEWN!++9=&
M2?7RP&,'V];UZM9UN(';I&S/6?M0Z_!$1;_#>B06KEEP44>&$+,4UQOETM<A
M/5$Z2=)%.#9.;O_^,B^;KT[W\C[@_@= !0  .!LP*3Y9U:2FJ*?LKZ=\S<)H
M_F[=#741&O7Q,>;3QRHR3U]P2Q<79J8[B#69?*48EEL$O,LS#)Z?BT!.86R4
M\^PW=2?E$%6^OM=VJU;LMG=$7@]<XY)FK7GU1:;SF2Z#R*O)<%F##!LWSX:=
MU'4'"F,M#0FR30!]J8!?V)/%OG,:6GYH8Y':2=\+=,2[TIRO>%UOG7$B-5L_
M6PITC:4[*^QJN[I&XH\ABF\NGM.A"ZW$\L9?VU$^(J2)YXP]?.OC_OFYZY,O
M<Q/7JC5]1JR3'SSM+!B[29%>BM1AC@U+*,J>^U7NZ9-1MVKR[>Z?X!E*%<9^
MIN*7*?/;1:Q*];'7SO#?1K=359FI\^S_[NZ@#"L'&^_.%^Z85&'*6A@P1:9O
MK-K\$? K=W,YN&\*5P7BS!<)4H8)*/2'1?Z2:151U0),E/1R3,^L*@8)0HI%
MCJ1<=I\MF9L Z%CSD$4BC7#^D7<((8A0F''N@G: V9?Q66MAY<</<A5[?OL.
MP^50#<*=PMRP(9J'T(B@(PR ?-2<?Z[NE=[;27'5*JY%X@TV]&1#&&J_"C>'
M2K[L O'$5UO\:+!8Z=BXOF$JWZPVJADTO0?GJ;WTY=&G\;*@NZ;[#FZ3S98D
M>R>?9;] <WVXH?#+EZ=E22THW/T\!_O)$@(+-BE!OMIG6V)"2S9(ULW$-95-
M)6WG6T-#POSMK\USG^67?6!)\*YF*J#.K1E/=_29IO 1*N^G*+PXML;O'/--
MUKZ('1$/>FGR]N<A4;7C .'CEY%J\81('F?A7BV?]LG0C@JXVX+/G_5?1P(L
M8!Z01N%GY'%><8O_(:IT<UCT6*:M\N@WN<R;"G I^.7>+\Q9LSV%;P.ZL954
M<IV=G*CYW,4GPL53DD;'H>Z8/[G1N#]-X@$=!4RAO IFE 8H;#BL\BRYKT%M
M-NI+O^]*TY>4I:]\(KZO[YC[WV(=!/$AEJNR\H5*']W.5YC->&^5O["9WM&N
MW$P6S)E L K:83(WI+[UP<-_+":0,)'FA'<UD6Z$I.I01&_VOE?X;OSUY?;V
MYC?+WT3?OP^76N=^6@&X!&#N*@/19]6W6109BGE;C\9.6:B+I/1:0H@U>>JW
MF;DGTVV,O;--A+]F2DH/#_INM[;N!AQE4-BJR%50K0A<1)\P4Z.=1#[TK%%+
M:9KL^^WZ+X_%XJ:9;EP#;C8+G/T'!9+=DZ>PO20(5\XMDHP(R7X7]#[^UF.(
MVYJ/(T7=NP12U4Z+_)B_"G(!UV22(K#6 MHZHKT#;! G->BJGQDX>7<MX"3D
M>85-ON%MZ^/ZN^0,+^#+ZN737@I7#FE6Y?Z9_^'%\Y<& ,_6TRQM#ND>.5HK
M"JVMV6GZ@07*Z7ELJ^9B7JLFUZ'!:>OY^\LEE_S&S>6PZY*J_89T+Y!:"$BK
MW 6H4[CHC^'ZNWS!%Q]\-_TK"OGEM#$&3@+JK2,&P 3):=)%FJF ;\L170D,
MG1UB<$8JX!$A]3X$,E+WQT"ZB;$8GMG6$Y,I6'DDTT+(B%5H%KJJ[NW37"+D
M.KA3'=QZ?4#5L.!1@)<\YPN43'"(S=0WRD=];ML?^3__7<W?_Q>6+7J:Q$L%
M' E2 ;'^Y$] S$./8!W0"YB$YCPJ"QCB67'>UZ5?QUSB3H]D5MBM3GOR"D*<
MC$0],64Y0I/?-X[$G2P7N%!^LFB_/!E8-2Z=[P_@'E14BLE\E-;,ERVJ@:A#
M.TN$24!8[U$!<?+!$"("4>6,"M^('+GX1%9U:"4.?'E*GCA45O2+3&9?11Q%
M$2Y@V6==EM3BVE@P$>!&B+-HJ\,#?_9LYGQG.\8?HLETFD*#9=5P4V =?&N4
M)DJ_6-#L<3K"!%_@@2#SC!CR[.UO\*=AN;3?S*9]>WR3]9DZP/8[&&<,)H@>
MP'&@/'"OD!3>H+HD]%W_; 4_BV:2U&^'/TT1R!L@!;VP]-<E*>K,W%PL%T]+
MF#9.NW91 9AT"C.BAX;6%JK@'%IA7NMCAA+BHPVKO],=_;Z&,7HL_7EEU+D"
M /KUYVP[7QO^M/Q+;[4X_Z1XOC&#LF6]O=^XDYJ!<<PO8%MI5-+ZYC\!L2[R
M#$S<SR!K*J60R^'H)2A+) NY4(6=@0#IW ^=UOOI2^DKAQA75G_*TO>I(^=H
ME7')"'8J*<:YJG=C4A<*ZD>VSV!29^/01PE+J0R+US]^W'P=5JO0F<X@H&4A
M)>D=WUDI_UCSU66*U>96 4%T@,0]NW;$0NB=!<9+?"G I";5<*J$6O%2!@M>
M.*Q/(P9OB%FO% GRI9V-XN4)-7X1:U/V1I_H!7%R.,H[\!UTLK !0;RGXWHZ
MQ!Y+OE5W,XV0;E<VR6@J=ZI);@\_ULFE4>J01BD9@]3K)?@YS,+;1;><MMU+
MGEG?TE@$Z#X9Q!06_/5FT"/^R'=A_S9(::CV#=SE(_AK?$P?L1H+@CQ<W["!
M1'P5<XQFEUD?C#J-T[/"T=54 ,Y@\0+L!YS'M\T.A^RYB8C7$8#\<"=*O/,^
MM@P-]C?VL%<^VQ8S*=;/S94<S=U&  _@R\]FN 4T%!6+S==DS_@<@MU;Q@,1
MSB)/O8O4<A^*!LFG2--,0HY#T>:OS<FY_1V4/A"=",89-9$_'<Z!$H&<#:O"
MYP.;CSUS(__L$7(#'Y^GB9'.UZ'8):X;TC^U_6A[,@$11+,3J0!(0<+1R4 O
M&XLC#M6C+=@[G1H"%<_L_]*3Y@/]<FYV<4 &5_FZS(\>=AP*Z0F'QT1JNQ3_
M4;5I\<TN[<R:RFK"QV.0"0#K.^:=]P$ Y@V\?*\11KH-(9NW\2UB#(0!%4*V
M=:@ U[!V#0)[M/-5R(WOCW;D8^6W=;;A,NLM*+GM.8<!=ZC C?XT/:X7=_1G
M/Q4] P@"#A!I*.]=@EQ(%VH&B>7.YYR8<\:#$ZH9>8_L63GOM7B*7G%+-^:D
M6R)PU[-C6=(<V4D7P13F%2B1G^ ,CZ, .IJ^$,HJ[]#O \3 ; XMR_=Z/GYY
MJ)O,#A#<4F@$X^ 6$S4J>0;8O3TLI+*U_++G6L[W]'M;QFYN6O7_ZNN->(VC
M GK$<RTH/X>AET&8Q-$AXO!!JB\B"GGBK$3#\!L%%D-;&_()[5:1;8NPI&GH
MGW='IYYQ DF9W$%2"(M"^]S>D3,TF0UBX[=(>#AQ+29J^HF-ZQ/)9^O?F]&O
M0Q&!B!70413Y0YL=43[RP5B;)[K=QD?2:>S)O$#2]X"/1/S=/"$U <5\Q@,1
M3O(%FMM(!: _4KAIKX@A74ZR'RN.,\/;9"7PQBNKPA?^C*<=CVNUG=>5HN18
MQMK0#>+I>EIRQ#J0,6V?=SMJV!O:"@SWPG^A]&)"9_D:8(B$!DA-GE@K0F4R
M<BH;^7/"7!_F'$7X]ZK5 B\<?T %,*SSMC151T!*_^1ZLP<$!05()?*'OK[H
M'JPE\XQ)[*#L4M,6\MQVY55\W"ME5-P"SX3*<,#]^K' *(GY'83\]1)./1\N
MUOI6(0 @"!$=!"=HJ*%5\Y9*Q[8/4N-Y3RQ^7*',Q)D^]_D%LKL#51S^'-1U
M:X:!V>P,09/"<IJ+[S$!]$%=-D6/G%V8MXN4'%T[RRT="^+X$9>4$ >6-OKN
M]UJAY_-\@V0/#YFA6X?C9WG,27_(\(AV85ZS;7X!;]90]<)B$EXMP;H<VQYK
M[7YI5P+QG=0X-Q(R-@3?(&+D^U!LI"!"2 FAOOMF>VDSANS%J5VRTLI5)W^;
M45VF,YKOP3D+1A$._=/;O+.GJ;=N'C28"'VA634U;4I(QA"<#N1,*?KOFAN_
M/&2ZT;P>)C7P%%V'7"X@<=$$L[P2UKG(:6LP7=(QJ7-Q,P/>.]C%_O;D21G=
M=O &/-ZO_9S:)PK.GO*<)+@D*(OE?:F\':(W(:?B(VR#-&F5';*C?_V[=\F_
MY3,ZF@T6T:MQSJ6;KTH6L_P7&AZPT]+O).\CU@3Y5N"3OJ8N)#:T<K?"MK'L
M_$C+WD:!X6KJBB26MV<;@C%,/@2Q$3),6T8/YR^N;,M[UUAZ9^U)=S'4'M(_
MX="ECV9SF=[-)EUTH3 !V;?+T6%:4'2$;"A,QN,&0/3L8S#G'(+4VLH%R#2(
M1&K#ECB*%6$W2?+_FC?K34#B51>[PZ$]H$L.7NG#R]]/8K-5\AJSU=US[;BO
MRAR*O<]_QG4+^/.W_( =S">;[%N\9.;G3'(PR3RV)<H7_?7-(11P/(6I7>\G
M.[\1MU DV)LN?INKV#S>&J!T 6MY$U!0^=06>,S!I67D^-+5-8?)NVZ"$C\%
ME)-G6J,FS*IZ \_$4U[_JPW=LPX^\EL*QWH^ PZ6G^L;\Z'SRDL&>:6@L"=0
M;-I,EMN.\8EMP>GL$N C$"NE$WZF6DNR,"QDMG%J+B_D@8)WMDU+/TN([.7E
M"@FSR</'O20BC>.G.7)%AD2A2*6,3AW6">[(>WCK<J% N2P<^=V*:9<(J1YX
M56'B(0KW"=JK7J33[Y<"947*@7Y)>E1G[%HX939M-<S7']8(?\.U*60-"29#
M9E7"=.8_"A<LD-*1&L1(>%>7D# YDZ+VF\#?Y<R-Q!].Q2C$.'9$@;::FO;+
M>^;NV*A=WQRL%Z!_:,NJ.S #K(W;CL"DSL'10IE+(RSU/6<Q'O+>K@_'_V0;
MIRHR*4R\BN8ODI4]WTAJ'9(U%=6L5ZJ]]GU +./W]-0BSA!%D H:V!(G&G8)
MU08]A0D2NI9JIS_,O]V^]%X_DN&X4&QG0$+5+_KVTG9H1K>CH%8!Y<*%T$2O
M[7G*WERE\[?#Y';!W8#E/6$N!14E39=9*[>MS.SF7XO!K8N3]E/:E93S3*?Y
M38C.D<0TTD-<26HF!LP_SSWU(?:&Z'B0ZA"?^GHV0"D0JQ]9D*</BR0I$?RJ
M(A\2X@H)MCU3_EZ7U^+E'W^N19K5#8F>O0]ZE)$. OP#^@=5SIX"/D=2(YJ3
M.*:UA!$#%TLPBSP/+@DN/9QAI3-4]E;_7=TX&1=TKN,Z[>V/:!P^_Y$<IW,3
M'$KLRY<8CWQ4^:!'O"QNJ:GN1M\3L;_.*\?I=_H4GUMA]+X-<:G^)<EB,P4D
M]&]>6@L_L/Z0"\V+>K-HYI2W79)?LQ;"&1IA>>%==Q.G?;)AV%9SQ"]X1 FB
M^LAPNJ".=VNNF/(551_W@B*T3A1B9[>[9LO+W&JZ/>2Z]IX*0,EJNGP6"?RG
M72)1%A=I<+4DO YAMV#A@YQ'!H],?QI]*>-78FJO8"S^2X[#7)\GX<-_4<!G
M2.LD4]KW-%/&+@OW%G#8V9,>X+E5F\+SOG/TBR*O<+JZFG\/0P-DV2G"[,1[
M\%%'/"_Y!$ES'H(PJ$NHY1I"):6'%WZBL;DK? JAN)0P*!(W/UHR0<MZ21LZ
M<-GM8]'F;HF>4%(8A%6. QGM^#EKP<(AL$J1\1)=RAJ17[D'=V29?2U8C064
MYE_FY>>[NPQ71-?RK;JD9EU@BB]069[<,):5W AE(.D('[VE @J;L?+$0R@5
MT+].@\H]E''A ULM?2H 1H-"A'G8.WBO(A5PA@I8]R'0'.<84R 5\/KT.M:5
M0D<%_)S#!U !YW+A5(#(]  <<5J'=0M/XZ4"%2#Z!SYI1M,W!:=1TSHJ0&E?
M\K]^<R"\AX9T/%-/9/-IQAAE0P60?%&F*"P?_!D5<*!*.ITU7TH[_%^5_SN[
M< [EISQ?HM';A:)+J?"#DZB ; I;]M^"'#]XUV/:OXYWM0$GY5\9?&VP+O<6
M)M(7<Z R2G"@L%03[X>Z6Z:$Z8A*E#._;V\\BBMKL\ 9,#VP'G D56G0_0$7
MLM,^;"B242J8T(J=\7YJ5E;VFIURQE:0]CJ"RG&7VA3M6QF1??(\GB$/_II5
MENG"^71>&#P4U=K/5WHO\/ +/ON,=62FE*[DY"BXV('XDE*%3P:&JQ3/_MD&
M;VP?YP-Q#I3S?H28#_-Z[*EM=!@XE]V.==A!6,FXKW7H[UZ-',&6UX!;X4^"
M$#^%?[%36"[@@$?=K4UC!PA.M=A(4,!+4UZP=?V7S%1<[U^%NZ'J5OXS:QZ(
M0?;9$ HC#W[I"%;?,M'@ P01D@OG=@(DGFU-5SQSE_-"&X&$@^5O'" 2@P1U
MEHPF)!M:HR$.E7:7I3_F,!M?*.^1E5Z^(1+-+I*X7MFI)5DP&E27\\FD37",
M"N 66LC?W%<HZW<TS+"VVE?7N#YN@RK.HG3@R3[FX!<%.%-VPG5D$A7@IFT(
MPJ7V;B;K]</9[;*X6]->S9:^:*<S6,LI%%P*^,+^I8>?_Y@!L]CKPX)=C&[8
MY0IUMZF=5I:SOZ*==UA<:.2NUZ\K].)TDK!N%[TMYKUU%X$4BZKOD^T&LTYW
M4P'?CD$K0>4GB^QX57;UHNT;/\; W,Z;I&DWE#9;A51AQ_T3#D3_(N&F*.7N
M=#>82 ^F2<YZY=%=%#\<O9[Z5Q;,!-_BI EM42%B-%*:"DC/C2NF25R", ]6
MF!0O2P7,%9PX@M)H&"X5N)=.!;R '_'"R9*YJ.(*B@_\__KPA)T?N.QG2&F7
M)\L8)F% I$2:$S<]0 44]YX6:WJ0M?[GUG[_KUVQE$/E3;X:L?F5N?XQ509U
M.DD>4CUE@@IHB(L'0D"ISE?QQPEN;A-!FQE7]=K:@N^S9\D&4@&/E9F+GK_G
M"I- E6/56(5T-V3_-M&.<B6LNR5[2Y9HZ95[=PY)NBHDFN5DV6-[]VWR=L[>
MPQ\*J[<?B+*;)G?Z@9L(DO'=>L+.F0X1=OK^0+&Y=/!?V0-GPQ5GV?N]0V?O
MEF@2U;_MRZNY7J0">#9&<FE[I60 &8$V*/3B+D%Z<B$-*PA$"R<C)%K&#\_Y
M8?C_F"VYBM@$U[I0 5ISK"XC\X\MBZ3 ,UX45S@Z!\Y(TL5G'^T1',H(P5-A
M-<J+G#.;:I8&U4V#4U-8C96<MU$_*][2+UW[VCS$3,FM_.O0MU7&$#.\9,OR
M9&,@U]Q)<!:5K;;Z;@-^)Q22\]C/SB56U-ITK^_8QFQ1?G#H@^T "F<+),BP
MI9(N'&.>W/1-E#MD3W"6?DX%U&Z+G2T:QZS8'SWZ68%D?)&\Q8ZK7-J2(8G3
M=&%:&UNU!Q@9_*[&>4#3X^0X=CO;-"=N9R!][UJM]*'-P^4@(?^CJVW"Y^ON
M27CFC?>XZ-"_KR8-!QYLD#*T4U2':_E@EEH&O-@66XK#'_AH6$,D[Y+PI0T4
M1YOU)TCNZL>02LCEAMV@L+"@*^F0G >T[]PS5GFGST-.NO2IST#FF_!WQ3?%
MOXMW9FS#B*JP,=@-<H:.O"=,#6?PZ<2ML5254<-#_HH8-/K)U_VKD0"KDW\8
M76T$!'GRPKDWQS,OCUJ\RLP-+RTP2"RR+Y%)K):8R&B!!([\*:(P'1.C0D%'
M-&TK#<5JGS>J"MH4,VK<YBR95\UX:BA:Z_$VVN+>HV<BF!BIXT1*) K]#*8T
MW:9$0W^RN+S8%,D,T/16$(OV8^4?/=Y-=?>JYF-_%;Z(#L]H\)\DGYO&[\8+
M*!F*#N?SGM]E$E>O*5>=+"@R6[#9@)OA?*,L58>RKM8U8'^#W<;,-J>H@*C3
M*'N<3M5_%?WJ*HCJ?YKDVO_O)KD2S&E[RJ1)=AN(^"@T&AJWR([PK89=^F/)
M&>1?W+\@D6/4^TK]ZKS1X!7BP-JCUQ_A>D T:D%VJDV."J"?P5_]<\$4*E1>
M/O-@0_'.W<^-8?Z#1J+,/VH_;NGQ:%VF1&X>CS 00"S.[#=[(\9>O7_8(I$>
M.=(Z;3:W"X$!L>Y<CZ6,7:VT)Z460)6FC8.M<BJ[3=/-^MRV!U<(;VT7P3@#
M88+L'9J032?)480(&WO&';R;M@S?\F)7<2O?7RG=T(;]Z,VXNA\=DA)RCG"Q
M=#QP+MG=_'3$9.[&SH9^+.,5/;$,30X>:\/_?>C%UQ%%1PE(3#[[9013T$:!
ML>0H@L!NDE\*>O?8?\O*[X'M[O6\RQL%- V K@9M/N;+PHJGJ]J)OCYG8_FZ
M\T!DO#*!G-O&7Q%YD_R>= 9#]G?[,M4@S/9G-OBCK$ #DF-V0*#*#"0^F6IY
M6#.+BJW4O5W\D3?PG>WNVCZPVO/;(+.I72,2*GJ:^E)$!2 ELHEG8,.V%,46
MI).>?>L;SUF>F*BYUFD;U\5HQF0>NYF4IU\$/B-6=[%E?7(12^Z]/NY]^5(3
M-2JI')!C4%A$B,+0W>WUFS+/7UI?LK9F!@"8R:<]Y',H'*$Q_>!ZY#.27:EA
M4$ A 6C]Q=19/=O_]G4+\<20'1[[JSGKK&BA0A2W[$E$UW<$DXE4Z$9PD)=J
M\4EQ?MK>V-A^RU9J)^G^=P6E[S;G0ZS0&29%/A!YG06;J!ES?5#)GQ#[U3*H
MJRM4>V5EN9*>0Y<OW6[Y,8^YU9-ZKEL ?V/$]#MCIX(<L;DZ8"@*O< ^*^M,
MF"9></*P/Q@.A@EM%,RT1/4(--??*$Z[LW@X$B!R<"NF,6H7K #O$D,]9DF=
M 1W=&2=I5BHB$P\WLZ8.?U8W/_R2QGF'V4"7LS^^."8:\Q6=>!*,B@]MY7S9
MZZZ>.R,;H6':Z%,0W/:NU;GL,/O\:*_YD)1%7Z27M XE=5CNTFE)3EG#OYN3
M )>"_Y_ [9$+A2V%"LBXB9\FIUC _["5P)1.&UVGMV(11%8GFK5>0_Q*):AJ
M4NYM#H"/-(QIEE0UDVR+S2:E+]Z$YY"..X7WS('&!<5OS/7A,L(__^,R "QU
MVJH:CDZ'L\.A8/9Y+[ K$H?J-7IT=:CW8IJ/TF?A:R$>ZKE::%_@S=26F<&"
MRD\U)*1RGRLA'OLYX.G[8,A>U/A&_JOE@8=/"8/R[ G1;YS_4 'V.L->J2L.
M1PGD/)(#49;D.!EY8<E'[J ]POBIH%*';/S<FUQ) 2U?#5;MKBYZ]DH@.FD1
M9\4_,M.*G4?%1%I_\B4X8%NKD;" R!:>\4<VV^?5;]^N2GJMFD>V9#OQHRF(
MTRG7,'O8++Q>[JBZ>*:2=!NGW88\4:Y%[$(?F[= E#;$[M\]/W9VG<7][S)B
M(U]X^+.C>[I9K*+L.TRND_B8WW;4M%MNB EXK6I3KN]IDP_SC)V.;97#1DN_
M$Q$HD9\*W0S7N.@QF9F9&6O]_*OHA&4E%D6XPKX=YD>\#^MMLK>I#9S6$2,$
M**ZK^6ZWF"0]?%XMKOTW56%Y;YA.Z/"H!'YMC<_)L97?E@Z,+9T]W")?KG<N
M.[CHD%J6W#W>-T9PRZ "GN^%GX6ITC@P*KQGT\%%!<Q</6VA9J@/KK,FS%$!
M#'?@W^P))E3 0QI*) OR1!6\!.Y9WC\HH*2)KFKI40%I9^%$FD=ADK ')'&N
M42S N%1*]RZ-^_NV!YG@8<2_>:B[Y$Y*H7%]NH0**#'"G\*Y-"?P"8&&Y]Z^
MY#8')PN7_<_./?A?ND*A)&[)HRL_45#PKQ$+G&_Y\J^-GZO[MR<&?7U4#ZU>
M0"WYW2&?-HJ/ :G^A2V?'PS.W,7U8E:&U)7'G2[?Z'M4_ECZ[DO783Y9E7FE
MO[<)K;@"9P(/7LD!!T^\)C:NLLL^KU*RTDH%T*6\$-KHC+414/PL&F.7SX-K
M*EI*Y?ISHIKJ[O=IHZ6DV][>OO/=\I?,&9FK*<OI9V%'\"YG(/KU*&51-5A(
M%A<TE?V19#CF0M3\%LHGUUCYZ/AQY@1739RX,.3IW?P;MAFGHY)HHL-['>@B
MS[,02@5@73S"D2FBY]BX%@8-OB!'BUQ[,Z"NCC_0F?2L5]WIL]4I[XNP4_9[
MT)H)R":3PZ]#_SW*Y@+YXKMU&)-E3V3($6+R$>G<[LBL-JIO;-ZY5:B+9D]S
M3AL;>%(!.!!-7)/(Q5G'!9Q:II=!B$415I&=+#_AOVM"8<!^XKO2GQTK1 /*
MA! =.9TBK):H(T)('.EI >:*)*RPB2$M7C\PY/9@^;K\S],/Z'_, !)-'?(D
M1]QQ)SPV?"2)9%WN\$='^*?/\/#*]^IG%>K,#'A-!>8*#;>'YXQY2,NT[S2"
MHS]TG,:@HTE![\ =1(,"3-2U=E1<0_!3F^[?^4[XKMQ[YX+7ZF(:]6'&W22U
M%"QIK%2)7Z)\8;^@P*C_V!8Y*+M<\$= -_^1.D0^EI^-9QAR&_B^9&K^!+D/
M.48<G88]7Y$$R0WR-=XP8<+@M.7DUI*2::ECEUS>^BN7Z[5W*YS.H5DDT$R
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M[AO.T&D$LH=(_Y*\Q-,9XL__7<XEO?@_GUH2'' =YP!^[P[P,5O].6 0!:X
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M0X0(FKI':O]3+I .1^99QV;C+4D\/X*24+L-&S<78LHA([!LX&_?;1@G1-.
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M%,B&*Q^K56Z:$& 1GT=B:WA[U3/IZE@#?]QA]U11E?1E1NF)FH%G*P%]D[]
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M0?9_H(OK98.!4$1BI$05D/UL2RIO!FWZLH.JW#[/'1+TEJBU13/(>R[1@7@
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MTD_%.\M1D2"//R0AW])1D/SYCM\R6]_2@7C.RBT3J&FQA%"J$'C]8L".LI&
M9-M?A#7^=KHG#+_R%A$,7]_PVX9E,7+!:+E!:C&H8P;,0_;<.>6K<7@;UIJ;
MS?('MF[\;7L!'((Z=@INYP!WND^$-7)1P>^6HNL?,X5M979&8P=BC56/WPA<
MN3-V$";?GCU:4)!>6!;KE'$[+=B@JK#^X\M8O;5=^$0X_93C8EH PQ/=,WJ,
MZI&(HNNXWG=5;2C[J2M(.U1XJ*PK*E_FW)?F:[HZQ_9O$GGHFHX50>;+"TX#
M/T=0):A.FO>*<3[&,\HG@2&QYX<!O;A3PVYRI6NJ[UH4*Q?O0A '!_#\TE1C
MC%>.E]SWHL'!+(?B+@<9#;-#]U_9<^1=8KO7DKA!I,L0F(<<R):+#4ZN9+DI
MY"[ZWL=JSYN8>_5*!0B(!T''OF[#7,.SU02/A<]"707)(HJA#6)(E3PR'<E\
M\("&"T5SI+ /MB*\\Y&4V<<-](]:#:VJ(5&^/!Z, 4='GA0G@9IJDSK4+L[Q
MZ(O[8SX)[X>-P91AEG.VWN0#3U3O#T@ZB#1)CL2G]9S,3ZZLFJE2*I]F2M0]
M^8$G65Z*>WM_*7YD<FJ4-A/;LZD WF E(\9>$XN)"\NN*#D?#82HR\&7^)M4
M52[6@DKKBY=NU6N-OLTJZBYS&!ZZC0$%G?CNN5'2W<R!9MAM!85.SFZ>]^8P
M\RVYS8TS/PJ_SC)N/+ R T9=62.U.@O]:GBN5Z'%]5V10K$&H-C)C^&K/^L+
M\C\.S--<40%.+GYN+=*GR%8'P0.<N$-T'(00=2QL[86F,WUH?A^EGU W67ED
M6W&?(V%RWO4W3U!4I&O(X?/UXU1E*T]2KCYOM8TQY=%TX]U'EA@%GU.G?\AL
M8MMQBV?':A"D\D7X3D'U&PJHC!EQR>ZG\R<_?(\2.SBB)^9L570[^.8Y(T-T
M)5#W!;OBBN!#+#S$0"+8 =<.'S(&C>'D/E;T\Q8PP1"91Z0\EF$F&3=B&"+I
MD.'>GM_R:\S1MY7X(?.,E0*NH3F^>9B0=81G$A!SZ"0(C9B?@:M[_FOTY-%_
M#:[TF-+?9!8R$_J60YFB.]&+&0S8['IM\QKRY3J#M W;.[T-:[\LL0TK3+H)
MWNQ;5XK$KAQ#KJ\@WF*F"5S A(?BUH;B3YE1"%X .>Q_5#W[BP/H&W,4.%T6
M8*;CQB%-KX1LM<R+ 5H[>+=AR.,[\S?TPC;L23XH@KX!.KIL0=\*M-QY-IIG
M)\[IPLS;3/FK: BO*'[")A22\5B&"T*8@F71\'2A*;]U"%]^Z"RE_1E,_8N8
MQ\83/"1:QR:V89NZ>V.@&[IBP+>CEG/V4)/:KN+K%'\Q(4U+V.1#4'7658!_
MBG#@II=!;L@7OTWP\0:_;26 <8G@2SF4"'X"@&]MP']JHX6!UB20F# 1&'X2
MUT;X_?<S2CQP6@H$:B[T8.BA/R%TS"BR7,$A>W3^*@[R48T;W*O8"W^+:?*W
MI5-JX[9A0\8SZ2 GU+LG\^A6VS /%$MUM*]O)SG,/P9"J.B=[6%3Y\%::, [
M)]!I#<#*J7H(DK\"LR<?=RE4&TI&%K8(RW]O8;LRIX=KA"!4+ILIN'R;WD3F
M-B7AZQ;O!<C478KNK7R'=SQND!+P\GBL"%N[-:V=E'FT_FC^NC%33([Q> 0D
M8(M=,0UXWA%UW&L-:=\O(S]$(5_:2@O[IA[Y?1Y>Z5M#<:$POJ7NZ]&0H@_I
M4I8B7*1HA06C6G<?N&&?.V6ZOTZ?:[2<MQ=P-Q+/A"\.-Y_*()[PDT,I=>D\
MQ94F+?1-HX]3S9][ 45G%')4/4MKJ[2>YR/],H<'Z?P4CF9X":$Q29&3+JI9
M0^6I"7AGX.<E'+5724\B5E"Y3^+TQ,G6Z1AD/A&BNDS1NR3X_MG>RNQFU^?S
M39?3/WG_ON";VF7T(J9=;9Q?7W,IY/CZ/-(.J%/"CZ7:"T%F& #IH-]K]#NU
MU&?YASTA=R#'&-K\1GCW:N6+MAYGLK?#NX<R,^%4>D?38[?3)5\&KJ=<EC-Z
MD)$Y'4"NLB94]7;\)@$\E/?.)K@/6F:YZY//FS4L!FHW*A='-@EUA $.$FJ!
MX2*&YJ(#) 1/R1U>C2[#,#<D.ZRD442,4<QO'Z4EL'G47\NZBQ:?,2G34T8<
M)70Z=08KKYCJG6ZS@MSG[40QXT;<0#%INMG&(K2I=@\%$^;@4 5*/[\N=(/W
MT^F,H"4>EY5LD L"^-T;]&L,!28WI2^R%DZ_RLLU;]T79FI<S5 8GAK4C?J\
M<O>N]Z/QS8_(KWG$[KZ%!VB7G>TZWA[9"Z%CREQHFK&P1.Y6[H#=+H"[8[-O
M1EQLZG:KXU?G@WE2^_1_RAK]L%K"/?3W%KOS9;5=KC=%N>+DS*"E$4M\AOGR
M+V,F*\4,B'"T=>RL]A4F&4)&^BEO*PM72FUAS>^#L.#1IO$^8*003L9,[)P;
MK,?T_7<='/S'BQ>:)O33$(7W@]"";QOV""' %"O\^I5"?*EVZJG\TN,Q:16O
MMJMY(HYN6?+E;<*;N@U'6YR0/[? %_BQ'#Q%&\,#CN"=J DA;FD40I.PZ[OC
M7M+HAGS9TWRJ\;#X.S"3<X%7OCUP/ZQ(0K48OZA59"762A)]=%J.""R'KB^J
M31FX!).OJPQ)NITKTNY7?BIEQ,,KP'(E9?F^O?>DW4=MU\V<W16D8K<V%<!7
MJ2\K;.@ZH.Q!,_WPNX4@$.'V=((H7RG5J6%X.L6[SQ3S,5QN+7T,\QDQE@10
M+("CD.ZIUN3Y\$'-D#*U%+"QM7OEC>M&P&R^V#8L-TXM)A#3>HSO*!" >(@;
MU*D'2K%U-3(M]EQX%Q:OI077U/%H%]^#\;$B-U<*/G-*I(T%F@4"[[&!\%W^
M=@Q=?ZTB"C;PJ>@V[.!\7\O9(>N6JGN[V/4D OK';2.K#J:K)8*AB+&WR"\C
M&POLC)/7QE@.M\J[JS7SG&_-5Q;;W!\:&C8X?-;7));M@5G@V:\OWPV[LPDP
M&>/BEG&=D1Y/!Z-E#>WE%G5LV@W2[:3Z7)^C>TC1=Q/-IAJZC6[[Y(LR% WY
MYZHK45F$+K04N@6^#WT.XD\N3=@#S'UD]3LO\OT^S3SK$^)C^W6^2/".ZBY=
M$8VL*@*/#\J(@@YUS7*Z'/ N(6L@.P'EY+BK;C<7JUN+S<R/S?(1KE[V7IY9
M8/8MUV95Z2&#WT\1=L'[W>.23\3YE92B:PC?D70Y&::0B0:GR^6^!GA0IY87
M>5[(3\&AT2C0(.#(3?WJ2W-/)%-TCW]X>5U"^-E/0C.D:X)N4A]6^.8Z)_0E
MOLO\=*-/R-+;\T+7<&N+_-*"P7D^/<E8/5P1?NPSGF* >(TM*F_""_C,R8GX
M:U&6&X^4-C$OUR1^$#5:G3CG:_EH[[WC[S\!7XF*WT7*>,-=MK9A#4R<3/VD
M>T[\Q=-/*S*KD_-S _*9E39]ELS?S1]"'%^WM*?>2S:SF8QN.QWEC4?C7T",
M84.G)27[&WR0MQE>S-'(X!7V@5M7_BH=47M3?/5)G+9'Y:F;3,@<12QVB[%W
M[T)DH.@R?8M*G]#]V"*.0/"$<Z7^#.0J4"<KRS :>K$B$R\S,,^,WTV=F]LG
MN9==1@01BZ?<0-&/RX0!3DZ0OS_B;Q%ZDX)Y<?LS;=!C[U%3>Z-T6&0=.Q#P
MXAG<'5:OR? = W8[P;G]CV;Y )I=BT]3A+3+#%3E5)\."93H[LK]1&.?<]DL
M;V*NGFPV"Q'E?#M?Q^BRD7)<0N;5UOBZN@[I+(%''HBD"B;/W[.).J7XC!=2
M !<KG;)368=R=M9;9>;2_ITXZ_^OV_X_J]MX(4H%S12!"3K4$[MGZ87YU^3?
M#!M^3)$5"BMKQ?B>L-YKVGUH>JEUPD$];S,;-^,"<@VQ=^R$&N@OVC]W'/WY
M]N<51CI#O_\^*,G;C$^U9N!VS]3=7\_-']'&?HQTW2R>\+?(E_G0F4&[:3PU
M*0?J@F_Q8['(/:X:>W:*LPG-EM&F1*,<="*0-?)?8_66KWQ5K>FY;S;]YB!/
MSYJ7+V'A)9D+"8T;_H"7W"FU(8/E_4Z>C:.YO3&'8OJWHIMKCN!3/,/7Y1SF
M+?*H^D]0/65H4H))L+R4K%FM</.IYY*?=S;?9M_967\T\[8T&;#1N_"]L&E_
MPC-U@2MMTAFX#U '%&S#2H8117T+ N-15J>#:TO)7!846C3[8DR!6WRZ/'91
M1RA)D554,%S.;BH:GOTJDVJD+S>U\&3<XV8]:3HLCU)W"=2?7JVBYK7(41'C
M,A'^-ZKJZ1'6U=W?/%;9+BS+:$#S!UW_3UJER9J5^T]+Q=VU<J91&L(IR@O)
M?)L7 (2/MTDWH4?/K9LXBNER/OD1'V<\\^7S-DP0:,W+@>PM [_%EK^?0'5D
MAE=B6<\A6__C2"[ =[@,$;O%@HAVD.?.BNO.EHH?GX"3+A0-O#]B;'AGV_]U
M@';>&=Y^!,RBQH'7N<!:G948YB8)Q8R&1(_]Y&8C8X<]3'IN'?Q[=MM_+6G6
M^I/_E#3+?0J[9(YO4&S#?E\$;B I^CM/-JXC,@1=@7C@?"GK+% GM]-"! >P
M8%4*FK/8QKV9$>[;L/552&,[CHOS;\-J^[9ANY@$]$X"WD^L[C^; \U GIUG
MOW""TZ3[H5E@.(E>LB3!F6*0*CL%ZT0L&$+LM3.IG650!SWWI"5=:@N.I4-C
M?D('/ EF0T:_EPZT&U1#1.I.P(YZ^ %<B6>RH.E9"U^)7=Y14?!;T!T\D;^D
M7,>5F)AQJ&?&-UL)#;R;_,#0"G-GH\RFRM;?S\^Q-8!=^!57X"!^P:H;O_9.
M'S2?W_K$R@8F!L'C0']Q#C K'\_,ZUO3>8G_UK35L!)#QT5@Q84Z 883ZS!0
MMP_J"0& "[&DL W+]AO<(M?N;+>#>J!=%A0$AFVV848;I>M-:,4F[(I:,] W
MB-VRQ70KHT M9>36!B]+"DXH9XKMH5J@7N,IMY!\3I^_]]9R=SV^X.)N+'R&
M*_O;(J,C 4XY,@+9A1>XSX9YDU6[#2O'W5UU9>Y)&Y[[$MOPJ#(F=E -9QJ<
M:,$AO(=M;%P#ZI<];TIC">!^1ZJKI-WGP8Q;;&"'];=VX* F+@<_!@W.P4%K
MIC\]+5-/-G^=]M+5Z\#]R&H/6]<G'/8'?F_#B.8LT40]DC(7"POZ:P)C^K+&
M2Z[8L >S]WS:&, F \%,2$I8T5G<6>)NUUE3_G/# *0RF4?YJ=RN3&BHZQ_E
M_O#V_N3<=72X^83N/4PD()0BHP+W3"/ /PLPJ="8/44X^2 >+=-/\KZ^UU4@
M.*U%D3]$?_B[T_!W*Z6XIH&M"_$HUJSUYW5GSU^\7?Y2'0_"R9P6Y55Z^L93
M%9;DY14-WL;'_NZ;\K/$T4_=ED1ONG2MXT]\$=2(Y/(&/$.DA,B2#<?G.H,6
MP /(G%10H= ,<L)OF0L 9CWKXLK;L)J[B ;%'W $29%1)L$T8;Z'S(-NLC7V
M+^P]_']R6<:!?=A"G0;BD!^IR\>[)5'6_K-J8LO-%YN6@[:A=%*"B'V0[).H
MEQ6&SYL$?@<W63281_FK)3L*/>TJ-NYNKMGOE5-I_C%3*-W0[OPFDY4/@6,0
M0A0-\^DD^4M\'/8WH'R.M";<[#1']^8-.)8IU-@^SUJ32/F6\G%Y 9KQNP_2
MZQA7Z04JU5Y9(_YG*/%5>;;#SB:81:Y2PMDZ5$I=(?/)HDGRBPD!'-%9;GV?
M3U-JM4S/(H^?3>KH1CZN XBOQKRT%YZ8YU]D+=D08\'ES,4?J!0F08X5AX#@
M)12 WFV2LOSBJ?#3_HG]*%0F:Y&6-8Y06Q6_O>*>OK_BN+F.P&KVSBEIKI>4
M#9J2P3(WW3S?/X#*QW?/1=073T9FXH^QLKQ:A[\B*F_4:@NWO'&9A-,5=9B'
M/<<Y7H!JSD2.M5.*_OQCW87E28N]+].JJ7P&!YTXD\4^LWWX."2^[VPM67,0
M(2<WJXQH4/KP:5IETM+$K.2MJ6O[UN@3XD3I4F]+:).83]&&/.Y4=BMIJ:SG
MK2NSD&6?:NPY@PI'4LR)@W!R2^1$;P$H[].A%Y/I=*+X]T61"U4GV50XC[_(
M+2J B6[P<4 D=JN/!H.F:9B: 65IA=B %W.HI#X,E7B%:;STYN.<!>P-(N#(
MHM7X43WA-S"@5VP_L_$CWO;[U_-2S21TCB6O@$!QN(G'FI,=VCC7<>J]N.P/
M]Z^8SZ;YTJ-SAB4L4Z@S[8X@\I A2(%J488.4SG4EE)6F$XO;KA<\CC0S]%J
M[*WX$273WZ':.K"@-U?4+*>1S,.6(/?L+U"25=6$94>WD/)]7[X##MP@JY];
M+XZC0=PNP5N-Q+N$@?DZ2./E@0?&0PBRT@)R/+.OFHTLER^KQ\FPBXA3B/Z8
M3G_X*@4W(QIBF_(Y.Q%\NS.=PK9:FK$#?77V"M2]D:/P7J96^I"S4*6');*H
M0_+NARO >YXG[$_81 C63%ZU-D][CJ86D82^&I4JN?6RLN1GS[V0IRW0;6^G
M*KP%29DAS28E8P5,7.^YD>>()CC!+0XRSB!6YD7,H8($>#V"_YJJWN0'QY6T
M,M-DOH>.AQ8WN(.&+FZ%0I_J@0"7EVY)<[@D?H;^1R40I>9[R&IQH6RSTB)\
M?+> !?O/#\;4+X,9_GEOQ,#@W_9N #G5,_$NF+?4&4&,G<5+#[DJ2KFL5ZJN
MH'A7JFO+>P7F]%Q_/$Q(U),"E(!CD M;-5WZMW7U).^X$#.>* #TWX,HIXXZ
M^CM05TA<<;2_##G==F/6\1)<,_!_+*F9RX2<6:S-M/$J(I7.#NK+S)Y?B]WQ
M\=?^P\?_YTON+W*GLV+_XC#R&G(_,)&5-HM@G=!I\OG?)U2?E<4G(?_YC[5!
MS81-,9-M& [R-_HQY)T2G"<J\>L0L,^>W0_QGB,(XS]+B/[5ALYN2S*>*;:Y
M#9,Y12&"31^ M9SY-0SD42<RTJ&&26%YR8K,U\Y;.W%,G1_;,,IUXJ8^O!ZS
MM9,.L2N@!] 18$+NO8X?F#P)[$?,+VULPPPWS%EBEJ4[W/[3_^+VWU?^QNW-
MC?\GMQ<W9W@PN1-H\:PWX D?\1%S7+7F1V/NUZA*MWC_#G^&;\Y10%'HG:=3
M7^S0\#5)H8,JT;<S;N%$V0,SQ#4Y KD!FWCZ3AE*Z#4#']O[[Z<7^U$Q]<_.
MZ8UA1>PV$[^[9W=\G+L%__">K=&T_+LP1?+A+>V9N@4**NS4W4*!<[E+[7E&
M<++UQ7DI%]\\M]\$<HB.Z:'0D+M:=EV5"73[\DUU%NK7UA#(/<$J60#/@]\5
M*%5FU9ID7*CHNT$98-3>R8WQ,>:Y8[OWV8/G2Z];(2ZB0RU7TBD<X\1PQ$/C
M"&M$5+5HCD8"[E&<[Q>]J-^MV:'16C/4RMC/V9_4HSE9HSNQ/JC77&I%P/[!
M2]AT>LA6RS?@X'MY4R?OU=?Y%_>Y:[CHO2<%B<<4\K''A,#.3E(57WC<?OS@
M1A<[A^QYMUMZ=O7&?KA)E,W:P)#!FCM<Y&8C*2V!/-EA(=N^#7-2^,S(3+>I
MZ5DO']PY478)G7S8Q-Z+H87NQ?( ][=A^S4*J>Q-E3JAKC3!<)&I$:]G5W[V
MW[%MD_"3Q?I;]/NK6Z\+R)Y]$C<@.80.$^G-WW_32[94.'_HF<'43W ;=C-(
M_TOBW-PCUWS7=*>'B9;[Q'33Y;^WO(#MCO6!6:Y"!K$G#7K%",5% D.S)8ON
M1DHB$5\.&M@=?WG<2R]IETM];:29K..;<-X]_3QYX/XHZ L55-Y%[ ._,<RN
M(:*/,>ES5-%$.\F+.T!'@C"H&RZ_#>N0<J@2>:@R6"/#/"0![E/P95SWZ3*@
M%U(Y#&.)I*4PY8K.Q].WLALM3;[(-AG;W+_[3B9,Y.J3JOF- GY2HII"<,+!
MZ4$S_5^A9H,0.9TLK6VO"G#=Y#TTW>,3>K#H!O:VTC(A<R<)@,4&PZC-E\E+
M-2595%"0S1R:5(&DV:TB*RMDV^.QSV\R1SXK><@%LEFN9!FV:YL7\>KOE&()
MNC-ARKCDKV?74>%O<$A"[86K*;P5-*>V,,7D*#_'O^TD:C#TO!WS8$7M0?KL
M8(9\PR1KF.MAG9&JJ&U,VV9-DS= <4M83$AC[J//DHU#:Z6[3W0]1I^0JG+R
M/O]%]Q;(>X;S V;_ SW.W<F"44)Y^[<*3N?87![#Y_^V?)N^KZ0Z\4EY%E[2
M?_I 5V:\AVF#^;/PMW\DK>(56$\WBS?X=@#+=.OPOYI8^A_E#I,71^2E*R%
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M3:^7OA*EB:1(01R9N0=CX\(R(5*H)(V9XCS+J=<L= Z8H4TP;ZX_WGT$#^_
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MQ]O9$QM/1]P@4#P54,K8=C3/N7&ZI(88*>-I:2SSB'EM%IX4.303;!&O^A:
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MH_B)'YK!J/&.^42!J?$LBRL@EBI<@:*$ODS)^G$\K7_RDY\Y\1PA-SL3CO?
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MS(G*&>;>-6K[U6%HIFE#A2NPUZT-_/BJV-RW8=@E7@U.$,ETE$#)J5ELY4A
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M(Z%S33*O SU? $/[]#\H40;QKG0 VTKXUB_P' XW6Q&2Y,#6Q$ _3JZ-';#
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M12H)BN,8QEF>09Q%"111(B%AC"$E(I'XU11V-SVW4*[QW&:;FGL@UX.NU7C
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MA$DF-V593I:%9[:H!#:5>I:9%41) DU"(4\Q*M=H)N?W*%L+;O[YP&U0372
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ME,7X*]YD*MLB+;$%7M6YH(8["-K6$8^Q6,Y]<JI-0\^UR-OO>5D[N VOFPX
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M);,%6+9>+5^6+MG[19@MNE@SORP+JH]71QOG\VND]<B9K;G!DM5I2;4U6"S
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M^UI?B*RE,D:!1R9 I2C 96L@*0S&T9^":;-\'Z-J5Q-VW[.O,(]&<XM60,+
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M4?N2C>EJ^>SNM#6K0_MAEL]PD!ET=ON#-\BK/]0OM:W\O_W+_P=02P,$%
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M7G.;G \5FUZ<,S$F@KTNB>:PT>+-D$;-H]/6*6N<'(4GK:/PE'%^2*.C\(\
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M,C$P-C,P+FAT;5!+ 0(4 Q0    ( "Q!"E-$C^A=BPD  "94   9
M      "  <_R  !C:S P,#$X,C0R.3,M,C R,3 V,S N>'-D4$L! A0#%
M  @ +$$*4RFG '6&#@  PWP  !T              ( !D?P  &-K,# P,3@R
M-#(Y,RTR,#(Q,#8S,%]C86PN>&UL4$L! A0#%     @ +$$*4P_316R^&P
M9R$! !T              ( !4@L! &-K,# P,3@R-#(Y,RTR,#(Q,#8S,%]D
M968N>&UL4$L! A0#%     @ +$$*4REE#/,E30$ ,'8! !P
M ( !2R<! &-K,# P,3@R-#(Y,RTR,#(Q,#8S,%]G,2YJ<&=02P$"% ,4
M"  L00I3G0BZYV-F  "J7 0 '0              @ &J= ( 8VLP,# Q.#(T
M,CDS+3(P,C$P-C,P7VQA8BYX;6Q02P$"% ,4    "  L00I3+9F9U=Q"  #V
M\P( '0              @ %(VP( 8VLP,# Q.#(T,CDS+3(P,C$P-C,P7W!R
M92YX;6Q02P$"% ,4    "  L00I3"/=QX74(  !)*P  %
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C;VXY,#9C97)T+FAT;5!+!08     "P + !H#  #O.0,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
